

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 26, 2005, 15:28:42 ; Search time 133.689 Seconds
(without alignments)
659.602 Million cell updates/sec

Title: US-09-545-998B-2
Perfect score: 1301
Sequence: 1 MGAWAWLYGVSMCLVLDLQ.....PEERGEQTEKCHLGRWP 228

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A Geneseq_16Dec04:*
1: Geneseqp1980s:*
2: Geneseqp1990s:*
3: Geneseqp2000s:*
4: Geneseqp2001s:*
5: Geneseqp2002s:*
6: Geneseqp2003as:*
7: Geneseqp2003bs:*
8: Geneseqp2004s:*

pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1301	100.0	228	2 AAW37838	Aaw37838 Amino aci
2	1301	100.0	228	2 AAW49016	Aaw49016 Mouse glu
3	1301	100.0	228	6 ADA09440	Ada09440 Murine GI
4	1301	100.0	228	8 ADH43110	Adh43110 Mouse glu
5	1079	82.9	222	2 AAW49018	Aaw49018 Mouse glu
6	1079	82.9	222	2 AAW49017	Aaw49017 Mouse glu
7	735.5	56.5	240	8 ADR46662	Adr46662 Cancer-as
8	735.5	56.5	241	2 AAW37839	Aaw37839 Amino aci
9	735.5	56.5	241	2 AAY06605	Aay06605 Human TNF
10	735.5	56.5	241	3 AAB33431	Aab33431 Human PRO
11	735.5	56.5	241	3 AAY71467	Aay71467 Human PRO
12	735.5	56.5	241	3 AAB27651	Aab27651 Human PRO
13	735.5	56.5	241	3 AAY95895	Aay95895 Human tum
14	735.5	56.5	241	3 AAB24409	Aab24409 Human PRO
15	735.5	56.5	241	4 AAB47054	Aab47054 Human PRO
16	735.5	56.5	241	4 AAB20115	Aab20115 Human imm
17	735.5	56.5	241	4 AAB53090	Aab53090 Human ang
18	735.5	56.5	241	4 AAB47289	Aab47289 PRO3164 po
19	735.5	56.5	241	4 AAB50982	Aab50982 Human PRO
20	735.5	56.5	241	4 AAB50910	Aab50910 Human PRO
21	735.5	56.5	241	5 AAE28161	Aae28161 Human TR1
22	735.5	56.5	241	6 ABO08442	Abu08442 Amino aci
23	735.5	56.5	241	6 AAO16574	Aao16574 Human tum
24	735.5	56.5	241	6 AAO23091	Aao23091 Human ene
25	735.5	56.5	241	7 ADN39966	Adn39966 Cancer/an

ALIGNMENTS

RESULT 1

AAW37838 standard; protein; 228 AA.

AAW37838;

28-JUL-1998 (first entry)

Amino acid sequence of the mouse 312C2 T cell protein.

Mouse 312C2 T cell protein; thymus cell; spleen cell; T cell;
antigen-specific T cell proliferation; cytokine production by T-cell;
apoptosis; cancer; haematopoietic cells; lymphoid cell;
autoimmune disorders.

Mus sp.

WO9806842-A1.

19-FEB-1998.

14-AUG-1997; 97WO-US013931.

16-AUG-1996; 96US-00689943.

07-OCT-1996; 96US-0027901P.

(SCHE) SCHERING CORP.

Gorman DM, Randall TD, Zlotnik A;

WPI; 1998-159534/14.

N-PSDB; AAV19152.

Isolated 312C2 T cell gene - used to develop products for treating, e.g.

cancers, auto-immune disorders, transplantation rejection and other T

cell disorders.

Claim 2; Page 57-58; 71pp; English.

This is the amino acid sequence of the mouse 312C2 T cell protein. The
312C2 proteins are expressed in thymus cells and are induced on T cells
and spleen cells following activation. Engagement of 312C2 stimulates
proliferation of T cell clones, antigen-specific proliferation and
cytokine production by T-cells, and potentiates T cell expansion or
apoptosis. The products can be used in the treatment of conditions
associated with abnormal physiology or development, including abnormal
proliferation, e.g. cancerous conditions or degenerative conditions. They
can be used in the regulation or development of haematopoietic cells,

XX Mus musculus.
 XX OS US6509173-B1.
 XX PN 21-JAN-2003.
 XX PD 21-OCT-1998; 98US-00176200.
 XX PF 21-OCT-1997; 97US-0063212P.
 XX PR (HUMA-) HUMAN GENOME SCI INC.
 XX PA Ni J, Ruben SM;
 XX PI WPI; 2003-352290/33.
 XX DR
 XX DT
 XX DE
 XX KW Novel nucleic acids encoding human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2, useful for treating blood coagulation disorders, blood platelet disorders, stroke and myocardial infarction.
 XX PS Disclosure; Fig 4; 70pp; English.
 XX CC The present invention relates to the isolation of novel human tumor necrosis factor (TNF) receptor-like proteins, designated TR11, TR11SV1 and TR11SV2 receptors, and the polynucleotide sequences encoding them.
 XX CC the polypeptide and polynucleotide sequences for TR11, TR11SV1, and TR11SV2 are useful in assays to test one or more biological activities of TR11, TR11SV1 and TR11SV2 polypeptides, for proliferation, differentiation and mobilisation of immune cells, and as markers or detectors of a particular immune system disease or disorder. They are also useful in treating or detecting deficiencies or disorders of haematopoietic cells, to increase differentiation and proliferation of haematopoietic cells, including pluripotent stem cells in an effort to treat disorders associated with a decrease in haematopoietic cells e.g. blood protein disorders, HIV-infection, anaemia and thrombocytopaenia.
 XX CC The sequences are also useful for modulating haemostatic or thrombolytic activity, for treating blood coagulation disorders, blood platelet disorders or wounds resulting from trauma, as well as for treating stroke, myocardial infarction and scarring. They may be used for detecting or treating autoimmune disorders (e.g. Addison's disease, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Grave's disease, diabetes mellitus, multiple sclerosis and autoimmune thyroiditis), for treating allergic reactions such as asthma, for treating and/or preventing organ rejection or graft versus host disease (GVHD), for treating hyperproliferative disorders including neoplasms and cancers, for treating or modulating inflammation or inflammatory conditions such as inflammation associated with infection (e.g. septic shock and sepsis, ischaemia-reperfusion injury, endotoxin lethality, induced lung injury and Crohn's disease), for treating or detecting infectious agents such as viruses, bacteria, parasites and fungi, for differentiating, proliferating and attracting cells for tissue regeneration, and as vaccines to raise immune response against infectious diseases. The polynucleotide sequences are also useful in ex vivo gene therapy, and for proliferating and differentiating peripheral nervous system diseases such as spinal cord disorders, cerebrovascular diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and Shy-Drager syndrome. The present sequence represents murine glucocorticoid-induced tumour necrosis factor receptor family related protein (GTR).

Query Match 100.0%; Score 1301; DB 6; Length 228;
 Best Local Similarity 100.0%; Pred. No. 1.6e-112;
 Matches 228; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGAWMLYGVSMLCVLDLGFVSVEEPGCGKVGQSGNTRCCSLYAPKEDCPKRC 60
 DB 1 MGAWMLYGVSMLCVLDLGFVSVEEPGCGKVGQSGNTRCCSLYAPKEDCPKRC 60
 QY 61 ICVTPEVHCXGDPQCKICKHYPCQGRVVSQGDIVFGFRVCACAMGTFSAAGDGHCR LWT 120

Db 61 ICVTPEVHCXGDPQCKICKHYPCQGRVVSQGDIVFGFRVCACAMGTFSAAGDGHCR LWT 120
 QY 121 NCSQFGFLTFPGNKTNAVCIPEPLPTEQYGH LTVIFLVMAACIFFLT TVQLGHLH IWL 180
 Db 121 NCSQFGFLTFPGNKTNAVCIPEPLPTEQYGH LTVIFLVMAACIFFLT TVQLGHLH IWL 180
 QY 181 RRQHMCPRETQFFAEVQLSADACSFPPEBERGEQTEKCHLGGRWP 228
 Db 181 RRQHMCPRETQFFAEVQLSADACSFPPEBERGEQTEKCHLGGRWP 228
 RESULT 4
 ADH43110
 ID ADH43110 standard; protein; 228 AA.
 XX
 AC ADH43110;
 XX
 DT 25-MAR-2004 (first entry)
 XX
 DE Mouse glucocorticoid-induced tumour necrosis factor receptor (GTR).
 XX
 KW antiinflammatory; osteopathic; immunosuppressive; neuroprotective;
 KW immunostimulant; antirheumatic; dermatological; antithyroid; haemostatic;
 KW antischismatic; antiarthritic; cytostatic; proliferation inhibitor;
 KW differentiation inhibitor; T-cell chemotaxis inhibitor;
 KW B-cell chemotaxis inhibitor; haemostasis; thrombolytic activity;
 KW TR11SV1; TR11SV2; tumour necrosis factor receptor-like protein;
 KW TNF receptor-like protein; inflammation; bone disease; Paget's disease;
 KW osteoporosis; craniofacial dysplasia;
 KW fibrodysplasia ossificans progressiva; gigantism; osteoclastoma;
 KW autoimmune disorder; autoimmune haemolytic anaemia; autoimmunocytopenia;
 KW multiple sclerosis; autoimmune thyroiditis; immunodeficiency disorder;
 KW severe combined immunodeficiency; Wiskott-Aldrich syndrome;
 KW rheumatoid arthritis; systemic lupus erythematosus;
 KW graft-versus-host disease; asthma; cancer; Grave's disease;
 KW blood coagulation disorder; platelet disorder; thrombocytopenia; TR11;
 KW tumour necrosis factor receptor family; mouse;
 KW glucocorticoid-induced tumour necrosis factor receptor; GTR.
 XX
 OS Mus musculus.
 OS US2003138426-A1.
 PN 24-JUL-2003.
 XX
 PD 30-OCT-2002; 2002US-00283105.
 XX
 PF 21-OCT-1997; 97US-0063212P.
 XX
 PR 21-OCT-1998; 98US-00176200.
 PR 24-FEB-1999; 99US-0121648P.
 PR 13-MAY-1999; 99US-0134172P.
 PR 16-JUL-1999; 99US-0144076P.
 PR 23-FEB-2000; 2000US-00512363.
 PR 28-JUL-2000; 2000US-0221577P.
 PR 27-JUL-2001; 2001US-00915593.
 PR 30-OCT-2001; 2001US-0330757P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Ni J, Ruben SM;
 XX
 XX WPI; 2004-068938/07.
 XX
 XX Novel isolated antibody binding to TR11SV1/TR11SV2 receptor, useful for treating inflammation, Paget's disease, thyroiditis.
 XX
 PS Disclosure; SEQ ID NO 7; 135pp; English.
 XX
 CC The invention describes an isolated antibody (I) or its portion specifically binding to a protein chosen from a protein with amino acid residues 1-62 or 51-62 of a fully defined TR11SV1 receptor sequence of 241 amino acids (S1) as given in specification, and a protein with amino acid residues 38-49 of a fully defined TR11SV2 receptor sequence of 240

CC amino acids as given in specification. (I) is useful for detecting tumour
 CC necrosis factor (TNF) receptor-like proteins TR1SV1 or TR1SV2 protein
 CC in a biological sample, which involves contacting the biological sample
 CC with (I), and detecting the TR1SV1 or TR1SV2 protein in the biological
 CC sample. (I) is a labeled antibody, the label is chosen from an enzyme
 CC label, a radioisotope, a fluorescent label, and biotin. The method
 CC described is useful for treating inflammation. Also described is a method
 CC useful for treating bone disease or a disorder such as Paget's disease,
 CC osteoporosis, craniometaphyseal dysplasia, fibrodysplasia ossificans
 CC progressive, gigantism, or osteoclastoma. (I) is useful for treating
 CC autoimmune disorders e.g. autoimmune haemolytic anaemia,
 CC immunodeficiency disorders e.g. severe combined immunodeficiency and etc.,
 CC immunodeficiency syndrome. (I) is also useful for treating rheumatoid
 CC arthritis, systemic lupus erythematosus, graft-versus-host disease,
 CC asthma, cancer, Grave's disease, blood coagulation disorders and platelet
 CC disorders (thrombocytopenia). This is the amino acid sequence of mouse
 CC glucocorticoid-induced tumour necrosis factor receptor (Gitr) used in a
 CC comparison with the novel tumour necrosis factor receptor family members
 CC TR11, TR1SV1 and TR1SV2.
 XX
 SQ Sequence 228 AA;

Query Match 100.0%; Score 1301; DB 8; Length 228;
 Best Local Similarity 100.0%; Pred. No. 1.6e-112; Indels 0; Gaps 0;
 Matches 228; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MGAWMLYGVSMCLVDLQGPSVVEEPCGPGKVGNGSNTRCCSLYAPGKEDCPKERC 60
 DB 1 MGAWMLYGVSMCLVDLQGPSVVEEPCGPGKVGNGSNTRCCSLYAPGKEDCPKERC 60
 QY 61 ICVTPEYHCGDPQCKICKHYPCQPQQRVESQGDIVFGFRCVACAMGTFSAGRDGHCRLWT 120
 DB 61 ICVTPEYHCGDPQCKICKHYPCQPQQRVESQGDIVFGFRCVACAMGTFSAGRDGHCRLWT 120
 QY 121 NCSQFGFLTMFPGNKNTHNAVCIPEPLPTEQYGHLTIVIFLVMAACIFFLTTLVGLHIWOL 180
 DB 121 NCSQFGFLTMFPGNKNTHNAVCIPEPLPTEQYGHLTIVIFLVMAACIFFLTTLVGLHIWOL 180
 QY 181 RQHMCPRETQPPFAEVLQSAEDACSFQFPPEERGEQTEKCHLGGWRP 228
 DB 181 RQHMCPRETQPPFAEVLQSAEDACSFQFPPEERGEQTEKCHLGGWRP 228

RESULT 5
 AAW49018
 ID AAW49018 standard; protein; 222 AA.
 XX
 AC AAW49018;
 XX
 DT 29-SEP-1998 (first entry)
 XX Mouse glucocorticoid induced TNFR-family related protein variant C.
 DE Mouse glucocorticoid induced TNFR-family related protein; lymphocyte;
 KW Gitr; tumour necrosis factor; apoptosis; hodgkin's disease; Gitr-B;
 KW Gitr-C.
 XX
 OS Mus sp.
 XX WO9824895-A1.
 XX
 PN 11-JUN-1998.
 XX
 PD 08-NOV-1997; 97WO-EP006252.
 XX
 PF 08-NOV-1997; 97WO-EP006252.
 XX
 PR 02-DEC-1996; 96GB-00025074.
 XX
 PA (PHAA) PHARMACIA & UPJOHN SPA.
 XX
 PI Riccardi C;
 XX
 DR WPI; 1998-333315/29.
 XX
 PT New isolated glucocorticoid induced TNFR related polypeptide - used to

DR N-PSDB; AAV32775.
 XX
 PT New isolated glucocorticoid induced TNFR related polypeptide - used to
 PT stimulate lymphocyte activity and cell death rescue, useful to, e.g.
 PT develop products to suppress lymphocyte activity and induce apoptosis.
 XX
 PS Claim 15; Page 43-44; 53pp; English.
 XX
 CC The present claimed sequence represents a mouse glucocorticoid induced
 CC TNFR-family related protein variant C (Gitr-C). The invention also claims
 CC for Gitr (AAW49016) and Gitr-B (AAW49017). The Gitr's are claimed to be
 CC useful for stimulating lymphocyte activity and cell death rescue. Gitr
 CC antagonists are claimed to be useful for suppressing the lymphocyte
 CC activity and for inducing apoptotic deletion. Gitr cDNAs and the proteins
 CC they encode are also claimed to be useful for suppressing growth of
 CC tumour cells over-expressing Gitr or for the treatment of refractory
 CC hodgkin's disease
 XX
 SQ Sequence 222 AA;

Query Match 82.9%; Score 1079; DB 2; Length 222;
 Best Local Similarity 100.0%; Pred. No. 6.4e-92;
 Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MGAWMLYGVSMCLVDLQGPSVVEEPCGPGKVGNGSNTRCCSLYAPGKEDCPKERC 60
 DB 1 MGAWMLYGVSMCLVDLQGPSVVEEPCGPGKVGNGSNTRCCSLYAPGKEDCPKERC 60
 QY 61 ICVTPEYHCGDPQCKICKHYPCQPQQRVESQGDIVFGFRCVACAMGTFSAGRDGHCRLWT 120
 DB 61 ICVTPEYHCGDPQCKICKHYPCQPQQRVESQGDIVFGFRCVACAMGTFSAGRDGHCRLWT 120
 QY 121 NCSQFGFLTMFPGNKNTHNAVCIPEPLPTEQYGHLTIVIFLVMAACIFFLTTLVGLHIWOL 180
 DB 121 NCSQFGFLTMFPGNKNTHNAVCIPEPLPTEQYGHLTIVIFLVMAACIFFLTTLVGLHIWOL 180
 QY 181 RQHMCPR 188
 DB 181 RQHMCPR 188

RESULT 6
 AAW49017
 ID AAW49017 standard; protein; 294 AA.
 XX
 AC AAW49017;
 XX
 DT 29-SEP-1998 (first entry)
 XX Mouse glucocorticoid induced TNFR-family related protein variant B.
 DE Mouse glucocorticoid induced TNFR-family related protein; lymphocyte;
 KW Gitr; tumour necrosis factor; apoptosis; hodgkin's disease; Gitr-B;
 KW Gitr-C.
 XX
 OS Mus sp.
 XX WO9824895-A1.
 XX
 PN 11-JUN-1998.
 XX
 PD 08-NOV-1997; 97WO-EP006252.
 XX
 PF 02-DEC-1996; 96GB-00025074.
 XX
 PR (PHAA) PHARMACIA & UPJOHN SPA.
 XX
 PI Riccardi C;
 XX
 DR WPI; 1998-333315/29.
 XX
 PT New isolated glucocorticoid induced TNFR related polypeptide - used to

PT stimulate lymphocyte activity and cell death rescue, useful to, e.g.
PT develop products to suppress lymphocyte activity and induce apoptosis.
XX Claim 14; Page 40-41; 53pp; English.
PS
XX The present claimed sequence represents a mouse glucocorticoid induced
CC TNFR-family related protein variant B (GTR-B). The invention also claims
CC for GTR (AAW49016) and GTR-C (AAW49018). The GTRs are claimed to be
CC useful for stimulating lymphocyte activity and cell death rescue. GTR
CC antagonists are claimed to be useful for suppressing the lymphocyte
CC activity and for inducing apoptotic deletion. GTR cDNAs and the proteins
CC they encode are also claimed to be useful for suppressing growth of
CC tumour cells over-expressing GTR or for the treatment of refractory
XX hodgkin's disease
XX
SQ Sequence 294 AA;

Query Match 82.9%; Score 1079; DB 2; Length 294;
Best Local Similarity 100.0%; Pred. No. 8.9e-92;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MGAWMLYGVSMCLVDLQPSVVEEPGCGPKGVQNGSGNTRCCSLYAPGKEDCPKERC 60
DB 1 MGAWMLYGVSMCLVDLQPSVVEEPGCGPKGVQNGSGNTRCCSLYAPGKEDCPKERC 60
QY 61 ICVTPEYHCGDPOCKICKHYPCQPGORVESQGDIVFGPRCVACAMGTFSGAGRDGHCLWT 120
DB 61 ICVTPEYHCGDPOCKICKHYPCQPGORVESQGDIVFGPRCVACAMGTFSGAGRDGHCLWT 120
QY 121 NCSQFGFLTFMFGNKTNAVCIPPELPTQYGHLTIVIFLVMAACIFFLTTVOLGLHIWOL 180
DB 121 NCSQFGFLTFMFGNKTNAVCIPPELPTQYGHLTIVIFLVMAACIFFLTTVOLGLHIWOL 180
QY 181 RRQHMCP 188
DB 181 RRQHMCP 188

RESULT 7
ADR46662
ID ADR46662 standard; protein; 240 AA.
AC ADR46662;
XX
DT 18-NOV-2004 (first entry)
XX
DE Cancer-associated protein, SEQ ID 75.
XX
KW Cytostatic; Gene Therapy; cancer; human.
XX
OS Homo sapiens.
XX
PN WO2004073657-A2.
XX
PD 02-SEP-2004.
XX
PF 19-FEB-2004; 2004WO-US005455.
XX
PR 19-FEB-2003; 2003US-0448784P.
XX
PA (PROT-) PROTEIN DESIGN LABS INC.
XX
PI Aziz N, Gish KC, Wilson KE, Zlotnik A;
XX
DR WPI; 2004-652787/63.
XX
DR N-PSDB; ADR46604.
XX
PT Detecting a pathological cell in a patient for diagnosing or treating
PT cancer by detecting in a biological sample from the patient genes whose
PT expression are up-regulated or down-regulated in specific cancers.
XX
PS Claim 1; SEQ ID NO 75; 375pp; English.
XX

CC The present invention relates to a method for detecting cancer in a
CC patient. The method comprises detecting in a biological sample from the
CC patient a nucleotide or protein sequence comprising a sequence that is at
CC least 80% identical to a nucleotide sequence (ADR46588-ADR46645) or
CC protein sequence (ADR46646-ADR46703). The method is useful for detecting
CC cancer for preparing a composition for diagnosing or treating cancer.
XX
SQ Sequence 240 AA;
Query Match 56.5%; Score 735.5; DB 8; Length 240;
Best Local Similarity 57.0%; Pred. No. 5.7e-60;
Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;
QY 1 MGAWMLYGVSMCLVDLQPSVVEEPGCGPKGVQNGSGNTRCCSLYA-----PGKE 53
DB 7 MGAPRALCGLALLCALSLGQ-RPTGGPGCGPGRLLLTGTDAACRVHTTRCCRDYPGSE 65
QY 54 DCPKERCICVTPEYHCGDPOCKICKHYPCQPGORVESQGDIVFGPRCVACAMGTFSGAGRD 113
DB 66 CGSEWDNCVQPEFHCPCCTTCRRHPCPPGQGVQSQKFSFGQCDICASGTFSGGHE 125
QY 114 GCHRLWNTCSQFGFLTFMFGNKTNAVCIPPELPTQYGHLTIVIFLVMAACIFFLTTVOL 173
DB 126 GHCKPWTCTQFGFLTFMFGNKTNAVCIPPELPTQYGHLTIVIFLVMAACIFFLTTVOL 185
QY 174 GLHIWQLRRQHMCPRPTQPFPAFVQLSABDACSFQPPPEERGSOT-BEKLHGLGRW 227
DB 186 GLHIWQLRSQCMWPRETQLLLEVPSTEDARSCQPPPEERGSABEKGRLGLDW 240
RESULT 8
AAW37839
ID AAW37839 standard; protein; 241 AA.
XX
AC AAW37839;
XX
DT 28-JUL-1998 (first entry)
XX
DE Amino acid sequence of the human 312C2 T cell protein.
XX
KW Human 312C2 T cell protein; thymus cell; spleen cell; T cell;
KW antigen-specific T cell proliferation; cytokine production by T-cell;
KW apoptosis; cancer; haematopoietic cells; lymphoid cell;
KW autoimmune disorders.
XX
OS Homo sapiens.
XX
PN WO9806842-A1.
XX
PD 19-FEB-1998.
XX
PF 14-AUG-1997; 97WO-US013931.
XX
PR 16-AUG-1996; 96US-00689943.
PR 07-OCT-1996; 96US-0027901P.
XX
PA (SCHE) SCHERING CORP.
XX
PI Gorman DM, Randall TD, Zlotnik A;
XX
DR WPI; 1998-159534/14.
DR N-PSDB; AAV19153.
XX
PT Isolated 312C2 T cell gene - used to develop products for treating, e.g.
PT cancers, auto-immune disorders, transplantation rejection and other T
PT cell disorders.
XX
PS Claim 2; Page 59-60; 71pp; English.
XX
CC This is the amino acid sequence encoding the human 312C2 T cell protein.
CC The 312C2 proteins are expressed in thymus cells and are induced on T
CC cells and spleen cells following activation. Engagement of 312C2
CC stimulates proliferation of T cell clones, antigen-specific proliferation
CC

CC and cytokine production by T-cells, and potentiates T cell expansion or
 CC apoptosis. The products can be used in the treatment of conditions
 CC associated with abnormal physiology or development, including abnormal
 CC proliferation, e.g. cancerous conditions or degenerative conditions. They
 CC can be used in the regulation or development of haematopoietic cells,
 CC e.g. lymphoid cells which affect immunological responses, e.g. autoimmune
 CC disorders

SQ Sequence 241 AA;

Query Match 56.5%; Score 735.5; DB 2; Length 241;
 Best Local Similarity 57.0%; Pred. No. 5.8e-60;
 Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;
 QY 1 MGAWMLYGVSMCLVLDLGQPSVVEEPCGPGKVGQSGNNTRCCSLYA-----PGKE 53
 DB 7 MGAFAALCGLALLCALSLGQ-RPTGGPGCGPGRLLLTGTDAACRCRVHTTRCCRDYPGEE 65
 QY 54 DCPKERCICVTPEYHCGDPQCKICKHYPCQQRVESQGDIVFGPCVACAMGTFSAGRD 113
 DB 66 CCSEWDCMCVQPEFHCGDPCCTTCRHHPCPPGQGVQSGKFSFGQCDICAGTFSGGHE 125
 QY 114 GHCLRWNTCSQFGFLTMPPGNKTHNAVCIPEPLPTEQYGHLTVIFLVMAACIFFLTITVQL 173
 DB 126 GHCKPWTDTCTQFGFLTVPFGNKTNAVCPGSPPAEPGLGWLTVLLVAACVLLLTSAQL 185
 QY 174 GLHIWQLRQHCMPRETQFAEVQLSAEDACSFQPPPEERGBOT-BEKCHLGGRW 227
 DB 186 GLHIWQLRSQCMWPRETQLLEVPSTEDARSCQFPPEERGSERSAEKGRLGDLW 240

RESULT 9
 AAY06605
 ID AAY06605 standard; protein; 241 AA.
 AC AAY06605;
 XX

26-OCT-1999 (first entry)

Human TNF receptor homologue PRO364.

PRO364; tumour necrosis factor receptor; human; apoptosis; inflammation;
 antiinflammatory; NF-KB activation; autoimmune disease; therapy.

Homo sapiens.

Key Location/Qualifiers
 FT Peptide 1..25 "signal peptide"
 FT Protein 26..241
 FT Modified-site 146 /note= "mature protein"
 FT FT /note= "N-glycosylated"
 FT Domain 162..180
 FT /note= "transmembrane domain"

WO9940196-A1.

12-AUG-1999.

09-FEB-1999; 99WO-US002642.

09-FEB-1998; 98US-0074087P.

(GETH) GENENTECH INC.

Ashkenazi AJ, Gurney AL, Marsters SA, Pitti RM, Wood WI;

Goddard A;

WPI; 1999-494296/41.

N-PSDB; AAX87670.

Tumor necrosis factor receptor homologue - useful for, e.g. modulating

PT apoptosis and NF-KB activation and proinflammatory or autoimmune
 PT responses.

XX Claim 17; Fig 2A; 104pp; English.

The present sequence represents human PRO364, a novel member of the
 tumour necrosis factor receptor family. The sequence was deduced from a
 bone marrow cDNA clone (see AAX87670). Methods for the recombinant
 production of PRO364 polypeptides, e.g. in CHO, Escherichia coli or yeast
 host cells, are provided. Claimed polypeptides comprise amino acids 1-
 241, 1-X, 26-241 (i.e. the mature protein) and 26-X of the present
 sequence, where X is any one of amino acid residues 157-167 of PRO364.
 PRO364 polypeptides are useful for modulating apoptosis, NF-KB activation
 and proinflammatory or autoimmune responses in mammalian cells (claimed).
 Chimeric molecules comprising a PRO364 polypeptide fused to a
 heterologous sequence such as epitope tag or immunoglobulin Fc region are
 also claimed. PRO364 can be used in assays to identify other proteins or
 molecules involved in binding interactions. This is useful for
 identifying inhibitors or agonists of receptor/ligand binding. The PRO364
 polypeptides may also be combined with an agent that is cytotoxic,
 chemotherapeutic or a growth inhibitor. PRO364 antibodies are useful in
 diagnostic methods, purification methods and also in therapy, e.g. as
 inhibitors

SQ Sequence 241 AA;

Query Match 56.5%; Score 735.5; DB 2; Length 241;
 Best Local Similarity 57.0%; Pred. No. 5.8e-60;
 Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;
 QY 1 MGAWMLYGVSMCLVLDLGQPSVVEEPCGPGKVGQSGNNTRCCSLYA-----PGKE 53
 DB 7 MGAFAALCGLALLCALSLGQ-RPTGGPGCGPGRLLLTGTDAACRCRVHTTRCCRDYPGEE 65
 QY 54 DCPKERCICVTPEYHCGDPQCKICKHYPCQQRVESQGDIVFGPCVACAMGTFSAGRD 113
 DB 66 CCSEWDCMCVQPEFHCGDPCCTTCRHHPCPPGQGVQSGKFSFGQCDICAGTFSGGHE 125
 QY 114 GHCLRWNTCSQFGFLTMPPGNKTHNAVCIPEPLPTEQYGHLTVIFLVMAACIFFLTITVQL 173
 DB 126 GHCKPWTDTCTQFGFLTVPFGNKTNAVCPGSPPAEPGLGWLTVLLVAACVLLLTSAQL 185
 QY 174 GLHIWQLRQHCMPRETQFAEVQLSAEDACSFQPPPEERGBOT-BEKCHLGGRW 227
 DB 186 GLHIWQLRSQCMWPRETQLLEVPSTEDARSCQFPPEERGSERSAEKGRLGDLW 240

RESULT 10

AAB33431
 ID AAB33431 standard; protein; 241 AA.

XX AAB33431;

29-JAN-2001 (first entry)

Human PRO364 protein UNQ319 SEQ ID NO:92.

Human; immune related disease; diagnosis; antiinflammatory; cardiant;
 dermatological; antiarthritic; antirheumatic; immunosuppressive;
 haemostatic; antithyroid; antidiabetic; nootropic; neuroprotective;
 antianaemic; hepatotropic; virucide; antipsoriatic; antiallergic;
 antiaschmatic; systemic lupus erythematosus; rheumatoid arthritis;
 osteoarthritis; spondyloarthropathy; systemic sclerosis; sarcoidosis;
 idiopathic inflammatory myopathy; Sjogren's syndrome; thyroiditis;
 systemic vasculitis; autoimmune haemolytic anaemia; diabetes mellitus;
 autoimmune thrombocytopaenia; immune-mediated renal disease;
 demyelinating disease; hepatobiliary disease; Whipple's disease;
 inflammatory bowel disease; gluten-sensitive enteropathy;
 autoimmune disease; immune-mediated skin disease; allergic disease;
 immunological disease; transplantation associated disease;
 graft rejection; graft-versus-host-disease.

XX Homo sapiens.

XX	WO200053758-A2.	CC	disease, gluten-sensitive enteropathy and Whipple's disease, autoimmune
PN		CC	or immune-mediated skin diseases, allergic diseases, immunological
PD		CC	diseases of the lung, and transplantation associated diseases including
PF	14-SEP-2000.	CC	graft rejection and graft-versus-host-disease. AAC58397 to AAC58578
PI		CC	represent PCR primers and hybridisation probes used in the isolation of
PP	02-MAR-2000; 2000WO-US005841.	CC	human PRO sequences. AAC58579 to AAC58642 and AAB33414 to AAB33477 the
XX		CC	represent human PRO polynucleotide and protein sequences given in the
XX		CC	exemplification of the present invention
XX		SQ	Sequence 241 AA;
PR	08-MAR-1999; 99WO-US005028.	Query Match	56.5%; Score 735.5; DB 3; Length 241;
PR	10-MAR-1999; 99US-0123618P.	Best Local Similarity	57.0%; Pred. No. 5.8e-60;
PR	12-MAR-1999; 99US-0123957P.	Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;	
PR	23-MAR-1999; 99US-0125775P.		
PR	12-APR-1999; 99US-0128849P.		
PR	20-APR-1999; 99WO-US008615.		
PR	28-APR-1999; 99US-0131445P.		
PR	04-MAY-1999; 99US-0132371P.		
PR	14-MAY-1999; 99US-0134287P.		
PR	02-JUN-1999; 99WO-US012252.		
PR	23-JUN-1999; 99US-0141037P.		
PR	20-JUL-1999; 99US-0144758P.		
PR	26-JUL-1999; 99US-0145698P.		
PR	28-JUL-1999; 99US-0146222P.		
PR	01-SEP-1999; 99WO-US020111.		
PR	08-SEP-1999; 99WO-US020594.		
PR	13-SEP-1999; 99WO-US020944.		
PR	15-SEP-1999; 99WO-US021090.		
PR	15-SEP-1999; 99WO-US021547.		
PR	29-OCT-1999; 99WO-US023089.		
PR	05-OCT-1999; 99US-0162506P.		
PR	29-NOV-1999; 99WO-US028214.		
PR	30-NOV-1999; 99WO-US028213.		
PR	30-NOV-1999; 99WO-US028409.		
PR	01-DEC-1999; 99WO-US028301.		
PR	01-DEC-1999; 99WO-US028634.		
PR	02-DEC-1999; 99WO-US028551.		
PR	02-DEC-1999; 99WO-US028564.		
PR	02-DEC-1999; 99WO-US028565.		
PR	16-DEC-1999; 99WO-US030095.		
PR	20-DEC-1999; 99WO-US030999.		
PR	30-DEC-1999; 99WO-US031274.		
PR	05-JAN-2000; 2000WO-US000219.		
PR	06-JAN-2000; 2000WO-US000277.		
PR	06-JAN-2000; 2000WO-US000376.		
PR	11-FEB-2000; 2000WO-US003565.		
PR	18-FEB-2000; 2000WO-US004341.		
PR	18-FEB-2000; 2000WO-US004342.		
PR	22-FEB-2000; 2000WO-US004414.		
XX			
PA	(GETH) GENENTECH INC.		
XX			
PI	Ashkenazi AJ, Baker KP, Goddard A, Gurney AL, Hebert C, Henzel W;		
PI	Kabakoff RC, Lu Y, Pan J, Pennica D, Shelton DL, Smith V;		
PI	Stewart TA, Tumas D, Watanabe CK, Wood WI, Yan M;		
XX			
XX	WPI: 2000-572271/53.		
DR	N-PSDB; AAC58596.		
XX			
PT	Sixty four PRO polypeptides, useful in the diagnosis and treatment of		
PT	immune related disorders, e.g. systemic lupus erythematosus, rheumatoid		
PT	arthritis, osteoarthritis, thyroiditis and diabetes mellitus.		
XX			
XX	Claim 33; Fig 36; 309pp; English.		
XX			
SS	The present invention describes sixty four human PRO proteins which can		
CC	be used in the treatment of immune related diseases. The human PRO		
CC	proteins, anti-PRO antibodies, agonists and antagonists are useful for		
CC	treating and diagnosing immune related disorders. The disorders are		
CC	selected from systemic lupus erythematosus, rheumatoid arthritis,		
CC	osteoarthritis, juvenile chronic arthritis, spondyloarthropathies,		
CC	systemic sclerosis, idiopathic inflammatory myopathies, Sjogren's		
CC	syndrome, systemic vasculitis, sarcoidosis, autoimmune haemolytic		
CC	anaemia, autoimmune thrombocytopaenia, thyroiditis, diabetes mellitus,		
CC	immune-mediated renal disease, demyelinating diseases of the central and		
CC	peripheral nervous systems, hepatobiliary diseases, inflammatory bowel		

```
FT Domain 163..183
FT /label= Transmembrane_domain
FT Binding-site 166..177
FT /note= "Prokaryotic membrane lipoprotein lipid attachment
FT site"
FT Region 171..193
FT /note= "Leucine zipper pattern"
XX WO200032778-A2.
XX
XX 08-JUN-2000.
XX
XX 30-NOV-1999; 99WO-US028409.
XX
XX 01-DEC-1998; 98WO-US025108.
XX 16-DEC-1998; 98US-01128508.
XX 22-DEC-1998; 98US-01132968.
XX 20-JUL-1999; 99US-0144758P.
XX 26-JUL-1999; 99US-0145698P.
XX
XX (GETH ) GENENTECH INC.
XX
XX Chen J, Goddard A, Gurney AL, Hillan K, Napier M, Wood WI;
XX WPI; 2000-412325/35.
XX N-PSDB; AAD01240.
XX
XX New composition useful for inhibiting neoplastic cell growth and for
XX treating cancers, comprises PRO655, PRO344 or PRO364 polypeptide or their
XX antagonists.
XX
XX Claim 31; Fig 4; 108pp; English.
XX
XX The present sequence is the human PRO364 protein, encoded by the cDNA
XX clone, designated as DNA47365-1206. It is isolated from human small
XX intestine tissue cDNA library, identified using probes based on the
XX consensus sequence DNA44825, relative to the Incyte expressed sequence
XX tag (EST) 3003460. This EST has homology to tumour necrosis factor
XX receptor (TNFR) family of polypeptides. PRO364 sequence also shows
XX homology to members of the TNFR family and mouse GTR protein. This clone
XX is assigned the ATCC deposit No: 209436. PRO364 functions as a neoplastic
XX cell growth inhibitor and is used for treating tumours, using an
XX effective amount of PRO655, PRO364 and PRO344. This composition is
XX especially useful for treatment of human cancers such as breast,
XX prostate, colon, lung, renal, ovarian and CNS, leukemia and melanoma
XX
XX Sequence 241 AA;
XX
XX Query Match 56.5%; Score 735.5; DB 3; Length 241;
XX Best Local Similarity 57.0%; Pred. No. 5.8e-60;
XX Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;
XX
XX QY 1 MGAWMLYGVSMLCVLDLGQPSVVEPGCGPKGVQNGSGNTRCCSLYA-----PGKE 53
XX 7 MGAFRALCGLALLCALSLGQ-RPTGGPGGPGRLLTGTGDARCCRVHTTRCCRDYPGEE 65
XX
XX QY 54 DCPKERCICVTPEYHCGDPQCKICKHYPCQQRVESQGDIVGFRFCVACAMGTFSGARD 113
XX 66 CCSEWDCMCVQBFHCGDPCCTTCRHHPCPPGGQVQSGKFSFGFCIDCASGTFSGGHE 125
XX
XX QY 114 GICRLWNTCSQSGFLTMFGNKNTHNVCIPPELPTQYGHLLTVIFLVMAACIFLTTVL 173
XX 126 GHCKPWTCTQFGFLTVFPNGKNTHNVCVPGSPPAEPLGLWLTVLLVAACVLLLTSAQL 185
XX
XX QY 174 GLHIWLRQHMCPRTQPPFAEVLQSAEDACSPFPPEERGEOT-BEKCHLGGWR 227
XX 186 GLHIWLRQHMCPRTQPPFAEVLQSAEDACSPFPPEERGEOT-BEKCHLGGWR 240
XX
XX RESULT 12
XX AAB27651
XX ID AAB27651 standard; protein; 241 AA.
XX
```

```
AC AAB27651;
XX
XX DT 26-JAN-2001 (first entry)
XX
XX DE Human protein PRO364.
XX
XX KW Cardiovascular; endothelial; angiogenic disorder; PRO179; PRO238; PRO364;
XX PRO844; PRO846; PRO1760; PRO205; PRO321; PRO333; PRO840; PRO877; PRO878;
XX PRO879; PRO882; PRO885; PRO887; gene therapy.
XX
XX OS Homo sapiens.
XX
XX FH Key Location/Qualifiers
XX Peptide 1..25
XX /label= Signal peptide
XX
XX PN WO200053757-A2.
XX
XX PD 14-SEP-2000.
XX
XX PF 24-FEB-2000; 2000WO-US005004.
XX
XX PR 08-MAR-1999; 99WO-US005028.
XX 12-MAR-1999; 99US-0123957P.
XX 02-JUN-1999; 99WO-US012252.
XX 20-JUL-1999; 99US-0144758P.
XX 26-JUL-1999; 99US-0145698P.
XX 01-SEP-1999; 99WO-US020111.
XX 15-SEP-1999; 99WO-US021090.
XX 30-NOV-1999; 99WO-US028313.
XX 02-DEC-1999; 99WO-US028409.
XX 05-JAN-2000; 2000WO-US000219.
XX 18-FEB-2000; 2000WO-US004341.
XX 22-FEB-2000; 2000WO-US004414.
XX
XX (GETH ) GENENTECH INC.
XX
XX Ashkenazi AJ, Baker KP, Ferrara N, Gerber H, Gerritsen ME;
XX Goddard A, Gurney AL, Hillan KJ, Marsters SA, Paoni NP, Pitti RM;
XX Watanabe CK, Williams PM, Wood WI;
XX WPI; 2000-611444/58.
XX N-PSDB; AAA99903.
XX
XX Novel PRO polypeptides and agonists and antagonists of them, used to
XX diagnose and treat cardiovascular, endothelial and angiogenic disorders.
XX
XX Claim 71; Fig 6; 181pp; English.
XX
XX The present invention relates to methods for stimulating or inhibiting
XX angiogenesis and cardiovascularization. The methods involve the use of
XX pharmaceutical compositions based on the following proteins, PRO179,
XX PRO238, PRO364, PRO844, PRO846, PRO1760, PRO205, PRO321, PRO333, PRO840,
XX PRO877, PRO878, PRO879, PRO882, PRO885 or PRO887. These proteins were
XX identified by isolating cDNA clones encoding secreted proteins. The
XX proteins of the invention may be used to diagnose and treat
XX cardiovascular, endothelial or angiogenic disorders. The present sequence
XX is one of the proteins of the invention
XX
XX SQ Sequence 241 AA;
XX
XX Query Match 56.5%; Score 735.5; DB 3; Length 241;
XX Best Local Similarity 57.0%; Pred. No. 5.8e-60;
XX Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;
XX
XX QY 1 MGAWMLYGVSMLCVLDLGQPSVVEPGCGPKGVQNGSGNTRCCSLYA-----PGKE 53
XX 7 MGAFRALCGLALLCALSLGQ-RPTGGPGGPGRLLTGTGDARCCRVHTTRCCRDYPGEE 65
XX
XX Db 54 DCPKERCICVTPEYHCGDPQCKICKHYPCQQRVESQGDIVGFRFCVACAMGTFSGARD 113
XX
XX QY 54 DCPKERCICVTPEYHCGDPQCKICKHYPCQQRVESQGDIVGFRFCVACAMGTFSGARD 113
```

Db 66 CCSEWDMCVQPEFHCGDPCCTTCRHHPCPPGQGVQSGKFSFGQCIDCASGTFSGGHE 125

QY 114 GHCRLLWNTCSQFGLTMFPGNKNTHNAVCIPPELPTQYGHLLTVIFLVMAACIFFLTTVOL 173

Db 126 GHCKPMTDCTQFGFLTVFPGNKNTHNAVCVPGSPAPLGLWLTVLLAVAAACVLLLTSAQL 185

QY 174 GLHIWOLRRQHMCPRTPQPPFAEVQLSAEDACSFQFPPEERGEQT-BEKCHLGGRW 227

Db 186 GLHIWOLRRSQMWPRTPQLLLVPPSTEDARSQFPPEERGERSAEKGRLGLDW 240

RESULT 13

AA95895

ID AAY95895 standard; protein; 241 AA.

AC AAY95895;

XX 20-NOV-2000 (first entry)

DE Human tumour necrosis factor receptor-like protein TR11 mutein.

XX TR11; human; tumour necrosis factor receptor-like protein; immunodeficiency; autoimmune disease; rheumatoid arthritis; immunosuppressive; antirheumatic; antiarthritic; haemostatic; dermatological; antiinflammatory; therapy; diagnosis; mutein; mutant.

XX Homo sapiens.

XX WO200050459-A1.

XX 31-AUG-2000.

XX 23-FEB-2000; 2000WO-US004572.

XX 24-FEB-1999; 99US-0121648P.

XX 13-MAY-1999; 99US-0134172P.

XX 16-JUL-1999; 99US-0144076P.

XX (HUMA-) HUMAN GENOME SCI INC.

PA Ruben SM, Ni J;

PI WPI; 2000-572072/53.

DR Human tumor necrosis factor receptor-like proteins useful for diagnosis, prevention and treatment of disease states associated with aberrant cell survival such as autoimmune disease and rheumatoid arthritis.

PT Disclosure; 294-295; 278pp; English.

XX The present sequence is that of human tumour necrosis factor receptor-like protein TR11 (see also AAY95879), a novel protein showing identity to murine glucocorticoid induced tumour necrosis factor receptor family-related gene. The invention provides highly conserved TR11, TR11SV1 and TR11SV2 proteins (see AAY95879-81), as well as vectors, host cells and recombinant methods for their production. TR11, TR11SV1 and/or TR11SV2 polypeptides are useful for treating, preventing, prognosis and/or diagnosis of an immunodeficiency, especially common variable immunodeficiency, X-linked agammaglobulinemia, severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome or X-linked immunoglobulin deficiency with hyper IgM. TR11, TR11SV1 and/or TR11SV2 antagonists (e.g. antibodies) are used to treat, prevent, prognosis and/or diagnose an autoimmune disease, especially rheumatoid arthritis, systemic lupus erythematosus, thrombocytopenia purpura or IgA nephropathy. The polypeptides, polynucleotides and/or antibodies can be administered to cells in vitro, ex vivo or in vivo or to a multicellular organism.

CC Soluble forms of the polypeptides may also be used. Methods for screening for agonist/antagonist compounds are also provided

XX Sequence 241 AA;

Query Match 56.5%; Score 735.5; DB 3; Length 241;

Best Local Similarity 57.0%; Pred. No. 5.8e-60;

Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;

QY 1 MCAWAMLYGVSMCLVDLQGPSVVEEPGCGKVGKQNGNTRCCSLYA-----PGKE 53

Db 7 MCAFRALCGIALCALSLGQ-RPTGGPGCGPRLLLGTGTDAACCRVHTTRCCRDYFGE 65

QY 54 DCPKERCICVTPPEYHCGDPQCKIKRHYPCQPGQGVQSGKFSFGQCIDCASGTFSGGHE 113

Db 66 CCSEWDMCVQPEFHCGDPCCTTCRHHPCPPGQGVQSGKFSFGQCIDCASGTFSGGHE 125

QY 114 GHCRLLWNTCSQFGLTMFPGNKNTHNAVCIPPELPTQYGHLLTVIFLVMAACIFFLTTVOL 173

Db 126 GHCKPMTDCTQFGFLTVFPGNKNTHNAVCVPGSPAPLGLWLTVLLAVAAACVLLLTSAQL 185

QY 174 GLHIWOLRRQHMCPRTPQPPFAEVQLSAEDACSFQFPPEERGEQT-BEKCHLGGRW 227

Db 186 GLHIWOLRRSQMWPRTPQLLLVPPSTEDARSQFPPEERGERSAEKGRLGLDW 240

RESULT 14

AAB24409

ID AAB24409 standard; protein; 241 AA.

XX AAB24409;

XX 07-NOV-2000 (first entry)

XX Human PRO364 protein sequence SEQ ID NO:117.

DE Human; PRO; promotion; inhibition; angiogenesis; cardiovascularisation; diagnosis; trauma; wound; cancer; atherosclerosis; cardiac hypertrophy; angiogenic; proliferative; cardiant; cardiovascular; antiatherosclerotic; cytostatic; gene therapy; vaccine.

XX Homo sapiens.

XX WO200032221-A2.

XX 08-JUN-2000.

XX 30-NOV-1999; 99WO-US028313.

XX 01-DEC-1998; 98WO-US025108.

XX 16-DEC-1998; 98US-0112850P.

XX 12-JAN-1999; 99US-0115554P.

XX 08-MAR-1999; 99WO-US005028.

XX 12-MAR-1999; 99US-0123357P.

XX 28-APR-1999; 99US-0131445P.

XX 14-MAY-1999; 99US-0134287P.

XX 02-JUN-1999; 99WO-US012252.

XX 23-JUN-1999; 99US-0141037P.

XX 20-JUL-1999; 99US-0144758P.

XX 26-JUL-1999; 99WO-US025698P.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 05-OCT-1999; 99WO-US023089.

XX 29-OCT-1999; 99US-0162506P.

(GETH) GENENTECH INC.

XX Ashkenazi AJ, Baker KP, Ferrara N, Gerber H, Hillan KJ;

PI Goddard A, Godowski FJ, Gurney AL, Klein RD, Kuo SS, Paoni NF;

PI Smith V, Watanabe CK, Williams PM, Wood WI;

XX WPI; 2000-412154/35.

DR N-PSDB; AAA77604.

XX Nucleic acids encoding PRO polypeptides useful for preventing, diagnosing and treating diagnosing a cardiovascular, endothelial or angiogenic disorders in mammals.

XX PS Claim 72; Fig 44; 315pp; English.

XX CC The present invention describes nucleic acids encoding PRO polypeptides

XX CC useful for preventing, diagnosing and treating atherosclerosis,

XX CC cardiovascular, endothelial or angiogenic disorder in mammals by

XX CC modulating cell proliferation, angiogenesis and cardiovascularization,

XX CC and for identifying agonists and antagonists of these processes. The

XX CC nucleic acids and the proteins they encode may be used in the prevention,

XX CC treatment and diagnosis of diseases associated with inappropriate PRO

XX CC expression such as cardiovascular, endothelial or angiogenic disorders in

XX CC mammals (e.g. atherosclerosis, cancers and cardiac hypertrophy). For

XX CC example, the nucleic acids (NCs) and vectors containing them and the PRO

XX CC polypeptide may be used to treat disorders associated with decreased PRO

XX CC expression. AAA77510 to AAA77721 and AAB24388 to AAB24435 represent

XX CC nucleotide and protein sequences used in the exemplification of the

XX CC present invention

XX SQ Sequence 241 AA;

Query Match 56.5%; Score 735.5; DB 3; Length 241;

Best Local Similarity 57.0%; Pred. No. 5.8e-60;

Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;

QY 1 MGAWMLYGVSMCLVLDLQPSVVEEPGCGKQVQSGNNTCCSLYA-----PGKE 53

DB 7 MGAFRALCGLALLCALSLGQ-RPTGGPGCGPGRLLGTGTDAACRCHVHTTCCRDYPGEE 65

QY 54 DCPKERCICVTPYHCGDPQCKIKHYPCQGORVESQGDIVGFRVCACAMGTFSGARD 113

DB 66 CSEWDCMVCQVEFFHCGDPCCTTCHHPCPPGQGVQSKFSGFCIDCASGTFSGGHE 125

QY 114 GHCLRWNTCSQFGFLTFMFGNKNTHNAVCIPEPLTEQYGHLLTVIFLVMAACIFFLTTVOL 173

DB 126 GHCKPWTDTCTQFGFLTVFPGNKNTHNAVCPGSPPAEPLGLWTLVLLAAVACVLLLTSAQL 185

QY 174 GLHIWQLRQHMCPRETQFFAEVQLSABDACSFPPEERGGQT-EEKCHLGGRW 227

DB 186 GLHIWQLRSQCMWPRETQLLLEVPPTEDARSQCFPEERGGERSABEKGRLGDLW 240

RESULT 15

AAB47054

ID AAB47054 standard; protein; 241 AA.

XX AAB47054;

XX DT 08-MAY-2001 (first entry)

XX DE Human PRO364.

XX KW PRO364; human; glucocorticoid-induced tumor necrosis factor; receptor;

XX KW hGTR; ligand; hGTR; PRO175; tumour necrosis factor receptor; TNFR;

XX KW human umbilical vein endothelial cell; HUVEC; cardiac hypertrophy;

XX KW myocardial infarction; PGP_2alpha; trauma; cancer; angiogenesis;

XX KW age-related macular degeneration; antibody; periodontal disease;

XX KW vascular-related drug targeting; atherosclerosis; hypertension;

XX KW inflammatory vasculitides; Reynaud's disease; aneurysm;

XX KW arterial restenosis; thrombophlebitis; tumor angiogenesis; lung; liver;

XX KW fibrosis; neuropathy; rheumatoid arthritis.

XX OS Homo sapiens.

XX FH Key

XX FT Peptide 1..26 Location/Qualifiers

FT /note= "Potential signal peptide"

FT Modified-site 146

FT Domain 162..180 /note= "N-glycosylated"

FT /note= "Potential transmembrane domain"

XX WO200103720-A2.

PD 18-JAN-2001.

XX 11-JUL-2000; 2000MO-US018867.

XX 12-JUL-1999; 99US-0143304P.

XX (GETH) GENENTECH INC.

XX Williams PM, Gerritsen ME;

XX WPI; 2001-138257/14.

XX N-PSDB; AAC85433.

XX Composition for diagnosing and treating cardiovascular, endothelial and

XX angiogenic disorders, comprises a PRO364 or PRO175 polypeptide.

XX Claim 1; Fig 1; 76pp; English.

XX This sequence represents PRO364 polypeptide, which is a human gluco-

XX corticoid-induced tumor necrosis factor receptor (hGTR). The

XX corresponding ligand (hGTR), PRO175, is given in AAB47056. PRO364 and

XX PRO175 may be used in a mixture with a cardiovascular, endothelial,

XX angiogenic or angiostatic agent for the treatment of a cardiovascular,

XX endothelial, angiogenic or angiostatic disorder. The PRO364 cDNA sequence

XX was isolated from an expressed sequence tag (EST) database as having

XX homology to members of the tumor necrosis factor receptor (TNFR) family

XX of polypeptides. The PRO175 cDNA sequence was isolated from a library of

XX cDNA fragments derived from human umbilical vein endothelial cells

XX (HUVEC). Administering an effective amount of PRO364 or PRO175 or their

XX antagonists is useful for treating cardiac hypertrophy (which is

XX initiated by myocardial infarction and characterized by the presence of

XX an elevated level of PGP_2alpha), trauma, a cancer, or age-related

XX macular degeneration in a human. Administering a therapeutically

XX effective amount of an antibody that binds PRO364 or PRO175 is useful for

XX inhibiting angiogenesis induced by PRO364 or PRO175 in a human suffering

XX from a tumor or a retinal disorder. PRO364 or PRO175, or their

XX antagonists, are useful for vascular-related drug targeting or as

XX therapeutic targets for the treatment or prevention of atherosclerosis,

XX hypertension, inflammatory vasculitides, Reynaud's disease, aneurysms,

XX arterial restenosis, thrombophlebitis, tumor angiogenesis, gut protection

XX or regeneration and treatment of lung or liver fibrosis, periodontal

XX diseases, attraction of bone-forming cells, central and peripheral

XX nervous system disease and neuropathies and rheumatoid arthritis

XX SQ Sequence 241 AA;

Query Match 56.5%; Score 735.5; DB 4; Length 241;

Best Local Similarity 57.0%; Pred. No. 5.8e-60;

Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;

QY 1 MGAWMLYGVSMCLVLDLQPSVVEEPGCGKQVQSGNNTCCSLYA-----PGKE 53

DB 7 MGAFRALCGLALLCALSLGQ-RPTGGPGCGPGRLLGTGTDAACRCHVHTTCCRDYPGEE 65

QY 54 DCPKERCICVTPYHCGDPQCKIKHYPCQGORVESQGDIVGFRVCACAMGTFSGARD 113

DB 66 CSEWDCMVCQVEFFHCGDPCCTTCHHPCPPGQGVQSKFSGFCIDCASGTFSGGHE 125

QY 114 GHCLRWNTCSQFGFLTFMFGNKNTHNAVCIPEPLTEQYGHLLTVIFLVMAACIFFLTTVOL 173

DB 126 GHCKPWTDTCTQFGFLTVFPGNKNTHNAVCPGSPPAEPLGLWTLVLLAAVACVLLLTSAQL 185

QY 174 GLHIWQLRQHMCPRETQFFAEVQLSABDACSFPPEERGGQT-EEKCHLGGRW 227

DB 186 GLHIWQLRSQCMWPRETQLLLEVPPTEDARSQCFPEERGGERSABEKGRLGDLW 240

Search completed: October 26, 2005, 15:47:39

Job time : 140.689 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 26, 2005, 15:40:08 ; Search time 28.6823 Seconds
(without alignments)
593.397 Million cell updates/sec

Title: US-09-545-998B-2
Perfect score: 1301
Sequence: 1 MGAWAWLVGVSMCLVDLQ.....PEERGEQTEKCHLGRWP 228

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA:*
1: /cgn2_6/prodata/1/iaa/5A COMB.pep.*
2: /cgn2_6/prodata/1/iaa/5B COMB.pep.*
3: /cgn2_6/prodata/1/iaa/6A COMB.pep.*
4: /cgn2_6/prodata/1/iaa/6B COMB.pep.*
5: /cgn2_6/prodata/1/iaa/6C COMB.pep.*
6: /cgn2_6/prodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1301	100.0	228	3	US-08-911-423-2
2	1301	100.0	228	4	US-09-512-363-7
3	1301	100.0	228	4	US-09-176-200-7
4	1301	100.0	228	4	US-09-915-593-7
5	735.5	56.5	241	3	US-08-911-423-4
6	735.5	56.5	241	4	US-09-512-363-28
7	735.5	56.5	241	4	US-09-915-593-28
8	735.5	56.5	241	4	US-09-949-016-7232
9	703	54.0	228	3	US-08-911-423-6
10	703	54.0	234	4	US-09-512-363-2
11	703	54.0	234	4	US-09-176-200-2
12	703	54.0	234	4	US-09-915-593-2
13	697	53.6	240	4	US-09-512-363-6
14	697	53.6	240	4	US-09-176-200-6
15	697	53.6	240	4	US-09-915-593-6
16	632.5	48.6	311	3	US-08-911-423-8
17	630.5	48.5	241	4	US-09-512-363-4
18	630.5	48.5	241	4	US-09-176-200-4
19	630.5	48.5	241	4	US-09-915-593-4
20	518	39.8	89	3	US-09-188-930-191
21	518	39.8	89	4	US-09-312-283C-191
22	287	22.1	232	3	US-08-911-423-7
23	228.5	17.6	255	1	US-08-236-918A-8
24	228.5	17.6	255	2	US-08-816-605-9
25	228.5	17.6	255	3	US-09-006-353A-11
26	228.5	17.6	255	3	US-09-007-097-2
27	228.5	17.6	255	3	US-09-150-864A-8

28	228.5	17.6	255	4	US-09-573-986-11	Sequence 11, Appl
29	228.5	17.6	255	4	US-09-578-764A-2	Sequence 2, Appl
30	228.5	17.6	255	4	US-09-623-545A-2	Sequence 2, Appl
31	228.5	17.6	255	5	PCT-US96-03965-8	Sequence 8, Appl
32	228.5	17.6	272	4	US-09-949-016-7520	Sequence 7520, Ap
33	222.5	17.1	219	2	US-08-816-605-2	Sequence 2, Appl
34	203.5	15.6	256	1	US-08-236-918A-6	Sequence 6, Appl
35	203.5	15.6	256	3	US-09-150-864A-6	Sequence 2, Appl
36	203.5	15.6	256	3	US-08-012-269A-2	Sequence 3, Appl
37	203.5	15.6	256	4	US-09-623-545A-3	Sequence 2, Appl
38	203.5	15.6	256	5	PCT-US96-03965-2	Sequence 2, Appl
39	162	12.5	191	3	US-08-974-022-52	Sequence 52, Appl
40	162	12.5	191	3	US-08-795-445A-52	Sequence 52, Appl
41	162	12.5	191	3	US-08-795-447A-52	Sequence 52, Appl
42	162	12.5	191	3	US-08-974-186-52	Sequence 52, Appl
43	162	12.5	191	3	US-08-795-446B-52	Sequence 52, Appl
44	162	12.5	191	3	US-08-706-945D-139	Sequence 139, App
45	162	12.5	191	4	US-08-577-788C-53	Sequence 53, Appl

ALIGNMENTS

RESULT 1
US-08-911-423-2
; Sequence 2, Application US/08911423
; Patent No. 6111090
; GENERAL INFORMATION:
; APPLICANT: Gorman, Daniel M.
; APPLICANT: Randall, Troy D.
; APPLICANT: Zlotnik, Albert
; TITLE OF INVENTION: MAMMALIAN CELL SURFACE ANTIGENS; RELATED
; TITLE OF INVENTION: REAGENTS
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESS: DNAX Research Institute
; STREET: 901 California Avenue
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94304-1104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/911,423
; FILING DATE: 14-AUG-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/023,419
; FILING DATE: 16-AUG-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/027,901
; FILING DATE: 07-OCT-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Ching, Edwin P.
; REGISTRATION NUMBER: 34,090
; REFERENCE/DOCKET NUMBER: DX0612K
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-852-9196
; TELEFAX: 650-496-1200
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 228 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-911-423-2
Query Match 100.0%; Score 1301; DB 3; Length 228;
Best Local Similarity 100.0%; Pred. No. 1.8e-121;

Query Match 100.0%; Score 1301; DB 4; Length 228;
Best Local Similarity 100.0%; Pred. No. 1.8e-121;
Matches 228; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGAWAMLYGVSMCLVLDLQGPSVVEPFGCGPKGVQSGNTRCCSLYA-60
DB 1 MGAWAMLYGVSMCLVLDLQGPSVVEPFGCGPKGVQSGNTRCCSLYA-60

QY 61 ICVTPEYHCGDPOCKICKHYPCQPGQORVESQSDIVFGFRVCACAMGTFSAGRDCHRLWT 120
DB 61 ICVTPEYHCGDPOCKICKHYPCQPGQORVESQSDIVFGFRVCACAMGTFSAGRDCHRLWT 120

QY 121 NCSQFGLTWFPGNKTTHNAVCIPEPLTPEYQYGHLTVIFLVMAACIFFLTTVQLGLHIWOL 180
DB 121 NCSQFGLTWFPGNKTTHNAVCIPEPLTPEYQYGHLTVIFLVMAACIFFLTTVQLGLHIWOL 180

QY 181 RROHMCPRPTQPPAEVOLSAEDACSFQFPPEERGEQTEKCHLGGWRP 228
DB 181 RROHMCPRPTQPPAEVOLSAEDACSFQFPPEERGEQTEKCHLGGWRP 228

RESULT 5
US-08-911-423-4
; Sequence 4, Application US/08911423
; Patent No. 611090
; GENERAL INFORMATION:
; APPLICANT: Gorman, Daniel M.
; APPLICANT: Randall, Troy D.
; APPLICANT: Zlotnik, Albert
; TITLE OF INVENTION: MAMMALIAN CELL SURFACE ANTIGENS; RELATED
; TITLE OF INVENTION: REAGENTS
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DNAX Research Institute
; STREET: 901 California Avenue
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94304-1104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/911,423
; FILING DATE: 14-AUG-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/023,419
; FILING DATE: 16-AUG-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/027,901
; FILING DATE: 07-OCT-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Ching, Edwin P.
; REGISTRATION NUMBER: 34,090
; REFERENCE/DOCKET NUMBER: DX0612K
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-852-9196
; TELEFAX: 650-496-1200
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 241 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-911-423-4

Query Match 56.5%; Score 735.5; DB 3; Length 241;
Best Local Similarity 57.0%; Pred. No. 3.1e-65;
Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;

QY 1 MGAWAMLYGVSMCLVLDLQGPSVVEPFGCGPKGVQSGNTRCCSLYA-----PGKE 53
DB 7 MGAFRALCGLALLCALSLGQ-RPTGGPGCGPRLLLGTGTDAACRVRHTTRCCRDYPGEE 65

QY 54 DCPKERCICVTPEYHCGDPOCKICKHYPCQPGQORVESQSDIVFGFRVCACAMGTFSAGRD 113
DB 66 CCSEWDCMCVQPFHCGDPCCTTCRHHPCPPQGVQSGKFSFGFCIDCASGTTFSGGHE 125

QY 114 GHCLRLWNTNCSQFGLTWFPGNKTTHNAVCIPEPLTPEYQYGHLTVIFLVMAACIFFLTTVQL 173
DB 126 GHCKPWTDCQTFGLTVFPGNKTTHNAVCPGSPPAEPLGLWLTVLLVAVACVLLLTSAQL 185

QY 174 GLHIWQLRRQHMCPRPTQPPAEVOLSAEDACSFQFPPEERGEQT-EKCHLGGWR 227
DB 186 GLHIWQLRRQHMCPRPTQPPAEVOLSAEDACSFQFPPEERGEQT-EKCHLGGWR 240

RESULT 6
US-09-512-363-28
; Sequence 28, Application US/09512363
; Patent No. 6503184
; GENERAL INFORMATION:
; APPLICANT: N1, Jian
; APPLICANT: Ruben, Steven M.
; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins
; TITLE OF INVENTION: TR11, TR11SV1, and TR11SV2
; FILE REFERENCE: PF396
; CURRENT APPLICATION NUMBER: US/09/512,363
; CURRENT FILING DATE: 2000-02-23
; EARLIER APPLICATION NUMBER: 60/063,212
; EARLIER FILING DATE: 1997-10-21
; EARLIER APPLICATION NUMBER: 09/176,200
; EARLIER FILING DATE: 1998-10-21
; EARLIER APPLICATION NUMBER: 60/121,648
; EARLIER FILING DATE: 1999-02-24
; EARLIER APPLICATION NUMBER: 60/134,172
; EARLIER FILING DATE: 1999-05-13
; EARLIER APPLICATION NUMBER: 60/144,076
; EARLIER FILING DATE: 1999-07-16
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 28
; LENGTH: 241
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-512-363-28

Query Match 56.5%; Score 735.5; DB 4; Length 241;
Best Local Similarity 57.0%; Pred. No. 3.1e-65;
Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;

QY 1 MGAWAMLYGVSMCLVLDLQGPSVVEPFGCGPKGVQSGNTRCCSLYA-----PGKE 53
DB 7 MGAFRALCGLALLCALSLGQ-RPTGGPGCGPRLLLGTGTDAACRVRHTTRCCRDYPGEE 65

QY 54 DCPKERCICVTPEYHCGDPOCKICKHYPCQPGQORVESQSDIVFGFRVCACAMGTFSAGRD 113
DB 66 CCSEWDCMCVQPFHCGDPCCTTCRHHPCPPQGVQSGKFSFGFCIDCASGTTFSGGHE 125

QY 114 GHCLRLWNTNCSQFGLTWFPGNKTTHNAVCIPEPLTPEYQYGHLTVIFLVMAACIFFLTTVQL 173
DB 126 GHCKPWTDCQTFGLTVFPGNKTTHNAVCPGSPPAEPLGLWLTVLLVAVACVLLLTSAQL 185

QY 174 GLHIWQLRRQHMCPRPTQPPAEVOLSAEDACSFQFPPEERGEQT-EKCHLGGWR 227
DB 186 GLHIWQLRRQHMCPRPTQPPAEVOLSAEDACSFQFPPEERGEQT-EKCHLGGWR 240

RESULT 7
US-09-915-593-28
; Sequence 28, Application US/09915593
; Patent No. 6689607

```
; GENERAL INFORMATION:
; APPLICANT: Ni, Jian
; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins
; TITLE OF INVENTION: Tr11, Tr11sV1, and Tr11sV2
; FILE REFERENCE: PF396P2
; CURRENT APPLICATION NUMBER: US/09/915,593
; CURRENT FILING DATE: 2001-07-27
; PRIOR APPLICATION NUMBER: 60/221,577
; PRIOR FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: 09/512,363
; PRIOR FILING DATE: 2000-02-23
; PRIOR APPLICATION NUMBER: 60/144,076
; PRIOR FILING DATE: 2000-07-16
; PRIOR APPLICATION NUMBER: 60/134,172
; PRIOR FILING DATE: 1999-05-13
; PRIOR APPLICATION NUMBER: 60/121,648
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 09/176,200
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/063,212
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 28
; LENGTH: 241
; TYPE: PRT
; ORGANISM: Homo sapiens
; ORGANISM: Homo sapiens
US-09-915-593-28

Query Match      56.5%; Score 735.5; DB 4; Length 241;
Best Local Similarity 57.0%; Pred. No. 3.1e-65;
Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;

QY 1 MGAWAMLYGVSMILCVLDLQPSVVEPQCGKVGKQVSGNNTCCSLYA-----PGKE 53
Db 7 MGAFRALCGLALLCALSLGQ-RPTGGPGCGPGRLLLTGTDAKCRVHTTCCRDYPGEE 65

QY 54 DCPKERCICVTPEYHCGDPQCKICKHYPCQPGQORVESQGDIVFGPRCVACAMGTFSAGRD 113
Db 66 CCSEWDNCVQPEFHCGDPCCTTCHHPCPPGQVQSGKSFQGCIDCASGTFSGGHE 125

QY 114 GHCLWNTCSQGFGLTMPPGNKTHNAVCIPEPLPTEQYGHILTVIFLVMAACIFFLTTVOL 173
Db 126 GHCKPWTDTCTQGFGLTVFPNGKTHNAVCPGSPPAEPLGLWLTVLLVAACVLLLTSAQL 185

QY 174 GLHIWLRQHCMPRETQPPFAEVQLSAEDACSFQFPPEERGEQT-EKCHLGGRW 227
Db 186 GLHIWQLRSQCMWPRETQLLLEVPPTEDARSQCFPEERGERSAEKGRLGDLW 240

RESULT 8
US-09-949-016-7232
; Sequence 7232 Application US/09949016
; Patent No. 6812339
; GENERAL INFORMATION:
; APPLICANT: VENTER, J. Craig et al.
; TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
; TITLE OF INVENTION: WITH HUMAN DISEASE, METHODS OF DETECTION AND USES THEREOF
; FILE REFERENCE: CL001307
; CURRENT APPLICATION NUMBER: US/09/949,016
; CURRENT FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/241,755
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/237,768
; PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: 60/231,498
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 207012
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7232
; LENGTH: 241
; TYPE: PRT
```

```
; ORGANISM: Human
US-09-949-016-7232

Query Match      56.5%; Score 735.5; DB 4; Length 241;
Best Local Similarity 57.0%; Pred. No. 3.1e-65;
Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;

QY 1 MGAWAMLYGVSMILCVLDLQPSVVEPQCGKVGKQVSGNNTCCSLYA-----PGKE 53
Db 7 MGAFRALCGLALLCALSLGQ-RPTGGPGCGPGRLLLTGTDAKCRVHTTCCRDYPGEE 65

QY 54 DCPKERCICVTPEYHCGDPQCKICKHYPCQPGQORVESQGDIVFGPRCVACAMGTFSAGRD 113
Db 66 CCSEWDNCVQPEFHCGDPCCTTCHHPCPPGQVQSGKSFQGCIDCASGTFSGGHE 125

QY 114 GHCLWNTCSQGFGLTMPPGNKTHNAVCIPEPLPTEQYGHILTVIFLVMAACIFFLTTVOL 173
Db 126 GHCKPWTDTCTQGFGLTVFPNGKTHNAVCPGSPPAEPLGLWLTVLLVAACVLLLTSAQL 185

QY 174 GLHIWLRQHCMPRETQPPFAEVQLSAEDACSFQFPPEERGEQT-EKCHLGGRW 227
Db 186 GLHIWQLRSQCMWPRETQLLLEVPPTEDARSQCFPEERGERSAEKGRLGDLW 240

RESULT 9
US-08-911-423-6
; Sequence 6, Application US/08911423
; Patent No. 6111090
; GENERAL INFORMATION:
; APPLICANT: Gorman, Daniel M.
; APPLICANT: Randall, Troy D.
; APPLICANT: Zlotnik, Albert
; TITLE OF INVENTION: MAMMALIAN CELL SURFACE ANTIGENS; RELATED
; TITLE OF INVENTION: REAGENTS
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESS: DNAX Research Institute
; STREET: 901 California Avenue
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94304-1104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/911,423
; FILING DATE: 14-AUG-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/023,419
; FILING DATE: 16-AUG-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/027,901
; FILING DATE: 07-OCT-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Ching, Edwin P.
; REGISTRATION NUMBER: 34,090
; REFERENCE/DOCKET NUMBER: DX0612K
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-852-9196
; TELEFAX: 650-496-1200
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 228 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-911-423-6
```



```
; ORGANISM: Homo sapiens
US-09-915-593-2

Query Match      54.0%; Score 703; DB 4; Length 234;
Best Local Similarity 54.9%; Pred. No. 5.2e-62;
Matches 129; Conservative 32; Mismatches 58; Indels 16; Gaps 4;

QY 1 MGAWMLYGVSMCLVLDLGQPSVVEEPCGPGKQVQSGNNTRCCSLYA-----PKGE 53
Db 7 MGAFRALCGLALLCALSLGQ-RPTGGPGCGPGRLLLTGTDCRCRVTTRCCRDYPAQL 65

QY 54 DCPKERCICVTPEYHCGDPQCKICKHYPCQQRVESQGDIVFGPRCVCAMGTFESAGRD 113
Db 66 CCSEWDCMCVQPEFHCGDPCCTCRHHPCCPGQVQSGKFSFGQDCASGTFSGGHE 125

QY 114 GRCRLWTNCSQSGFGLTMFPGNKTHNAVCIPEPLTEQYGHILTVIFLWMAACIFFLTTVQL 173
Db 126 GHCKPWTCTQGFGLTVFPGKTHNAVCPVPGSPPAEPLGLWLTIVLLAVACVLLTSAQL 185

QY 174 GLHIWQLRRQHMCPRETQPPFAEVQLSAEDACSFQPFEEERGEOT-EEKCHLGRW 227
Db 186 GLHIWQLRK-----TQLLEVPSTEDARSCQPFEEERGEERSAEKGRGLDLW 233

RESULT 13
US-09-512-363-6
; Sequence 6, Application US/09512363
; Patent No. 6503184
; GENERAL INFORMATION:
; APPLICANT: Ni, Jian
; APPLICANT: Ruben, Steven M.
; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins
; FILE REFERENCE: PF396
; CURRENT APPLICATION NUMBER: US/09/512,363
; EARLIER FILING DATE: 2000-02-23
; EARLIER FILING DATE: 1997-10-21
; EARLIER FILING DATE: 1998-10-21
; EARLIER FILING DATE: 1999-02-24
; EARLIER FILING DATE: 1999-05-13
; EARLIER FILING DATE: 1999-07-16
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 6
; LENGTH: 240
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-512-363-6

Query Match      53.6%; Score 697; DB 4; Length 240;
Best Local Similarity 52.2%; Pred. No. 2.1e-61;
Matches 129; Conservative 32; Mismatches 58; Indels 28; Gaps 4;

QY 1 MGAWMLYGVSMCLVLDLGQPSVVEEPCGPGKQVQSGNNTRCCSLY----- 48
Db 1 MGAFRALCGLALLCALSLGQ-RPTGGPGCGPGRLLLTGTDCRCRVTTRCCRDYPAQL 59

QY 49 -----APGEDCPKERCICVTPEYHCGDPQCKICKHYPCQQRVESQGDIVFGRCV 101
Db 60 LGMPVSPCGECCSEWDCMCVQPEFHCGDPCCTCRHHPCCPGQVQSGKFSFGQCI 119

QY 102 ACAMGTFPSAGRGHCLWNTCSQGFGLTMFPGNKTHNAVCIPEPLTEQYGHILTVIFLW 161
Db 120 DCASGTFSGGHEGCKPWTCTQGFGLTVFPGKTHNAVCPVPGSPPAEPLGLWLTIVLLAV 179

QY 162 AACIFFLTTVOLGLHIWQLRRQHMCPRETQPPFAEVQLSAEDACSFQPFEEERGEOT-EEK 220
Db 180 AACVLLTSAQLGLHIWQLRK-----TQLLEVPSTEDARSCQPFEEERGEERSAEK 232

RESULT 14
US-09-176-200-6
; Sequence 6, Application US/09176200
; Patent No. 6509173
; GENERAL INFORMATION:
; APPLICANT: Ni, Jian
; APPLICANT: Ruben, Steven M.
; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins
; FILE REFERENCE: PF396
; CURRENT APPLICATION NUMBER: US/09/176,200
; EARLIER FILING DATE: 1998-10-21
; EARLIER APPLICATION NUMBER: 60/063,212
; EARLIER FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 6
; LENGTH: 240
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-176-200-6

Query Match      53.6%; Score 697; DB 4; Length 240;
Best Local Similarity 52.2%; Pred. No. 2.1e-61;
Matches 129; Conservative 32; Mismatches 58; Indels 28; Gaps 4;

QY 1 MGAWMLYGVSMCLVLDLGQPSVVEEPCGPGKQVQSGNNTRCCSLY----- 48
Db 1 MGAFRALCGLALLCALSLGQ-RPTGGPGCGPGRLLLTGTDCRCRVTTRCCRDYPAQL 59

QY 49 -----APGEDCPKERCICVTPEYHCGDPQCKICKHYPCQQRVESQGDIVFGRCV 101
Db 60 LGMPVSPCGECCSEWDCMCVQPEFHCGDPCCTCRHHPCCPGQVQSGKFSFGQCI 119

QY 102 ACAMGTFPSAGRGHCLWNTCSQGFGLTMFPGNKTHNAVCIPEPLTEQYGHILTVIFLW 161
Db 120 DCASGTFSGGHEGCKPWTCTQGFGLTVFPGKTHNAVCPVPGSPPAEPLGLWLTIVLLAV 179

QY 162 AACIFFLTTVOLGLHIWQLRRQHMCPRETQPPFAEVQLSAEDACSFQPFEEERGEOT-EEK 220
Db 180 AACVLLTSAQLGLHIWQLRK-----TQLLEVPSTEDARSCQPFEEERGEERSAEK 232

RESULT 15
US-09-915-593-6
; Sequence 6, Application US/09915593
; Patent No. 6689607
; GENERAL INFORMATION:
; APPLICANT: Ni, Jian
; APPLICANT: Ruben, Steven M.
; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins
; FILE REFERENCE: PF396P2
; CURRENT APPLICATION NUMBER: US/09/915,593
; CURRENT FILING DATE: 2001-07-27
; PRIOR APPLICATION NUMBER: 60/221,577
; PRIOR FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: 09/512,363
; PRIOR FILING DATE: 2000-02-23
; PRIOR APPLICATION NUMBER: 60/144,076
; PRIOR FILING DATE: 2000-07-16
; PRIOR APPLICATION NUMBER: 60/134,172
; PRIOR FILING DATE: 1999-05-13
```

```
; ORGANISM: Homo sapiens
US-09-915-593-2

Query Match      54.0%; Score 703; DB 4; Length 234;
Best Local Similarity 54.9%; Pred. No. 5.2e-62;
Matches 129; Conservative 32; Mismatches 58; Indels 16; Gaps 4;

QY 1 MGAWMLYGVSMCLVLDLGQPSVVEEPCGPGKQVQSGNNTRCCSLYA-----PKGE 53
Db 7 MGAFRALCGLALLCALSLGQ-RPTGGPGCGPGRLLLTGTDCRCRVTTRCCRDYPAQL 65

QY 54 DCPKERCICVTPEYHCGDPQCKICKHYPCQQRVESQGDIVFGPRCVCAMGTFESAGRD 113
Db 66 CCSEWDCMCVQPEFHCGDPCCTCRHHPCCPGQVQSGKFSFGQDCASGTFSGGHE 125

QY 114 GRCRLWTNCSQSGFGLTMFPGNKTHNAVCIPEPLTEQYGHILTVIFLWMAACIFFLTTVQL 173
Db 126 GHCKPWTCTQGFGLTVFPGKTHNAVCPVPGSPPAEPLGLWLTIVLLAVACVLLTSAQL 185

QY 174 GLHIWQLRRQHMCPRETQPPFAEVQLSAEDACSFQPFEEERGEOT-EEKCHLGRW 227
Db 186 GLHIWQLRK-----TQLLEVPSTEDARSCQPFEEERGEERSAEKGRGLDLW 233

RESULT 13
US-09-512-363-6
; Sequence 6, Application US/09512363
; Patent No. 6503184
; GENERAL INFORMATION:
; APPLICANT: Ni, Jian
; APPLICANT: Ruben, Steven M.
; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins
; FILE REFERENCE: PF396
; CURRENT APPLICATION NUMBER: US/09/512,363
; EARLIER FILING DATE: 2000-02-23
; EARLIER FILING DATE: 1997-10-21
; EARLIER FILING DATE: 1998-10-21
; EARLIER FILING DATE: 1999-02-24
; EARLIER FILING DATE: 1999-05-13
; EARLIER FILING DATE: 1999-07-16
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 6
; LENGTH: 240
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-512-363-6

Query Match      53.6%; Score 697; DB 4; Length 240;
Best Local Similarity 52.2%; Pred. No. 2.1e-61;
Matches 129; Conservative 32; Mismatches 58; Indels 28; Gaps 4;

QY 1 MGAWMLYGVSMCLVLDLGQPSVVEEPCGPGKQVQSGNNTRCCSLY----- 48
Db 1 MGAFRALCGLALLCALSLGQ-RPTGGPGCGPGRLLLTGTDCRCRVTTRCCRDYPAQL 59

QY 49 -----APGEDCPKERCICVTPEYHCGDPQCKICKHYPCQQRVESQGDIVFGRCV 101
Db 60 LGMPVSPCGECCSEWDCMCVQPEFHCGDPCCTCRHHPCCPGQVQSGKFSFGQCI 119

QY 102 ACAMGTFPSAGRGHCLWNTCSQGFGLTMFPGNKTHNAVCIPEPLTEQYGHILTVIFLW 161
Db 120 DCASGTFSGGHEGCKPWTCTQGFGLTVFPGKTHNAVCPVPGSPPAEPLGLWLTIVLLAV 179

QY 162 AACIFFLTTVOLGLHIWQLRRQHMCPRETQPPFAEVQLSAEDACSFQPFEEERGEOT-EEK 220
Db 180 AACVLLTSAQLGLHIWQLRK-----TQLLEVPSTEDARSCQPFEEERGEERSAEK 232
```

; PRIOR APPLICATION NUMBER: 60/121,648
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 09/176,200
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/063,212
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 240
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-915-593-6

Query Match 53.6%; Score 697; DB 4; Length 240;
Best Local Similarity 52.2%; Pred. No. 2.le-61;
Matches 129; Conservative 32; Mismatches 58; Indels 28; Gaps 4;

QY 1 MGAWAMLYGVSMLCVLDLQGPSVVEBPQGGPGKVGQNGSGNTRCCSLY----- 48
Db 1 MGAFRALCGLALLCALUSLGO-RPTGGPGCGPGRLLLGTDARCCRVHTTRCCRDYPAQL 59

QY 49 -----APGKEDCPKERCICVTPEYHCGDPOCKICKHYPCQPGQSVESQGDIVFGRCV 101
Db 60 LGGMPVSCFGECCSEWDCMCVQPEFHGDPCCCTCRHHPCPPGQGVQSQKFSFGQCI 119

QY 102 ACAMGTFAGRDGHCRLWNCQSGFLTPPGNKTNAVCIPEPLTEQYGHLTVIFLYM 161
Db 120 DCASGTFSGGHEGCKPWTDTCTQFGLTVFPNGKTNVAVCPGSPPAEPLGLWLTVVLLAV 179

QY 162 AACIFELTTVOLGLHTWOLRRQHCMPRETQPPFAEVQLSAEDACSFQPPPEERGEOT-EEK 220
Db 180 AACVLLTSAQLGLHIWQURK-----TOLLLEVPFSTEDARSCQPPPEERGERSAEEK 232

QY 221 CHLGGRW 227
Db 233 GRGLDLW 239

Search completed: October 26, 2005, 15:53:37
Job time : 29.6823 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 26, 2005, 15:51:55 ; Search time 109.362 Seconds
(without alignments)
870.278 Million cell updates/sec

Title: US-09-545-998B-2
Perfect score: 1301
Sequence: 1 MGAWMLYGVSMCLVDLGGQ.....PEERGEQTEKHLGGRWP 228

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1862994 seqs, 417510619 residues

Total number of hits satisfying chosen parameters: 1862994

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA:*
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep.*
17: /cgn2_6/ptodata/1/pubpaa/US10E_PUBCOMB.pep.*
18: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
19: /cgn2_6/ptodata/1/pubpaa/US11A_PUBCOMB.pep.*
20: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
21: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
22: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1301	100.0	228	9	US-09-915-593-7
2	1301	100.0	228	13	US-10-116-378-24
3	1301	100.0	228	14	US-10-283-105-7
4	1301	100.0	228	14	US-10-277-966-7
5	1301	100.0	228	17	US-10-959-537-24
6	735.5	56.5	240	16	US-10-783-528-75
7	735.5	56.5	241	9	US-09-915-593-28
8	735.5	56.5	241	13	US-10-116-378-3
9	735.5	56.5	241	14	US-10-283-105-28
10	735.5	56.5	241	14	US-10-277-966-28
11	735.5	56.5	241	15	US-10-295-027-1284

12	735.5	56.5	241	17	US-10-959-537-3
13	735.5	56.5	241	20	US-11-032-294-3
14	703	54.0	234	9	US-09-915-593-2
15	703	54.0	234	14	US-10-283-105-2
16	703	54.0	234	14	US-10-277-966-2
17	697	53.6	240	9	US-09-915-593-6
18	697	53.6	240	14	US-10-283-105-6
19	697	53.6	240	14	US-10-277-966-6
20	697	53.6	246	15	US-10-264-237-1762
21	630.5	48.5	241	9	US-09-915-593-4
22	630.5	48.5	241	14	US-10-283-105-4
23	630.5	48.5	241	14	US-10-277-966-4
24	518	39.8	89	10	US-09-866-050A-191
25	506.5	38.9	317	13	US-10-116-378-26
26	506.5	38.9	317	17	US-10-959-537-26
27	228.5	17.6	255	9	US-09-739-394-9
28	228.5	17.6	255	9	US-09-826-212-11
29	228.5	17.6	255	9	US-09-938-727-13
30	228.5	17.6	255	10	US-09-877-336-2
31	228.5	17.6	255	11	US-09-877-338-2
32	228.5	17.6	255	13	US-10-097-330-9
33	228.5	17.6	255	13	US-10-027-199-2
34	228.5	17.6	255	14	US-10-170-997-2
35	228.5	17.6	255	14	US-10-186-643-11
36	228.5	17.6	255	14	US-10-207-655-160
37	228.5	17.6	255	15	US-10-418-242-13
38	228.5	17.6	255	16	US-10-646-308-18
39	228.5	17.6	255	16	US-10-755-889-174
40	228.5	17.6	255	16	US-10-748-112-15
41	228.5	17.6	255	16	US-10-723-860-588
42	228.5	17.6	255	17	US-10-491-997-32
43	228.5	17.6	255	17	US-10-981-352-2
44	222.5	17.1	219	9	US-09-739-394-2
45	222.5	17.1	219	13	US-10-097-330-2

ALIGNMENTS

RESULT 1
US-09-915-593-7
; Sequence 7, Application US/09915593
; Patent No. US20020098525A1
; GENERAL INFORMATION:
; APPLICANT: Ni, Jian
; APPLICANT: Ruben, Steven M.
; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins
; FILE REFERENCE: TR11, TR11SV1, and TR11SV2
; FILE REFERENCE: PF396P2
; CURRENT APPLICATION NUMBER: US/09/915,593
; PRIOR FILING DATE: 2001-07-27
; PRIOR APPLICATION NUMBER: 60/221,577
; PRIOR FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: 09/512,363
; PRIOR FILING DATE: 2000-02-23
; PRIOR APPLICATION NUMBER: 60/144,076
; PRIOR FILING DATE: 2000-07-16
; PRIOR APPLICATION NUMBER: 60/134,172
; PRIOR FILING DATE: 1999-05-13
; PRIOR APPLICATION NUMBER: 60/121,648
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 09/176,200
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/063,212
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 7
; LENGTH: 228
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-915-593-7

```
Query Match      100.0%; Score 1301; DB 9; Length 228;
Best Local Similarity 100.0%; Pred. No. 2.3e-114;
Matches 228; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGAWAMLYGVSMCLVDLQPSVVEPGCGKVGQSGNNTRCCSLYAPGKEDCPKERC 60
DB 1 MGAWAMLYGVSMCLVDLQPSVVEPGCGKVGQSGNNTRCCSLYAPGKEDCPKERC 60

QY 61 ICVTPEYHCGDPQCKICKHYPCQQRVESQGDIVFGFRVCACAMGTFSSAGRDGHCRLWT 120
DB 61 ICVTPEYHCGDPQCKICKHYPCQQRVESQGDIVFGFRVCACAMGTFSSAGRDGHCRLWT 120

QY 121 NCSQFGFLTMFPNGKTHNAVCIPEPLPTEQYGHLTIVFLVMAACIFFLTTLVGLHIIWL 180
DB 121 NCSQFGFLTMFPNGKTHNAVCIPEPLPTEQYGHLTIVFLVMAACIFFLTTLVGLHIIWL 180

QY 181 RQHMCPRETQPPFAEVQLSAEDACSFQFPEERGETEKEKCHLGGWRP 228
DB 181 RQHMCPRETQPPFAEVQLSAEDACSFQFPEERGETEKEKCHLGGWRP 228

RESULT 2
US-10-116-378-24
; Sequence 24, Application US/10116378
; Publication No. US2002015093A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Goddard, Audrey
; APPLICANT: Gurney, Austin
; APPLICANT: Marsters, Scott A.
; APPLICANT: Pitti, Robert M.
; APPLICANT: Wood, William
; TITLE OF INVENTION: NOVEL TUMOR NECROSIS FACTOR RECEPTOR HOMOLOG AND
; TITLE OF INVENTION: NUCLEIC
; FILE REFERENCE: P1206R1
; CURRENT APPLICATION NUMBER: US/10/116,378
; PRIOR FILING DATE: 2002-04-04
; PRIOR APPLICATION NUMBER: EARLIER FILING DATE: 1999-02-09
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-02-09
; NUMBER OF SEQ ID NOS: 31
; SEQ ID NO 24
; LENGTH: 228
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-116-378-24

Query Match      100.0%; Score 1301; DB 13; Length 228;
Best Local Similarity 100.0%; Pred. No. 2.3e-114;
Matches 228; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGAWAMLYGVSMCLVDLQPSVVEPGCGKVGQSGNNTRCCSLYAPGKEDCPKERC 60
DB 1 MGAWAMLYGVSMCLVDLQPSVVEPGCGKVGQSGNNTRCCSLYAPGKEDCPKERC 60

QY 61 ICVTPEYHCGDPQCKICKHYPCQQRVESQGDIVFGFRVCACAMGTFSSAGRDGHCRLWT 120
DB 61 ICVTPEYHCGDPQCKICKHYPCQQRVESQGDIVFGFRVCACAMGTFSSAGRDGHCRLWT 120

QY 121 NCSQFGFLTMFPNGKTHNAVCIPEPLPTEQYGHLTIVFLVMAACIFFLTTLVGLHIIWL 180
DB 121 NCSQFGFLTMFPNGKTHNAVCIPEPLPTEQYGHLTIVFLVMAACIFFLTTLVGLHIIWL 180

QY 181 RQHMCPRETQPPFAEVQLSAEDACSFQFPEERGETEKEKCHLGGWRP 228
DB 181 RQHMCPRETQPPFAEVQLSAEDACSFQFPEERGETEKEKCHLGGWRP 228

RESULT 3
US-10-283-105-7
; Sequence 7, Application US/10283105
```

```
Publication No. US20030138426A1
; GENERAL INFORMATION:
; APPLICANT: Ruben, Steven M
; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins Tr11, Tr11SV1,
; FILE REFERENCE: PF396P3
; CURRENT APPLICATION NUMBER: US/10/283,105
; PRIOR FILING DATE: 2002-10-30
; PRIOR APPLICATION NUMBER: 60/330,757
; PRIOR FILING DATE: 2001-10-30
; PRIOR APPLICATION NUMBER: 09/915,593
; PRIOR FILING DATE: 2001-07-27
; PRIOR APPLICATION NUMBER: 60/221,577
; PRIOR FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: 09/512,363
; PRIOR FILING DATE: 2000-02-23
; PRIOR APPLICATION NUMBER: 60/144,076
; PRIOR FILING DATE: 1999-07-16
; PRIOR APPLICATION NUMBER: 60/134,172
; PRIOR FILING DATE: 1999-05-13
; PRIOR APPLICATION NUMBER: 60/121,648
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 09/176,200
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/063,212
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 228
; TYPE: PRT
; ORGANISM: mus musculus
US-10-283-105-7

Query Match      100.0%; Score 1301; DB 14; Length 228;
Best Local Similarity 100.0%; Pred. No. 2.3e-114;
Matches 228; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGAWAMLYGVSMCLVDLQPSVVEPGCGKVGQSGNNTRCCSLYAPGKEDCPKERC 60
DB 1 MGAWAMLYGVSMCLVDLQPSVVEPGCGKVGQSGNNTRCCSLYAPGKEDCPKERC 60

QY 61 ICVTPEYHCGDPQCKICKHYPCQQRVESQGDIVFGFRVCACAMGTFSSAGRDGHCRLWT 120
DB 61 ICVTPEYHCGDPQCKICKHYPCQQRVESQGDIVFGFRVCACAMGTFSSAGRDGHCRLWT 120

QY 121 NCSQFGFLTMFPNGKTHNAVCIPEPLPTEQYGHLTIVFLVMAACIFFLTTLVGLHIIWL 180
DB 121 NCSQFGFLTMFPNGKTHNAVCIPEPLPTEQYGHLTIVFLVMAACIFFLTTLVGLHIIWL 180

QY 181 RQHMCPRETQPPFAEVQLSAEDACSFQFPEERGETEKEKCHLGGWRP 228
DB 181 RQHMCPRETQPPFAEVQLSAEDACSFQFPEERGETEKEKCHLGGWRP 228

RESULT 4
US-10-277-966-7
; Sequence 7, Application US/10277966
; Publication No. US20030153499A1
; GENERAL INFORMATION:
; APPLICANT: Ruben, Steven
; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins Tr11, Tr11SV2
; FILE REFERENCE: PF396P1D1
; CURRENT APPLICATION NUMBER: US/10/277,966
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: 09/512,363
; PRIOR FILING DATE: 2000-02-23
; PRIOR APPLICATION NUMBER: 60/121,648
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/134,172
```



```

; PRIOR FILING DATE: 1999-05-13
; PRIOR APPLICATION NUMBER: 60/144,076
; PRIOR FILING DATE: 1999-07-16
; PRIOR APPLICATION NUMBER: 09/176,200
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/063,212
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 7
; LENGTH: 228
; TYPE: PRT
; ORGANISM: mouse
US-10-277-966-7

Query Match      100.0%; Score 1301; DB 14; Length 228;
Best Local Similarity 100.0%; Pred. No. 2.3e-114;
Matches 228; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGAWAMLYGVSMCLVLDLGPVSVEEPGCGKVGQVSGNNTCCSLYAPGKEDCPKERC 60
DB 1 MGAWAMLYGVSMCLVLDLGPVSVEEPGCGKVGQVSGNNTCCSLYAPGKEDCPKERC 60

QY 61 ICVTPEYHCGDPCKICKHYPCQPGQVSGQDIVFGFRCVACAMGTFSAGRDGHCLWT 120
DB 61 ICVTPEYHCGDPCKICKHYPCQPGQVSGQDIVFGFRCVACAMGTFSAGRDGHCLWT 120

QY 121 NCSQFGFLTMFPNGKTHNAVCIPEPLTEQYGHLTWIFLVMAACIFFLTTVQLGLHIWQL 180
DB 121 NCSQFGFLTMFPNGKTHNAVCIPEPLTEQYGHLTWIFLVMAACIFFLTTVQLGLHIWQL 180

QY 181 RROHMCPRTOPFAEVQLSAEDACSFQFPPEERGETEKEKCHLGGWRP 228
DB 181 RROHMCPRTOPFAEVQLSAEDACSFQFPPEERGETEKEKCHLGGWRP 228

Query Match      100.0%; Score 1301; DB 17; Length 228;
Best Local Similarity 100.0%; Pred. No. 2.3e-114;
Matches 228; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGAWAMLYGVSMCLVLDLGPVSVEEPGCGKVGQVSGNNTCCSLYAPGKEDCPKERC 60
DB 1 MGAWAMLYGVSMCLVLDLGPVSVEEPGCGKVGQVSGNNTCCSLYAPGKEDCPKERC 60

QY 61 ICVTPEYHCGDPCKICKHYPCQPGQVSGQDIVFGFRCVACAMGTFSAGRDGHCLWT 120
DB 61 ICVTPEYHCGDPCKICKHYPCQPGQVSGQDIVFGFRCVACAMGTFSAGRDGHCLWT 120

QY 121 NCSQFGFLTMFPNGKTHNAVCIPEPLTEQYGHLTWIFLVMAACIFFLTTVQLGLHIWQL 180
DB 121 NCSQFGFLTMFPNGKTHNAVCIPEPLTEQYGHLTWIFLVMAACIFFLTTVQLGLHIWQL 180

QY 181 RROHMCPRTOPFAEVQLSAEDACSFQFPPEERGETEKEKCHLGGWRP 228
DB 181 RROHMCPRTOPFAEVQLSAEDACSFQFPPEERGETEKEKCHLGGWRP 228

RESULT 5
US-10-959-537-24
; Sequence 24, Application US/10959537
; Publication No. US20050069983A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Goddard, Audrey
; APPLICANT: Gurney, Austin
; APPLICANT: Marsters, Scot A.
; APPLICANT: Pitti, Robert M.
; APPLICANT: Wood, William
; TITLE OF INVENTION: NOVEL TUMOR NECROSIS FACTOR RECEPTOR HOMOLOG AND NUCLEIC
; FILE REFERENCE: P1206R1
; CURRENT APPLICATION NUMBER: US/10/959,537
; CURRENT FILING DATE: 2004-10-06
; PRIOR APPLICATION NUMBER: US/09/247,225
; PRIOR FILING DATE: 1999-02-09
; PRIOR APPLICATION NUMBER: US 60/074,087
; PRIOR FILING DATE: 1998-02-09
; NUMBER OF SEQ ID NOS: 31
; SEQ ID NO 24
; LENGTH: 228
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-959-537-24

Query Match      100.0%; Score 1301; DB 17; Length 228;
Best Local Similarity 100.0%; Pred. No. 2.3e-114;
Matches 228; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGAWAMLYGVSMCLVLDLGPVSVEEPGCGKVGQVSGNNTCCSLYAPGKEDCPKERC 60
DB 1 MGAWAMLYGVSMCLVLDLGPVSVEEPGCGKVGQVSGNNTCCSLYAPGKEDCPKERC 60

QY 61 ICVTPEYHCGDPCKICKHYPCQPGQVSGQDIVFGFRCVACAMGTFSAGRDGHCLWT 120
DB 61 ICVTPEYHCGDPCKICKHYPCQPGQVSGQDIVFGFRCVACAMGTFSAGRDGHCLWT 120

```

```

DB 61 ICVTPEYHCGDPCKICKHYPCQPGQVSGQDIVFGFRCVACAMGTFSAGRDGHCLWT 120
QY 121 NCSQFGFLTMFPNGKTHNAVCIPEPLTEQYGHLTWIFLVMAACIFFLTTVQLGLHIWQL 180
DB 121 NCSQFGFLTMFPNGKTHNAVCIPEPLTEQYGHLTWIFLVMAACIFFLTTVQLGLHIWQL 180
QY 181 RROHMCPRTOPFAEVQLSAEDACSFQFPPEERGETEKEKCHLGGWRP 228
DB 181 RROHMCPRTOPFAEVQLSAEDACSFQFPPEERGETEKEKCHLGGWRP 228

RESULT 6
US-10-783-528-75
; Sequence 75, Application US/10783528
; Publication No. US20040219579A1
; GENERAL INFORMATION:
; APPLICANT: Aziz, Natasha
; APPLICANT: Gish, Kurt
; APPLICANT: Wilson, Keith
; APPLICANT: Zlotnik, Albert
; TITLE OF INVENTION: METHODS OF DIAGNOSIS OF CANCER, COMPOSITIONS AND
; FILE REFERENCE: 05882.0191.NPUS01
; CURRENT APPLICATION NUMBER: US/10/783,528
; CURRENT FILING DATE: 2004-02-19
; NUMBER OF SEQ ID NOS: 116
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 75
; LENGTH: 240
; TYPE: PRT
; ORGANISM: Homo Sapiens
US-10-783-528-75

Query Match      56.5%; Score 735.5; DB 16; Length 240;
Best Local Similarity 57.0%; Pred. No. 5e-61;
Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;

QY 1 MGAWAMLYGVSMCLVLDLGPVSVEEPGCGKVGQVSGNNTCCSLYA-----PGKE 53
DB 7 MGAFRALCGLALLCALSLGQ-RPTGGPGCGPGRLLLTGTGDARCCRVHTTRCCRDYPGEE 65

QY 54 DCPKERCICVTPEYHCGDPCKICKHYPCQPGQVSGQDIVFGFRCVACAMGTFSAGRD 113
DB 66 CCSEWDCMCVQPEFHCGDPCCCTTCRHHPCPPGGVQSGQKFSFGQCIDCASGTFSGGHE 125

QY 114 GHCLWLNCSQFGFLTMFPNGKTHNAVCIPEPLTEQYGHLTWIFLVMAACIFFLTTVQL 173
DB 126 GHCKPWTDCTQFGFLTMFPNGKTHNAVCIPEPLTEQYGHLTWIFLVMAACIFFLTTVQL 185

QY 174 GLHIWQLRRQHMCPRETQPPFAEVQLSAEDACSFQFPPEERGETEKEKCHLGGWRP 227
DB 186 GLHIWQLRRQHMCPRETQPPFAEVQLSAEDACSFQFPPEERGETEKEKCHLGGWRP 240

RESULT 7
US-09-915-593-28
; Sequence 28, Application US/09915593
; Patent No. US20020098525A1
; GENERAL INFORMATION:
; APPLICANT: Ni, Jian
; APPLICANT: Ruben, Steven M.
; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins
; FILE REFERENCE: PP396P2
; CURRENT APPLICATION NUMBER: US/09/915,593
; CURRENT FILING DATE: 2001-07-27
; PRIOR APPLICATION NUMBER: 60/221,577
; PRIOR FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: 09/512,363
; PRIOR FILING DATE: 2000-02-23
; PRIOR APPLICATION NUMBER: 60/144,076
; PRIOR FILING DATE: 2000-07-16
; PRIOR APPLICATION NUMBER: 60/134,172
; PRIOR FILING DATE: 1999-05-13

```



```

; PRIOR FILING DATE: 2001-11-13
; PRIOR APPLICATION NUMBER: US 60/335,394
; PRIOR FILING DATE: 2001-11-15
; PRIOR APPLICATION NUMBER: US 60/332,464
; PRIOR FILING DATE: 2001-11-21
; PRIOR APPLICATION NUMBER: US 60/334,393
; PRIOR FILING DATE: 2001-11-29
; PRIOR APPLICATION NUMBER: US 60/340,376
; PRIOR FILING DATE: 2001-12-14
; PRIOR APPLICATION NUMBER: US 60/347,211
; PRIOR FILING DATE: 2002-01-08
; PRIOR APPLICATION NUMBER: US 60/347,349
; PRIOR FILING DATE: 2002-01-10
; PRIOR APPLICATION NUMBER: US 60/355,250
; PRIOR FILING DATE: 2002-02-08
; PRIOR APPLICATION NUMBER: US 60/356,714
; PRIOR FILING DATE: 2002-02-13
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1386
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1284
; LENGTH: 241
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-295-027-1284

Query Match 56.5%; Score 735.5; DB 15; Length 241;
Best Local Similarity 57.0%; Pred. No. Se-61;
Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;

QY 1 MGAWAMLYGVSMLCVLDLQSPVVEBPGCGKVGQNGNNTCCSLYA-----PGKE 53
Db 7 MGAFRALCGALLCALSLQ-QRTGCGGCGPGRLLILGTGTDAKCCRVHTTCCRDYFGEE 65

QY 54 DCPKERCICVTEHYHCGDPQCKTCKHYPCQPGQVRVESQGDIVFGRCVCAMGTFFSAGR 113
Db 66 CCSEWDCMCVQPEFHGCDPCCTTCRHHPCPPGGVQSQGKFSFGFCIDCASGTFSGGHE 125

QY 114 GCRLLWTNCSQGFGLTMPGNKTHNAVCIPEIPTQYGHLYTIFLYVMAACIFLTTVOL 173
Db 126 GHCKPMTDCTQGFGLTVFPGNKTHNAVCVPGSPPAFLGLTVVLLAVAACVLLLTSAQL 185

QY 174 GLHIWQLRRQHCMPRETQPPAEVLSAEDACSFQFPEERGEOT-BEKCHLGGRW 227
Db 186 GLHIWQLRSQCMWPRETQLLLEVPSTEDARSCQFPEERGERSAEEKGRGLDLW 240

RESULT 12
US-10-959-537-3
; Sequence 3, Application US/10959537
; Publication No. US20050069983A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Goddard, Audrey
; APPLICANT: Gurney, Austin
; APPLICANT: Marsters, Scot A.
; APPLICANT: Pitti, Robert M.
; APPLICANT: Wood, William
; TITLE OF INVENTION: NOVEL TUMOR NECROSIS FACTOR RECEPTOR HOMOLOG AND NUCLEOTIDE SEQUENCE THEREOF
; FILE REFERENCE: P1206R1
; CURRENT APPLICATION NUMBER: US/10/959,537
; CURRENT FILING DATE: 2004-10-06
; PRIOR APPLICATION NUMBER: US/09/247,225
; PRIOR FILING DATE: 1999-02-09
; PRIOR APPLICATION NUMBER: US 60/074,087
; PRIOR FILING DATE: 1998-02-09
; NUMBER OF SEQ ID NOS: 31
; SEQ ID NO 3
; LENGTH: 241
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-959-537-3

```


Thu Oct 27 11:13:25 2005

```
; PRIOR APPLICATION NUMBER: 60/121,648
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 09/176,200
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/063,212
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 234
; TYPE: PRT
; ORGANISM: human
US-10-283-105-2

Query Match      54.0%; Score 703; DB 14; Length 234;
Best Local Similarity 54.9%; Pred. No. 5.6e-58;
Matches 129; Conservative 32; Mismatches 58; Indels 16; Gaps 4;

QY      1  MGAWAMLYGVSMCLVDLQPSVVEEPGPGKVGQSGNNTCCSLYA-----PGKE 53
Db      7  MGAFRALCGLALLCALSLGQ-RFTGGPGCGPGRLLILGTGTDAECRCVHTTRCCEDYPGE 65

QY      54  DCPKERCICVTPYHCGDPQCKICKHYPCQPGQGVESQGDIVFGFRCVACAMGTFSAGRD 113
Db      66  CCSEWDCMCVQPEFHCGDPCTTCRHHPCPGPGQGVQSQGKFSFGQCIDCASGTFSGGHE 125

QY      114  GHCLRLWNCQFGFLTMFPNGKTHNAVCIPEPLPTQYGHILTVIFLVMAACIFFLTTVOL 173
Db      126  GHCKPWTDCQTQFGLTVFPNGKTHNAVCVPGSPABPLGLWLTVLLAVAAACVILLTSAQL 185

QY      174  GLHIWLRQHMCPRETQPPAEVOLSAEDACSPQFPEEEERGEQT-BEKCHLGGRW 227
Db      186  GLHIWLRK-----TQLLEVPPTEDARSCQFPEEEERGEERSABEKGLGLDW 233
```

Search completed: October 26, 2005, 16:11:20
Job time : 111.382 secs

THIS PAGE BLANK

Result No.	Score	Query		DB	ID	Description
		Match	Length			
1	228.5	17.6	255	2	I38426	lymphocyte activat
2	203.5	15.6	256	2	B32393	T-cell antigen 4-1
3	134	10.3	272	2	I48700	gene ox40 protein
4	126.5	9.7	271	2	S12783	Ox40 antigen precu
5	125.5	9.6	250	1	A49053	CD27 antigen precu
6	122	9.4	277	2	I37552	Ox40 homolog - hum
7	119	9.1	1113	2	JE0315	low-density lipopor
8	118.5	9.1	277	2	A60771	B-cell activation
9	115	8.8	435	2	I54182	tumor necrosis fac
10	107.5	8.3	459	2	I48854	gene murine tumour
11	106.5	8.2	474	2	B38634	tumor necrosis fac
12	104.5	8.0	305	2	A46476	B cell-associated
13	102.5	7.9	461	1	A35356	tumor necrosis fac
14	102.5	7.9	1260	1	TVRNU	protein-tyrosine k
15	102.5	7.9	4543	1	A53102	alpha-2-macroglobu
16	100.5	7.7	1254	2	I48161	p-185 precursor -
17	100.5	7.7	2321	2	S78549	alpha-2-macroglobu
18	100	7.7	260	1	A46517	p-185 precursor -
19	99.5	7.6	651	2	JC7705	notch3 protein - h
20	99.5	7.6	1797	2	A55677	CD27 antigen precu
21	99	7.6	655	2	JC7850	death receptor-6 -
22	99	7.6	1964	2	T09059	laminin beta-2 cha
23	98	7.5	1251	2	A57293	disintegrin and me
24	95.5	7.3	918	2	JC4361	notch4 - mouse
25	95	7.3	344	1	A27701	latent transformin
26	95	7.3	344	2	A32141	scavenger receptor
27	95	7.3	344	2	T45894	folliclatin precu
28	95	7.3	3635	2	T10053	folliclatin 1 prec
29	94.5	7.3	329	2	A48805	folliclatin - bovi

```
QY 205 SFQPFPEERG 214
| : |||||
Db 242 SCRFPEERG 251

RESULT 2
B32393
T-cell antigen 4-1BB precursor - mouse
C:Species: Mus musculus (house mouse)
C:Date: 17-Jul-1992 #sequence_revision 17-Jul-1992 #text_change 09-Jul-2004
C:Accession: B32393; I48879
R:Kwon, B.S.; Weisman, S.M.
Proc. Natl. Acad. Sci. U.S.A. 86, 1963-1967, 1989
A:Title: cDNA sequence of two inducible T-cell genes.
A:Reference number: A32393; MUID:89184547; PMID:2784565
A:Accession: B32393
A:Molecule type: mRNA
A:Residues: 1-256 <KWO>
A:Cross-references: UNIPROT:P20334; GB:J04492; NID:G201121; PIDN:AAA40167.1; PID:G201122
R:Kwon, B.S.; Kozak, C.A.; Kim, K.K.; Pickard, R.T.
J. Immunol. 152, 2256-2262, 1994
A:Title: Genomic Organization and Chromosomal Localization of the T-Cell Antigen 4-1BB.
A:Reference number: I48879; MUID:94179805; PMID:8133039
A:Accession: I48879
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-256 <RES>
A:Cross-references: EMBL:U02567; NID:g1117783; PIDN:AAA93113.1; PID:g409178
C:Genetics:
C:Introns: 35/1; 69/1; 115/1; 138/2; 156/3; 181/1; 225/1
C:Superfamily: CD27 antigen; NGF receptor repeat homology
C:Keywords: transmembrane protein
F:1-23/Domain: signal sequence #status predicted <SIG>
F:24-256/Product: 4-1BB protein #status predicted <MAT>

Query Match 15.6%; Score 203.5; DB 2; Length 256;
Best Local Similarity 29.8%; Pred. No. 9e-10;
Matches 64; Conservative 26; Mismatches 84; Indels 41; Gaps 10;

QY 22 SVVEBPGCGKVGQSGNTRCCSLYAPGKEDCP---KERCICVTPTPEYHGDGPOCKICK 78
| : |||||
Db 54 SIGGQVNC-----NICRVACGYFREKFKCSSTHNAECI-EGHCLGPGQCTRC 102

QY 79 HYPQCPQGVESQGDIVFGFRCVACAMGTFSS-AGRDGHCLRLWNCSSQFGFLTMFPENKTH 137
| : |||||
Db 103 K-DCRPQELTKG-----CKTCSLGTFTNDQNGTGVCRPWTCNSLDGRSVLKTGTTEK 154

QY 138 NAVCIP-----EPLPTEQY-----GH-----LTVFLVMAACIFPLTTVOLGLHIWQLR 181
| : |||||
Db 155 DVVCGPPVVSFPSTTISVTTPBGGPGHSLQVLTLFLALTSALLALIFITLLFSVLKWI 214

QY 182 ROHMCPRPQFAEVQLSA--EDACSFQPFPEERG 214
| : |||||
Db 215 RKKFPHIFKQPKTKTGAAQEDACSCRCPQEEG 249

RESULT 3
I48700
gene ox40 protein - mouse
N:Alternate names: Ox40 antigen
C:Species: Mus musculus (house mouse)
C:Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 09-Jul-2004
C:Accession: I48700; I48334; S34377
R:Calderhead, D.M.; Buhlmann, J.E.; van den Eertwegh, A.J.; Claassen, E.; Noelle, R.J.;
J. Immunol. 151, 5261-5271, 1993
A:Title: Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell int
A:Reference number: I48700; MUID:94044750; PMID:8228223
A:Accession: I48700
A:Status: translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-272 <RES>
A:Cross-references: UNIPROT:P47741; EMBL:Z21674; NID:g312827; PIDN:CAA79772.1; PID:g3128
```

```
R:Birkeland, M.L.; Copeland, N.G.; Gilbert, D.J.; Jenkins, N.A.; Barclay, A.N.
Eur. J. Immunol. 25, 926-930, 1995
A:Title: Gene structure and chromosomal localization of the mouse homologue of rat OX40 I
A:Reference number: I48334; MUID:95255413; PMID:7737295
A:Accession: I48334
A:Status: translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-14, 'G', 16-272 <RE2>
A:Cross-references: EMBL:X85214; NID:g732818; PIDN:CAA59476.1; PID:g732819
C:Genetics:
A:Gene: ox40
C:Introns: 45/1; 86/1; 122/1; 144/2; 210/1; 250/1
C:Superfamily: CD27 antigen; NGF receptor repeat homology

Query Match 10.3%; Score 134; DB 2; Length 272;
Best Local Similarity 22.9%; Pred. No. 0.00057;
Matches 66; Conservative 25; Mismatches 103; Indels 94; Gaps 15;

QY 1 MGAMNLYGVSMCLVLDLQGPSSVVEEPCGPGKVGQSGNTRCCSLYAPGK---EDCPK 57
| : |||||
Db 1 MYVWVQQPTALLLLALTILG--VTARRLNC-----VXHTYPSGHKKCCRECPGHGWSRCDH 54

QY 58 ER---C-ICVTPEYH-----CGDPQCKICKHYF-----CQPGQORVE 89
| : |||||
Db 55 TRDILCHPCETGTFYNEAVNYDTC--KQCTQCNRHSGSELKQNCITPTQDTVCRCPGTQPR 112

QY 90 SQGDIVFGFRCVACAMGTFSSAGRDGHCLRLWNCSSQFGFLTMFPNGKTHNAVC----- 141
| : |||||
Db 113 QDSGYKLVGDCVPCPPGHFSPGNNAQCKPWTNCTLSGQTRHPASDLSLDAVCEDESRLLAT 172

QY 142 -----IPELPT--EQYGHILTIVFLVMAACIFPLTTVOL 173
| : |||||
Db 173 LLWETQRPRTFRTTVOQSTVMPRTSELSP-PTLVTPPGPAPAVLLGLGLALPLTVLL 231

QY 174 GLHIWQLRRQHCMPRETQPFQFAEVQLSAEDAC---SFQPFPEERGRQTE 218
| : |||||
Db 232 ALYL--LKNWRLPNTPKP-----CWGNSFRTPIQE--EHTD 264

RESULT 4
S12783
Ox40 antigen precursor - rat
N:Alternate names: nerve growth factor receptor homolog
C:Species: Rattus norvegicus (Norway rat)
C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004
C:Accession: S12783; S08036
R:Mallett, S.; Fossum, S.; Barclay, A.N.
EMBO J. 9, 1063-1068, 1990
A:Title: Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes
A:Reference number: S12783; MUID:90214614; PMID:2157591
A:Accession: S12783
A:Molecule type: mRNA
A:Residues: 1-271 <MAL>
A:Cross-references: UNIPROT:P15725; EMBL:X17037; NID:g57830; PIDN:CAA34897.1; PID:g57831
C:Superfamily: CD27 antigen; NGF receptor repeat homology
C:Keywords: growth factor receptor; transmembrane protein
F:1-19/Domain: signal sequence #status predicted <SIG>
F:20-271/Product: Ox40 antigen #status predicted <MAT>
F:211-235/Domain: transmembrane #status predicted <TMM>

Query Match 9.7%; Score 126.5; DB 2; Length 271;
Best Local Similarity 21.6%; Pred. No. 0.0024;
Matches 62; Conservative 27; Mismatches 105; Indels 93; Gaps 13;

QY 1 MGAMNLYGVSMCLVLDLQGPSSVVEEPCGPGKVGQSGNTRCCSLYAPGK---EDCPK 57
| : |||||
Db 1 MYVWVQQPTAFLLLSLGLG--VTVKLNC-----VKDTPSGHKCCRECPGHGWSRCDH 53

QY 58 ER---CICVTPEYH-----CGDPQCKICKH-----YPCQPGQORVE 89
| : |||||
Db 54 TRDITVCHPCETGTFYNEAVNYDTC--KQCTQCNRHSGSELKQNCITPTEDTVCCRCRPGTQPR 111

QY 90 SQGDIVFGFRCVACAMGTFSSAGRDGHCLRLWNCSSQFGFLTMFPNGKTHNAVC----- 141
| : |||||
```


Db 112 QDSSHLKGVDCVPCPPGPHFSGNQACKWNTCTLSGKQIRIPANSLSLTVCEDRSLAT 171
Qy 142 -----IPE-----PLPTEQYGHLTWIFLWMAACIFLFTTVQIG 174
Db 172 LLWETQRTTFRPTVSTTWPRTSQLPSTPLVAPEGFAFVILGLGLLAPLTVLLA 231
Qy 175 LHIWQLRRQHMCPRETPQPAEVLSDAC---SFQFPEERGEOTE 218
Db 232 LYL--LRKAWRSNTPKP-----CWGNSFRTPQE--EQTD 263

RESULT 5
A49053
CD27 antigen precursor - mouse
N;Alternate names: CD27L receptor; T cell activation antigen CD27
C;Species: Mus musculus (house mouse)
C;Date: 19-Dec-1993 #sequence_revision 22-Apr-1995 #text_change 09-Jul-2004
C;Accession: A49053
R;Gravestein, L.A.; Blom, B.; Nolten, L.A.; de Vries, E.; van der Horst, G.; Ossendorp, Eur. J. Immunol. 23, 943-950, 1993
A;Title: Cloning and expression of murine CD27: comparison with 4-1BB, another lymphocyte A;Reference number: A49053; MUID:93209296; PMID:8384562
A;Accession: A49053
A;Molecule type: mRNA
A;Residues: 1-250 <GRA>
A;Cross-references: UNIPROT:P41272
A;Note: sequence extracted from NCBI backbone (NCBIN:128168, NCBI:P128169)
C;Superfamily: CD27 antigen; NGF receptor repeat homology
C;Keywords: duplication; glycoprotein; homodimer; receptor; surface antigen; T-cell; tra F;1-20/Domain: signal sequence #status predicted <SIG>
F;21-250/Product: CD27 antigen #status predicted <MAT>
F;21-182/Domain: extracellular #status predicted <EXT>
F;27-63/Domain: NGF receptor repeat homology <NG1>
F;65-105/Domain: NGF receptor repeat homology <NG2>
F;121-179/Region: proline/serine/threonine-rich
F;183-202/Domain: transmembrane #status predicted <TMN>
F;203-250/Domain: intracellular #status predicted <INT>
F;95,162/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 9.6%; Score 125.5; DB 1; Length 250;
Best Local Similarity 20.8%; Pred. No. 0.0027;
Matches 55; Conservative 30; Mismatches 93; Indels 87; Gaps 13;

Qy 3 AWAMLYGVSMCLVLDLQGPSVVEEPGCGKVGQNGNTRCCSLYAPGK---EDCPKER 59
Db 2 AWPPPYWLCMLGTL-VGLSATLAPNSCPDKHYWTGG--LCCRMCEPFGTFVVKDCQDR 57

Qy 60 -----CI---CVTPYHCGDPOCKICKHYPCQPGQGVESQDIVFGFRCVACAMGTF 109
Db 58 TAAQCDCPCIPGTSPPDYHT-RPHCESCRH--CNSGFLIRN-----CTVTANAEC 105

Qy 110 AGRDGHCR-----LWNTCSQFGFLTM 130

Db 106 CSKNWQCRDOECEDCPDLPALTRQSETSPPOPPPHLPHGTEKSWPLHRLQPNSTV 165

Qy 131 FPGNKTNAVCIPEPLPT-EQYGHLTWIFLWMAACIFLFTTVOLGLHIWQLRRQHMCPRE 189

Db 166 YQSRSSHRPLCSSCIRIFVTFSSMFLIF-VLGAIIFF-----HQRRNH----- 208

Qy 190 TQPPAEVQLSADACSFQFPEERG 214

Db 209 -GPNEDRQAVPEEPCPYSCPREEG 232

RESULT 6
OX40 homolog - human
C;Species: Homo sapiens (man)
C;Date: 29-May-1998 #sequence_revision 29-May-1998 #text_change 09-Jul-2004
C;Accession: I37552
R;Latza, U.; Durkop, H.; Schnittger, S.; Ringeling, J.; Eitelbach, F.; Hummel, M.; Fonat Eur. J. Immunol. 24, 677-683, 1994

A;Title: The human OX40 homolog: cDNA structure, expression and chromosomal assignment of A;Reference number: I37552; MUID:94170844; PMID:7510240
A;Accession: I37552
A;Status: Preliminary; translated from GB/EMBL/DBJ
A;Molecule type: mRNA
A;Residues: 1-277 <RES>
C;Cross-references: UNIPROT:P43489; EMBL:X75962; NID:9472957; PIDN:CAA53576.1; PID:94729; C;Superfamily: CD27 antigen; NGF receptor repeat homology

Query Match 9.4%; Score 122; DB 2; Length 277;
Best Local Similarity 21.1%; Pred. No. 0.0057;
Matches 54; Conservative 22; Mismatches 80; Indels 100; Gaps 8;

Qy 13 LCVLDLQGPSVVEEPGCGKVGQNGNTRCCSLYAPGKEDCPKERCICVTPEYHCGDP 72
Db 16 LLLGLGLSTVT-----GLHCVGDTVPSNDRCHCECPGNGMVS-----CSRS 59

Qy 73 QKCKIKHYPCQPG-----ORVESQDIVF----- 96

Db 60 QNTVCR--PCGPGFYNDVVSSKPKCTWCNLRSGSERKQLCTATQDTCRCRAGTQPLD 117

Qy 97 ----GPRCVACAMGTFAGRDGHCRLTWNTCSQFGFLTMFPGNKTNAVCIPEPLTEQYG 152

Db 118 SYKPGVDCAPCPGPHFSPGDNQACKPWTNCTLAKKITLQPASNSDAICEDRDPPTAQ-- 175

Qy 153 HLTVIPLVMAACIFFLFTTVOLGLHIWQLRRQHMCPRETQ--PFAEVQLSADACSFQFPE 210

Db 176 -----PQETQGPAPRPIVQPTQTEA----WPR 197

Qy 211 EERGEQTEKCHLGG 226

Db 198 TSQGPSTRPVEVPG 213

RESULT 7
JE0315
Low-density lipoprotein receptor-related protein - mouse
C;Species: Mus musculus (house mouse)
C;Date: 16-Jul-1999 #sequence_revision 16-Jul-1999 #text_change 09-Jul-2004
C;Accession: JE0315
R;Tomita, Y.; Kim, D.; Magoori, K.; Fujino, T.; Yamamoto, T.T.
J. Biochem. 124, 784-789, 1998
A;Title: A novel low-density lipoprotein receptor-related protein with type II membrane I A;Reference number: JE0315; MUID:98429596; PMID:9756624
A;Accession: JE0315
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-1113 <TOM>
A;Cross-references: UNIPROT:Q92319; DBJ:AB013874; NID:93869144; PIDN:BAA34371.1; PID:938 C;Superfamily: mouse low-density lipoprotein receptor-related protein; LDL receptor ligar F;337-372/Domain: LDL receptor ligand-binding repeat homology <LDL1>
F;374-408/Domain: LDL receptor ligand-binding repeat homology <LDL2>
F;410-445/Domain: LDL receptor ligand-binding repeat homology <LDL3>
F;447-482/Domain: LDL receptor ligand-binding repeat homology <LDL4>
F;648-682/Domain: LDL receptor ligand-binding repeat homology <LDL5>
F;684-720/Domain: LDL receptor ligand-binding repeat homology <LDL6>
F;723-757/Domain: LDL receptor ligand-binding repeat homology <LDL7>
F;869-1097/Domain: trypsin homology <TRY>

Query Match 9.1%; Score 119; DB 2; Length 1113;
Best Local Similarity 25.4%; Pred. No. 0.035;
Matches 75; Conservative 26; Mismatches 96; Indels 98; Gaps 20;

Qy 11 SMLC--VLDLGPQS-----VVEPGCGPGK-----VONGSGNTRC-----CS 46
Db 390 SLLCDGVDDCGDPSDEQNCNLTKEHRCGDRGRCIAAEWVCGDHD---CVDKSEVNCS 446

Qy 47 LYAPGEDCKERCICVTPEYHC-GDPQCK-----IC--KHYPQCGQGVESQDIVFG 97

Db 447 CHSQGLECTSGQCIPST--FQCDGDECDKDGSEENCSDSQTCPGE-----QG--CFG 498

Qy 98 FRCVACAMGTFAGRDGHCRLTWNTCSQFGFLTM-----FPGNKTNAVCI 142

Db 499 SSCVSCAGSSLCDSDSSI---SNCSQCEPITILELCLMNLNLYNHTHPNVYLGHRTQKEASI 555
QY 143 -----PEPLTEQYGHITVIFLVMAACIFPL--TTVOLGLHI--WQLRQHMCPRFTQ 191
Db 556 SWESSLPFALVQTCYK-----YLMFFACTILVPKCDVNTQRIIPCRLLCEHSKERCES 610
QY 192 PFAEVQLS-AEDACSFQPFEEERGEOT-----EE-----KCHLGG 226
Db 611 VLGI VGLQWLPEDTDCNQPFEESSDNQTLCLPNEDVEECSPSHFKCRSGRCVLGSR 665

RESULT 8
A60771
B-cell activation protein CD40 precursor - human
A:Alternate names: B-cell surface antigen Bp50
C:Species: Homo sapiens (man)
C:Date: 03-Jun-1993 #sequence_revision 03-Feb-1994 #text_change 09-Jul-2004
C:Accession: S04460; A60771
R:Stamenkovic, I.; Clark, E.A.; Seed, B.
EMBO J. 8, 1403-1410, 1989
A:Title: A B-lymphocyte activation molecule related to the nerve growth factor receptor
A:Reference number: S04460; MUID:89356608; PMID:2475341
A:Accession: S04460
A:Molecule type: mRNA
A:Residues: 1-277 <STA>
A:Cross-references: UNIPROT:P25942; EMBL:X60592; NID:G29850; PIDN:CAA43045.1; PID:G29851
R:Braesch-Andersen, S.; Paulie, S.; Koho, H.; Nika, H.; Aspenstroem, P.; Perlmann, P.
J. Immunol. 142, 562-567, 1989
A:Title: Biochemical characteristics and partial amino acid sequence of the receptor-like
A:Reference number: A60771; MUID:89093941; PMID:2463309
A:Accession: A60771
A:Molecule type: protein
A:Residues: 21-50 <BRA>
A:Experimental source: Burkitt lymphoma cell line Raji
C:Genetics:
A:Gene: GDB:CD40
A:Cross-references: GDB:215268; OMIM:109535
A:Map position: 20q12-20q13.2
C:Superfamily: CD27 antigen; NGF receptor repeat homology
C:Keywords: B-cell; glycoprotein; phosphoprotein; surface antigen; transmembrane protein
F:1-20/Domain: signal sequence #status predicted <SIG>
F:21-277/Product: B-cell activation protein CD40 #status experimental <MAT>
F:21-193/Domain: extracellular #status predicted <EXT>
F:194-215/Domain: transmembrane #status predicted <TM>
F:216-277/Domain: intracellular #status predicted <CYT>
F:153.180/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 9.1%; Score 118.5; DB 2; Length 277;
Best Local Similarity 21.0%; Pred. No. 0.011; Mismatches 88; Indels 71; Gaps 10;
Matches 50; Conservative 29

QY 41 NTRCCSLYAPGKE---DCPK-----ERC----- 60
Db 34 NSQCCSLCPGGKLVSDCTEFTETECPCGESEFLDTWNRTHCHQHKYCDPNLGLRVQ 93

QY 61 -----ICVTP-E-VHCGDPQCKIC-KHYPCQPGQGVESQGDIVPGFPCVACAMGTFPS- 109
Db 94 KGTSETDTICTCEGWHCTSEACESCVLHRSCTSGFGVKQIATGVSDDTICEPCPVGFFSN 153

QY 110 -AGRDGHCHLWNTCSQFGLTFPPGKNKTNVACIPELPLEQYGHITVIFLVMAACIFPL 168
Db 154 VSFAEKHPWTSCTEYKQDILVQVQAGNKTDDVVGQP-----DLRALVLPITP-GILFAI 208

QY 169 TTVQLGLHIWQLRRQHMCPRFTQPFPAEVLASADACSFQPFEEERGEOT-----EEKCH 222
Db 209 LLVLVFIKKVAKPTNKAFHPKQEPQEI-----NFPDDLPGSNTAAPVQETLH 256

RESULT 9
I54182
tumor necrosis factor receptor 2-related protein - human
C:Species: Homo sapiens (man)
C:Date: 24-May-1996 #sequence_revision 24-May-1996 #text_change 09-Jul-2004

C:Accession: I54182
R:Saens, M.; Chaffanet, M.; Cassiman, J.J.; Van den Berghe, H.; Marynen, P.
Genomics 16, 214-218, 1993
A:Title: Construction and evaluation of a hncDNA library of human 12p transcribed sequence
A:Reference number: I54182; MUID:93252381; PMID:8486360
A:Accession: I54182
A>Status: preliminary; translated from GB/EMBL/DBDJ
A:Molecule type: mRNA
A:Residues: 1-435 <RES>
A:Cross-references: UNIPROT:P36941; GB:I04270; NID:G339761; PIDN:AAA36757.1; PID:G339762
C:Genetics:
A:Gene: GDB:LTBR
A:Cross-references: GDB:1230195; OMIM:600979
A:Map position: 12p13.3-12p13.1
C:Superfamily: tumor necrosis factor receptor type 1 (TNFR1); NGF receptor repeat homology

Query Match 8.8%; Score 115; DB 2; Length 435;
Best Local Similarity 22.2%; Pred. No. 0.033; Mismatches 23; Indels 72; Gaps 13;
Matches 54; Conservative 23

QY 3 AWAMLYGVSMCLVLDLGGQSVV-----EPPGCGPGKQVNGSGNNTCCSLYAPG---KED 54
Db 13 AWGPLV-LGLFGLLAASQFOAVPPYASENQTCRDQKEYVEPQHRRICCSRCPPGTIVSAK 71

QY 55 CPKER-CICVTPVYHCG-----DP-----OQKI- 76
Db 72 CSRI RDTVCAT-----CAENSYNEHWNLYITICLCRPCDPVPMGLEIAPCTSKRKTQCRQ 127

QY 77 -----CKH-----YPCQPGQGVESQGDIVFG-FRCVACAMGTF---SAGRDHCHRL 118
Db 128 PGMFCAAWALECTHCELLSDCPGTEAEKDEVGKNNHCVPCKAGHFQNTSSPSARCQP 187

QY 119 WTNCSQFGFLTFMFGKTNHVCIP--EPLPTEQYGHITVIFLVMAACIFPLTTVOLGLH 176
Db 188 HTRCENQGLVEAAPGTAQSDTTCKNPLEPLPEMSGTM-LMLAVLLFLAFLLLATVFSC 246

QY 177 IWQ 179
Db 247 IWK 249

RESULT 10
I48854
gene murine tumor necrosis factor receptor 2 protein - mouse (fragment)
C:Species: Mus musculus (house mouse)
C:Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 09-Jul-2004
C:Accession: I48854
R:Powell, E.E.; Wicker, L.S.; Peterson, L.B.; Todd, J.A.
Mamm. Genome 5, 726-727, 1994
A:Title: Allelic variation of the type 2 tumor necrosis factor receptor gene.
A:Reference number: I48854; MUID:95178848; PMID:7873884
A:Accession: I48854
A>Status: preliminary; translated from GB/EMBL/DBDJ
A:Molecule type: mRNA
A:Residues: 1-459 <RES>
A:Cross-references: UNIPROT:Q62327; EMBL:X76401; NID:G433830; PIDN:CAA53981.1; PID:G43383
C:Superfamily: tumor necrosis factor receptor type 2 (TNFR2); NGF receptor repeat homology
F:151-186/Domain: NGF receptor repeat homology <NGF>

Query Match 8.3%; Score 107.5; DB 2; Length 459;
Best Local Similarity 26.1%; Pred. No. 0.14; Mismatches 13; Indels 77; Gaps 13;
Matches 54; Conservative 13

QY 4 WAMLYGVSMCLVLDLGGQSVVEEPG-----CGPGKQVNGSGNNT- 42
Db 2 WATGHTVPAQVVLTPYKP-----EPGYEQIISQEYYDRKAQMCCKACPPQGVYKHFCKNTS 57

QY 43 -----RCCSLYAPGKE-----CPKER---CICVTEY-----H 68
Db 58 DTVACDCEASMYTVQVMNQFRCTLSCSSSCSTDQVETRACTKQONRVCAEAGRYCALKTH 117

QY 69 CGDPOCKICKHY-PCQPGQGVES-----QGDIVFGFRCVACAMGTFPS--AGRDGHCHRLWNT 121

Db 118 SG--SCRCQWRLSKCGPGVASSRAPNGVNL-----CKACAPGTFSDTTSTSDVCRPHRI 171

Qy 122 CSQFGFLTMPPGKNTNNAVCIPPELPT 148

Db 172 CS-----ILAIPGNASTDAVCAPES-PT 193

RESULT 11

B38634

tumor necrosis factor receptor type 2 precursor - mouse

C;Species: Mus musculus (house mouse)

C;Date: 30-Jun-1992 #sequence_revision 30-Jun-1992 #text_change 09-Jul-2004

C;Accession: B38634; A40254; S54816

R;Lewis, M.; Tartaglia, L.A.; Lee, A.; Bennett, G.L.; Rice, G.C.; Wong, G.H.W.; Chen, E.

Proc. Natl. Acad. Sci. U.S.A. 88, 2830-2834, 1991

A;Title: Cloning and expression of cDNAs for two distinct murine tumor necrosis factor

A;Reference number: A38634; MUID:91187885; PMID:1849278

A;Accession: B38634

A;Molecule type: mRNA

A;Residues: 1-474 <LEW>

A;Cross-references: UNIPROT:P25119; GB:M60469; NID:g199827; PIDN:AAA39752.1; PID:g199828

R;Goodwin, R.G.; Anderson, D.; Jerzy, R.; Davis, T.; Brannan, C.I.; Copeland, N.G.; Jenk

Mol. Cell. Biol. 11, 3020-3026, 1991

A;Title: Molecular cloning and expression of the type 1 and type 2 murine receptors for

A;Reference number: A40254; MUID:91246168; PMID:1645445

A;Accession: A40254

A;Molecule type: mRNA

A;Residues: 1-474 <GOO>

A;Cross-references: GB:M60469; NID:g199827; PIDN:AAA39752.1; PID:g199828

R;Kisssoneghis, M.; Felloes, R.; Feldmann, M.; Chernajovsky, Y.

submitted to the EMBL Data Library, May 1995

A;Description: Characterization of the promoter region of the murine p75-TNF receptor.

A;Reference number: S54816

A;Accession: S54816

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-22 <KTS>

A;Cross-references: EMBL:X87128; NID:g809043; PIDN:CAA60618.1; PID:g809044

C;Superfamily: tumor necrosis factor receptor type 2 (TNFR2); NGF receptor repeat homolo

F;1-22/Domain: signal sequence #status predicted <SIG>

F;23-474/Product: tumor necrosis factor receptor type 2 #status predicted <MAT>

F;40-77/Domain: NGF receptor repeat homology <NGL>

F;79-120/Domain: NGF receptor repeat homology <NG2>

F;166-203/Domain: NGF receptor repeat homology <NG4>

Query Match 8.2%; Score 106.5; DB 2; Length 474;

Best Local Similarity 26.1%; Pred. No. 0.18;

Matches 54; Conservative 13; Mismatches 63; Indels 77; Gaps 13;

Qy 4 WAMLYGVSMICVLDLGQPSVVEBP-----CPGKQVQNGSGNNT- 42

Db 17 WATGHTVPAQVLTTPYKP-----EPGYEQISOEYDRAKQMCCKAKPPGQVVKHFCNKTS 72

Qy 43 -----RCCSLYAPGKED-----CPKER---CICVTPEY-----H 68

Db 73 DTVACDCEASMYTQVNOFRCLSCSSCTTQDVEIRACTQKQNRVACAEGRYCALKTH 132

Qy 69 CGDPQCKICKHY-PCQPGQRVES-----QGDIVFGFRCVACAMGTFSS--AGRDGHCRILMTN 121

Db 133 SG--SCRCQWRLSKCGFGVASSRAPNGVNL-----CKACAPGTFSDTTSTSDVCRPHRI 186

Qy 122 CSQFGFLTMPPGKNTNNAVCIPPELPT 148

Db 187 CS-----ILAIPGNASTDAVCAPES-PT 208

RESULT 12

A46476

B cell-associated surface molecule CD40, long splice form - mouse

C;Species: Mus musculus (house mouse)

C;Date: 18-Jun-1993 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004

C;Accession: A46476; A46515

R;Torres, R.M.; Clark, E.A.

J. Immunol. 148, 620-626, 1992

A;Title: Differential increase of an alternatively polyadenylated mRNA species of murine

A;Reference number: A46476; MUID:92105763; PMID:1370315

A;Accession: A46476

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-305 <TOR>

A;Cross-references: UNIPROT:P27512; GB:M83312; NID:g1553058

A;Note: sequence extracted from NCBI backbone (NCBIN:75206, NCBI:P:75207)

A;Note: this translation is not annotated in GenBank entry MUSCD40A, release 113.0

R;Grimaldi, J.C.; Torres, R.; Kozak, C.A.; Chang, R.; Clark, E.A.; Howard, M.; Cockayne,

J. Immunol. 149, 3921-3926, 1992

A;Title: Genomic structure and chromosomal mapping of the murine CD40 gene.

A;Reference number: A46515; MUID:93094586; PMID:1281194

A;Accession: A46515

A;Status: preliminary; not compared with conceptual translation

A;Molecule type: nucleic acid

A;Residues: 1-287, 'IV' <GRI>

A;Cross-references: GB:M83312; NID:g1553058; PIDN:AA808705.1; PID:g1553059; GB:M94126; N1

A;Experimental source: BALB/c, liver

A;Note: sequence extracted from NCBI backbone (NCBI:P:120357)

C;Comment: For an alternative splice form, see PIR:A46515.

C;Comment: For an alternative splice form, see PIR:A46476.

C;Superfamily: CD27 antigen; NGF receptor repeat homology

C;Keywords: alternative splicing; transmembrane protein

F;105-144/Domain: NGF receptor repeat homology <NGF>

Query Match 8.0%; Score 104.5; DB 2; Length 305;

Best Local Similarity 25.2%; Pred. No. 0.18;

Matches 38; Conservative 13; Mismatches 71; Indels 29; Gaps 8;

Qy 17 DLGQP-----SVVEPCGCP---GKQNGSGNNTRC-----CSLYAPG-----KED 54

Db 39 DLCPGSRLLTSHCTALEKTCQCHPCDSEFSAQNNREIRCHQHRHCE---PNOGLRVKKG 95

Qy 55 CPKERCICVTPE-YHCGDPQCKIC-RHYPCQPGQRVESQGDIVFGFRCVACAMGTFSS--A 110

Db 96 TAESDVTCTCKEQHCTSKDCEACQHTPCIPGFGVMEATETDTVTCHPCPVGFFSNQS 155

Qy 111 GRDGHRLWTNCSQGFGLTFPFGNKTNAVC 141

Db 156 SLPEKCYPTWTSCEDKNLEVLQKGTSTQTNVIC 186

RESULT 13

A35356

tumor necrosis factor receptor 2 precursor [validated] - human

N;Alternate names: 75K tumor necrosis factor receptor; TNF receptor type 2

C;Species: Homo sapiens (man)

C;Date: 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 09-Jul-2004

C;Accession: A35356; A36475; A48416; A36007; A23666; B35010; I38094

R;Smith, C.A.; Davis, T.; Anderson, D.; Solam, L.; Beckmann, M.P.; Jerzy, R.; Dower, S.K.

Science 248, 1019-1023, 1990

A;Title: A receptor for tumor necrosis factor defines an unusual family of cellular and

A;Reference number: A35356; MUID:90260639; PMID:2160731

A;Accession: A35356

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-461 <SMI>

A;Cross-references: UNIPROT:P20333; GB:M32315; NID:g189185; PIDN:AAA59929.1; PID:g189186

R;Kohn, T.; Brewer, M.T.; Baker, S.L.; Schwartz, P.E.; King, M.W.; Hale, K.K.; Squires,

Proc. Natl. Acad. Sci. U.S.A. 87, 8331-8335, 1990

A;Title: A second tumor necrosis factor receptor gene product can shed a naturally occur

A;Reference number: A36475; MUID:91045991; PMID:2172983

A;Accession: A36475

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-195, 'R', 197-461 <KOH>

A;Cross-references: GB:M55994; GB:M38549; NID:g339757; PIDN:AAA36755.1; PID:g339758

R;Dembic, Z.; Loetscher, H.; Gubler, U.; Pan, Y.C.; Lahm, H.W.; Gentz, R.; Brockhaus, M.;

Cytokine 2, 231-237, 1990

A;Title: Two human TNF receptors have similar extracellular, but distinct intracellular,

A:Reference number: A48416; MUID:91370690; PMID:1966549

A:Accession: A48416

A>Status: preliminary

A:Molecule type: mRNA; protein

A:Residues: 23-461 <DEM>

A:Cross-references: GB:S63368; NID:9235648; PIDN:AAB19824.1; PID:9235649

A>Note: sequence extracted from NCBI backbone (NCBIN:63368, NCBI:P:63371)

R:Hellier, R.A.; Song, K.; Onasch, M.A.; Fischer, W.H.; Chang, D.; Ringold, G.M.

Proc. Natl. Acad. Sci. U.S.A. 87, 6151-6155, 1990

A:Title: Complementary DNA cloning of a receptor for tumor necrosis factor and demonstration of its role in tumor necrosis factor-induced apoptosis

A:Reference number: A36007; MUID:90349572; PMID:2166946

A:Accession: A36007

A>Status: preliminary

A:Molecule type: mRNA

A:Residues: 116-140, 'P', '142-195, 'R', '197-362, 'T', '364-461 <HEL>

A:Cross-references: GB:M35857; NID:9339751; PIDN:AAAG3262.1; PID:9339752

R:Loetscher, H.; Schlaeger, E.J.; Lahm, H.W.; Pan, Y.C.E.; Lesslauer, W.; Brockhaus, M.

J. Biol. Chem. 265, 20131-20138, 1990

A:Title: Purification and partial amino acid sequence analysis of two distinct tumor necrosis factor receptors

A:Reference number: A23666; MUID:91056048; PMID:2173696

A:Accession: A23666

A>Status: preliminary

A:Molecule type: protein

A:Residues: 23-40; 65-69; 136-141; 300-306 <LOE>

R:Engelmann, H.; Novick, D.; Wallach, D.

J. Biol. Chem. 265, 1531-1536, 1990

A:Title: Two tumor necrosis factor-binding proteins purified from human urine. Evidence for two distinct receptors

A:Reference number: A35010; MUID:90110215; PMID:2153136

A:Accession: B35010

A>Status: preliminary

A:Molecule type: protein

A:Residues: 27-31 <ENG>

R:Kuhnert, P.; Kemper, O.; Wallach, D.

Gene 150, 381-386, 1994

A:Title: Cloning, sequencing and partial functional characterization of the 5' region of the human TNF receptor

A:Reference number: I38094; MUID:95121934; PMID:7821811

A:Accession: I38094

A>Status: preliminary; translated from GB/EMBL/DDBJ

A:Molecule type: DNA

A:Residues: 1-37 <RES>

A:Cross-references: EMBL:X80021; NID:g666044; PIDN:CAA56324.1; PID:9825701

A:Gene: GDB:TNFR2

A:Map position: lp36.2-lp36.2

A:Introns: 26/3

A>Note: the list of introns is incomplete

C:Superfamily: tumor necrosis factor receptor type 2 (TNFR2); NGF receptor repeat homology

C:Keywords: duplication; glycoprotein; receptor; transmembrane protein

F:1-22/Domain: signal sequence #status predicted <SIG>

F:23-416/Product: tumor necrosis factor receptor 2 #status experimental <MAT>

F:40-76/Domain: NGF receptor repeat homology <NG1>

F:78-119/Domain: NGF receptor repeat homology <NG2>

F:120-162/Domain: NGF receptor repeat homology <NG3>

F:164-201/Domain: NGF receptor repeat homology <NG4>

F:262-279/Domain: transmembrane #status predicted <TMN>

F:280-461/Domain: intracellular #status predicted <INT>

F:171,193/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 7.9%; Score 102.5; DB 1; Length 461;

Best Local Similarity 22.4%; Pred. No. 0.38;

Matches 52; Conservative 18; Mismatches 67; Indels 95; Gaps 12;

29 CGPG---KVQNGSGNNTRC-----CSLYAPGKEDCPKER-- 59

57 CSPGQAKVFCYTKSTDTVCDSCEDSTYTQLNWWPFLCSGSRCSDDQVETQACTREQNR 116

60 -CICVTPEYHCG---DPQCKICKHY-PCPGQGVESQGDIVFGFRVCVACAMGTFSS--AGR 112

117 ICTC-RPGWYCALSKQEGCRCLCAPLKRCPGFGVARGPTGSDVVCPCAPGTFSTSS 175

113 DGHCLRWTCNSQGFLLTMFPGNKTHNVC-----IPEPLTEQYGHLYVI 157

29 CGPG---KVQNGSGNNTRC-----CSLYAPGKEDCPKER-- 59

57 CSPGQAKVFCYTKSTDTVCDSCEDSTYTQLNWWPFLCSGSRCSDDQVETQACTREQNR 116

60 -CICVTPEYHCG---DPQCKICKHY-PCPGQGVESQGDIVFGFRVCVACAMGTFSS--AGR 112

117 ICTC-RPGWYCALSKQEGCRCLCAPLKRCPGFGVARGPTGSDVVCPCAPGTFSTSS 175

113 DGHCLRWTCNSQGFLLTMFPGNKTHNVC-----IPEPLTEQYGHLYVI 157

29 CGPG---KVQNGSGNNTRC-----CSLYAPGKEDCPKER-- 59

57 CSPGQAKVFCYTKSTDTVCDSCEDSTYTQLNWWPFLCSGSRCSDDQVETQACTREQNR 116

60 -CICVTPEYHCG---DPQCKICKHY-PCPGQGVESQGDIVFGFRVCVACAMGTFSS--AGR 112

117 ICTC-RPGWYCALSKQEGCRCLCAPLKRCPGFGVARGPTGSDVVCPCAPGTFSTSS 175

113 DGHCLRWTCNSQGFLLTMFPGNKTHNVC-----IPEPLTEQYGHLYVI 157

29 CGPG---KVQNGSGNNTRC-----CSLYAPGKEDCPKER-- 59

57 CSPGQAKVFCYTKSTDTVCDSCEDSTYTQLNWWPFLCSGSRCSDDQVETQACTREQNR 116

60 -CICVTPEYHCG---DPQCKICKHY-PCPGQGVESQGDIVFGFRVCVACAMGTFSS--AGR 112

117 ICTC-RPGWYCALSKQEGCRCLCAPLKRCPGFGVARGPTGSDVVCPCAPGTFSTSS 175

113 DGHCLRWTCNSQGFLLTMFPGNKTHNVC-----IPEPLTEQYGHLYVI 157

Db 176 TDICRPHOICN----VVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVST----- 222

Qy 158 FLVMAACIFFLTTLVQLGLHIMQLRRQHCMPRETQPPFAEVQLSAEDACSFQFP 209

Db 223 -----RSQH-----TQTPPEP--STADPTSTFLLP 244

RESULT 14

TVRTNU

C:Species: Rattus norvegicus (Norway rat)

C>Date: 31-Dec-1988 #sequence_revision 31-Dec-1988 #text_change 09-Jul-2004

C:Accession: A24562; A61204

R:Bargmann, C.I.; Hung, M.C.; Weinberg, R.A.

Nature 319, 226-230, 1986

A:Title: The new oncogene encodes an epidermal growth factor receptor-related protein.

A:Reference number: A34562; MUID:86118662; PMID:3945311

A:Accession: A24562

A:Molecule type: mRNA

A:Residues: 1-1260 <BAR>

A:Cross-references: UNIPROT:P06494; EMBL:X03362; NID:g56745; PIDN:CAA27059.1; PID:g56746

R:Masui, T.; Mann, A.M.; Macatee, T.L.; Garland, E.M.; Okamura, T.; Smith, R.A.; Cohen, E.

Carcinogenesis 12, 1975-1978, 1991

A:Title: Direct DNA sequencing of the rat neu oncogene transmembrane domain reveals no m

2-thiazolylformamide or N-methyl-N-nitrosourea.

A:Reference number: A61204; MUID:92035293; PMID:1682063

A:Accession: A61204

A>Status: preliminary

A:Molecule type: DNA

A:Residues: 637-663, 'V', '665-702 <MAS>

A>Note: authors translated the codon GCA for residue 25 as Val

C:Genetics:

A:Gene: neu

C:Superfamily: epidermal growth factor receptor; protein kinase homology

C:Keywords: ATP; autophosphorylation; duplication; glycoprotein; phosphoprotein; phosphot

F:1-19/Domain: signal sequence #status predicted <SIG>

F:20-1260/Product: protein-tyrosine kinase neu #status predicted <MAT>

F:658-680/Domain: transmembrane #status predicted <TMN>

F:723-988/Domain: protein kinase ATP-binding motif

F:731-739/Region: protein kinase ATP-binding motif

F:71,191,263,535,576,634/Binding site: carbohydrate (Asn) (covalent) #status predicted

F:691/Binding site: phosphate (Thr) (covalent) #status predicted

F:758/Active site: Lys #status predicted (Tyr) (covalent) #status predicted

F:882,1227,1253/Binding site: phosphate (Tyr) (covalent) #status predicted

Query Match 7.9%; Score 102.5; DB 1; Length 1260;

Best Local Similarity 26.6%; Pred. No. 0.92;

Matches 46; Conservative 21; Mismatches 73; Indels 33; Gaps 9;

Qy 30 GPGKVQNGSGNNTRC--CSLYAPGKEDCPKERICVTPEYHCGDPOCKICKHYPCQPGOR 87

Db 527 GSGP-----TQCVNGSHFLRGQECVEECRWKGLPREYVSDKRLCLPC-HPECPQ--- 574

Qy 88 VESQGDIVFGF---RCVACAMGTFESAGRDGHC-----RLWTNCSQGFLLTMFPG 133

Db 575 -QNSSETCFGSDADQCAAHYKDSVSCVARGPSGKPDLSYMPDWKYDEEGICQCPFI 633

Qy 134 NKTHNAVICPE--PLPTEQYGH--LTVIFLVMAACIFFLTTLVQLGLHIMQLRRQ 183

Db 634 NCTHSCVDLDERGCPAEQASPVTFIATVEGVLFLILVVVVGILI-KRRRQ 685

RESULT 15

A53102

alpha-2-macroglobulin receptor precursor - chicken

N:Alternate names: CD91; LDL receptor-related protein 1; low density lipoprotein receptor

C:Species: Gallus gallus (chicken)

C>Date: 04-Sep-1998 #sequence_revision 04-Sep-1998 #text_change 09-Jul-2004

C:Accession: A53102

R:Nimf, J.; Stifani, S.; Bilous, P.T.; Schneider, W.J.

J. Biol. Chem. 269, 212-219, 1994

A:Title: The somatic cell-specific low density lipoprotein receptor-related protein of t

A:Reference number: A53102; MUID:94103212; PMID:7506255

A:Accession: A53102
A:Status: Preliminary
A:Molecule type: mRNA
A:Residues: 1-4543 <NIM>
A:Cross-references: UNIPROT:P98157; GB:X74904; NID:G438006; PIDN:CAA52870.1; PID:G438007
C:Complex: The alpha-2-macroglobulin receptor complex consists of noncovalently-associated dimer.
C:Superfamily: alpha-2-macroglobulin receptor; LDL receptor ligand-binding
C:Keywords: beta-hydroxyaspartic acid; calcium binding; glycoprotein

F:1-17/Domain: signal sequence #status predicted <SIG>
F:18-3942/Domain: alpha-2-macroglobulin receptor 515K chain #status predicted <515K>
F:18-3942,3943-4543/Product: alpha-2-macroglobulin receptor #status predicted <MAT>
F:29-66/Domain: LDL receptor ligand-binding repeat homology <LDL1>
F:74-110/Domain: LDL receptor ligand-binding repeat homology <LDL2>
F:117-150/Domain: EGF homology <EG1>
F:156-190/Domain: EGF homology <EG2>
F:200-241/Domain: LDL receptor YWTD-containing repeat homology <YW01>
F:242-283/Domain: LDL receptor YWTD-containing repeat homology <YW02>
F:294-336/Domain: LDL receptor YWTD-containing repeat homology <YW03>
F:337-380/Domain: LDL receptor YWTD-containing repeat homology <YW04>
F:381-422/Domain: LDL receptor YWTD-containing repeat homology <YW05>
F:423-470/Domain: LDL receptor YWTD-containing repeat homology <YW06>
F:480-521/Domain: EGF homology <EG3>
F:573-615/Domain: LDL receptor YWTD-containing repeat homology <YW07>
F:616-661/Domain: LDL receptor YWTD-containing repeat homology <YW08>
F:662-712/Domain: LDL receptor YWTD-containing repeat homology <YW09>
F:713-754/Domain: LDL receptor YWTD-containing repeat homology <YW10>
F:755-797/Domain: LDL receptor YWTD-containing repeat homology <YW11>
F:805-840/Domain: EGF homology <EG4>
F:852-888/Domain: LDL receptor ligand-binding repeat homology <LDL3>
F:893-929/Domain: LDL receptor ligand-binding repeat homology <LDL4>
F:934-969/Domain: LDL receptor ligand-binding repeat homology <LDL5>
F:974-1009/Domain: LDL receptor ligand-binding repeat homology <LDL6>
F:1013-1049/Domain: LDL receptor ligand-binding repeat homology <LDL7>
F:1060-1095/Domain: LDL receptor ligand-binding repeat homology <LDL8>
F:1102-1138/Domain: LDL receptor ligand-binding repeat homology <LDL9>
F:1143-1180/Domain: LDL receptor ligand-binding repeat homology <LDLA>
F:1183-1219/Domain: EGF homology <EG5>
F:1225-1259/Domain: EGF homology <EG6>
F:1267-1306/Domain: LDL receptor YWTD-containing repeat homology <YW12>
F:1307-1353/Domain: LDL receptor YWTD-containing repeat homology <YW13>
F:1354-1396/Domain: LDL receptor YWTD-containing repeat homology <YW14>
F:1397-1443/Domain: LDL receptor YWTD-containing repeat homology <YW15>
F:1444-1486/Domain: LDL receptor YWTD-containing repeat homology <YW16>
F:1487-1529/Domain: LDL receptor YWTD-containing repeat homology <YW17>
F:1538-1576/Domain: EGF homology <EG7>
F:1581-1624/Domain: LDL receptor YWTD-containing repeat homology <YW18>
F:1625-1667/Domain: LDL receptor YWTD-containing repeat homology <YW19>
F:1668-1711/Domain: LDL receptor YWTD-containing repeat homology <YW20>
F:1712-1751/Domain: LDL receptor YWTD-containing repeat homology <YW21>
F:1752-1794/Domain: LDL receptor YWTD-containing repeat homology <YW22>
F:1795-1842/Domain: LDL receptor YWTD-containing repeat homology <YW23>
F:1846-1882/Domain: EGF homology <EG8>
F:1930-1972/Domain: LDL receptor YWTD-containing repeat homology <YW24>
F:1973-2015/Domain: LDL receptor YWTD-containing repeat homology <YW25>
F:2016-2059/Domain: LDL receptor YWTD-containing repeat homology <YW26>
F:2060-2101/Domain: LDL receptor YWTD-containing repeat homology <YW27>
F:2102-2147/Domain: LDL receptor YWTD-containing repeat homology <YW28>
F:2155-2190/Domain: EGF homology <EG9>
F:2195-2237/Domain: LDL receptor YWTD-containing repeat homology <YW29>
F:2247-2288/Domain: LDL receptor YWTD-containing repeat homology <YW30>
F:2338-2382/Domain: LDL receptor YWTD-containing repeat homology <YW31>
F:2424-2467/Domain: LDL receptor YWTD-containing repeat homology <YW32>
F:2476-2511/Domain: EGF homology <EG10>
F:2518-2555/Domain: LDL receptor ligand-binding repeat homology <LDLB>
F:2560-2594/Domain: LDL receptor ligand-binding repeat homology <LDLC>
F:2599-2633/Domain: LDL receptor ligand-binding repeat homology <LDLD>
F:2646-2682/Domain: LDL receptor ligand-binding repeat homology <LDLE>
F:2690-2724/Domain: LDL receptor ligand-binding repeat homology <LDLF>
F:2732-2767/Domain: LDL receptor ligand-binding repeat homology <LDLG>
F:2772-2810/Domain: LDL receptor ligand-binding repeat homology <LDLH>
F:2816-2851/Domain: LDL receptor ligand-binding repeat homology <LDLI>

F:2856-2895/Domain: LDL receptor ligand-binding repeat homology <LDLJ>
F:2902-2936/Domain: LDL receptor ligand-binding repeat homology <LDLK>
F:2941-2977/Domain: EGF homology <EG11>
F:2983-3018/Domain: EGF homology <EG12>
F:3028-3065/Domain: LDL receptor YWTD-containing repeat homology <YW34>
F:3066-3110/Domain: LDL receptor YWTD-containing repeat homology <YW35>
F:3111-3153/Domain: LDL receptor YWTD-containing repeat homology <YW36>
F:3154-3197/Domain: LDL receptor YWTD-containing repeat homology <YW37>
F:3198-3238/Domain: LDL receptor YWTD-containing repeat homology <YW38>
F:3239-3281/Domain: LDL receptor YWTD-containing repeat homology <YW39>
F:3291-3327/Domain: EGF homology <EG13>
F:3331-3366/Domain: LDL receptor ligand-binding repeat homology <LDLL>
F:3371-3405/Domain: LDL receptor ligand-binding repeat homology <LDLM>
F:3410-3445/Domain: LDL receptor ligand-binding repeat homology <LDLN>
F:3450-3486/Domain: LDL receptor ligand-binding repeat homology <LDLO>
F:3491-3528/Domain: LDL receptor ligand-binding repeat homology <LDLP>
F:3533-3567/Domain: LDL receptor ligand-binding repeat homology <LDLQ>
F:3572-3606/Domain: LDL receptor ligand-binding repeat homology <LDLR>
F:3610-3644/Domain: LDL receptor ligand-binding repeat homology <LDLS>
F:3651-3687/Domain: LDL receptor ligand-binding repeat homology <LDLT>
F:3692-3728/Domain: LDL receptor ligand-binding repeat homology <LDLU>
F:3738-3774/Domain: LDL receptor ligand-binding repeat homology <LDLV>
F:3783-3820/Domain: EGF homology <EG14>
F:3826-3858/Domain: EGF homology <EG15>
F:3866-3909/Domain: LDL receptor YWTD-containing repeat homology <YW40>
F:3910-3968/Domain: LDL receptor YWTD-containing repeat homology <YW41>
F:3943-4543/Domain: alpha-2-macroglobulin receptor 85K chain #status predicted <85K>
F:3943-4420/Domain: 85K chain extracellular #status predicted <EXT>
F:3969-4011/Domain: LDL receptor YWTD-containing repeat homology <YW42>
F:4012-4055/Domain: LDL receptor YWTD-containing repeat homology <YW43>
F:4056-4098/Domain: LDL receptor YWTD-containing repeat homology <YW44>
F:4099-4141/Domain: LDL receptor YWTD-containing repeat homology <YW45>
F:4150-4181/Domain: EGF homology <EG16>
F:4199-4230/Domain: EGF homology <EG17>
F:4235-4266/Domain: EGF homology <EG18>
F:4271-4302/Domain: EGF homology <EG19>
F:4307-4338/Domain: EGF homology <EG20>
F:4343-4373/Domain: EGF homology <EG21>
F:4376-4408/Domain: EGF homology <EG22>
F:4421-4443/Domain: transmembrane #status predicted <TMM>
F:4444-4543/Domain: intracellular #status predicted <INT>
F:116,138,187,276,359,448,731,926,1048,1152,1193,1216,1305,1509,1556,1573,1614,1643,
3485,3659,3786,3837,3952,4074,4124,4178,4278/Binding site: carboxylate (Asn) (covalent)
F:168,2995/Modified site: erythro-beta-hydroxyasparagine (Asn) #status predicted
F:2955/Modified site: erythro-beta-hydroxyaspartic acid (Asp) #status predicted

Query Match 7.9%; Score 102.5; DB 1; Length 4543;

Best Local Similarity 28.0%; Pred. No. 2.9;

Matches 47; Conservative 12; Mismatches 44; Indels 65; Gaps 14;

QY 5 AMLYGVSMLC--VLDLQPSVVEPCGPGKVGQNGNTRCCSLYAPGKEDCPKERCIC 62

Db 2658 SLCYAPSWVCDGANDCGDYS--DERNC-PG-----GRKPKCPANYFA----CPSGRCIP 2704

QY 63 VT-----PEYHCGDPQCKICKHYPCQPGQVRVESQGDIVF---GFRCAV---- 102

Db 2705 MTWTCDEKDDCENGEDETHCSERQDKFC--YPVQ-----PECNNHRCISKLWV 2750

QY 103 -----CAMGTFPSAGRDGCHRLWTNCSQFGFLTFPGKTHNAVCIP 144

Db 2751 CDGADDCGDG---SDSDSRCL--TTCSTGSF---QCPC---TYVCVPE 2788

Search completed: October 26, 2005, 15:52:33

Job time : 27.307 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 26, 2005, 15:29:08 ; Search time 112.299 Seconds
(without alignments)
1039.676 Million cell updates/sec

Title: US-09-545-998B-2
Perfect score: 1301
Sequence: 1 MGAWALYGVSMCLVLDLQ.....PEERGEQTEKHLGRWP 228

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues 1612378

Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Uniprot 03:.*
1: uniprot_prot.*
2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Match	Query Length	ID	Description
1	1301	100.0	228	1 TR18_MOUSE	Q35714 mus musculus
2	1294	99.5	250	2 Q8C4K3	Q8C4K3 mus musculus
3	735.5	56.5	241	1 TR18_HUMAN	Q9Y5U5 homo sapien
4	228.5	17.6	255	1 TNR9_HUMAN	Q07011 homo sapien
5	203.5	15.6	256	1 TNR9_MOUSE	P20334 mus musculus
6	184	14.1	211	2 Q8R037	Q8R037 mus musculus
7	175	13.5	276	2 Q9DD2	Q9DD2 gallus gall
8	154	11.8	275	2 Q80W9	Q80W9 mus musculus
9	149.5	11.5	276	2 Q7IF55	Q7IF55 mus musculus
10	145.5	11.2	196	2 Q8VC17	Q8VC17 mus musculus
11	139	10.7	318	2 Q7T2H3	Q7T2H3 oncorhynch
12	138.5	10.6	270	2 Q75SV8	Q75SV8 felis silve
13	137.5	10.6	290	2 Q76LB4	Q76LB4 paralicthy
14	136	10.5	401	2 Q6PI12	Q6PI12 mus musculus
15	135.5	10.4	467	2 Q80010	Q80010 gallus gall
16	134	10.3	272	1 TNR4_MOUSE	P47741 mus musculus
17	128	9.8	401	1 T11B_MOUSE	Q08712 mus musculus
18	127.5	9.8	267	2 Q02764	Q02764 oryctolagus
19	127	9.8	278	2 Q8SQ34	Q8SQ34 sus scrofa
20	127	9.8	401	1 T11B_RAT	Q08727 rattus norv
21	126.5	9.7	271	1 TNR4_RAT	P15725 rattus norv
22	125.5	9.6	250	1 TNR7_MOUSE	P41272 mus musculus
23	125	9.6	625	1 TR11_MOUSE	Q35305 mus musculus
24	122	9.4	277	1 TNR4_HUMAN	P43489 homo sapien
25	122	9.4	401	1 T11B_HUMAN	Q00300 homo sapien
26	121.5	9.3	269	1 TNR5_BOVIN	Q28203 bos taurus
27	120.5	9.3	415	1 TNR3_MOUSE	P50284 mus musculus
28	120	9.2	616	1 TR11_HUMAN	Q7Y666 homo sapien
29	119.5	9.2	274	2 Q7YRL5	Q7YRL5 canis famil
30	119.5	9.2	277	2 Q8WMO2	Q8WMO2 ovis aries
31	119	9.1	1113	1 COR1_MOUSE	Q92319 mus musculus

32	118.5	9.1	277	1 TNR5_HUMAN	P25942 homo sapien
33	118.5	9.1	387	2 Q6GLN3	Q6GLN3 xenopus lae
34	115.5	8.9	223	2 Q86YK5	Q86YK5 homo sapien
35	115.5	8.9	302	2 Q9PUS0	Q9pus0 salvelinus
36	115	8.8	435	1 TNR3_HUMAN	P36941 homo sapien
37	114	8.8	308	1 ZDH7_HUMAN	Q9Nxf8 homo sapien
38	110.5	8.5	300	1 TR6B_HUMAN	Q9S407 homo sapien
39	110.5	8.5	461	2 Q6VAU8	Q6vaus rattus norv
40	110.5	8.5	474	1 TR1B_RAT	Q80wy6 rattus norv
41	110.5	8.5	1259	2 Q8K3F9	Q8K3f9 rattus norv
42	108.5	8.3	186	2 Q7Z2Y5	Q7zzy5 gallus gall
43	108	8.3	285	2 Q9W71	Q9ow71 oncorhynch
44	107.5	8.3	169	2 Q9JKE0	Q9jke0 rattus norv
45	107.5	8.3	459	2 Q62327	Q62327 mus musculus

ALIGNMENTS

RESULT 1

ID TR18_MOUSE STANDARD; PRT; 228 AA.
AC Q35714; Q9JKE2; Q9JKE3;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 25-OCT-2004 (Rel. 45, Last annotation update)
DE Tumor necrosis factor receptor superfamily member 18 precursor
DE (Glucocorticoid-induced TNFR-related protein).
GN Name=TNfrsf18; Synonyms=Gitr;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORM A).
RX STRAIN=C3H;
RX MEDLINE=97322352; PubMed=9177197; DOI=10.1073/pnas.94.12.6216;
RA Nocentini G., Giunchi L., Ronchetti S., Krausz L.T., Bartoli A., Moraca R., Migliorati G., Riccardi C.;
RT "A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis.";
RT Proc. Natl. Acad. Sci. U.S.A. 94:6216-6221(1997).
RN [2]
RP SEQUENCE FROM N.A. (ISOFORM A).
RX STRAIN=BALB/c;
RX MEDLINE=20256302; PubMed=10798444; DOI=10.1089/104454900314474;
RA Nocentini G., Bartoli A., Ronchetti S., Giunchi L., Cupelli A., Delfino D., Migliorati G., Riccardi C.;
RT "Gene structure and chromosomal assignment of mouse GITR, a member of the tumor necrosis factor/nerve growth factor receptor family.";
RT DNA Cell Biol. 19:205-217(2000).
RN [3]
RP SEQUENCE FROM N.A. (ISOFORMS B; C AND D).
RX TISSUE=Thymus;
RX MEDLINE=20292073; PubMed=10836847;
RA Nocentini G., Ronchetti S., Bartoli A., Spinicelli S., Delfino D., Brunetti L., Migliorati G., Riccardi C.;
RT "Identification of three novel mRNA splice variants of GITR.";
RT Cell Death Differ. 7:408-410(2000).
RN [4]
RP SEQUENCE FROM N.A. (ISOFORM A).
RX STRAIN=C57BL/6J; TISSUE=Thymus;
RX MEDLINE=22354683; PubMed=12466851; DOI=10.1038/nature01266;
RA Okazaki Y., Furuno M., Kasukawa T., Adachi J., Bono H., Kondo S., Nikado I., Osato N., Saito R., Suzuki H., Yamanaka I., Kiyosawa H., Yagi K., Tomaru Y., Hasegawa Y., Nogami A., Schonbach C., Gojobori T., Baldarelli R., Hill D.P., Bult C., Hume D.A., Quackenbush J., Schriml L.M., Kanapin A., Matsuda H., Batalov S., Beisel K.W., Blake J.A., Bradt D., Brusic V., Chothia C., Corbani L.B., Cousins S., Dalla E., Dragani T.A., Fletcher C.F., Forrest A., Frazer K.S., Gaasterland T., Gariboldi M., Giesi C., Godzik A., Gough J., Grimmond S., Gustincich S., Hirokawa N., Jackson I.J., Jarvis B.D., Kanai A., Kawaji H., Kawasaki Y., Kedzierski R.M., King B.L.,

RA Kongaya A., Kurochkin I.V., Lee Y., Lenhard B., Lyons P.A.,
RA Maglott D.R., Maltais L., Marchionni L., McKenzie L., Miki H.,
RA Nagashima T., Numata K., Okido T., Pavan W.J., Pertea G., Pesole G.,
RA Petrovsky N., Pillai R., Pontius J.U., Qi D., Ramachandran S.,
RA Ravasi T., Reed J.C., Reed D.J., Reid J., Ring B.Z., Ringwald M.,
RA Sandelin A., Schneider C., Sample C.A., Setou M., Shinada K.,
RA Sultana R., Takenaka Y., Taylor M.S., Teasdale R.D., Tomita M.,
RA Verardo R., Wagner L., Wahlstedt C., Wang Y., Watanabe Y., Wells C.,
RA Wilming L.G., Wynshaw-Boris A., Yanagisawa M., Yang I., Yang L.,
RA Yuan Z., Zavalan A., Zhu Y., Zimmer K.A., Carninci P., Hayatsu N.,
RA Hirozane-Kishikawa T., Konno H., Nakamura M., Sakazume N., Sato K.,
RA Shiraki T., Waki K., Kawai J., Aizawa K., Arakawa T., Fukuda S.,
RA Hara A., Hashizume W., Imotani K., Ishii Y., Itoh M., Kagawa I.,
RA Miyazaki A., Sakai K., Sasaki D., Shibata K., Shinagawa A.,
RA Yasunishi A., Yoshino M., Waterston R., Lander E.S., Rogers J.,
RA Birney E., Hayashizaki Y.;
RA "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs";
RT Nature 420:563-573(2002).
CC -!- FUNCTION: Receptor for TNFSF18. Seems to be involved in
CC interactions between activated T lymphocytes and endothelial cells
CC and in the regulation of T cell receptor-mediated cell death.
CC Mediated NF-kappa-B activation via the TRAF2/NIK pathway (By
CC similarity).
CC -!- SUBUNIT: Binds to TRAF1, TRAF2, and TRAF3, but not TRAF5 and TRAF6
CC (By similarity).
CC -!- SUBCELLULAR LOCATION: Type I membrane protein (isoforms A, B and
CC C); secreted (isoform D).
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=4;
CC Name=A;
CC IsoId=O35714-1; Sequence=Displayed;
CC Name=B;
CC IsoId=O35714-2; Sequence=VSP_006510;
CC Name=C;
CC IsoId=O35714-3; Sequence=VSP_006511;
CC Name=D;
CC IsoId=O35714-4; Sequence=VSP_006509;
CC -!- TISSUE SPECIFICITY: Preferentially expressed in activated T
CC lymphocytes.
CC -!- INDUCTION: Up-regulated in peripheral mononuclear cells after
CC antigen stimulation/lymphocyte activation.
CC -!- SIMILARITY: Contains 3 TNFR-Cys repeats.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; U82534; AAB91243.1; --
DR EMBL; AF109216; AAF14231.1; --
DR EMBL; AF229432; AAF61566.1; --
DR EMBL; AF229433; AAF61567.1; --
DR EMBL; AF229434; AAF61568.1; --
DR EMBL; AK020762; BAC25639.1; --
DR MGD; MGI:894675; Tnfrsf18.
DR InterPro; IPR006210; IEGF.
DR InterPro; IPR001368; TNFR_c6.
DR SMART; SM00181; EGF; 1.
DR SMART; SM00208; TNFR; 2.
DR PROSITE; PS00652; TNFR_NGFR_1; FALSE NEG.
DR PROSITE; PS50050; TNFR_NGFR_2; FALSE NEG.
KW Alternative splicing; Glycoprotein; Receptor; Repeat; Signal;
KW Transmembrane.
FT SIGNAL 1 19 Potential.
FT CHAIN 20 228 Tumor necrosis factor receptor
FT superfamily member 18.
FT DOMAIN 20 153 Extracellular (Potential).
FT TRANSMEM 154 174 Potential.
FT DOMAIN 175 228 Cytoplasmic (Potential).
FT

FT REPEAT 28 61 TNFR-Cys 1.
FT REPEAT 62 101 TNFR-Cys 2.
FT REPEAT 102 142 TNFR-Cys 3.
FT DISULFID 29 44 By similarity.
FT DISULFID 62 74 By similarity.
FT DISULFID 69 82 By similarity.
FT DISULFID 103 122 By similarity.
FT DISULFID 116 141 By similarity.
FT CARBOHYD 36 36 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 40 40 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 121 121 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 134 134 N-linked (GlcNAc...) (Potential).
FT VARSPLIC 121 228 NCSQGFGLTMFGNKNTHNAVCIPELPTQYGHLLTVFLVW
FT AACIFLTVQLGLHIWQLRQHMCPRETQPPFAEVQLSAED
FT ACSFQPEERGEOTEKCHLGGWRP -> KDPAIRGGAVV
FT S (in isoform D).
FT /FTid=VSP_006509.
FT ETQPPAEVQLSAEDACSFQPEERGEOTEKCHLGGWRP
FT -> VLLQPSHSRRSCQLRLMAASSLRNAGSRQKKSVI
FT WGVGHEAWSSVPOARRIKTCTPAIPLVNAGMLCTLPWAW
FT PCSQQQWRKVVYSGELRLGPMWAAFLI (in isoform
FT B).
FT /FTid=VSP_006510.
FT ETQPPAEVQLSAEDACSFQPEERGEOTEKCHLGGWRP
FT -> GOLCPREGENVSQAHPILQPFYRDPAIRGGAVVS (in
FT isoform C).
FT /FTid=VSP_006511.
FT SQ SEQUENCE 228 AA; 25334 MW; 50D8C275D9C56259 CRC64;
Query Match 100.0%; Score 1301; DB 1; Length 228;
Best Local Similarity 100.0%; Pred. No. 5.3e-106; Mismatches 0; Indels 0; Gaps 0;
Matches 228; Conservative 0;
QY 1 MGAWMLYGVSNMLCVLDLGQPSVVEEPCGPGKVGQSGNNTRCCSLYAPGKEDCPKERC 60
DB 1 MGAWMLYGVSNMLCVLDLGQPSVVEEPCGPGKVGQSGNNTRCCSLYAPGKEDCPKERC 60
QY 61 ICVTPEYHCGDPQCKICKHYPCQPQQRVESQGDIVFGFRVCACAMGTFSGAGRDGHCRLWT 120
DB 61 ICVTPEYHCGDPQCKICKHYPCQPQQRVESQGDIVFGFRVCACAMGTFSGAGRDGHCRLWT 120
QY 121 NCSQGFGLTMFGNKNTHNAVCIPELPTQYGHLLTVFLVMAACIFFLTVQLGLHIWQL 180
DB 121 NCSQGFGLTMFGNKNTHNAVCIPELPTQYGHLLTVFLVMAACIFFLTVQLGLHIWQL 180
QY 181 RQHMCPRETQPPFAEVQLSAEDACSFQPEERGEOTEKCHLGGWRP 228
DB 181 RQHMCPRETQPPFAEVQLSAEDACSFQPEERGEOTEKCHLGGWRP 228
RESULT 2
Q8C4K3 PRELIMINARY; PRT; 250 AA.
AC Q8C4K3
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Mus musculus 16 days embryo head cDNA, RIKEN full-length enriched
DE library, clone: C130084C11 product:tumor necrosis factor receptor
DE superfamily, member 18, full insert sequence.
GN Name=Tnfrsf18;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]_TaxID=10090;
RP SEQUENCE FROM N.A.
RX STRAIN=C57BL/6J; TISSUE=Head;
RX MEDLINE=99279253; PubMed=10349636; DOI=10.1016/S0076-6879(99)03004-9;
RT Carninci P., Hayashizaki Y.;
RL "High-efficiency full-length cDNA cloning.";
RL Meth. Enzymol. 303:19-44(1999).
RN [2]

RN [6] SEQUENCE FROM N.A.
RA Pearce A.;
RL Submitted (OCT-1999) to the EMBL/GenBank/DBJ databases.
RP [7]
RN TISSUE=Kidney;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altshul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton L., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahney J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whitling M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnurch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [8]
RX SEQUENCE OF 24-38.
RP PubMed=15340161; DOI=10.1110/ps.04682504;
RA Zhang Z., Henzel W.J.;
RT "Signal peptide prediction based on analysis of experimentally
verified cleavage sites";
RL Protein Sci. 13:2819-2824(2004).
RN [9]
RX INTERACTIONS WITH TRAF1; TRAF2 AND TRAF3.
RP MEDLINE=98078711; PubMed=9418902;
RA Arch R.H., Thompson C.B.;
RT "4-1BB and Oxa40 are members of a tumor necrosis factor (TNF)-nerve
growth factor receptor subfamily that bind TNF receptor-associated
factors and activate nuclear factor kappaB";
RL Mol. Cell. Biol. 18:558-565(1998).
RN [10]
RX INTERACTIONS WITH TRAF1 AND TRAF2.
RP MEDLINE=98270914; PubMed=9607925;
RA Saouli K., Lee S.Y., Cannons J.L., Yeh W.C., Santana A.,
RA Goldstein M.D., Bangia N., DeBenedette M.A., Mak T.W., Choi Y.,
RA Watts T.H.;
RT "CD28-independent, TRAF2-dependent costimulation of resting T cells by
4-1BB ligand";
RL J. Exp. Med. 187:1849-1862(1998).
RN [11]
RX INTERACTION WITH LRR-REPEAT PROTEIN 1/LRR-1.
RP MEDLINE=21662677; PubMed=11804328; Hill J.M., Kim J.-D., Kwon B.S.;
RA Jang I.-K., Lee Z.-H., Kim H.-H., Hill J.M., Kim J.-D., Kwon B.S.;
RT "A novel leucine-rich repeat protein (LRR-1): potential involvement in
4-1BB-mediated signal transduction";
RL Mol. Cells 12:304-312(2001).
RN -1- FUNCTION: Receptor for TNFSF14/4-1BBL. Possibly active during T
cell activation.
CC -1- SUBUNIT: Interacts with TRAF1, TRAF2 and TRAF3. Interacts with
LRR-repeat protein 1/LRR-1.
CC -1- SUBCELLULAR LOCATION: Type I membrane protein.
CC -1- TISSUE SPECIFICITY: Expressed on the surface of activated T cells.
CC -1- SIMILARITY: Contains 4 TNFR-Cys repeats.
CC -1- DATABASE: NAME=PROV; NOTE=CD guide CDw137 entry;
WWW="http://www.ncbi.nlm.nih.gov/prov/cd/cdw137.htm".
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way

CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; U03397; AAA53133.1; -;
DR EMBL; L12964; AAA62478.2; -;
DR EMBL; AY438976; AAR05440.1; -;
DR EMBL; AL009183; CAB57398.1; -;
DR EMBL; BC006196; AAH06196.1; -;
DR EIR; I38426; I38426.
DR HSSP; Q92956; LJMA.
DR H-InvDB; HIX0000096; -;
DR MIM; 602250; -;
DR GO; GO:0005887; C:integral to plasma membrane; TAS.
DR GO; GO:0004872; F:receptor activity; TAS.
DR GO; GO:0006917; P:induction of apoptosis; TAS.
DR GO; GO:0008285; P:negative regulation of cell proliferation; TAS.
DR InterPro; IPR001368; TNFR_c6.
DR Pfam; PF00020; TNFR_c6; 2.
DR SMART; SM00208; TNFR_2.
DR PROSITE; PS00652; TNFR_NGFR_1; 1.
DR PROSITE; PS00500; TNFR_NGFR_2; 1.
KW Direct protein sequencing; Glycoprotein; Polymorphism; Receptor;
Repeat; Signal; Transmembrane.
FT SIGNAL 1 23
FT CHAIN 24 255
FT DOMAIN 24 186
FT TRANSMEM 187 213
FT DOMAIN 214 255
FT REPEAT 24 45
FT REPEAT 47 86
FT REPEAT 87 118
FT REPEAT 119 159
FT REPEAT 214 255
FT DISULFID 28 37
FT DISULFID 31 45
FT DISULFID 48 62
FT DISULFID 65 78
FT DISULFID 68 86
FT DISULFID 88 94
FT DISULFID 99 106
FT DISULFID 102 117
FT DISULFID 121 133
FT DISULFID 139 158
FT CARBOHYD 138 138
FT CARBOHYD 149 149
FT VARIANT 56 56
FT VARIANT 115 115
FT VARIANT 176 176
FT SEQUENCE 255 AA; 27899 MW; F3A563FE5F00460 CRC64;
Query Match 17.6%; Score 228.5; DB 1; Length 255;
Best Local Similarity 27.2%; Pred. No. 5.2e-12;
Matches 68; Conservative 30; Mismatches 97; Indels 55; Gaps 10;
QY 11 SMLCVLDLGGPSVVEEP-----CCGPKVONGSGNNT-----RCCS 46
DB 11 TLLVLNFERSLQDPCSNCPAGTFCDDNNRNQICSPCPNPSFSSAGGQRTCDICRCKG 70
QY 47 LYAPGKE--DCPKERCICVTPEYHCGPQCKICKYHCQCORVESOGDIVFGRCVACA 104
DB 71 VFTRKECSSTNAECDC-TFGFCHLGAGCSMCBQ-DCKQGQLTKKG-----CKDC 121
QY 105 MGTESAGRDGCHLWNCSCFGFLTMFPGNKTHNAVCPE-----PLPTQY 151
DB 122 FGTNDQKRGICRPWTNCSLDGKSVLVNGTKERDVCGSPADLSPGNASSVTPAPAREP 181
QY 152 GHLTVIF-----LVAAACIFLTTVLGLHLIWLRRQHMCPRETQPFAB-VQLS-AEDAC 204

```

Db      182 GSPQIISFFALTALLFLFLRFSVVKRKKLLYIFKQPFMRPVQTTQEDGC 241
Qy      205 SFQFPEERG 214
Db      242 SCRFPEERG 251

RESULT 5
TNR9 MOUSE
ID TNR9 MOUSE STANDARD; PRT; 256 AA.
AC P20334;
DT 01-FEB-1991 (Rel. 17, Created)
DT 01-FEB-1991 (Rel. 17, Last sequence update)
DT 25-OCT-2004 (Rel. 45, Last annotation update)
DE Tumor necrosis factor receptor superfamily member 9 precursor (4-1BB
DE ligand receptor) (T-cell antigen 4-1BB) (CD137 antigen).
GN Name=Tnfrsf9; Synonyms=Cd137, Cd157, ILA, Ly63;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]_TaxID=10090;
RP SEQUENCE FROM N.A.
RX MEDLINE=89184547; PubMed=2784565;
RA Kwon B.S., Weissman S.M.;
RT "cDNA sequences of two inducible T-cell genes."
RL Proc. Natl. Acad. Sci. U.S.A. 86:1963-1967(1989).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=BALE/c;
RX MEDLINE=94179805; PubMed=8133039;
RA Kwon B.S., Kozak C.A., Kim K.K., Pickard R.T.;
RT "Genomic organization and chromosomal localization of the T-cell
RT antigen 4-1BB."
RL J. Immunol. 152:2256-2262(1994).
RN [3]
RP CHARACTERIZATION, AND SEQUENCE OF 24-29.
RX MEDLINE=93139510; PubMed=7678621;
RA Pollok K.E., Kim Y.-J., Zhou Z., Hurtado J., Kin K.K., Pickard R.T.,
RA Kwon B.S.;
RT Inducible T cell antigen 4-1BB. Analysis of expression and
RT function."
RL J. Immunol. 150:771-781(1993).
CC -!- FUNCTION: Receptor for TNFSF14/4-1BBL. Possibly active during T
CC cell activation.
CC -!- SUBUNIT: Principally an homodimer, but also found as a monomer.
CC Associates with p56-LCK. Interacts with TRAF1, TRAF2 and TRAF3 (By
CC similarity).
CC -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC -!- TISSUE SPECIFICITY: Expressed on the surface of activated T cells.
CC -!- INDUCTION: Optimal by PMA and ionomycin.
CC -!- SIMILARITY: Contains 4 TNFR-Cys repeats.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; J04492; AAA40167.1; -.
CC EMBL; U02567; AAA93113.1; -.
CC PIR; B32393; B32393.
CC FDB; ID00; X-ray; G/H/I/J/K-230-236.
CC MGD; MGI:1101059; Tnfrsf9.
CC InterPro; IPR009030; Grow_fac_recept.
CC InterPro; IPR001368; TNFR_c6.
CC Pfam; PF00020; TNFR_c6; 1.
CC SMART; SM00208; TNFR; 2.
CC PROSITE; PS00652; TNFR_NGFR_1; 1.
CC PROSITE; PS50050; TNFR_NGFR_2; FALSE_NEG.

```

```

KW 3D-structure; Direct protein sequencing; Glycoprotein; Receptor;
KW Repeat; Signal; Transmembrane.
FT SIGNAL 1 23
FT CHAIN 24 256
FT Tumor necrosis factor receptor
FT superfamily member 9.
FT Extracellular (Potential).
FT Potential.
FT Cytoplasmic (Potential).
FT TNFR-Cys 1.
FT TNFR-Cys 2.
FT TNFR-Cys 3.
FT TNFR-Cys 4.
FT By similarity.
FT DISULFID 28 37
FT DISULFID 31 44
FT DISULFID 47 61
FT DISULFID 64 77
FT DISULFID 67 85
FT DISULFID 87 93
FT DISULFID 98 105
FT DISULFID 101 116
FT DISULFID 119 133
FT DISULFID 139 158
FT CARBOHYD 128 128
FT CARBOHYD 138 138
FT SEQUENCE 256 AA; 27598 MW; 93A10D03C60813C4 CRC64;
SQ

Query Match 15.6%; Score 203.5; DB 1; Length 256;
Best Local Similarity 29.8%; Pred. No. 8.1e-10;
Matches 64; Conservative 26; Mismatches 84; Indels 41; Gaps 10;

Qy 22 SVVEPGCGPGKVGNGNTRCCSLYAPGKEDCP---KERCICVTPYVHCGDPOCKICK 78
Db 54 SIGGGPNC-----NIRCVAGYFRFKKFCSTHNAECECI-EGFHCIGPOCTRCE 102
Qy 79 HYPQPGQGVESQGDIVFGRCVACAMGTFS-AGRDGHCRLWTNCSQGFGLTMFPGNKTH 137
Db 103 K-DCRPGQELTKG-----CKTCSLGTENDQNGTGVCRPWNTCSLDGSRVLKGTTEK 154
Qy 138 NAVCIP-----EPLPTEQY-----GH-----LTVIFLVMAACIFFLTTVQGLHWQLR 181
Db 155 DWVCGPPVVSFSPSTTISVTPEGGPGHSLQVLTLFLALTSALLLALIFITLLFSLVKWI 214
Qy 182 RQHMCPRTOPFAEVOLSA--EDACSFQFPPEERG 214
Db 215 RKKPPIHFKQPFKKTGTGAQEDACSCRCPOERG 249

RESULT 6
QBR037 PRELIMINARY; PRT; 211 AA.
AC QBR037;
DT 01-JUN-2002 (TReMBLrel. 21, Created)
DT 01-JUN-2002 (TReMBLrel. 21, Last sequence update)
DT 01-MAR-2004 (TReMBLrel. 26, Last annotation update)
DE Tnfrsf9 protein.
DE Name=Tnfrsf9;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]_TaxID=10090;
RP SEQUENCE FROM N.A.
RX TISSUE=Uterus;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loguercio N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,

```



```

Db 94 GTQEECLPWNCSAQF-QEVRGRTNSTDTTCSSQ-----VVYYVW-SILLPLVI 140
Qy 171 VOGLHWHQWLR-RQHM-----CRPEOPFAEVQLSAEDACSFQPEEREG-EQTEEK 220
Db 141 VGVGIAGLICTRRHLSHTVAKLEFPQOEQ-----QENTIRFPVTEVGFATTEE 192

RESULT 11
Q7T2H3
ID Q7T2H3 PRELIMINARY; PRT; 318 AA.
AC Q7T2H3;
DT 01-OCT-2003 (T:EMBLrel. 25, Created)
DT 01-OCT-2003 (T:EMBLrel. 25, Last sequence update)
DT 01-MAR-2004 (T:EMBLrel. 26, Last annotation update)
DE Tumour necrosis factor receptor.
GN Name=tnfr;
OS Oncorhynchus mykiss (Rainbow trout) (Salmo gairdneri).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;
OC Protacanthopterygii; Salmoniformes; Salmonidae; Oncorhynchus.
OX NCBI_TaxID=8022;
RN [1]
SEQUENCE FROM N.A.
RP TISSUE=Head kidney;
RA Zou J., Secombes C.J.;
RL Submitted (NOV-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ517804; CAD57165.1; -.
DR HSSP; Q92956; IJMA.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR001368; TNFR_c6.
DR InterPro; IPR001368; TNFR_c6.
DR Pfam; PF00020; TNFR_c6; 2.
DR SMART; SM00208; TNFR; 4.
DR PROSITE; PS01186; EGF_2; 1.
DR PROSITE; PS00652; TNFR_NGFR_1; UNKNOWN_2.
DR PROSITE; PS50050; TNFR_NGFR_2; 4.
KW Receptor.
KW Receptor.
SQ SEQUENCE 318 AA; 35254 MW; 78F8135011283B43 CRC64;

Query Match 10.7%; Score 139; DB 2; Length 318;
Best Local Similarity 23.7%; Pred. No. 0.00045;
Matches 50; Conservative 28; Mismatches 91; Indels 42; Gaps 9;

Qy 29 CGFGKVGSGNN--TRCCSLYAPGKDCPKERCICVTPEYHCGDPOCKICKHP-CQPG 85
Db 61 CLPFCVYSSNQKVLREC-----EASSDRQCVCCKT-GYCTDGCCEHCLPVLCLPG 112
Qy 86 QRVESQDIVFGFRVCACAMGTFSAGRDG--HCLRLWNCQFGLTFMFGNKNTHNVC-- 141
Db 113 SGVYNQANPQNDTVCAPCQPGTYSNFDAFTHCQSHTRCGDLGKVKASGTETTDVCGA 172
Qy 142 ----IPLEPLTEQVGHITVI-FLVMAACIFFLTVQLGLHIWQLRRQHMCPRET----- 190
Db 173 FISRWHLTSLWAGLVVTSLLIILICV-----WRAKQSYNPANSSSPGIP 221
Qy 191 -----QFAEVQLSAEDACSFQPEEREGQ 216
Db 222 VEPAPSSFAPEALKFPFECNHSWLSLDQKATE 252

RESULT 12
Q75SV8
ID Q75SV8 PRELIMINARY; PRT; 270 AA.
AC Q75SV8;
DT 05-JUL-2004 (T:EMBLrel. 27, Created)
DT 05-JUL-2004 (T:EMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (T:EMBLrel. 27, Last annotation update)
DE CD134 homologue.
OS Felis silvestris catus (Cat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Carnivora; Fissipedia; Felidae; Felis.
OX NCBI_TaxID=9685;
RN [1]

```

```

RP SEQUENCE FROM N.A.
RA Shimajima M., Miyazawa T., Ikeda Y., McMonagle E.L., Haining H.,
RA Akashi H., Takeuchi Y., Hosie M.J., Willett B.J.;
RT "Use of CD134 as a primary receptor by the feline immunodeficiency
RT virus.";
RL Science 0:0-0(2004).
DR EMBL; AB128982; BAD11363.1; -.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR001368; TNFR_c6.
DR Pfam; PF00020; TNFR_c6; 2.
DR SMART; SM00208; TNFR; 3.
DR PROSITE; PS00652; TNFR_NGFR_1; 2.
DR PROSITE; PS50050; TNFR_NGFR_2; 2.
SQ SEQUENCE 270 AA; 28731 MW; 36A40BAD261140D1 CRC64;

Query Match 10.6%; Score 138.5; DB 2; Length 270;
Best Local Similarity 26.3%; Pred. No. 0.00042;
Matches 59; Conservative 18; Mismatches 72; Indels 75; Gaps 12;

Qy 29 CGFGKVGSGNNTRC-----CSLYAPG-----KEDC-----PKERC 61
Db 47 CFP-----GYGMESRCGQDQTKLQCASGFYNVYEPKPCCTCQNRSGSEPKQRC- 100
Qy 62 CVTPEYHCGDPOCKICKHPQCPQGVESQGLIVFGRCVACAMGTFSAGRDGCHRLWLN 121
Db 101 --TP-----TQDTVCR---CRPG--TEPQDGYDRGVDCAPCPPGHFSPGDDQACKPWTN 147
Qy 122 CSQFGLTFMFGNKNTHNVCIPPEPLTEQVGHITVFLVMAACIFFLTVQLGLHIWQLR 181
Db 148 CTLAGKRTLRPASQSGSDAVCEDRSPPA-----TTP-----WETQ 181
Qy 182 RQHMCPRTPQFAEVQLSAEDACSFQFP--EEERGEQTEKCHLG 224
Db 182 GPVPRPTTQPTTAWPRTSQE--PFTTPAEPGPGQLAAVIGLG 223

RESULT 13
Q76LB4
ID Q76LB4 PRELIMINARY; PRT; 290 AA.
AC Q76LB4;
DT 05-JUL-2004 (T:EMBLrel. 27, Created)
DT 05-JUL-2004 (T:EMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (T:EMBLrel. 27, Last annotation update)
DE CD40.
GN Name=CD40;
OS Paralicthys olivaceus (Japanese flounder).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
OC Acanthomorpha; Acanthopterygii; Percomorpha; Pleuronectiformes;
OC Pleuronectoidae; Paralicthyidae; Paralicthys.
OX NCBI_TaxID=8255;
RN [1]
RP SEQUENCE FROM N.A.
RA Park C., Hirano I., Aoki T.;
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RA Park C., Hirano I., Aoki T.;
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB081752; BAC87848.1; -.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR006209; EGF_Like.
DR InterPro; IPR001368; TNFR_c6.
DR SMART; SM00208; TNFR; 2.
DR PROSITE; PS01186; EGF_2; UNKNOWN_1.
DR PROSITE; PS50050; TNFR_NGFR_2; 1.
SQ SEQUENCE 290 AA; 32396 MW; B6FCF9E35305DFAA CRC64;

Query Match 10.6%; Score 137.5; DB 2; Length 290;
Best Local Similarity 22.9%; Pred. No. 0.00056;
Matches 46; Conservative 28; Mismatches 74; Indels 53; Gaps 11;

Qy 26 EPGCGPGKVQNGSGNNTRCCSLYAPGKDCPKERCICVTPEYHCGDPOCKIC-KHYPCQP 84

```



```
Db 78 QYCDPNK-----NLRVTKPESKTKQ-----SPICILL-GFHCSSGTCVTCVPHATCKP 125
QY 85 GQVRSQGDIVFGFRVCACAMGTFSSAGR--DGHCLRWNCSSQGFGLTTFPGNKTHNAVCI 142
Db 126 GQWAKIKGNLTHDTCVSCSPESFSTSHSWSSVCTKWTCC-BSGYHIQESGTINESDNICV 184
QY 143 BEPLPTEQYGHVTVFLVNAACIFFLTVQ-IGLHIWQLRRQHMCPRETQPPAEVQLSAE 201
Db 185 E---PpRHGGGL-----IACVAVGSLAVVGLMVC-----LCKGET----- 217
QY 202 DACSQFPPEEREGEOTEKCH 222
Db 218 -----KORAKDYLESCH 229

RESULT 14
Q6P112 PRELIMINARY; PRT; 401 AA.
AC Q6P112;
DT 05-JUL-2004 (Tremblrel. 27, Created)
DT 05-JUL-2004 (Tremblrel. 27, Last sequence update)
DT 05-JUL-2004 (Tremblrel. 27, Last annotation update)
DE Tumor necrosis factor receptor superfamily, member 11b
DE (Osteoprotegerin).
GN Name=TnfRsf11b;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Limb;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.W., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Uddin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skaleka U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RN Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
[2]
RP SEQUENCE FROM N.A.
RC TISSUE=Limb;
RA Strausberg R.;
RL Submitted (MAR-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC049782; AH49782.1; -.
DR GO; GO:0005578; C:extracellular matrix (sensu Metazoa); IDA.
DR GO; GO:0005615; C:extracellular space; TAS.
DR GO; GO:0042489; P:negative regulation of ontogenesis (sensu. .; IDA.
DR InterPro; IPR000488; Death.
DR InterPro; IPR011029; DEATH like.
DR InterPro; IPR001368; TNFR_c6.
DR Pfam; PF00020; TNFR_c6; 2.
DR SMART; SM00005; DEATH; 1.
DR SMART; SM00208; TNFR; 4.
DR PROSITE; PS00652; TNFR_NGFR_1; 1.
DR PROSITE; PS50050; TNFR_NGFR_2; 2.
KW Receptor.
```

```
SQ SEQUENCE 401 AA; 45965 MW; 7C708B52EB46BA0E CRC64;
Query Match 10.5%; Score 136; DB 2; Length 401;
Best Local Similarity 28.2%; Pred. No. 0.001;
Matches 44; Conservative 10; Mismatches 54; Indels 48; Gaps 7;
QY 45 CSLVAPG---KEDCP-KERCICV-----TPEVHCGD-----PQCK----- 75
Db 41 CDKCAPGYLKQHCRTVRRKTLCLVCPDHSYTDSTWHTSDCVCSVPCKELQSVKQECNRT 100
QY 76 ---IC-----KHVPQGPQRVSQGDIVFGFRVCACAMGTFSS--AGRDGHC 116
Db 101 HNRVCECEEGRYLEIEFCLKHRSCTPGSGVQAGTPEQNTVCKKCPDGFSGTSSKAPC 160
QY 117 RLWNCSSQGFGLTTFPGNKTHNAVCIPEPLTEQYQ 152
Db 161 RKHTNCSTFGLLLIQKGNATHDNCVSGNREATQKCG 196

RESULT 15
Q80010 PRELIMINARY; PRT; 467 AA.
AC Q80010;
DT 01-JUN-2003 (Tremblrel. 24, Created)
DT 01-JUN-2003 (Tremblrel. 24, Last sequence update)
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)
DE CD30 protein precursor.
GN Name=CD30;
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
OX NCBI_TaxID=9031;
RN [1]
RP SEQUENCE FROM N.A.
RX PubMed=15356338;
RA Burgess S.C., Young J.R., Baaten B.J.G., Hunt L., Ross L.N.J.,
RA Parcells M.S., Kumar M.S., Tregaskes C.A., Lee L.F., Davison T.F.;
RT "Marek's disease is a natural model for lymphomas overexpressing
RT Hodgkin's disease antigen (CD30).";
RL Proc. Natl. Acad. Sci. U.S.A. 101:13879-13884(2004).
[2]
RP SEQUENCE FROM N.A.
RA Burgess S.C.;
RL Thesis (1998); Bristol University, UK.
DR EMBL; AJ276964; CAC79223.1; -.
DR HSSP; O92956; 1JWA.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0004872; F:receptor activity; IEA.
DR GO; GO:0005031; F:tumor necrosis factor receptor activity; IEA.
DR GO; GO:0019221; P:cytokine and chemokine mediated signaling p. .; IEA.
DR InterPro; IPR011366; TNFRc6_2.
DR InterPro; IPR001368; TNFR_c6.
DR Pfam; PF00020; TNFR_c6; 1.
DR FIRSF; FIRSF001968; TNFR_2; 1.
DR SMART; SM00208; TNFR; 4.
DR PROSITE; PS00652; TNFR_NGFR_1; UNKNOWN_2.
DR PROSITE; PS50050; TNFR_NGFR_2; 1.
KW Signal.
FT SIGNAL. 1 21 Potential.
FT CHAIN 22 467 CD30 protein.
SQ SEQUENCE 467 AA; 51350 MW; F9AD4F7DDEEC8588 CRC64;
Query Match 10.4%; Score 135.5; DB 2; Length 467;
Best Local Similarity 21.1%; Pred. No. 0.0013;
Matches 71; Conservative 33; Mismatches 95; Indels 137; Gaps 18;
QY 1 MGAWMLYGVSMCLVLDLQPSVSEPGGPKGVONGSGNWT--RCC-----SLYAPCK-- 52
Db 8 LGLWLLLL---LQDIQGAFPQPPFTSSHSC--DTLKNWFYDTELGRCCYQCPSGYAKKSC 62
QY 53 -----EDC-----PKERC-ICV--TPEYH-----CGDPQCKIC----- 77
```


Db 63 PMDPDEDCMRGPEQYLNQSPKPRCDACVLCTKEPLVEKAPCSFNSSRVCSRCRPGMFCQ 122
QY 78 -----KHYPQOPQORVESQGDIVGFRFCVACAMGTFS--AGRDGHCLWNCNQ 124
Db 123 TAAKNTCMRCORHTACKPGFGVKIRGTSETDVSCECPGTFSDQSSSTDVCKPHTDCAK 182
QY 125 FGFLTMFPNGKTHNVC----- 141
Db 183 LNKVAQKGNATHDQVCTDQLPSYLTPTDTSSIRITNETDDSDVLKENANPVTLASILSSA 242
QY 142 ---IPEPLPTEQ-----YCHLTVIFLVMAACIFFLTTVOLG-LHIWQLRROHMCP 187
Db 243 TTEIPGSTPEEEALAGTSPTLAKGETTTRGLVFWAVVLSVMVLPVGMLSFWOK---VCK 299
QY 188 RE-----TQPPFAEVOLSAEDACSFQPEEE 212
Db 300 KRIFILKQKRSDLVDKYAKITLTT-DKC-----PEEE 330

Search completed: October 26, 2005, 15:51:38
Job time : 118.299 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 26, 2005, 15:28:42 ; Search time 141.311 Seconds
(without alignments)
659.602 Million cell updates/sec

Title: US-09-545-998B-4
Perfect score: 1386
Sequence: 1 MAQHGAMGAFRALCGLALIC.....EEBGRSAEEKRLGLMW 241

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A Geneseq_16Dec04:*
1: geneseqp1980s:*
2: geneseqp1980s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1386	100.0	241	2 AAW37839	Aaw37839 Amino aci
2	1386	100.0	241	2 AAY06605	Aay06605 Human TNF
3	1386	100.0	241	3 AAB33431	Aab33431 Human PRO
4	1386	100.0	241	3 AAY71467	Aay71467 Human PRO
5	1386	100.0	241	3 AAB27651	Aab27651 Human pro
6	1386	100.0	241	3 AAY95895	Aay95895 Human tum
7	1386	100.0	241	3 AAB24409	Aab24409 Human PRO
8	1386	100.0	241	4 AAB47054	Aab47054 Human PRO
9	1386	100.0	241	4 AAB20115	Aab20115 Human imm
10	1386	100.0	241	4 AAB53090	Aab53090 Human ang
11	1386	100.0	241	4 AAB47289	Aab47289 PRO364 po
12	1386	100.0	241	4 AAB50982	Aab50982 Human PRO
13	1386	100.0	241	4 AAB50910	Aab50910 Human PRO
14	1386	100.0	241	5 AAE28161	Aae28161 Human TR1
15	1386	100.0	241	6 ABO08442	Abu08442 Amino aci
16	1386	100.0	241	6 AAO16574	Aao16574 Human tum
17	1386	100.0	241	7 ADN39966	Adn39966 Cancer/an
18	1386	100.0	241	7 AAO23091	Aao23091 Human ene
19	1386	100.0	241	8 ADH43131	Adh43131 Human TNF
20	1386	100.0	241	8 ADL91869	Adl91869 Human PRO
21	1386	100.0	241	8 ADO20289	Ado20289 Human PRO
22	1386	100.0	241	8 ADP55559	Adp55559 Human PRO
23	1386	100.0	241	8 ADT94287	Adt94287 Human PRO
24	1382	99.7	240	8 ADR46662	Adr46662 Cancer-as
25	1347	97.2	235	3 AAY44825	Aay44825 Human mol

26	1347	97.2	235	6 AAO16576	Aao16576 Human tum
27	1347	97.2	235	6 AAO23093	Aao23093 Human ene
28	1322.5	95.4	234	3 AAY95879	Aay95879 Human tum
29	1322.5	95.4	234	3 AAY52158	Aay52158 Tumour ne
30	1322.5	95.4	234	5 AAE28158	Aae28158 Human TR1
31	1322.5	95.4	234	6 ABU08439	Abu08439 Amino aci
32	1322.5	95.4	234	6 AAO16575	Aao16575 Human tum
33	1322.5	95.4	234	6 ADA09435	Ada09435 Human TR1
34	1322.5	95.4	234	6 AAO23092	Aao23092 Human ene
35	1322.5	95.4	234	8 ADH43105	Adh43105 Human TNF
36	1322.5	95.4	234	8 ADO20305	Ado20305 Human PRO
37	1306.5	94.3	246	5 ABB89386	Abb89386 Human pol
38	1293.5	93.3	228	6 AAO23094	Aao23094 Human ene
39	1290.5	93.1	228	2 AAW37840	Aaw37840 Truncated
40	1290.5	93.1	228	6 AAO16577	Aao16577 Human tum
41	1290.5	93.1	228	6 AAO23099	Aao23099 Human ene
42	1274.5	92.0	240	3 AAY95881	Aay95881 Human tum
43	1274.5	92.0	240	3 AAY52160	Aay52160 TR1SV2 a
44	1274.5	92.0	240	5 AAE28160	Aae28160 Human TR1
45	1274.5	92.0	240	6 ABU08441	Abu08441 Amino aci

ALIGNMENTS

RESULT 1

AAW37839
ID AAW37839 standard; protein; 241 AA.

XX AC AAW37839;

XX DT 28-JUL-1998 (first entry)

XX DE Amino acid sequence of the human 312C2 T cell protein.

XX KW Human 312C2 T cell protein; thymus cell; spleen cell; T cell;
XX KW antigen-specific T cell proliferation; cytokine production by T-cell;
XX KW apoptosis; cancer; haematopoietic cells; lymphoid cell;
XX KW autoimmune disorders.

XX OS Homo sapiens.

XX PN WO9806842-A1.

XX PD 19-FEB-1998.

XX PF 14-AUG-1997; 97WO-US013931.

XX PR 16-AUG-1996; 96US-00689943.

XX PA 07-OCT-1996; 96US-0027901P.

XX (SCHE) SCHERING CORP.

XX Gorman DM, Randall TD, Zlotnik A;

XX WPI; 1998-159534/14.

XX N-PSDB; AAV19153.

XX Isolated 312C2 T cell gene - used to develop products for treating, e.g. cancers, auto-immune disorders, transplantation rejection and other T cell disorders.

XX Claim 2; Page 59-60; 71pp; English.

XX This is the amino acid sequence encoding the human 312C2 T cell protein.
XX The 312C2 proteins are expressed in thymus cells and are induced on T cells and spleen cells following activation. Engagement of 312C2 stimulates proliferation of T cell clones, antigen-specific proliferation and cytokine production by T-cells, and potentiates T cell expansion or apoptosis. The products can be used in the treatment of conditions associated with abnormal physiology or development, including abnormal proliferation, e.g. cancerous conditions or degenerative conditions. They can be used in the regulation or development of haematopoietic cells,

CC e.g. lymphoid cells which affect immunological responses, e.g. autoimmune
 CC disorders
 XX
 SQ Sequence 241 AA;

Query Match 100.0%; Score 1386; DB 2; Length 241;
 Best Local Similarity 100.0%; Pred. No. 2.2e-101; Mismatches 0; Indels 0; Gaps 0;
 Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAQHGAMGAFRALCGIALCALSLGQRTGCGGCGPGRLLLTGTDTDARCCRVHTTRCCRD 60
 DB 1 MAQHGAMGAFRALCGIALCALSLGQRTGCGGCGPGRLLLTGTDTDARCCRVHTTRCCRD 60

QY 61 YPGECCSEWDCMCVQPEFHCGDPCCTTCRHHPCPPGQGVQSGKFSFGFCIDCASGTF 120
 DB 61 YPGECCSEWDCMCVQPEFHCGDPCCTTCRHHPCPPGQGVQSGKFSFGFCIDCASGTF 120

QY 121 SGGHEGCHKPWTDCQFGFLTVFPGNKTHNAVCPGSPAEPLGMLTVVLLAAVACVLL 180
 DB 121 SGGHEGCHKPWTDCQFGFLTVFPGNKTHNAVCPGSPAEPLGMLTVVLLAAVACVLL 180

QY 181 TSAQLGLHIWQLRSQCMWPRETQLLEVPSTEDARSCOFFPEERGERSAEKGRLGDLW 240
 DB 181 TSAQLGLHIWQLRSQCMWPRETQLLEVPSTEDARSCOFFPEERGERSAEKGRLGDLW 240

QY 241 V 241
 DB 241 V 241

RESULT 2
 ID AAY06605
 AAAY06605 standard; protein; 241 AA.
 AC
 XX
 XX
 26-OCT-1999 (first entry)
 XX
 XX
 DE
 XX
 KW PRO364; tumour necrosis factor receptor; human; apoptosis; inflammation;
 KW antiinflammatory; NF-KB activation; autoimmune disease; therapy.
 XX
 OS Homo sapiens.

Key Location/Qualifiers
 FT Peptide 1..25
 FT /note= "signal peptide"
 FT Protein 26..241
 FT /note= "mature protein"
 FT Modified-site 146
 FT /note= "N-glycosylated"
 FT Domain 162..180
 FT /note= "transmembrane domain"

XX
 PN W09940196-A1.
 XX
 XX
 PD 12-AUG-1999.
 XX
 PF 09-FEB-1999; 99WO-US002642.
 XX
 PR 09-FEB-1998; 98US-0074087P.
 XX
 XX (GETH) GENENTECH INC.
 XX
 PI Ashkenazi AJ, Gurney AL, Marsters SA, Pitti RM, Wood WI;
 PI Goddard A;
 XX
 XX WPI; 1999-494296/41.
 DR N-PSDB; AAX87670.
 XX
 XX Tumor necrosis factor receptor homologue - useful for, e.g. modulating
 PT apoptosis and NF-KB activation and proinflammatory or autoimmune

PT responses.
 XX
 PS
 XX Claim 17; Fig 2A; 104pp; English.

The present sequence represents human PRO364, a novel member of the tumour necrosis factor receptor family. The sequence was deduced from a bone marrow cDNA clone (see AAX87670). Methods for the recombinant production of PRO364 polypeptides, e.g. in CHO, Escherichia coli or yeast host cells, are provided. Claimed polypeptides comprise amino acids 1-241, 1-X, 26-241 (i.e. the mature protein) and 26-X of the present sequence, where X is any one of amino acid residues 157-167 of PRO364. PRO364 polypeptides are useful for modulating apoptosis, NF-KB activation and proinflammatory or autoimmune responses in mammalian cells (claimed). Chimeric molecules comprising a PRO364 polypeptide fused to a heterologous sequence such as epitope tag or immunoglobulin Fc region are also claimed. PRO364 can be used in assays to identify other proteins or molecules involved in binding interactions. This is useful for identifying inhibitors or agonists of receptor/ligand binding. The PRO364 polypeptides may also be combined with an agent that is cytotoxic, chemotherapeutic or a growth inhibitor. PRO364 antibodies are useful in diagnostic methods, purification methods and also in therapy, e.g. as inhibitors

XX
 SQ Sequence 241 AA;

Query Match 100.0%; Score 1386; DB 2; Length 241;
 Best Local Similarity 100.0%; Pred. No. 2.2e-101; Mismatches 0; Indels 0; Gaps 0;
 Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAQHGAMGAFRALCGIALCALSLGQRTGCGGCGPGRLLLTGTDTDARCCRVHTTRCCRD 60
 DB 1 MAQHGAMGAFRALCGIALCALSLGQRTGCGGCGPGRLLLTGTDTDARCCRVHTTRCCRD 60

QY 61 YPGECCSEWDCMCVQPEFHCGDPCCTTCRHHPCPPGQGVQSGKFSFGFCIDCASGTF 120
 DB 61 YPGECCSEWDCMCVQPEFHCGDPCCTTCRHHPCPPGQGVQSGKFSFGFCIDCASGTF 120

QY 121 SGGHEGCHKPWTDCQFGFLTVFPGNKTHNAVCPGSPAEPLGMLTVVLLAAVACVLL 180
 DB 121 SGGHEGCHKPWTDCQFGFLTVFPGNKTHNAVCPGSPAEPLGMLTVVLLAAVACVLL 180

QY 181 TSAQLGLHIWQLRSQCMWPRETQLLEVPSTEDARSCOFFPEERGERSAEKGRLGDLW 240
 DB 181 TSAQLGLHIWQLRSQCMWPRETQLLEVPSTEDARSCOFFPEERGERSAEKGRLGDLW 240

QY 241 V 241
 DB 241 V 241

RESULT 3
 AAB33431
 ID AAB33431 standard; protein; 241 AA.
 XX
 AC AAB33431;
 XX
 XX
 DT 29-JAN-2001 (first entry)
 XX
 XX Human PRO364 protein UNQ319 SEQ ID NO:92.
 DE
 XX
 KW Human; immune related disease; diagnosis; antiinflammatory; cardiant;
 KW dermatological; antiarthritic; antirheumatic; immunosuppressive;
 KW haemostatic; antithyroid; antidiabetic; nootropic; neuroprotective;
 KW antianaemic; hepatotropic; virucide; antipsoriatic; antiallergic;
 KW antiasthmatic; systemic lupus erythematosus; rheumatoid arthritis;
 KW osteoarthritis; spondyloarthropathy; systemic sclerosis; sarcoidosis;
 KW idiopathic inflammatory myopathy; Sjogren's syndrome; thyroiditis;
 KW systemic vasculitis; autoimmune haemolytic anaemia; diabetes mellitus;
 KW autoimmune thrombocytopaenia; immune-mediated renal disease;
 KW demyelinating disease; hepatobiliary disease; Whipple's disease;
 KW inflammatory bowel disease; gluten-sensitive enteropathy;
 KW autoimmune disease; immune-mediated skin disease; allergic disease;
 KW immunological disease; transplantation associated disease;

FT Modified-site /note= "N-myristoylation site"
 FT 122..128
 FT /note= "N-myristoylation site"
 FT 146..150
 FT /note= "Asn is N-glycosylated"
 FT 156..162
 FT /note= "N-myristoylation site"
 FT 163..183
 FT /label= Transmembrane_domain
 FT 166..177
 FT /note= "Prokaryotic membrane lipoprotein lipid attachment site"
 FT 171..193
 FT /note= "Leucine zipper pattern"
 XX
 XX WO200032778-A2.
 XX
 XX 08-JUN-2000.
 XX
 XX 30-NOV-1999; 99WO-US028409.
 XX
 XX 01-DEC-1998; 98WO-US025108.
 XX 16-DEC-1998; 98US-0112850P.
 XX 22-DEC-1998; 98US-0113296P.
 XX 20-JUL-1999; 99US-0144758P.
 XX 26-JUL-1999; 99US-0145698P.
 XX
 XX (GETH) GENENTECH INC.
 XX
 XX Chen J, Goddard A, Gurney AL, Hillan K, Napier M, Wood WI;
 PI WPI; 2000-412325/35.
 DR N-PSDB; AAD01240.
 DR
 XX New composition useful for inhibiting neoplastic cell growth and for
 PT treating cancers, comprises PRO655, PRO344 or PRO364 polypeptide or their
 PT antagonists.
 XX
 XX Claim 31; Fig 4; 108pp; English.
 XX
 XX The present sequence is the human PRO364 protein, encoded by the cDNA
 CC clone, designated as DNA7365-1206. It is isolated from human small
 CC intestine tissue cDNA library, identified using probes based on the
 CC consensus sequence DNA4825, relative to the incyte expressed sequence
 CC tag (EST) 3003460. This EST has homology to tumour necrosis factor
 CC receptor (TNFR) family of polypeptides. PRO364 sequence also shows
 CC homology to members of the TNFR family and mouse GTR protein. This clone
 CC is assigned the ATCC deposit No: 209436. PRO364 functions as a neoplastic
 CC cell growth inhibitor and is used for treating tumours, using an
 CC effective amount of PRO655, PRO364 and PRO344. This composition is
 CC especially useful for treatment of human cancers such as breast,
 CC prostate, colon, lung, renal, ovarian and CNS, leukemia and melanoma
 XX
 XX Sequence 241 AA;
 SQ
 Query Match 100.0%; Score 1386; DB 3; Length 241;
 Best Local Similarity 100.0%; Pred. No. 2.2e-101;
 Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MAQHGWAGAFRALCGLLALCNLSLGPRTGGCGGPRLLLTGTDTARCCRVHTTRCCRD 60
 DB 1 MAQHGWAGAFRALCGLLALCNLSLGPRTGGCGGPRLLLTGTDTARCCRVHTTRCCRD 60
 QY 61 YPEEECCSEWDCMCVPEPHCGDPCCTTCRHHPCPPGQGVQSGKFSFGQICDCASGTF 120
 DB 61 YPEEECCSEWDCMCVPEPHCGDPCCTTCRHHPCPPGQGVQSGKFSFGQICDCASGTF 120
 QY 121 SGHEHGCKPWTCTQFGFLTVPFGNKTNAVCPGSPPAEPGLGWLTVVLLAAACVLL 180
 DB 121 SGHEHGCKPWTCTQFGFLTVPFGNKTNAVCPGSPPAEPGLGWLTVVLLAAACVLL 180
 QY 181 TSAQLGLHIWQLRSQCMWPRETQLLLEVPSTEDARSCQFPEERGERSAEBKGLGLDLW 240

Db 181 TSAQLGLHIWQLRSQCMWPRETQLLLEVPSTEDARSCQFPEERGERSAEBKGLGLDLW 240
 QY 241 V 241
 Db 241 V 241
 RESULT 5
 AAB27651
 ID AAB27651 standard; protein; 241 AA.
 XX
 XX AAB27651;
 XX
 XX 26-JAN-2001 (first entry)
 XX
 XX Human protein PRO364.
 XX
 XX Cardiovascular; endothelial; angiogenic disorder; PRO179; PRO238; PRO364;
 KW PRO844; PRO846; PRO1760; PRO205; PRO321; PRO333; PRO840; PRO877; PRO878;
 KW PRO879; PRO882; PRO885; PRO887; gene therapy.
 XX
 XX Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FT Peptide 1..25
 FT /label= Signal peptide
 XX
 XX WO200053757-A2.
 XX
 XX 14-SEP-2000.
 XX
 XX 24-FEB-2000; 2000WO-US005004.
 XX
 XX 08-MAR-1999; 99WO-US005028.
 XX 12-MAR-1999; 99US-0123957P.
 XX 02-JUN-1999; 99WO-US012252.
 XX 20-JUL-1999; 99US-0144758P.
 XX 26-JUL-1999; 99US-0145698P.
 XX 01-SEP-1999; 99WO-US020111.
 XX 15-SEP-1999; 99WO-US021090.
 XX 30-NOV-1999; 99WO-US028313.
 XX 02-DEC-1999; 99WO-US028409.
 XX 05-JAN-2000; 2000WO-US000219.
 XX 18-FEB-2000; 2000WO-US004341.
 XX 22-FEB-2000; 2000WO-US004342.
 XX
 XX (GETH) GENENTECH INC.
 XX
 XX Ashkenazi AJ, Baker KP, Ferrara N, Gerber H, Gerritsen ME;
 PI Goddard A, Gurney AL, Hillan KJ, Marsters SA, Paoni NF, Pitti RM;
 PI Watanabe CK, Williams PM, Wood WI;
 XX
 XX WPI: 2000-611444/58.
 XX N-PSDB; AAA99903.
 XX
 XX Novel PRO polypeptides and agonists and antagonists of them, used to
 PT diagnose and treat cardiovascular, endothelial and angiogenic disorders.
 XX
 XX Claim 71; Fig 6; 181pp; English.
 XX
 XX The present invention relates to methods for stimulating or inhibiting
 CC angiogenesis and cardiovascularization. The methods involve the use of
 CC pharmaceutical compositions based on the following proteins, PRO179,
 CC PRO238, PRO364, PRO844, PRO846, PRO1760, PRO205, PRO321, PRO333, PRO840,
 CC PRO877, PRO878, PRO879, PRO882, PRO885 or PRO887. These proteins were
 CC identified by isolating cDNA clones encoding secreted proteins. The
 CC proteins of the invention may be used to diagnose and treat
 CC cardiovascular, endothelial or angiogenic disorders. The present sequence
 CC is one of the proteins of the invention
 XX
 XX Sequence 241 AA;

Query Match 100.0%; Score 1386; DB 3; Length 241;
Best Local Similarity 100.0%; Pred. No. 2.2e-101;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAQHGMAGAFRALCGLALLCALSLGQRTGGCGGPRLLLTGTGDARCCRVHTTRCCRD 60
DB 1 MAQHGMAGAFRALCGLALLCALSLGQRTGGCGGPRLLLTGTGDARCCRVHTTRCCRD 60

QY 61 YPGECCSEWDCMCVQPEFHCGDPCCTTCRHHPCPPGQGVQSQGKFSFGQICDCASGTF 120
DB 61 YPGECCSEWDCMCVQPEFHCGDPCCTTCRHHPCPPGQGVQSQGKFSFGQICDCASGTF 120

QY 121 SGHEGHCXKFWTDCTQFGFLTVPFGKNTNNAVCVPGSPPAEPLGWLTVLLVAACVLLL 180
DB 121 SGHEGHCXKFWTDCTQFGFLTVPFGKNTNNAVCVPGSPPAEPLGWLTVLLVAACVLLL 180

QY 181 TSAQLGLHIWQLRSQCMWPRETQLLLEVPSTEDARSCQFPEEERGERSAEKGRIGDLW 240
DB 181 TSAQLGLHIWQLRSQCMWPRETQLLLEVPSTEDARSCQFPEEERGERSAEKGRIGDLW 240

QY 241 V 241
DB 241 V 241

RESULT 6
AA95895
ID AA95895 standard; protein; 241 AA.
AC AA95895;
XX
DT 20-NOV-2000 (first entry)
XX
DE Human tumour necrosis factor receptor-like protein TR11 mutein.
XX
KW TR11; human; tumour necrosis factor receptor-like protein;
KW immunodeficiency; autoimmune disease; rheumatoid arthritis;
KW immunosuppressive; antirheumatic; antiarthritic; haemostatic;
KW dermatological; antiinflammatory; therapy; diagnosis; mutein; mutant.
XX
OS Homo sapiens.
XX
PN WO200050459-A1.
XX
PD 31-AUG-2000.
XX
PF 23-FEB-2000; 2000WO-US004572.
XX
PR 24-FEB-1999; 99US-0121648P.
PR 13-MAY-1999; 99US-0134172P.
PR 16-JUL-1999; 99US-0144076P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Ni J;
XX
DR WPI; 2000-572072/53.
XX
PT Human tumor necrosis factor receptor-like proteins useful for diagnosis,
PT prevention and treatment of disease states associated with aberrant cell
PT survival such as autoimmune disease and rheumatoid arthritis.
XX
PS Disclosure; 294-295; 278pp; English.
XX
CC The present sequence is that of human tumour necrosis factor receptor-
CC like protein TR11 (see also AA95895), a novel protein showing identity
CC to murine glucocorticoid induced tumour necrosis factor receptor family-
CC related gene. The invention provides highly conserved TR11, TR11SV1 and
CC TR11SV2 proteins (see AA95879-81), as well as vectors, host cells and
CC recombinant methods for their production. TR11, TR11SV1 and/or TR11SV2
CC polypeptides are useful for treating, preventing, prognosis and/or
CC diagnosis of an immunodeficiency, especially common variable

CC immunodeficiency, X-linked agammaglobulinemia, severe combined
CC immunodeficiency (SCID), Wiskott-Aldrich syndrome or X-linked
CC immunoglobulin deficiency with hyper IgM. TR11, TR11SV1 and/or TR11SV2
CC antagonists (e.g. antibodies) are used to treat, prevent, prognosis and/or
CC diagnosis of an autoimmune disease, especially rheumatoid arthritis, systemic
CC lupus erythematosus, thrombocytopenia purpura or IGA nephropathy. The
CC polypeptides, polynucleotides and/or antibodies can be administered to
CC cells in vitro, ex vivo or in vivo or to a multicellular organism.
CC Soluble forms of the polypeptides may also be used. Methods for screening
CC for agonist/antagonist compounds are also provided
XX
SQ Sequence 241 AA;
Query Match 100.0%; Score 1386; DB 3; Length 241;
Best Local Similarity 100.0%; Pred. No. 2.2e-101;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAQHGMAGAFRALCGLALLCALSLGQRTGGCGGPRLLLTGTGDARCCRVHTTRCCRD 60
DB 1 MAQHGMAGAFRALCGLALLCALSLGQRTGGCGGPRLLLTGTGDARCCRVHTTRCCRD 60

QY 61 YPGECCSEWDCMCVQPEFHCGDPCCTTCRHHPCPPGQGVQSQGKFSFGQICDCASGTF 120
DB 61 YPGECCSEWDCMCVQPEFHCGDPCCTTCRHHPCPPGQGVQSQGKFSFGQICDCASGTF 120

QY 121 SGHEGHCXKFWTDCTQFGFLTVPFGKNTNNAVCVPGSPPAEPLGWLTVLLVAACVLLL 180
DB 121 SGHEGHCXKFWTDCTQFGFLTVPFGKNTNNAVCVPGSPPAEPLGWLTVLLVAACVLLL 180

QY 181 TSAQLGLHIWQLRSQCMWPRETQLLLEVPSTEDARSCQFPEEERGERSAEKGRIGDLW 240
DB 181 TSAQLGLHIWQLRSQCMWPRETQLLLEVPSTEDARSCQFPEEERGERSAEKGRIGDLW 240

QY 241 V 241
DB 241 V 241

RESULT 7
AAB24409
ID AAB24409 standard; protein; 241 AA.
XX
AC AAB24409;
XX
DT 07-NOV-2000 (first entry)
XX
DE Human PRO364 protein sequence SEQ ID NO:117.
XX
KW Human; PRO; promotion; inhibition; angiogenesis; cardiovascularisation;
KW diagnosis; trauma; wound; cancer; atherosclerosis; cardiac hypertrophy;
KW angiogenic; proliferative; cardiant; cardiovascular; antiatherosclerotic;
KW cytostatic; gene therapy; vaccine.
XX
OS Homo sapiens.
XX
PN WO200032221-A2.
XX
PD 08-JUN-2000.
XX
PF 30-NOV-1999; 99WO-US028313.
XX
PR 01-DEC-1998; 98WO-US025108.
PR 16-DEC-1998; 98US-0112850P.
PR 12-JAN-1999; 99US-0115554P.
PR 08-MAR-1999; 99WO-US0005028.
PR 12-MAR-1999; 99US-0123957P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.

```

PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-OCT-1999; 99US-0162506P.
XX (GETH ) GENENTECH INC.
PA Ashkenazi AJ, Baker KP, Ferrara N, Gerber H, Hillan KJ;
PI Goddard A, Godowski PJ, Gurney AL, Klein RD, Kuo SS, Paoni NF;
PI Smith V, Watanabe CK, Williams PM, Wood WI;
XX
XX WPI; 2000-412154/35.
XX N-PSDB; AAA77604.
XX
XX Nucleic acids encoding PRO polypeptides useful for preventing, diagnosing
XX and treating diagnosing a cardiovascular, endothelial or angiogenic
XX disorders in mammals.
XX
XX Claim 72; Fig 44; 315pp; English.
XX
XX The present invention describes nucleic acids encoding PRO polypeptides
XX useful for preventing, diagnosing and treating diagnosing a
XX cardiovascular, endothelial or angiogenic disorder in mammals by
XX modulating cell proliferation, angiogenesis and cardiovascularisation,
XX and for identifying agonists and antagonists of these processes. The
XX nucleic acids and the proteins they encode may be used in the prevention,
XX treatment and diagnosis of diseases associated with inappropriate PRO
XX expression such as cardiovascular, endothelial or angiogenic disorders in
XX mammals (e.g. atherosclerosis, cancers and cardiac hypertrophy). For
XX example, the nucleic acids (NCs) and vectors containing them and the PRO
XX polypeptide may be used to treat disorders associated with decreased PRO
XX expression. AAA77510 to AAA77721 and AAB24388 to AAB24435 represent
XX nucleotide and protein sequences used in the exemplification of the
XX present invention
XX
XX Sequence 241 AA;
XX
Query Match 100.0%; Score 1386; DB 3; Length 241;
Best Local Similarity 100.0%; Pred. No. 2.2e-101;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAQHGGAMGAFRALCGLLALLCALSLGQRTGGPGCGPGRLLLTGTGTARDCCRVHTTRCCRD 60
Db 1 MAQHGGAMGAFRALCGLLALLCALSLGQRTGGPGCGPGRLLLTGTGTARDCCRVHTTRCCRD 60
QY 61 YPGECCSEBDCMCVQPEFHCGDPCCCTCRHHPCPGQGVQSGKFSFGQCIDCASGTF 120
Db 61 YPGECCSEBDCMCVQPEFHCGDPCCCTCRHHPCPGQGVQSGKFSFGQCIDCASGTF 120
QY 121 SGHGHGCKPWTDTCTQFGFLTVPFGNKTNNAVCPGSPPAEPGLGMLTVLLVAACVLL 180
Db 121 SGHGHGCKPWTDTCTQFGFLTVPFGNKTNNAVCPGSPPAEPGLGMLTVLLVAACVLL 180
QY 181 TSAQLGLHITWQLRSQCMWRETQLLEVPSTEDARSCQFPPEERGERSAEBKRGRLGLDW 240
Db 181 TSAQLGLHITWQLRSQCMWRETQLLEVPSTEDARSCQFPPEERGERSAEBKRGRLGLDW 240
QY 241 V 241
Db 241 V 241
XX
XX AAB47054 standard; protein; 241 AA.
XX
XX AAB47054;
XX
XX 08-MAY-2001 (first entry)
XX
XX Human PRO364.

```

```

XX KW PRO364; human; glucocorticoid-induced tumor necrosis factor; receptor;
XX KW hGfTR; ligand; hGfTRL; PRO175; tumour necrosis factor receptor; TNFR;
XX KW human umbilical vein endothelial cell; HUVEC; cardiac hypertrophy;
XX KW myocardial infarction; PGF 2alpha; trauma; cancer; angiogenesis;
XX KW age-related macular degeneration; antibody; periodontal disease;
XX KW vascular-related drug targeting; atherosclerosis; hypertension;
XX KW inflammatory vasculitides; Reynaud's disease; aneurysm;
XX KW arterial restenosis; thrombophlebitis; tumor angiogenesis; lung; liver;
XX KW fibrosis; neuropathy; rheumatoid arthritis.
XX OS Homo sapiens.
XX
XX Key Location/Qualifiers
XX FT Peptide 1..26
XX FT /note= "Potential signal peptide"
XX FT Modified-site 146
XX FT /note= "N-glycosylated"
XX FT Domain 162..180
XX FT /note= "Potential transmembrane domain"
XX
XX WO200103720-A2.
XX
XX 18-JAN-2001.
XX
XX 11-JUL-2000; 2000WO-US018867.
XX
XX 12-JUL-1999; 99US-0143304P.
XX (GETH ) GENENTECH INC.
XX
XX Williams PM, Gerritsen ME;
XX
XX WPI; 2001-138257/14.
XX N-PSDB; AAC85433.
XX
XX Composition for diagnosing and treating cardiovascular, endothelial and
XX angiogenic disorders, comprises a PRO364 or PRO175 polypeptide.
XX
XX Claim 1; Fig 1; 76pp; English.
XX
XX This sequence represents PRO364 polypeptide, which is a human gluco-
XX corticoid-induced tumor necrosis factor receptor (hGfTR). The
XX corresponding ligand (hGfTRL), PRO175, is given in AAB47056. PRO364 and
XX PRO175 may be used in a mixture with a cardiovascular, endothelial,
XX angiogenic or angiostatic agent for the treatment of a cardiovascular,
XX endothelial, angiogenic or angiostatic disorder. The PRO364 cDNA sequence
XX was isolated from an expressed sequence tag (EST) database as having
XX homology to members of the tumour necrosis factor receptor (TNFR) family
XX of polypeptides. The PRO175 cDNA sequence was isolated from a library of
XX cDNA fragments derived from human umbilical vein endothelial cells
XX (HUVEC). Administering an effective amount of PRO364 or PRO175 or their
XX antagonists is useful for treating cardiac hypertrophy (which is
XX initiated by myocardial infarction and characterized by the presence of
XX an elevated level of PGF 2alpha), trauma, a cancer, or age-related
XX macular degeneration in a human. Administering a therapeutically
XX effective amount of an antibody that binds PRO364 or PRO175 is useful for
XX inhibiting angiogenesis induced by PRO364 or PRO175 in a human suffering
XX from a tumor or a retinal disorder. PRO364 or PRO175, or their
XX antagonists, are useful for vascular-related drug targeting or as
XX therapeutic targets for the treatment or prevention of atherosclerosis,
XX hypertension, inflammatory vasculitides, Reynaud's disease, aneurysms,
XX arterial restenosis, thrombophlebitis, tumor angiogenesis, gut protection
XX or regeneration and treatment of lung or liver fibrosis, periodontal
XX diseases, attraction of bone-forming cells, central and peripheral
XX nervous system disease and neuropathies and rheumatoid arthritis
XX
XX Sequence 241 AA;
XX
Query Match 100.0%; Score 1386; DB 4; Length 241;
Best Local Similarity 100.0%; Pred. No. 2.2e-101;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```


QY 1 MAOHGAMGAFRALCGLALLCALSLGORTPTGGCGCGPGRLLLTGTDTARCCRVHTTRCCRD 60
Db |||||
QY 61 YPGECCSEWDCMCVQPEPHCGDPCCTTCRHHPCPPGQVQSGKSPFGFCIDCASGTF 120
Db |||||
QY 121 SGHGHGCKPWTCTQFGFLTVPFGNKNHNAVCPGSPPAEPLGMLTVVLLAAVACVLL 180
Db |||||
QY 181 TSAQLGLHWTQLSQCMWPRETQLLEVPSTEDARSCQFPPEERGERSAEKRGILDLW 240
Db |||||
QY 241 V 241
Db 241 V 241

RESULT 9
AAB20115
ID AAB20115 standard; protein; 241 AA.
AC AAB20115;
XX
DT 30-APR-2001 (first entry)
XX Human immunostimulant PRO364.
DE
XX PRO364; UNQ319; human; immune disease; autoimmune disease; antirheumatic;
KW antiarthritic; antiinflammatory; antianaemic; immunosuppressive;
KW antithyroid; antidiabetic; neuroprotective; hepatotropic; virucide;
KW dermatological; antipsoriatic; antiasthmatic; antiallergic;
KW immunostimulant.
XX
OS Homo sapiens.
XX
FH Key
FT Peptide 1..25 Location/Qualifiers
FT /label= Signal_peptide
FT Modified-site 5..11
FT /note= "N-myristoylation site"
FT Modified-site 8..14
FT /note= "N-myristoylation site"
FT Modified-site 25..31
FT /note= "N-myristoylation site"
FT Protein 26..241
FT /label= Mature_protein
FT Modified-site 30..36
FT /note= "N-myristoylation site"
FT Modified-site 33..39
FT /note= "N-myristoylation site"
FT Modified-site 118..124
FT /note= "N-myristoylation site"
FT Modified-site 122..128
FT /note= "N-myristoylation site"
FT Modified-site 146..150
FT /note= "Asn is N-glycosylated"
FT Modified-site 156..162
FT /note= "N-myristoylation site"
FT Domain 163..183
FT /note= "transmembrane domain"
FT Peptide 166..177
FT /note= "prokaryotic membrane lipoprotein lipid attachment site"
FT Peptide 171..193
FT /note= "leucine zipper pattern"
PN WO200105972-A1.
XX 25-JAN-2001.

XX 15-MAR-2000; 2000WO-US006884.
XX 20-JUL-1999; 99US-0144758P.
XX (GETH) GENENTECH INC.
XX Ashkenazi AJ, Baker KP, Fong S, Goddard A, Godowski PJ, Tumas D;
PI Gurney AL, Hillan KJ, Mark MR, Marsters SA, Pitti RM, Watanabe CK, Wood WT;
PI Watanabe CK, Wood WT;
XX WPI; 2001-103149/11.
DR N-PSDB; AAF30057.
XX
PT New PRO polypeptides, nucleic acids and (ant)agonists, useful for
PT diagnosing and treating immune-related disorders, such as multiple
PT sclerosis, rheumatoid arthritis and diabetes.
XX
PS Claim 20; Fig 16; 127pp; English.
XX
CC The present sequence is that of novel human immunomodulator PRO364
CC (UNQ319), as deduced from cDNA (see AAF30057) isolated from a small
CC intestine library. PRO364 (26 kDa, pI 6.34) shows sequence homology to
CC mouse G1TR protein and may be its human counterpart. The invention
CC provides polynucleotides (see AAF30050-62) encoding novel human PRO
CC proteins (see AAB20108-20) including PRO364. Claimed compositions
CC comprising these proteins or their agonists are useful for increasing
CC infiltration of inflammatory cells into a tissue of a mammal, stimulating
CC or enhancing an immune response, or increasing the proliferation of T-
CC lymphocytes in a mammal in response to an antigen. Claimed compositions
CC comprising a PRO polypeptide or its antagonist have the opposite effect.
CC A claimed method for treating an immune related disorder, such as a T
CC cell disorder, involves administering a PRO polypeptide, an agonist
CC antibody or an antagonist antibody. The disorder is selected from
CC systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis,
CC juvenile chronic arthritis, spondyloarthritis, systemic sclerosis,
CC idiopathic inflammatory myopathy, Sjogren's syndrome, systemic
CC vasculitis, sarcoidosis, autoimmune haemolytic anaemia, autoimmune
CC thrombocytopaenia, thyroiditis, diabetes mellitus, immune-mediated renal
CC disease, demyelinated diseases (such as multiple sclerosis), autoimmune
CC chronic active hepatitis, primary biliary cirrhosis, granulomatous
CC hepatitis, sclerosing cholangitis, inflammatory bowel disease (ulcerative
CC colitis and Crohn's disease), gluten-sensitive enteropathy, Whipple's
CC disease, (auto)immune-mediated skin diseases (such as bullous skin
CC disease, erythema multiforme and psoriasis), allergic diseases (such as
CC asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity and
CC urticaria), immunologic diseases of the lung and transplantation
CC associated diseases (such as graft rejection and graft-versus-host
CC disease) (all claimed). Claimed methods of diagnosing these disorders
CC comprise detecting the level of expression of the PRO gene. Also claimed
CC are a method of identifying a compound capable of inhibiting the
CC expression or activity of the PRO polypeptide, vectors, host cells,
CC antibodies, and a method of stimulating the proliferation of T
CC lymphocytes using PRO364
XX
SQ Sequence 241 AA;
Query Match 100.0%; Score 1386; DB 4; Length 241;
Best Local Similarity 100.0%; Pred. No. 2.2e-101;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAOHGAMGAFRALCGLALLCALSLGORTPTGGCGCGPGRLLLTGTDTARCCRVHTTRCCRD 60
Db 1 MAOHGAMGAFRALCGLALLCALSLGORTPTGGCGCGPGRLLLTGTDTARCCRVHTTRCCRD 60
QY 61 YPGECCSEWDCMCVQPEPHCGDPCCTTCRHHPCPPGQVQSGKSPFGFCIDCASGTF 120
Db 61 YPGECCSEWDCMCVQPEPHCGDPCCTTCRHHPCPPGQVQSGKSPFGFCIDCASGTF 120
QY 121 SGHGHGCKPWTCTQFGFLTVPFGNKNHNAVCPGSPPAEPLGMLTVVLLAAVACVLL 180
Db 121 SGHGHGCKPWTCTQFGFLTVPFGNKNHNAVCPGSPPAEPLGMLTVVLLAAVACVLL 180

QY 181 TSAQLGLHIWQLRSQCMWPRETQLLEVPSTEDARSCQFPEERGERSAEKGRGLDLW 240
 DB 181 TSAQLGLHIWQLRSQCMWPRETQLLEVPSTEDARSCQFPEERGERSAEKGRGLDLW 240
 QY 241 V 241
 DB 241 V 241

RESULT 10
 AAB53090
 ID AAB53090 standard; protein; 241 AA.
 AC AAB53090;
 XX
 DT 28-FEB-2001 (first entry)
 XX
 DE Human angiogenesis-associated protein PRO364, SEQ ID NO:142.
 XX
 KW Human; angiogenesis-associated protein; PRO; endothelial cell growth;
 KW cardiac hypertrophy; cardiovascular disorder; endothelial disorder;
 KW angiogenic disorder; atherosclerosis; osteoporosis; hypertension;
 KW myocardial infarction; diabetic retinopathy; rheumatoid arthritis;
 KW Crohn's disease; psoriasis; endometriosis; ulcer; wound healing; cancer;
 KW Alzheimer's disease; Huntington's disease; stroke; drug screening;
 KW gene therapy; transgenic animal.
 XX
 OS Homo sapiens.
 XX
 PN WO200053753-A2.
 XX
 PD 14-SEP-2000.
 XX
 PF 05-JAN-2000; 2000WO-US000219.
 XX
 PR 08-MAR-1999; 99WO-US005028.
 PR 12-MAR-1999; 99US-0123957P.
 PR 14-MAY-1999; 99US-0134287P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 23-JUN-1999; 99US-0141037P.
 PR 20-JUL-1999; 99US-0144758P.
 PR 26-JUL-1999; 99US-0145698P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Ashkenazi AJ, Baker KP, Ferrara N, Gerber H, Goddard A;
 PI Godowski PJ, Gurney AL, Hillan KO, Kuo SS, Mark MR, Marsters SA;
 PI Paoni NF, Pitti RM, Watanabe CK, Williams PM, Wood WI;
 XX
 DR WPI: 2001-090793/10.
 DR N-PSDB; AAC97479.
 XX
 XX New isolated nucleic acid for producing a PRO polypeptide, analyzing
 PT genetic disorders and treating cardiovascular, endothelial or angiogenic
 PT disorders, such as atherosclerosis, wounds or cancer.
 XX
 PS Claim 69; Fig 54; 293pp; English.
 XX
 XX The invention relates to novel human angiogenesis-associated proteins
 CC designated PRO proteins (AAB53064-B53097), and to nucleic acids encoding
 CC PRO proteins. The invention also relates to vectors and host cells
 CC comprising a PRO nucleic acid, the recombinant production of a PRO
 CC protein, PRO antibodies specific for a PRO protein, fusion proteins
 CC comprising a PRO protein, agonists or antagonists of a PRO protein, and

CC compounds which inhibit the expression of a PRO gene. The invention
 CC additionally encompasses methods of identifying modulators of PRO
 CC expression or activity; diagnosing a cardiovascular, endothelial or
 CC angiogenic disorder, or a susceptibility to such a disorder by detecting
 CC mutations in a PRO gene, or the expression level of a PRO gene within a
 CC particular tissue; treating a cardiovascular, endothelial or angiogenic
 CC disorder via the administration of a PRO protein, PRO nucleic acid, or
 CC PRO agonist or antagonist; a retroviral gene therapy vector comprising a
 CC PRO nucleic acid; and methods of inhibiting or stimulating endothelial
 CC cell growth, cardiac hypertrophy or PRO-induced angiogenesis via the
 CC administration of a PRO protein, or an agonist or antagonist thereof. PRO
 CC nucleic acids, PRO proteins, antibodies against PRO proteins, PRO
 CC agonists and PRO antagonists may be used as therapeutic agents to treat
 CC cardiovascular, endothelial or angiogenic disorders, such as
 CC atherosclerosis, osteoporosis, myocardial infarction, hypertension,
 CC diabetic retinopathy, rheumatoid arthritis, Crohn's disease, psoriasis,
 CC endometriosis, ulcers, wounds, cancer, Alzheimer's disease, Huntington's
 CC disease, or stroke. PRO nucleic acids are additionally useful in the
 CC recombinant production of PRO proteins, as hybridisation probes to screen
 CC libraries to isolate cDNAs with sequence identity to PRO proteins, to map
 CC genes encoding PRO proteins, to analyse genetic disorders, and in gene
 CC therapy. PRO nucleic acids can also be used to produce transgenic animals
 CC useful for the development and screening of potential therapeutic agents.
 CC The present sequence represents a PRO protein of the invention
 XX
 SQ Sequence 241 AA;

Query Match 100.0%; Score 1386; DB 4; Length 241;
 Best Local Similarity 100.0%; Pred. No. 2.2e-101;
 Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAQHGAMGAFRALCGLALLCALSLGQRTGGPGCGPGRLLLTGTGDARCCRVHTTCCRD 60
 DB 1 MAQHGAMGAFRALCGLALLCALSLGQRTGGPGCGPGRLLLTGTGDARCCRVHTTCCRD 60
 QY 61 YPGECCSEWDCMCVQPEFHGDPCCCTTCRHHPCPPGQVQSQGKFSFGFCIDCASGTF 120
 DB 61 YPGECCSEWDCMCVQPEFHGDPCCCTTCRHHPCPPGQVQSQGKFSFGFCIDCASGTF 120
 QY 121 SGGHEGHCKPMTDCTQFGFLTVPFGNKTHNAVCPGSPAPPLGLWLTVVLLAAVACVLL 180
 DB 121 SGGHEGHCKPMTDCTQFGFLTVPFGNKTHNAVCPGSPAPPLGLWLTVVLLAAVACVLL 180
 QY 181 TSAQLGLHIWQLRSQCMWPRETQLLEVPSTEDARSCQFPEERGERSAEKGRGLDLW 240
 DB 181 TSAQLGLHIWQLRSQCMWPRETQLLEVPSTEDARSCQFPEERGERSAEKGRGLDLW 240
 QY 241 V 241
 DB 241 V 241

RESULT 11
 AAB47289
 ID AAB47289 standard; protein; 241 AA.
 XX
 AC AAB47289;
 XX
 DT 22-AUG-2001 (first entry)
 XX
 DE PRO364 polypeptide.
 XX
 KW PRO; type II transmembrane protein; tumour necrosis factor; stroke;
 KW heart hypertrophy; cardiovascular; endothelial; angiogenic; disorder;
 KW myocardial infarction; cardiac hypertrophy; PGF 2alpha; trauma; bone;
 KW cancer; age-related macular degeneration; wound; burn; hypertension;
 KW diabetes mellitus; osteoporosis; ischaemia; atherosclerosis; psoriasis;
 KW rheumatoid arthritis; Crohn's disease; amyotrophic lateral sclerosis;
 KW endometriosis; angina; neoplasms; periodontal disease; cartilage; TNF;
 KW Alzheimer's disease; Parkinson's disease; Huntington's disease.
 OS Homo sapiens.
 XX

Key Location/Qualifiers
FT Peptide 1..25 /label= Signal peptide
FT Modified-site 5..11 /label= N-myristoylation site
FT Modified-site 8..14 /label= N-myristoylation site
FT Modified-site 25..31 /label= N-myristoylation site
FT Protein 26..241 /label= N-myristoylation site
FT Modified-site 30..36 /label= Mature PRO364
FT Modified-site 33..39 /label= N-myristoylation site
FT Modified-site 118..124 /label= N-myristoylation site
FT Modified-site 122..128 /label= N-myristoylation site
FT Modified-site 146..150 /label= N-myristoylation site
FT Modified-site 156..162 /label= N-linked glycosylation site
FT Domain 162..180 /label= Potential transmembrane domain
FT Binding-site 166..177 /label= Prokaryotic membrane lipoprotein attachment site
FT Domain 171..193 /label= Leucine zipper
WO20010464-A1.
07-JUN-2001.
11-AUG-2000; 2000WO-US022031.
30-NOV-1999; 99WO-US028313.
30-NOV-1999; 99WO-US028409.
05-JAN-2000; 2000WO-US000219.
24-FEB-2000; 2000WO-US005004.
15-MAR-2000; 2000WO-US006884.
30-MAR-2000; 2000WO-US008439.
17-MAY-2000; 2000WO-US013705.
30-MAY-2000; 2000WO-US014941.
28-JUL-2000; 2000WO-US020710.
(GETH) GENENTECH INC.
Ashkenazi AJ, Baker KP, Ferrara N, Godowski PJ, Gurney AL;
Hillan KJ, Mark MR, Marsters SA, Paoni NF, Pitti RM, Wood WI;
WPI; 2001-381383/40.
N-PSDB; AAC85947.
Isolated PRO polypeptide useful in treating and diagnosing a
cardiovascular, endothelial or angiogenic disorder e.g. cancer, diabetes
mellitus, myocardial infarction, arthritis.
Claim 56; Fig 6; 144pp; English.
The sequences given in AAB47287-90 show PRO polypeptides, PRO175 shows
type II transmembrane protein typology, and portions of PRO364 show
homology to members of the tumour necrosis factor (TNF) family, thereby
indicating that it may be a novel member of the TNF family. PRO175 and
PRO185 stimulated heart hypertrophy. PRO cDNA's may be used to identify a
compound that inhibits PRO, diagnosing a cardio-vascular, endothelial or
angiogenic disorder in a mammal by detecting PRO cDNA, treating
cardiovascular, endothelial or angiogenic disorder in a mammal, and
inducing cardiac hypertrophy or inhibiting endothelial cell growth or
angiogenesis in a mammal. The mammal is a human which has suffered
myocardial infarction, cardiac hypertrophy characterized by the presence
of elevated PGP 2alpha, trauma, cancer or age-related macular
degeneration. Trauma includes wounds or burns. Other treatable diseases

CC include diabetes mellitus, osteoporosis, ischaemia, hypertension,
CC rheumatoid arthritis, Crohn's disease, atherosclerosis, psoriasis,
CC endometriosis, angina, neoplasms, periodontal disease, bone and cartilage
CC repair, Alzheimer's disease, Parkinson's disease, Huntington's disease,
CC amyotrophic lateral sclerosis, and stroke
XX
SQ Sequence 241 AA;
Query Match 100.0%; Score 1386; DB 4; Length 241;
Best Local Similarity 100.0%; Pred. No. 2.2e-101;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAQHGAMGAFRALCGALLCALSLGQRTGPGCGPGRLLLTGTDDARCCRVHTTRCCRD 60
DB 1 MAQHGAMGAFRALCGALLCALSLGQRTGPGCGPGRLLLTGTDDARCCRVHTTRCCRD 60
QY 61 YPGECCSEWDCMCVQPEFHCGDPCTTCRHHPCPPGQVQSGKFSFGQCIDCASGTF 120
DB 61 YPGECCSEWDCMCVQPEFHCGDPCTTCRHHPCPPGQVQSGKFSFGQCIDCASGTF 120
QY 121 SGHGHGCHKPMTDCTQFGFLTVPFGNKTNAVCVPGSPPAEPLGMLTVVLLAAVACVLL 180
DB 121 SGHGHGCHKPMTDCTQFGFLTVPFGNKTNAVCVPGSPPAEPLGMLTVVLLAAVACVLL 180
QY 181 TSAQLGLHIWQLRSQCMMPRETQLLEVPSTEDARSCQFPPEERGERSAEKGRLGDLW 240
DB 181 TSAQLGLHIWQLRSQCMMPRETQLLEVPSTEDARSCQFPPEERGERSAEKGRLGDLW 240
QY 241 V 241
DB 241 V 241
RESULT 12
AAB50982
ID AAB50982 standard; protein; 241 AA.
XX
AC AAB50982;
DT 21-MAR-2001 (first entry)
XX Human PRO364 protein.
XX Human; PRO; cardiac; antiangiogenic; antiarteriosclerotic; hypotensive;
XX vasotropic; antirheumatic; antiarthritic; antiinflammatory; cytostatic;
XX vulnery; antianginal; gene therapy; cardiovascular disease;
XX endothelial disorder; angiogenic disorder; cancer; periodontal disease;
XX wound healing.
XX Homo sapiens.
XX WO200073445-A2.
XX 07-DEC-2000.
XX 17-MAY-2000; 2000WO-US013705.
XX 02-JUN-1999; 99WO-US012252.
XX 23-JUN-1999; 99US-0141037P.
XX 20-JUL-1999; 99US-0144758P.
XX 26-JUL-1999; 99US-0145698P.
XX 28-JUL-1999; 99US-0146222P.
XX 01-SEP-1999; 99WO-US020111.
XX 30-NOV-1999; 99WO-US028313.
XX 02-DEC-1999; 99WO-US028565.
XX 16-DEC-1999; 99WO-US030095.
XX 05-JAN-2000; 2000WO-US000219.
XX 06-JAN-2000; 2000WO-US000376.
XX 11-FEB-2000; 2000WO-US000365.
XX 18-FEB-2000; 2000WO-US000431.
XX 18-FEB-2000; 2000WO-US000432.
XX 24-FEB-2000; 2000WO-US000504.

PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Ferrara N, Gerber H, Gernitsen ME;
PI Goddard A, Godowski PJ, Gurney AL, Kuo SS, Mark MR, Marsters SA;
PI Paoni NF, Pitti RM, Watanabe CK, Williams PM, Wood WI;
XX
XX WPI; 2001-025251/03.
DR N-PSDB; AAC90566.
XX
XX Seventeen nucleic acids encoding PRO polypeptides which are useful in
PT diagnosis and treatment of cardiovascular, endothelial or angiogenic
PT disorders in a mammal.
XX
XX Claim 71; Fig 8; 182pp; English.
XX
XX The present sequence is one of seventeen novel PRO polypeptides. The PRO
CC nucleic acids, polypeptides, agonists and antagonists are useful for
CC treating cardiovascular, endothelial or angiogenic disorders in a mammal.
CC Examples of these disorders include cardiac hypertrophy, trauma, cancer,
CC age-related macular degeneration, atherosclerosis, hypertension, arterial
CC infarctions, Reynaud's disease, rheumatoid arthritis, angina, myocardial
CC infarctions, thrombophlebitis and lymphangitis. The PRO polypeptides and
CC antagonists are also used to prevent tumour angiogenesis and for treating
CC periodontal diseases. They are also used to stimulate wound healing and
CC tissue regeneration. The PRO nucleic acids, polypeptides and anti-PRO
CC antibodies are useful for diagnosing a cardiovascular, endothelial or
CC angiogenic disorder
XX
SQ Sequence 241 AA;
Query Match 100.0%; Score 1386; DB 4; Length 241;
Best Local Similarity 100.0%; Pred. No. 2.2e-101;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAQHGAWGAFRALCGLLALCALSLGORTGCGPCGPRLLLTGTGDARCCRVHTTCCRD 60
DB 1 MAQHGAWGAFRALCGLLALCALSLGORTGCGPCGPRLLLTGTGDARCCRVHTTCCRD 60
QY 61 YPGEECCSEWDCMCVQPEFHGCDPCCTTCRHHPCPFGQVQSGKFSFGFCIDCASGTF 120
DB 61 YPGEECCSEWDCMCVQPEFHGCDPCCTTCRHHPCPFGQVQSGKFSFGFCIDCASGTF 120
QY 121 SGHGHGCHKPWTCTQFGFLTVPFGNKTNAVCPGSPPAEPLGWLTVVLLVAACVLLL 180
DB 121 SGHGHGCHKPWTCTQFGFLTVPFGNKTNAVCPGSPPAEPLGWLTVVLLVAACVLLL 180
QY 181 TSAQLGLHIWQLRSQCWMPRETOLLLEVPSTEDARSCOPPEERGERSAEKGRGLDLM 240
DB 181 TSAQLGLHIWQLRSQCWMPRETOLLLEVPSTEDARSCOPPEERGERSAEKGRGLDLM 240
QY 241 V 241
DB 241 V 241
RESULT 13
AAB50910
ID AAB50910 standard; protein; 241 AA.
XX
XX AAB50910;
XX
XX 21-MAR-2001 (first entry)
XX Human PRO364 protein.
XX Human; PRO; antiinflammatory; dermatological; antiarthritic;
XX antirheumatic; cardiant; antianaemic; immunosuppressive; antithyroid;

KW antidiabetic; nootropic; neuroprotective; hepatotropic; virucide;
KW antiallergic; antiasthmatic; immune related disorder;
KW hepatobiliary disease; autoimmune disease; allergy.
XX
OS Homo sapiens.
XX
XX WO200073452-A2.
XX
XX 07-DEC-2000.
XX
XX 02-JUN-2000; 2000WO-US015264.
XX
XX 02-JUN-1999; 99WO-US012252.
XX 20-JUL-1999; 99US-0144732P.
XX 20-JUL-1999; 99US-0144758P.
XX 28-JUL-1999; 99US-0146222P.
XX 01-SEP-1999; 99WO-US020111.
XX 15-SEP-1999; 99WO-US021090.
XX 15-SEP-1999; 99WO-US021547.
XX 29-OCT-1999; 99US-0162506P.
XX 30-NOV-1999; 99WO-US028313.
XX 01-DEC-1999; 99WO-US028634.
XX 02-DEC-1999; 99WO-US028551.
XX 02-DEC-1999; 99WO-US028565.
XX 09-DEC-1999; 99US-0170262P.
XX 20-DEC-1999; 99WO-US030911.
XX 05-JAN-2000; 2000WO-US000219.
XX 06-JAN-2000; 2000WO-US000376.
XX 11-FEB-2000; 2000WO-US003565.
XX 18-FEB-2000; 2000WO-US004341.
XX 18-FEB-2000; 2000WO-US004342.
XX 22-FEB-2000; 2000WO-US004414.
XX 24-FEB-2000; 2000WO-US004914.
XX 24-FEB-2000; 2000WO-US005004.
XX 01-MAR-2000; 2000WO-US005601.
XX 02-MAR-2000; 2000WO-US005841.
XX 03-MAR-2000; 2000US-0187202P.
XX 15-MAR-2000; 2000WO-US006884.
XX 20-MAR-2000; 2000WO-US007377.
XX 21-MAR-2000; 2000WO-US007532.
XX 30-MAR-2000; 2000WO-US008439.
XX 17-MAY-2000; 2000WO-US013705.
XX 22-MAY-2000; 2000WO-US014042.
XX (GETH) GENENTECH INC.
XX
XX Ashkenazi AJ, Baker KP, Chan B, Goddard A, Godowski PJ;
XX Gurney AL, Hebert C, Henzel W, Kabakoff RC, Shelton DL, Tumas D;
XX Watanabe CK, Wood WI;
XX WPI; 2001-025253/03.
XX N-PSDB; AAC91469.
XX
XX Thirty three nucleic acids encoding PRO polypeptides which are useful in
PT the diagnosis and treatment of immune related disorders, e.g. systemic
PT lupus erythematosus, rheumatoid arthritis, osteoarthritis, thyroiditis
PT and diabetes mellitus.
XX
XX Claim 58; Fig 18; 218pp; English.
XX
XX The present sequence is one of thirty three novel PRO polypeptides. The
CC PRO polypeptides, anti-PRO antibodies, agonists and antagonists are
CC useful for treating and diagnosing immune related disorders such as
CC systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis,
CC juvenile chronic arthritis, spondyloarthropathies, systemic sclerosis,
CC idiopathic inflammatory myopathies, Sjogren's syndrome, systemic
CC vasculitis, sarcoidosis, autoimmune haemolytic anaemia, autoimmune
CC thrombocytopaenia, thyroiditis, diabetes mellitus, immune-mediated renal
CC disease, demyelinating diseases of the central and peripheral nervous
CC systems (such as multiple sclerosis, idiopathic demyelinating
CC polyneuropathy or Guillain-Barre syndrome, and chronic inflammatory
CC demyelinating polyneuropathy), hepatobiliary diseases (such as
CC infectious, autoimmune chronic active hepatitis, primary biliary

CC cirrhosis, granulomatous hepatitis and sclerosing cholangitis),
CC inflammatory bowel disease, gluten-sensitive enteropathy and Whipple's
CC disease, autoimmune or immune-mediated skin diseases (such as bullous
CC skin diseases, erythema multiforme, contact dermatitis, psoriasis),
CC allergic diseases such as asthma, allergic rhinitis, atopic dermatitis,
CC food hypersensitivity and urticaria), immunological diseases of the lung
CC (such as eosinophilic pneumonias, idiopathic pulmonary fibrosis and
CC hypersensitivity pneumonitis), transplantation associated diseases
CC including graft rejection and graft-versus-host diseases
XX
XX Sequence 241 AA;

Query Match 100.0%; Score 1386; DB 4; Length 241;
Best Local Similarity 100.0%; Pred. No. 2.2e-101;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAQHGMGAFRALCGIALCALSLGQRTGGPGCGPRLLLGTGTARCCRVHTTRCCRD 60
Db 1 MAQHGMGAFRALCGIALCALSLGQRTGGPGCGPRLLLGTGTARCCRVHTTRCCRD 60
QY 61 YPGECCSEWDCMCVQPEPHCGDPCTTCRHHPCPPGQVQSGKFSFGQICDASGTF 120
Db 61 YPGECCSEWDCMCVQPEPHCGDPCTTCRHHPCPPGQVQSGKFSFGQICDASGTF 120
QY 121 SGHEGHCKPWTDTCTQFGLTVFPNGKTHNAVCPGSPPAEPGLGWLTVLLVAACVLL 180
Db 121 SGHEGHCKPWTDTCTQFGLTVFPNGKTHNAVCPGSPPAEPGLGWLTVLLVAACVLL 180
QY 181 TSAQLGLHIWQLRSQCMWPRETQLLEVPSTEDARSCQPFPEERGSERAEKRGDLW 240
Db 181 TSAQLGLHIWQLRSQCMWPRETQLLEVPSTEDARSCQPFPEERGSERAEKRGDLW 240
QY 241 V 241
Db 241 V 241

RESULT 14
AAE28161
ID AAE28161 standard; protein; 241 AA.

AC AAE28161;
XX
XX 27-DEC-2002 (first entry)
XX Human TR11 receptor protein #2.
XX Human; tumour necrosis factor receptor; TNF; allergic encephalomyelitis;
KW autoimmune disease; autoimmune haemolytic anaemia; multiple sclerosis;
KW systemic lupus erythematosus; Goodpasture's syndrome; diabetes mellitus;
KW rheumatoid arthritis; Sjogren's syndrome; scleroderma; immunodeficiency;
KW urticaria; DiGeorge anomaly; natural killer deficiency; asthma; allergy;
KW inflammatory condition; respiratory disorder; graft-versus-host-disease;
KW transplantation rejection; type II collagen-induced arthritis; cancer;
KW cardiovascular disorder; atherosclerosis; gastrointestinal disorder;
KW myocarditis; inflammatory bowel disease; traumatic brain injury; stroke;
KW Alzheimer's disease; inflammation; trauma; septic shock; thrombolytic;
KW gout; haemostatic; blood coagulation disorder; blood platelet disorder;
KW thrombocytopaenia; wound; trauma; surgery; gene therapy; immuno therapy;
KW TR11 receptor.
OS Homo sapiens.
XX
XX US2002098525-A1.
XX 25-JUL-2002.
XX 27-JUL-2001; 2001US-00915593.
XX 21-OCT-1997; 97US-0063212P.
XX 21-OCT-1998; 98US-00176200.
XX 24-FEB-1999; 99US-0121648P.
XX 13-MAY-1999; 99US-0134172P.

PR 16-JUL-1999; 99US-0144076P.
PR 23-FEB-2000; 2000US-00512363.
PR 28-JUL-2000; 2000US-0221577P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX Ni J, Ruben SM;
XX WIPI; 2002-673824/72.
XX
XX Novel antibody or its portion which specifically binds to two tumor
XX necrosis factor receptor-related protein splice variants, TR11SV1 and
XX TR11SV2, useful for treating autoimmune hemolytic anemia, and
XX Goodpasture's syndrome.
XX Disclosure; Page 122; 135pp; English.

XX The present invention relates to novel antibodies or their portion which
XX specifically bind tumour necrosis factor (TNF) receptor-related protein
XX splice variants, TR11SV1 or TR11SV2. Sequences of the invention are
XX useful for treating, detecting and/or preventing diseases, disorders or
XX conditions associated with aberrant expression and/or activity of TR11,
XX TR11SV1 and TR11SV2 polypeptides, e.g., autoimmune diseases such as
XX autoimmune haemolytic anaemia, allergic encephalomyelitis, multiple
XX sclerosis, systemic lupus erythematosus, Goodpasture's syndrome, diabetes
XX mellitus, rheumatoid arthritis, Sjogren's syndrome, scleroderma with anti-
XX collagen antibodies, urticaria, conditions associated with immuno-
XX deficiency e.g. T-cell related deficiencies such as DiGeorge anomaly,
XX natural killer deficiency, inflammatory conditions such as respiratory
XX disorders (e.g. asthma, allergy), allergic reactions such as asthma,
XX graft-versus-host-disease, transplantation rejections, type II collagen-
XX induced arthritis, cancers (ovarian lung, bladder or liver cancer),
XX cardiovascular disorders (atherosclerosis, myocarditis), gastrointestinal
XX disorders (inflammatory bowel disease), central nervous system disorders
XX (e.g. traumatic brain injury, Alzheimer's disease, stroke) and disorders
XX characterised by inflammation (e.g. gout, trauma, septic shock). They are
XX used for modulating haemostatic or thrombolytic activity and thus is used
XX for treating blood coagulation disorders, the blood platelet disorders
XX (e.g. thrombocytopaenia) or wounds resulting from trauma, surgery or
XX other causes. Polynucleotides of the invention are useful in gene therapy
XX and immuno therapy. The present sequence is human TR11 receptor protein
XX

SQ Sequence 241 AA;

Query Match 100.0%; Score 1386; DB 5; Length 241;
Best Local Similarity 100.0%; Pred. No. 2.2e-101;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAQHGMGAFRALCGIALCALSLGQRTGGPGCGPRLLLGTGTARCCRVHTTRCCRD 60
Db 1 MAQHGMGAFRALCGIALCALSLGQRTGGPGCGPRLLLGTGTARCCRVHTTRCCRD 60
QY 61 YPGECCSEWDCMCVQPEPHCGDPCTTCRHHPCPPGQVQSGKFSFGQICDASGTF 120
Db 61 YPGECCSEWDCMCVQPEPHCGDPCTTCRHHPCPPGQVQSGKFSFGQICDASGTF 120
QY 121 SGHEGHCKPWTDTCTQFGLTVFPNGKTHNAVCPGSPPAEPGLGWLTVLLVAACVLL 180
Db 121 SGHEGHCKPWTDTCTQFGLTVFPNGKTHNAVCPGSPPAEPGLGWLTVLLVAACVLL 180
QY 181 TSAQLGLHIWQLRSQCMWPRETQLLEVPSTEDARSCQPFPEERGSERAEKRGDLW 240
Db 181 TSAQLGLHIWQLRSQCMWPRETQLLEVPSTEDARSCQPFPEERGSERAEKRGDLW 240
QY 241 V 241
Db 241 V 241

RESULT 15
ABU08442
ID ABU08442 standard; protein; 241 AA.
XX

AC ABU08442;
XX 13-JUN-2003 (first entry)
XX Amino acid sequence for human TR11 polypeptide.
DE Human; tumour necrosis factor receptor family; TNF receptor; TR11;
KW endokine-alpha; endokine-alpha receptor; immunodeficiency disease;
KW severe combined immunodeficiency-X linked; SCID-X linked; SLE;
DE Bruton's disease; dysgammaglobulinaemia; autoimmune disease;
KW systemic lupus erythematosus; rheumatoid arthritis; dermatitis;
KW allergic encephalomyelitis; immunostimulant; dermatological;
KW immunosuppressive; antiinflammatory; antirheumatic; antiarthritic;
KW antiallergic.
XX Homo sapiens.
OS US6503184-B1.
XX 07-JAN-2003.
XX 23-FEB-2000; 2000US-00512363.
XX 21-OCT-1997; 97US-0063212P.
PR 21-OCT-1998; 98US-00176200.
PR 24-FEB-1999; 99US-0121648P.
PR 13-MAY-1999; 99US-0134172P.
PR 16-JUL-1999; 99US-0144076P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX Ni J, Ruben SM;
PI WPI; 2003-352213/33.
XX Inhibiting binding of endokine-alpha to endogenous endokine-alpha
PT receptors in a mammal, by administering to a mammal a fragment of human
PT tumor necrosis factor receptor-related protein.
XX Disclosure; Col 201-202; 114pp; English.
XX The present invention relates to the isolation of novel members of the
CC tumour necrosis factor (TNF) family of receptors, referred to as TNF
CC receptor-related proteins and designated TR11, TR11SV1 and TR11SV2.
CC TR11SV1 and TR11SV2 represent splice variants of TR11. The invention also
CC discloses the polynucleotide sequences encoding the TR11 receptors, and a
CC method of inhibiting endokine-alpha binding to endogenous endokine-alpha
CC receptors in mammals. The method of the invention is useful for
CC inhibiting the binding of endokine-alpha to endogenous endokine-alpha
CC receptors in a mammal, preferably humans. The method is useful for
CC treating or preventing immunodeficiency diseases (e.g. severe combined
CC immunodeficiency (SCID)-X linked, Bruton's disease,
CC dysgammaglobulinaemia), and autoimmune diseases (e.g. systemic lupus
CC erythematosus (SLE), rheumatoid arthritis, dermatitis, allergic
CC encephalomyelitis). The present sequence represents human TR11
CC polypeptide
XX
SQ Sequence 241 AA;

Query Match 100.0%; Score 1386; DB 6; Length 241;
Best Local Similarity 100.0%; Pred. No. 2.2e-101;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAQHGMAGAFRALCGLALLCALSLGQRTGGPGCGPGRLLLTGTGTDCRCRVHTTRCCRD 60
DB 1 MAQHGMAGAFRALCGLALLCALSLGQRTGGPGCGPGRLLLTGTGTDCRCRVHTTRCCRD 60
QY 61 YPGECCSVDWDCMCVQPEFHCGDPCTTCRHHPCPPGQGVQSGKFSFGQICDASGTF 120
DB 61 YPGECCSVDWDCMCVQPEFHCGDPCTTCRHHPCPPGQGVQSGKFSFGQICDASGTF 120
QY 121 SGGHEGHCKPWTDCTQFGFLTVPFGNKTHNAVCPGSPPAEPLGWLTVVLLAAVACVLLL 180

Db 121 SGGHEGHCKPWTDCTQFGFLTVPFGNKTHNAVCPGSPPAEPLGWLTVVLLAAVACVLLL 180
QY 181 TSAQLGLHIWQLRSQCMWMPRETQLLLLEVPPTEDARSQCFPEERGERSABEKGLGLIW 240
Db 181 TSAQLGLHIWQLRSQCMWMPRETQLLLLEVPPTEDARSQCFPEERGERSABEKGLGLIW 240
QY 241 V 241
Db 241 V 241

Search completed: October 26, 2005, 15:47:40
Job time : 142.311 secs

GenCore version 5.1.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 26, 2005, 15:51:55 ; Search time 115.618 Seconds
(without alignments)
870.278 Million cell updates/sec

Title: US-09-545-998B-4
Perfect score: 1386
Sequence: 1 MAQHGMAGFRALCGLALIC.....EEGERSAEEKRLGDLWV 241

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1862994 seqs, 417510619 residues

Total number of hits satisfying chosen parameters: 1862994

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA.*
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep.*
17: /cgn2_6/ptodata/1/pubpaa/US10E_PUBCOMB.pep.*
18: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
19: /cgn2_6/ptodata/1/pubpaa/US11A_PUBCOMB.pep.*
20: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
21: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
22: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1386	100.0	241	9	US-09-915-593-28
2	1386	100.0	241	13	US-10-116-378-3
3	1386	100.0	241	14	US-10-283-105-28
4	1386	100.0	241	14	US-10-277-966-28
5	1386	100.0	241	15	US-10-295-027-1284
6	1386	100.0	241	17	US-10-959-537-3
7	1386	100.0	241	20	US-11-032-294-3
8	1382	99.7	240	16	US-10-783-528-75
9	1322.5	95.4	234	9	US-09-915-593-2
10	1322.5	95.4	234	14	US-10-283-105-2
11	1322.5	95.4	234	14	US-10-277-966-2

12	1306.5	94.3	246	15	US-10-264-237-1762
13	1274.5	92.0	240	9	US-09-915-593-6
14	1274.5	92.0	240	14	US-10-283-105-6
15	1274.5	92.0	240	14	US-10-277-966-6
16	1056	76.2	241	9	US-09-915-593-4
17	1056	76.2	241	14	US-10-283-105-4
18	1056	76.2	241	14	US-10-277-966-4
19	953	68.8	317	13	US-10-116-378-26
20	953	68.8	317	17	US-10-959-537-26
21	735.5	53.1	228	9	US-09-915-593-7
22	735.5	53.1	228	13	US-10-116-378-24
23	735.5	53.1	228	14	US-10-283-105-7
24	735.5	53.1	228	14	US-10-277-966-7
25	735.5	53.1	228	17	US-10-959-537-24
26	255	18.4	89	10	US-09-866-050A-191
27	201.5	14.5	276	15	US-10-369-300-4
28	197	14.2	256	13	US-10-027-199-10
29	197	14.2	256	14	US-10-067-122-2
30	197	14.2	256	17	US-10-981-352-4
31	195.5	14.1	255	9	US-09-739-394-9
32	195.5	14.1	255	9	US-09-826-213-11
33	195.5	14.1	255	9	US-09-935-727-13
34	195.5	14.1	255	10	US-09-877-336-2
35	195.5	14.1	255	11	US-09-877-338-2
36	195.5	14.1	255	13	US-10-097-330-9
37	195.5	14.1	255	13	US-10-027-199-2
38	195.5	14.1	255	14	US-10-170-997-2
39	195.5	14.1	255	14	US-10-186-643-11
40	195.5	14.1	255	14	US-10-207-655-160
41	195.5	14.1	255	15	US-10-418-242-13
42	195.5	14.1	255	16	US-10-646-308-18
43	195.5	14.1	255	16	US-10-755-889-174
44	195.5	14.1	255	16	US-10-748-112-15
45	195.5	14.1	255	16	US-10-723-860-588

ALIGNMENTS

RESULT 1
US-09-915-593-28
; Sequence 28, Application US/09915593
; Patent No. US20020098525A1
; GENERAL INFORMATION:
; APPLICANT: Ni, Jian
; APPLICANT: Ruben, Steven M.
; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins
; TITLE OF INVENTION: TR11, TR11SV1, and TR11SV2
; FILE REFERENCE: PF396P2
; CURRENT APPLICATION NUMBER: US/09/915,593
; CURRENT FILING DATE: 2001-07-27
; PRIOR APPLICATION NUMBER: 60/221,577
; PRIOR FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: 09/512,363
; PRIOR FILING DATE: 2000-02-23
; PRIOR APPLICATION NUMBER: 60/144,076
; PRIOR FILING DATE: 2000-07-16
; PRIOR APPLICATION NUMBER: 60/134,172
; PRIOR FILING DATE: 1999-05-13
; PRIOR APPLICATION NUMBER: 60/121,648
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 09/176,200
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/063,212
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 28
; LENGTH: 241
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-915-593-28

Query Match 100.0%; Score 1386; DB 9; Length 241;
Best Local Similarity 100.0%; Pred. No. 1.1e-106;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAQHGMGAFRALCGLALLCALSLGQRTGGPGCGPGRLLLTGTGDARCCRVHTTRCCRD 60
DB 1 MAQHGMGAFRALCGLALLCALSLGQRTGGPGCGPGRLLLTGTGDARCCRVHTTRCCRD 60

QY 61 YGEECCSEWDCMCVQPEFHCGDPCCCTTCRHHPCPPGQGVQSGKFSFGFCIDCASGTF 120
DB 61 YGEECCSEWDCMCVQPEFHCGDPCCCTTCRHHPCPPGQGVQSGKFSFGFCIDCASGTF 120

QY 121 SGHGHGCKPWTDCQFGFLTVPFGNKNTHNAVCPGSPPAEPGLWLTVVLLAAVACVLL 180
DB 121 SGHGHGCKPWTDCQFGFLTVPFGNKNTHNAVCPGSPPAEPGLWLTVVLLAAVACVLL 180

QY 181 TSAQLGLHIWQLRSQCMWPRETQLLLEVPSPSTEDARSCQFPPEERGERSAEEKRGLDLM 240
DB 181 TSAQLGLHIWQLRSQCMWPRETQLLLEVPSPSTEDARSCQFPPEERGERSAEEKRGLDLM 240

QY 241 V 241
DB 241 V 241

RESULT 2
US-10-116-378-3
; Sequence 3, Application US/10116378
; Publication No. US20020150993A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Goddard, Audrey
; APPLICANT: Gurney, Austin
; APPLICANT: Marsters, Scot A.
; APPLICANT: Pitti, Robert M.
; APPLICANT: Wood, William
; TITLE OF INVENTION: NOVEL TUMOR NECROSIS FACTOR RECEPTOR HOMOLOG AND
; TITLE OF INVENTION: NUCLEIC
; FILE REFERENCE: P1206R1
; CURRENT APPLICATION NUMBER: US/10/116,378
; PRIOR FILING DATE: 2002-04-04
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 09/247,225
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-02-09
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/074,087
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-02-09
; NUMBER OF SEQ ID NOS: 31
; SEQ ID NO 3
; LENGTH: 241
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-116-378-3

Query Match 100.0%; Score 1386; DB 13; Length 241;
Best Local Similarity 100.0%; Pred. No. 1.1e-106;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAQHGMGAFRALCGLALLCALSLGQRTGGPGCGPGRLLLTGTGDARCCRVHTTRCCRD 60
DB 1 MAQHGMGAFRALCGLALLCALSLGQRTGGPGCGPGRLLLTGTGDARCCRVHTTRCCRD 60

QY 61 YGEECCSEWDCMCVQPEFHCGDPCCCTTCRHHPCPPGQGVQSGKFSFGFCIDCASGTF 120
DB 61 YGEECCSEWDCMCVQPEFHCGDPCCCTTCRHHPCPPGQGVQSGKFSFGFCIDCASGTF 120

QY 121 SGHGHGCKPWTDCQFGFLTVPFGNKNTHNAVCPGSPPAEPGLWLTVVLLAAVACVLL 180
DB 121 SGHGHGCKPWTDCQFGFLTVPFGNKNTHNAVCPGSPPAEPGLWLTVVLLAAVACVLL 180

QY 181 TSAQLGLHIWQLRSQCMWPRETQLLLEVPSPSTEDARSCQFPPEERGERSAEEKRGLDLM 240
DB 181 TSAQLGLHIWQLRSQCMWPRETQLLLEVPSPSTEDARSCQFPPEERGERSAEEKRGLDLM 240

QY 241 V 241
DB 241 V 241

RESULT 3
US-10-283-105-28
; Sequence 28, Application US/10283105
; Publication No. US20030138426A1
; GENERAL INFORMATION:
; APPLICANT: Ni, Jian
; APPLICANT: Ruben, Steven M
; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins TR11, TR11SV1,
; TITLE OF INVENTION: TR11SV22
; FILE REFERENCE: PF396P3
; CURRENT APPLICATION NUMBER: US/10/283,105
; PRIOR FILING DATE: 2002-10-30
; PRIOR APPLICATION NUMBER: 60/330,757
; PRIOR FILING DATE: 2001-10-30
; PRIOR APPLICATION NUMBER: 09/915,593
; PRIOR FILING DATE: 2001-07-27
; PRIOR APPLICATION NUMBER: 60/221,577
; PRIOR FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: 09/512,363
; PRIOR FILING DATE: 2000-02-23
; PRIOR APPLICATION NUMBER: 60/144,076
; PRIOR FILING DATE: 1999-07-16
; PRIOR APPLICATION NUMBER: 60/134,172
; PRIOR FILING DATE: 1999-05-13
; PRIOR APPLICATION NUMBER: 60/121,648
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 09/176,200
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/063,212
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 28
; LENGTH: 241
; TYPE: PRT
; ORGANISM: human
US-10-283-105-28

Query Match 100.0%; Score 1386; DB 14; Length 241;
Best Local Similarity 100.0%; Pred. No. 1.1e-106;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAQHGMGAFRALCGLALLCALSLGQRTGGPGCGPGRLLLTGTGDARCCRVHTTRCCRD 60
DB 1 MAQHGMGAFRALCGLALLCALSLGQRTGGPGCGPGRLLLTGTGDARCCRVHTTRCCRD 60

QY 61 YGEECCSEWDCMCVQPEFHCGDPCCCTTCRHHPCPPGQGVQSGKFSFGFCIDCASGTF 120
DB 61 YGEECCSEWDCMCVQPEFHCGDPCCCTTCRHHPCPPGQGVQSGKFSFGFCIDCASGTF 120

QY 121 SGHGHGCKPWTDCQFGFLTVPFGNKNTHNAVCPGSPPAEPGLWLTVVLLAAVACVLL 180
DB 121 SGHGHGCKPWTDCQFGFLTVPFGNKNTHNAVCPGSPPAEPGLWLTVVLLAAVACVLL 180

QY 181 TSAQLGLHIWQLRSQCMWPRETQLLLEVPSPSTEDARSCQFPPEERGERSAEEKRGLDLM 240
DB 181 TSAQLGLHIWQLRSQCMWPRETQLLLEVPSPSTEDARSCQFPPEERGERSAEEKRGLDLM 240

QY 241 V 241
DB 241 V 241

RESULT 4
US-10-277-966-28
; Sequence 28, Application US/10277966
; Publication No. US20030153499A1
; GENERAL INFORMATION:


```

RESULT 5
US -10-295-027-1284
; Sequence 1284, Application US/10295027
; Publication NO. US20030232350A1
; GENERAL INFORMATION:
; APPLICANT: Afar, Daniel
; APPLICANT: Aziz, Nataasha
; APPLICANT: Ginsberg, Wendy M.
; APPLICANT: Gish, Kurt C.
; APPLICANT: Glynnne, Richard
; APPLICANT: Hevezi, Peter A.
; APPLICANT: Mack, David H.
; APPLICANT: Murray, Richard
; APPLICANT: Watson, Susan R.
; APPLICANT: Eos Biotechnology, Inc.
; TITLE OF INVENTION: Methods of screening
; TITLE OF INVENTION: Methods of screening
; FILE REFERENCE: 018501-012500US
; CURRENT APPLICATION NUMBER: US/10/295027
; CURRENT FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: US 09/663,717

```

```

RESULT 6
US-10-959-537-3
Sequence 3, Application US/10959537
Publication No. US20050069983A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Goddard, Audrey
APPLICANT: Gurney, Austyn
APPLICANT: Marsters, Scott A.
APPLICANT: Pitti, Robert M.
APPLICANT: Wood, William
TITLE OF INVENTION: NOVEL TUMOR NE
TITLE OF INVENTION: ACIDS ENCODING
FILE REFERENCE: P1206R1
CURRENT APPLICATION NUMBER: US/10/
CURRENT FILING DATE: 2004-10-06
PRIOR APPLICATION NUMBER: US/09/24
PRIOR FILING DATE: 1999-02-09
PRIOR APPLICATION NUMBER: US 60/07
PRIOR FILING DATE: 1998-02-09

```

; NUMBER OF SEQ ID NOS: 31
; SEQ ID NO 3
; LENGTH: 241
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-959-537-3

Query Match 100.0%; Score 1386; DB 17; Length 241;
Best Local Similarity 100.0%; Pred. No. 1.1e-106;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAQHGAMGAFRALCGLLALLCALSLGQRTGPGCGPGRLLLTGTDTARCCRVHTTRCCRD 60
DB 1 MAQHGAMGAFRALCGLLALLCALSLGQRTGPGCGPGRLLLTGTDTARCCRVHTTRCCRD 60
QY 61 YPGECCSNDWCVCQVPEFHCGDPCTTCRHHPCPPGQVQSGKFSFGFCIDCASGTF 120
DB 61 YPGECCSNDWCVCQVPEFHCGDPCTTCRHHPCPPGQVQSGKFSFGFCIDCASGTF 120
QY 121 SGGHEGCHKPWTCTQFGFLTVPFGNKTNAVCVPGSPPAEPLGMLTVVLLAAVACVLL 180
DB 121 SGGHEGCHKPWTCTQFGFLTVPFGNKTNAVCVPGSPPAEPLGMLTVVLLAAVACVLL 180
QY 181 TSAQLGLHIWQLRSQCMWPRETQLLLEVPSTEDARSCQFPPEERGERSAEEKGRGLDLM 240
DB 181 TSAQLGLHIWQLRSQCMWPRETQLLLEVPSTEDARSCQFPPEERGERSAEEKGRGLDLM 240
QY 241 V 241
DB 241 V 241

RESULT 7

US-11-032-294-3
; Sequence 3, Application US/11032294
; Publication No. US2005020208A1
; GENERAL INFORMATION:
; APPLICANT: P. Mickey Williams
; APPLICANT: Mary E. Gerritsen
; TITLE OF INVENTION: PROMOTION OR INHIBITION OF ANGIOGENESIS AND
; TITLE OF INVENTION: CARDIOVASCULARIZATION BY TUMOR NECROSIS FACTOR
; TITLE OF INVENTION: LIGAND/RECEPTOR HOMOLOGS
; FILE REFERENCE: PI765R1
; CURRENT APPLICATION NUMBER: US/11/032,294
; PRIOR FILING DATE: 2005-01-10
; PRIOR APPLICATION NUMBER: CURRENT FILING DATE: 2000-07-11
; PRIOR FILING DATE: 2000-07-11
; PRIOR APPLICATION NUMBER: US 60/143,304
; PRIOR FILING DATE: 1999-07-12
; NUMBER OF SEQ ID NOS: 22
; SEQ ID NO 3
; LENGTH: 241
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-032-294-3

Query Match 100.0%; Score 1386; DB 20; Length 241;
Best Local Similarity 100.0%; Pred. No. 1.1e-106;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAQHGAMGAFRALCGLLALLCALSLGQRTGPGCGPGRLLLTGTDTARCCRVHTTRCCRD 60
DB 1 MAQHGAMGAFRALCGLLALLCALSLGQRTGPGCGPGRLLLTGTDTARCCRVHTTRCCRD 60
QY 61 YPGECCSNDWCVCQVPEFHCGDPCTTCRHHPCPPGQVQSGKFSFGFCIDCASGTF 120
DB 61 YPGECCSNDWCVCQVPEFHCGDPCTTCRHHPCPPGQVQSGKFSFGFCIDCASGTF 120
QY 121 SGGHEGCHKPWTCTQFGFLTVPFGNKTNAVCVPGSPPAEPLGMLTVVLLAAVACVLL 180
DB 121 SGGHEGCHKPWTCTQFGFLTVPFGNKTNAVCVPGSPPAEPLGMLTVVLLAAVACVLL 180
QY 181 TSAQLGLHIWQLRSQCMWPRETQLLLEVPSTEDARSCQFPPEERGERSAEEKGRGLDLM 240

DB 181 TSAQLGLHIWQLRSQCMWPRETQLLLEVPSTEDARSCQFPPEERGERSAEEKGRGLDLM 240
QY 241 V 241
DB 241 V 241
RESULT 8
US-10-783-528-75
; Sequence 75, Application US/10783528
; Publication No. US20040219579A1
; GENERAL INFORMATION:
; APPLICANT: Aziz, Natasha
; APPLICANT: Gish, Kurt
; APPLICANT: Wilson, Keith
; APPLICANT: Zlotnik, Albert
; TITLE OF INVENTION: METHODS OF DIAGNOSIS OF CANCER, COMPOSITIONS AND
; FILE REFERENCE: 05882.0191.NPUS01
; CURRENT APPLICATION NUMBER: US/10/783,528
; CURRENT FILING DATE: 2004-02-19
; NUMBER OF SEQ ID NOS: 116
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 75
; LENGTH: 240
; TYPE: PRT
; ORGANISM: Homo Sapiens
US-10-783-528-75

Query Match 99.7%; Score 1382; DB 16; Length 240;
Best Local Similarity 100.0%; Pred. No. 2.4e-106;
Matches 240; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAQHGAMGAFRALCGLLALLCALSLGQRTGPGCGPGRLLLTGTDTARCCRVHTTRCCRD 60
DB 1 MAQHGAMGAFRALCGLLALLCALSLGQRTGPGCGPGRLLLTGTDTARCCRVHTTRCCRD 60
QY 61 YPGECCSNDWCVCQVPEFHCGDPCTTCRHHPCPPGQVQSGKFSFGFCIDCASGTF 120
DB 61 YPGECCSNDWCVCQVPEFHCGDPCTTCRHHPCPPGQVQSGKFSFGFCIDCASGTF 120
QY 121 SGGHEGCHKPWTCTQFGFLTVPFGNKTNAVCVPGSPPAEPLGMLTVVLLAAVACVLL 180
DB 121 SGGHEGCHKPWTCTQFGFLTVPFGNKTNAVCVPGSPPAEPLGMLTVVLLAAVACVLL 180
QY 181 TSAQLGLHIWQLRSQCMWPRETQLLLEVPSTEDARSCQFPPEERGERSAEEKGRGLDLM 240
DB 181 TSAQLGLHIWQLRSQCMWPRETQLLLEVPSTEDARSCQFPPEERGERSAEEKGRGLDLM 240

RESULT 9

US-09-915-593-2
; Sequence 2, Application US/09915593
; Patent No. US20020098525A1
; GENERAL INFORMATION:
; APPLICANT: NI, Jian
; APPLICANT: Ruben, Steven M.
; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins
; TITLE OF INVENTION: TR11, TR11SV1, and TR11SV2
; FILE REFERENCE: PF396P2
; CURRENT APPLICATION NUMBER: US/09/915,593
; CURRENT FILING DATE: 2001-07-27
; PRIOR APPLICATION NUMBER: 60/221,577
; PRIOR FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: 09/512,363
; PRIOR FILING DATE: 2000-02-23
; PRIOR APPLICATION NUMBER: 60/144,076
; PRIOR FILING DATE: 2000-07-16
; PRIOR APPLICATION NUMBER: 60/134,172
; PRIOR FILING DATE: 1999-05-13
; PRIOR APPLICATION NUMBER: 60/121,648
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 09/176,200

;; PRIOR FILING DATE: 1998-10-21
;; PRIOR APPLICATION NUMBER: 60/063,212
;; PRIOR FILING DATE: 1997-10-21
;; NUMBER OF SEQ ID NOS: 28
;; SOFTWARE: PatentIn Ver. 2.0
;; SEQ ID NO 2
;; LENGTH: 234
;; TYPE: PRT
;; ORGANISM: Homo sapiens
; US-09-915-593-2

Query Match 95.4%; Score 1322.5; DB 9; Length 234;
Best Local Similarity 96.7%; Pred. No. 1.9e-101;
Matches 233; Conservative 1; Mismatches 0; Indels 7; Gaps 1;
QY 1 MAQHGAMGAFRALCGLLALLCALSLGQRTGPGCGGGRLLLTGTDAARCRVHTTRCCRD 60
DB 1 MAQHGAMGAFRALCGLLALLCALSLGQRTGPGCGGGRLLLTGTDAARCRVHTTRCCRD 60
QY 61 YPGECCSEWDCMCVQPEFHCGDPCCTTCRHHPCPPGQGVQSGKFSFGFCIDCASGTF 120
DB 61 YPGECCSEWDCMCVQPEFHCGDPCCTTCRHHPCPPGQGVQSGKFSFGFCIDCASGTF 120
QY 121 SGGHEGCHKPWTDTCTQFGFLTVPFGNKNTHNAVCPGSPPAEPLGWLTVVLLAVAAACVLLL 180
DB 121 SGGHEGCHKPWTDTCTQFGFLTVPFGNKNTHNAVCPGSPPAEPLGWLTVVLLAVAAACVLLL 180
QY 181 TSAQLGLHIWQLRSQCMWPRETOLLLEVPSTEDARSCQPPPEERGERSAEEKRGLDGLW 240
DB 181 TSAQLGLHIWQL-----RKTQLLEVPSTEDARSCQPPPEERGERSAEEKRGLDGLW 233
QY 241 V 241
DB 234 V 234

RESULT 10

US-10-283-105-2
; Sequence 2, Application US/10283105
; Publication No. US20030138426A1
; GENERAL INFORMATION:
; APPLICANT: Ni, Jian
; APPLICANT: Ruben, Steven M
; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins TR11, TR11SV1,
; FILE REFERENCE: TR11SV22
; CURRENT APPLICATION NUMBER: US/10/283,105
; PRIOR FILING DATE: 2002-10-30
; PRIOR FILING DATE: 2001-07-27
; PRIOR FILING DATE: 2001-07-27
; PRIOR FILING DATE: 2000-07-28
; PRIOR FILING DATE: 2000-07-28
; PRIOR FILING DATE: 2000-02-23
; PRIOR FILING DATE: 1999-07-16
; PRIOR FILING DATE: 1999-07-16
; PRIOR FILING DATE: 1999-05-13
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 234
; TYPE: PRT
; ORGANISM: human
US-10-283-105-2

Query Match 95.4%; Score 1322.5; DB 14; Length 234;
Best Local Similarity 96.7%; Pred. No. 1.9e-101;
Matches 233; Conservative 1; Mismatches 0; Indels 7; Gaps 1;
QY 1 MAQHGAMGAFRALCGLLALLCALSLGQRTGPGCGGGRLLLTGTDAARCRVHTTRCCRD 60
DB 1 MAQHGAMGAFRALCGLLALLCALSLGQRTGPGCGGGRLLLTGTDAARCRVHTTRCCRD 60
QY 61 YPGECCSEWDCMCVQPEFHCGDPCCTTCRHHPCPPGQGVQSGKFSFGFCIDCASGTF 120
DB 61 YPGECCSEWDCMCVQPEFHCGDPCCTTCRHHPCPPGQGVQSGKFSFGFCIDCASGTF 120
QY 121 SGGHEGCHKPWTDTCTQFGFLTVPFGNKNTHNAVCPGSPPAEPLGWLTVVLLAVAAACVLLL 180
DB 121 SGGHEGCHKPWTDTCTQFGFLTVPFGNKNTHNAVCPGSPPAEPLGWLTVVLLAVAAACVLLL 180
QY 181 TSAQLGLHIWQLRSQCMWPRETOLLLEVPSTEDARSCQPPPEERGERSAEEKRGLDGLW 240
DB 181 TSAQLGLHIWQL-----RKTQLLEVPSTEDARSCQPPPEERGERSAEEKRGLDGLW 233
QY 241 V 241
DB 234 V 234

RESULT 11

US-10-277-966-2
; Sequence 2, Application US/10277966
; Publication No. US20030153499A1
; GENERAL INFORMATION:
; APPLICANT: Ni, Jian
; APPLICANT: Ruben, Steven
; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins TR11, TR11SV1,
; FILE REFERENCE: TR11SV2
; CURRENT APPLICATION NUMBER: US/10/277,966
; PRIOR FILING DATE: 2002-10-23
; PRIOR FILING DATE: 2000-02-23
; PRIOR FILING DATE: 2000-02-23
; PRIOR FILING DATE: 1999-02-24
; PRIOR FILING DATE: 1999-02-24
; PRIOR FILING DATE: 1999-05-13
; PRIOR FILING DATE: 1999-07-16
; PRIOR FILING DATE: 1999-07-16
; PRIOR FILING DATE: 1998-10-21
; PRIOR FILING DATE: 1998-10-21
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 234
; TYPE: PRT
; ORGANISM: human
US-10-277-966-2

Query Match 95.4%; Score 1322.5; DB 14; Length 234;
Best Local Similarity 96.7%; Pred. No. 1.9e-101;
Matches 233; Conservative 1; Mismatches 0; Indels 7; Gaps 1;
QY 1 MAQHGAMGAFRALCGLLALLCALSLGQRTGPGCGGGRLLLTGTDAARCRVHTTRCCRD 60
DB 1 MAQHGAMGAFRALCGLLALLCALSLGQRTGPGCGGGRLLLTGTDAARCRVHTTRCCRD 60
QY 61 YPGECCSEWDCMCVQPEFHCGDPCCTTCRHHPCPPGQGVQSGKFSFGFCIDCASGTF 120
DB 61 YPGECCSEWDCMCVQPEFHCGDPCCTTCRHHPCPPGQGVQSGKFSFGFCIDCASGTF 120
QY 121 SGGHEGCHKPWTDTCTQFGFLTVPFGNKNTHNAVCPGSPPAEPLGWLTVVLLAVAAACVLLL 180
DB 121 SGGHEGCHKPWTDTCTQFGFLTVPFGNKNTHNAVCPGSPPAEPLGWLTVVLLAVAAACVLLL 180

```
QY 181 TSAQLGLHQLWLRSCQWMPRETQLLEVPSTEDARSCQFPPEERGERSAEBKRLGLDLW 240
|:|||||
Db 181 TSAQLGLHQLWLRSCQWMPRETQLLEVPSTEDARSCQFPPEERGERSAEBKRLGLDLW 233
|:|||||
QY 241 V 241
|:|||||
Db 234 V 234
|:|||||

RESULT 12
US-10-264-237-1762
; Sequence 1762, Application US/10264237
; Publication No. US20040009491A1
; GENERAL INFORMATION:
; APPLICANT: Birse et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PA131P1
; CURRENT APPLICATION NUMBER: US/10/264,237
; CURRENT FILING DATE: 2002-10-04
; PRIOR APPLICATION NUMBER: PCT/US01/16450
; PRIOR FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: US 60/205,515
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 2876
; SOFTWARE: PatentIn Ver. 3.1
; SEQ ID NO 1762
; LENGTH: 246
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-264-237-1762

Query Match 94.3%; Score 1306.5; DB 15; Length 246;
Best Local Similarity 92.1%; Pred. No. 4.3e-100;
Matches 233; Conservative 1; Mismatches 0; Indels 19; Gaps 2;

QY 1 MAQHGAMGAFRALCGLLALCALSLGQRTGGPGCGPGRLLLTGTGTARCCRVHTTRCCRD 60
|:|||||
Db 1 MAQHGAMGAFRALCGLLALCALSLGQRTGGPGCGPGRLLLTGTGTARCCRVHTTRCCRD 60
|:|||||
QY 61 Y-----PGECCSEWDCMCVQPEFHCQDPCCCTTCRHHPCPGQGVQSQGKFSF 108
|:|||||
Db 61 YFAQLLGHPVSCFGECCSEWDCMCVQPEFHCQDPCCCTTCRHHPCPGQGVQSQGKFSF 120
|:|||||
QY 109 GFQCIDCASGTFSGGHEGCHKPWTCTQFGFLTVPFGNKNHNAVCPGSPPAEPLGWLTV 168
|:|||||
Db 121 GFQCIDCASGTFSGGHEGCHKPWTCTQFGFLTVPFGNKNHNAVCPGSPPAEPLGWLTV 180
|:|||||
QY 169 VLLAVAAVLLLTSAQLGLHQLWLRSCQWMPRETQLLEVPSTEDARSCQFPPEERGER 228
|:|||||
Db 181 VLLAVAAVLLLTSAQLGLHQLWLRSCQWMPRETQLLEVPSTEDARSCQFPPEERGER 233
|:|||||
QY 229 SAEKGRGLDLW 241
|:|||||
Db 234 SAEKGRGLDLW 246
|:|||||

RESULT 13
US-09-915-593-6
; Sequence 6, Application US/09915593
; Patent No. US20020098525A1
; GENERAL INFORMATION:
; APPLICANT: Ni, Jian
; APPLICANT: Ruben, Steven M.
; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins
; TITLE OF INVENTION: TR11, TR11SV1, and TR11SV2
; FILE REFERENCE: PF396P2
; CURRENT APPLICATION NUMBER: US/09/915,593
; CURRENT FILING DATE: 2001-07-27
; PRIOR APPLICATION NUMBER: 60/221,577
; PRIOR FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: 09/512,363
; PRIOR FILING DATE: 2000-02-23
```

```
; PRIOR APPLICATION NUMBER: 60/144,076
; PRIOR FILING DATE: 2000-07-16
; PRIOR APPLICATION NUMBER: 60/134,172
; PRIOR FILING DATE: 1999-05-13
; PRIOR APPLICATION NUMBER: 60/121,648
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 09/176,200
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/063,212
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 240
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-915-593-6

Query Match 92.0%; Score 1274.5; DB 9; Length 240;
Best Local Similarity 91.9%; Pred. No. 1.9e-97;
Matches 227; Conservative 1; Mismatches 0; Indels 19; Gaps 2;

QY 7 MGAFFRALCGLALLCALSLGQRTGGPGCGPGRLLLTGTGTARCCRVHTTRCCRDY----- 61
|:|||||
Db 1 MGAFFRALCGLALLCALSLGQRTGGPGCGPGRLLLTGTGTARCCRVHTTRCCRDYPAQLL 60
|:|||||
QY 62 -----PGECCSEWDCMCVQPEFHCQDPCCCTTCRHHPCPGQGVQSQGKFSFGQCID 114
|:|||||
Db 61 GGWPVSCFGECCSEWDCMCVQPEFHCQDPCCCTTCRHHPCPGQGVQSQGKFSFGQCID 120
|:|||||
QY 115 CASGTFSGGHEGCHKPWTCTQFGFLTVPFGNKNHNAVCPGSPPAEPLGWLTVVLLAVA 174
|:|||||
Db 121 CASGTFSGGHEGCHKPWTCTQFGFLTVPFGNKNHNAVCPGSPPAEPLGWLTVVLLAVA 180
|:|||||
QY 175 ACVLLLTSAQLGLHQLWLRSCQWMPRETQLLEVPSTEDARSCQFPPEERGERSAEKG 234
|:|||||
Db 181 ACVLLLTSAQLGLHQLWLRSCQWMPRETQLLEVPSTEDARSCQFPPEERGERSAEKG 233
|:|||||
QY 235 RLGLDLW 241
|:|||||
Db 234 RLGLDLW 240
|:|||||

RESULT 14
US-10-283-105-6
; Sequence 6, Application US/10283105
; Publication No. US20030138426A1
; GENERAL INFORMATION:
; APPLICANT: Ni, Jian
; APPLICANT: Ruben, Steven M
; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins TR11, TR11SV1,
; TITLE OF INVENTION: TR11SV2
; FILE REFERENCE: PF396P3
; CURRENT APPLICATION NUMBER: US/10/283,105
; CURRENT FILING DATE: 2002-10-30
; PRIOR APPLICATION NUMBER: 60/330,757
; PRIOR FILING DATE: 2001-10-30
; PRIOR APPLICATION NUMBER: 09/915,593
; PRIOR FILING DATE: 2001-07-27
; PRIOR APPLICATION NUMBER: 60/221,577
; PRIOR FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: 09/512,363
; PRIOR FILING DATE: 2000-02-23
; PRIOR APPLICATION NUMBER: 60/144,076
; PRIOR FILING DATE: 1999-07-16
; PRIOR APPLICATION NUMBER: 60/134,172
; PRIOR FILING DATE: 1999-05-13
; PRIOR APPLICATION NUMBER: 60/121,648
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 09/176,200
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/063,212
; PRIOR FILING DATE: 1997-10-21
```

NUMBER OF SEQ ID NOS: 28
 SOFTWARE: PatentIn version 3.1
 SEQ ID NO 6
 LENGTH: 240
 TYPE: PRT
 ORGANISM: human
 US-10-283-105-6

Query Match 92.0%; Score 1274.5; DB 14; Length 240;
 Best Local Similarity 91.9%; Pred. No. 1.9e-97;
 Matches 227; Conservative 1; Mismatches 0; Indels 19; Gaps 2;
 QY 7 MGAFRALCGLALCALSLGQRTGPGCGPGRLLLGTTDARCRVHTTRCCRDY----- 61
 DB 1 MGAFRALCGLALCALCALSLGQRTGPGCGPGRLLLGTTDARCRVHTTRCCRDYPAQLL 60
 QY 62 -----PGECCSEWDCMCVQPEFHGCDPCCTTCRRHPCPPGCGVQSGKFSFGQCID 114
 DB 61 GGPVSCPGEECCSEWDCMCVQPEFHGCDPCCTTCRRHPCPPGCGVQSGKFSFGQCID 120
 QY 115 CASGTFSGGHEGCHKPWTDTQFGFLTVPFGKNTNNAVCVPGSPPAEPLGMLTVLLAVA 174
 DB 121 CASGTFSGGHEGCHKPWTDTQFGFLTVPFGKNTNNAVCVPGSPPAEPLGMLTVLLAVA 180
 QY 175 ACVLLLTSAQLGLHIWQLRSQCMWPRETQLLLEVPSTEDARSCQFPEERGERSAEEKG 234
 DB 181 ACVLLLTSAQLGLHIWQL-----RKTQLLLEVPSTEDARSCQFPEERGERSAEEKG 233
 QY 235 RLGDLMV 241
 DB 234 RLGDLMV 240

Search completed: October 26, 2005, 16:11:21
 Job time : 116.618 secs

RESULT 15
 US-10-277-966-6
 Sequence 6, Application US/10277966
 Publication No. US2003015349A1
 GENERAL INFORMATION:
 APPLICANT: Ni, Jian
 TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins Tr11, Tr11sv1,
 TITLE OF INVENTION: Tr11sv2
 FILE REFERENCE: PF396PDI
 CURRENT APPLICATION NUMBER: US/10/277,966
 CURRENT FILING DATE: 2002-10-23
 PRIOR APPLICATION NUMBER: 09/512,363
 PRIOR FILING DATE: 2000-02-23
 PRIOR APPLICATION NUMBER: 60/121,648
 PRIOR FILING DATE: 1999-02-24
 PRIOR APPLICATION NUMBER: 60/134,172
 PRIOR FILING DATE: 1999-05-13
 PRIOR APPLICATION NUMBER: 60/144,076
 PRIOR FILING DATE: 1999-07-16
 PRIOR APPLICATION NUMBER: 09/176,200
 PRIOR FILING DATE: 1998-10-21
 PRIOR APPLICATION NUMBER: 60/063,212
 PRIOR FILING DATE: 1997-10-21
 NUMBER OF SEQ ID NOS: 28
 SOFTWARE: PatentIn version 3.1
 SEQ ID NO 6
 LENGTH: 240
 TYPE: PRT
 ORGANISM: human
 US-10-277-966-6

Query Match 92.0%; Score 1274.5; DB 14; Length 240;
 Best Local Similarity 91.9%; Pred. No. 1.9e-97;
 Matches 227; Conservative 1; Mismatches 0; Indels 19; Gaps 2;
 QY 7 MGAFRALCGLALCALSLGQRTGPGCGPGRLLLGTTDARCRVHTTRCCRDY----- 61
 DB 1 MGAFRALCGLALCALSLGQRTGPGCGPGRLLLGTTDARCRVHTTRCCRDYPAQLL 60

QY 62 -----PGECCSEWDCMCVQPEFHGCDPCCTTCRRHPCPPGCGVQSGKFSFGQCID 114
 DB 61 GGPVSCPGEECCSEWDCMCVQPEFHGCDPCCTTCRRHPCPPGCGVQSGKFSFGQCID 120
 QY 115 CASGTFSGGHEGCHKPWTDTQFGFLTVPFGKNTNNAVCVPGSPPAEPLGMLTVLLAVA 174
 DB 121 CASGTFSGGHEGCHKPWTDTQFGFLTVPFGKNTNNAVCVPGSPPAEPLGMLTVLLAVA 180
 QY 175 ACVLLLTSAQLGLHIWQLRSQCMWPRETQLLLEVPSTEDARSCQFPEERGERSAEEKG 234
 DB 181 ACVLLLTSAQLGLHIWQL-----RKTQLLLEVPSTEDARSCQFPEERGERSAEEKG 233
 QY 235 RLGDLMV 241
 DB 234 RLGDLMV 240

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 26, 2005, 15:38:30 ; Search time 25.693 Seconds
(without alignments)
902.513 Million cell updates/sec

Title: US-09-545-998B-4
Perfect score: 1386
Sequence: 1 MAQHGMGAFRALCGLALIC.....EEEGERSAEEKRLGLIWL 241

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 79.*
1: pir1.*
2: pir2.*
3: pir3.*
4: pir4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	197	14.2	256	2 B32393	T-cell antigen 4-1
2	195.5	14.1	255	2 I38426	lymphocyte activat
3	175	12.6	272	2 I48700	gene ox40 protein
4	168.5	12.2	271	2 S12783	OX40 antigen precu
5	162	11.7	277	2 I37552	OX40 homolog - hum
6	144.5	10.4	305	2 A46476	B cell-associated
7	139	10.0	295	2 JC5559	lectin-B - Virgini
8	134.5	9.7	1801	1 MWRTS	laminin beta-2 cha
9	133	9.6	435	2 I54182	tumor necrosis fac
10	130.5	9.4	651	2 JC7705	death receptor-6 -
11	129	9.3	461	1 A35366	tumor necrosis fac
12	127.5	9.2	1574	2 T13954	MEGf6 protein - ra
13	124	8.9	277	2 A50771	B-cell activation
14	121.5	8.8	459	2 I48854	gene murine tumour
15	121	8.7	474	2 B38634	tumor necrosis fac
16	119.5	8.6	1798	2 S53869	laminin beta-2 cha
17	119	8.6	3635	2 T10053	laminin alpha 5 ch
18	118.5	8.5	1797	2 A55677	laminin beta-2 cha
19	117.5	8.5	1687	2 T30176	EGF repeat transme
20	115.5	8.3	1371	2 A33837	insulin-like growt
21	114.5	8.3	329	2 A48805	insulin-like growt
22	112	8.1	152	2 T18975	hypothetical prote
23	111	8.0	1111	2 T26972	hypothetical prote
24	111	8.0	2318	2 S45306	notch 3 protein -
25	110.5	8.0	2907	2 A57278	fibrillin-2 precur
26	110	7.9	1522	2 H88380	protein T22F7.3 [i
27	109.5	7.9	164	2 T24272	hypothetical prote
28	109.5	7.9	2531	2 A46019	notch-1 protein -
29	109	7.9	996	2 J50237	apolipoprotein E r

30 108 7.8 540 2 B47417 insulin receptor-x
31 106.5 7.7 2918 2 A54105 fibrillin-2 precur
32 106 7.6 788 2 T25061 hypothetical prote
33 105.5 7.6 1113 2 JE0315 low-density lipopr
34 105.5 7.6 1251 2 A57293 latent transformin
35 105 7.6 188 2 T15651 hypothetical prote
36 105 7.6 1172 1 TSHUP2 thrombospondin 2 p
37 105 7.6 3566 1 A40701 tenascin-X precurs
38 104.5 7.5 2825 2 T14271 Doc4 protein, stre
39 103.5 7.5 1737 2 T00209 MEGF8 protein - hu
40 102.5 7.4 770 2 T00204 LDL receptor-relat
41 102.5 7.4 770 2 T00203 LDL receptor-relat
42 102.5 7.4 956 1 A46016 thrombospondin 3
43 102 7.4 186 2 A28401 agglutinin isolect
44 102 7.4 1364 2 T00250 MEGF2 protein - hu
45 102 7.4 2871 2 A55567 fibrillin I - bovi

ALIGNMENTS

RESULT 1

B32393
T-cell antigen 4-1BB precursor - mouse
C;Species: Mus musculus (house mouse)
C;Date: 17-Jul-1992 #sequence_revision 17-Jul-1992 #text_change 09-Jul-2004
C;Accession: B32393; I48879
R;Kwon, B.S.; Weissman, S.M.
Proc. Natl. Acad. Sci. U.S.A. 86, 1963-1967, 1989
A;Title: cDNA sequence of two inducible T-cell genes.
A;Reference number: A32393; MUID:89184547; PMID:2784565
A;Accession: B32393
A;Molecule type: mRNA
A;Residues: 1-256 <KWO>
A;Cross-references: UNIPROT:P20334; GB:J04492; NID:G201121; PIDN:AAA0167.1; PID:G201122
R;Kwon, B.S.; Kozak, C.A.; Kim, K.K.; Pickard, R.T.
J. Immunol. 152, 2256-2262, 1994
A;Title: Genomic Organization and Chromosomal Localization of the T-Cell Antigen 4-1BB.
A;Reference number: I48879; MUID:94179805; PMID:8133039
A;Accession: I48879
A;Status: preliminary; translated from GB/EMBL/DBD
A;Molecule type: DNA
A;Residues: 1-256 <RES>
A;Cross-references: EMBL:U02567; NID:G1117783; PIDN:AAA93113.1; PID:G409178
C;Genetics:
A;Introns: 35/1; 69/1; 115/1; 138/2; 156/3; 181/1; 225/1
C;Superfamily: CD27 antigen; NGF receptor repeat homology
C;Keywords: transmembrane protein
F;1-23/Domain: signal sequence #status predicted <SIG>
F;24-256/Product: 4-1BB protein #status predicted <MAT>

Query Match 14.2%; Score 197; DB 2; Length 256;
Best Local Similarity 28.8%; Pred. No. 2.9e-08;
Matches 64; Conservative 25; Mismatches 85; Indels 48; Gaps 10;

Qy 34 CGPGRLL-LLGFGTDARCCRVHTTCCRDYDGECCSEW---DCMCVQPEFHCGDPCCCTTC 89
Db 47 CPSTFSSIGGQPCNCRV-----CAGYFRFKFCSTHNAECIE-GFHCLGPQCCTRC 101
Qy 90 RHHPCCPGQVQSQKFSGFCQICDASGTFSGGH-EGHCKPWTDTCTQFGFLTVPFGNKT 148
Db 102 -EKDCRFGQELTKG-----CKTCSLGTFTNDQNGTGVCRPTNCSLDGRSLVKGTGTE 153
Qy 149 HNAVVCVP-----GSPPAEPGLWLTVVLLAVAAACVLLTSLQGLHIWQL 192
Db 154 KDVVCGPPVWSFSPTTISVTPEGGPGGHSLSQVLTFLALTSLALLAL-----IFITLL 207
Qy 193 RSQCMWPRETQLLEVP-----STEDARSCQFPEEERG 226
Db 208 FSVLKWIRKFFPHIFKFFKTTGAAQEEACSCRCFOEEEG 249

RESULT 2

I38426
Lymphocyte activation-induced receptor ILA precursor - human
C:Species: Homo sapiens (man)
C>Date: 29-May-1998 #sequence_revision 29-May-1998 #text_change 09-Jul-2004
C:Residues: 1-14, 'G', 16-272 <RES2>
C:Accession: I38426; J07052
R:Alderson, M.R.; Smith, C.A.; Tough, T.W.; Davis-Smith, T.; Armitage, R.J.; Falk, B.; R
Eur. J. Immunol. 24, 2219-2227, 1994
A:Title: Molecular and biological characterization of human 4-1BB and its ligand.
A:Reference number: I38426; MUID:94374434; PMID:8088337
A:Accession: I38426
A>Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-255 <RES>
A:Cross-references: UNIPROT:Q07011; EMBL:U03397; NID:G571320; PIDN:AAAS3133.1; PID:G5713
R:Schwarz, H.; Tuckwell, J.; Lotz, M.
Gene 134, 295-298, 1993
A:Title: A receptor induced by lymphocyte activation (ILA): a new member of the human ne
A:Reference number: J07052; MUID:94085794; PMID:8262389
A:Accession: J07052
A:Molecule type: mRNA
A:Residues: 1-106, 'R', 108-255 <SCH>
C:Comment: This receptor belongs to a member of the human nerve-growth-factor/tumor-necro
C:Comment: This receptor recognizes soluble, cell-surface bound or extracellular matrix
C:Superfamily: CD27 antigen; NGF receptor repeat homology
C:Keywords: glycoprotein; phosphoprotein; receptor; transmembrane protein
F:1-17/Domain: signal sequence #status predicted <SIG>
F:18-255/Product: lymphocyte activation-induced receptor ILA #status predicted <MAT>
F:187-213/Domain: transmembrane #status predicted <TMM>
F:138,149/Binding site: carboxylate (Asn) (covalent) #status predicted
F:234,235/Binding site: phosphate (Thr) (covalent) (by casein kinase II) #status predict
F:242/Binding site: phosphate (Ser) (covalent) (by protein kinase C) #status predicted

Query Match 14.1%; Score 195.5; DB 2; Length 255;
Best Local Similarity 28.8%; Pred. No. 3.8e-08;
Matches 66; Conservative 21; Mismatches 81; Indels 61; Gaps 12;
QY 34 CGPGRLLLTGTGTDARCCRVHTTRCCRDYDG-----EECCS-----EWDNCVQPEFHCGDP 84
DB 48 CPNPSFSSAGG--QRTCDI-----CQCKGVFRTRKECSSTNAECDC--TPGFHCLGA 97
QY 85 CCTTCRHHPCPGQVQSQGKFSFGQCIDCASGTFSGGHEGCKEWTCTQFGFLTVP 144
DB 98 GCSMC-EQCKQGOELTKG-----CKDCFGTFNDQKRGICRPTWNCSDGKSVLVN 149
QY 145 GNKTHNAVCPG-----SPPA---EPUGLWTVV--LLAVAACVLLTSAQLGLH 188
DB 150 GTKERDVVCGSPADLSPGASVTPPAPAREPGHSPQIISFFLALTSTALLFLFLTLR 209
QY 189 -----IWQLRSQCMWPRETOLLLEVPSTEDARSCQPPERE 226
DB 210 FSVVKRGRKKLLYIFKOPFMRPVOT-----TOEEDGCSCRPEE 251

RESULT 3
I48700
Gene ox40 protein - mouse
N:Alternate names: Ox40 antigen
C:Species: Mus musculus (house mouse)
C>Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 09-Jul-2004
C:Accession: I48700; I48334; S34377
R:Calderhead, D.M.; Buhlmann, J.E.; van den Eertwegh, A.J.; Claassen, E.; Noelle, R.J.;
J. Immunol. 151, 5261-5271, 1993
A:Title: Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell int
A:Reference number: I48700; MUID:94044750; PMID:8228223
A:Accession: I48700
A>Status: translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-272 <RES>
A:Cross-references: UNIPROT:P47741; EMBL:Z21674; NID:G312827; PIDN:CAA79772.1; PID:G3128
R:Birkeland, M.L.; Copeland, N.G.; Gilbert, D.J.; Jenkins, N.A.; Barclay, A.N.
Eur. J. Immunol. 25, 926-930, 1995
A:Title: Gene structure and chromosomal localization of the mouse homologue of rat Ox40
A:Reference number: I48334; MUID:95255413; PMID:7737295

A:Accession: I48334
A>Status: translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-14, 'G', 16-272 <RES2>
A:Cross-references: EMBL:X85214; NID:G732818; PIDN:CAA59476.1; PID:G732819
C:Genetics:
A:Gene: ox40
A:Introns: 45/1; 86/1; 122/1; 144/2; 210/1; 250/1
C:Superfamily: CD27 antigen; NGF receptor repeat homology

Query Match 12.6%; Score 175; DB 2; Length 272;
Best Local Similarity 26.7%; Pred. No. 1.6e-06;
Matches 58; Conservative 19; Mismatches 70; Indels 70; Gaps 10;
QY 39 LLLGTGTAR--CCRVHT-----TRCRD-YPG-----EECCSEWDCMCVQPEFHCGDPC-- 85
DB 14 LALLTGVTAARLNCVKHTYPSGHKKCCRCQPGHGMVSRCDHTRDTLC-----HPCST 65
QY 86 -----CTTCRHHP-----CPPGQVQSQGKFSFGQCID 114
DB 66 GFYNNAVNDYCKQCTQCNRHSGSELKNCNCTPTQDTVCRCRPTQPRQDSGYKLGVDVCP 125
QY 115 CASGTFSGGHEGCKEWTCTQFGFLTVPFGNKNTHNAVCPGSPPAEPLGLWTVVLLAVA 174
DB 126 CPPGHFSPGNQACKPTWNTLSGKQTRHPASDSLDAVCEDRS-----LLA-- 171
QY 175 ACVLLTSAQLGLHIVQWRSQCMWPRETOLLLEVPSP 211
DB 172 --LLIWEQRTFRPTTQSTTVPWPTSE--LPSPT 204

RESULT 4
SI2783
OX40 antigen precursor - rat
N:Alternate names: nerve growth factor receptor homolog
C:Species: Rattus norvegicus (Norway rat)
C>Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004
C:Accession: SI2783; S08036
R:Mallett, S.; Fossum, S.; Barclay, A.N.
EMBO J. 9, 1063-1068, 1990
A:Title: Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocyte
A:Reference number: SI2783; MUID:90214614; PMID:2157591
A:Accession: SI2783
A:Molecule type: mRNA
A:Residues: 1-271 <NAL>
A:Cross-references: UNIPROT:P15725; EMBL:X17037; NID:G57830; PIDN:CAA34897.1; PID:G57831
C:Superfamily: CD27 antigen; NGF receptor repeat homology
C:Keywords: growth factor receptor; transmembrane protein
F:1-19/Domain: signal sequence #status predicted <SIG>
F:20-271/Product: OX40 antigen #status predicted <MAT>
F:211-235/Domain: transmembrane #status predicted <TMM>

Query Match 12.2%; Score 168.5; DB 2; Length 271;
Best Local Similarity 27.7%; Pred. No. 4.9e-06;
Matches 62; Conservative 17; Mismatches 80; Indels 65; Gaps 11;
QY 26 QRTPGCGGCGRLLLG--TGTARCCRVHT-----RCCRD-YGEECCSWE----- 71
DB 6 QQPT-----AFLLLGLSLGVTVKLVNCKVTPSGHKCCRCQPGHGMVSRCDHTRDTV 58
QY 72 CMCVQPEFHCG---DPC--CTTCRH-----PCPGQVQSQGKFSF 108
DB 59 CHPCPEFGFNEAVNYDTCKQCQCNHRSGSELKQNCPTPTEDVTCRCRPTQPRQDSHKL 118
QY 109 GFQCIDCASGTFSGGHEGCKEWTCTQFGFLTVPFGNKNTHNAVCPGSPPAEPLGLWTV 168
DB 119 GVDVCPGPGHSPGSNQACKPTWNTLSGKQIRHPASNSLDTVCEDRS----- 167
QY 169 VLLAVAACVLLTSAQLGLHIVQWRSQCMWPRETOLLLEVPSP 212
DB 168 --LLA---TLLIWEQRTFRPTTVPWPTSE--LPSPT 201

C:Function:

A:Description: interact with cells and with other basement membrane proteins to promote C:Superfamily: laminin beta-1 chain; laminin-type EGF-like homology C:Keywords: basement membrane; calcium binding; cell binding; coiled coil; extracellular F:1-35/Domain: signal sequence #status predicted <SIG> F:36-1801/Product: laminin beta-2 chain #status predicted <MAT> F:36-285/Domain: VI <DOM6> F:286-555/Domain: V <DOM5> F:286-347/Domain: laminin-type EGF-like homology <LE01> F:350-410/Domain: laminin-type EGF-like homology <LE02> F:413-470/Domain: laminin-type EGF-like homology <LE03> F:473-522/Domain: laminin-type EGF-like homology <LE04> F:525-555/Domain: laminin-type EGF-like homology #status atypical <LE05> F:556-784/Domain: IV <DOM4> F:786-831/Domain: laminin-type EGF-like homology <LE06> F:788-1196/Domain: III <DOM3> F:834-877/Domain: laminin-type EGF-like homology <LE07> F:880-927/Domain: laminin-type EGF-like homology <LE08> F:930-986/Domain: laminin-type EGF-like homology <LE09> F:989-1038/Domain: laminin-type EGF-like homology <LE10> F:1041-1095/Domain: laminin-type EGF-like homology <LE11> F:1098-1143/Domain: laminin-type EGF-like homology <LE12> F:1146-1190/Domain: laminin-type EGF-like homology <LE13> F:1197-1412/Domain: II <DOM2> F:1197-1412/Region: heptad repeats F:1413-1445/Domain: alpha <ALP> F:1446-1801/Region: heptad repeats F:1446-1801/Domain: I <DOM1> F:45-50/Disulfide bonds: #status predicted F:251,371,1088,1252,1311,1351,1502/binding site: carbohydrate (Asn) (covalent) #status F:1193,1196,1800/Disulfide bonds: interchain #status predicted

Query Match 9.7%; Score 134.5; DB 1; Length 1801;
Best Local Similarity 26.9%; Pred. No. 0.0088;
Matches 63; Conservative 6; Mismatches 60; Indels 105; Gaps 15;
QY 8 GAFRALC-GLALLCALSLG-----QRPTGG-PGCGP-----GRLLIGTGTARCCRV 52
DB 840 GALSALCEGTSQCLRTGAFGLRCDHCQRGWGPFNCRPCVNGR-----ADECD 891
QY 53 HTTRC---CHDYGERCCSWDCMCVQPEPHCGDPCT---TCRHHPCPGQVQSGKFS 107
DB 892 HTGACLGCRDYGGEHCER-----CI-AGFH-GDPRLPYGGQCRPCPCPGPG--SORHPA 943
QY 108 -----FGQCICDCASGTF----- 120
DB 944 TSCHRDGYQQIVCHRCAGYTLGRCEACAPGHFGDPSKPGRCQLCECSGNIDPTDPGAC 1003
QY 121 -----SGHGHCXKPTWDTCTQGFGLTVFPNGKTHNAV-VPGSPP 159
DB 1004 DPHTGQCLRLHHTGPHGCHCKP-----GFHQGAARQSCHRCTCNLLGTD 1050

RESULT 9
154182
tumor necrosis factor receptor 2-related protein - human
C:Species: Homo sapiens (man)
C:Date: 24-May-1996 #sequence_revision 24-May-1996 #text_change 09-Jul-2004
C:Accession: I54182
R:Baens, M.; Chaffanet, M.; Cassiman, J.J.; Van den Berghe, H.; Marynen, P.
Genomics 16, 214-219, 1993
A:Title: Construction and evaluation of a hncDNA library of human 12p transcribed sequen
A:Reference number: I54182; MUID:93252381; PMID:8486360
A:Accession: I54182
A>Status: preliminary; translated from GB/EMBL/DDBJ
A:Molecule type: mRNA
A:Residues: 1-435 <RES>
A:Cross-references: UNIPROT:P36941; GB:L04270; NID:g339761; PIDN:AAA36757.1; PID:g339762
C:Genetics:
A:Gene: GDB:LTBR
A:Cross-references: GDB:1230195; OMIM:600979
A:Map position: 12p13.3-12p13.1
C:Superfamily: tumor necrosis factor receptor type 1 (TNFR1); NGF receptor repeat homolo

Query Match 9.6%; Score 133; DB 2; Length 435;
Best Local Similarity 25.0%; Pred. No. 0.004;
Matches 57; Conservative 17; Mismatches 86; Indels 68; Gaps 13;
QY 34 CGPGLLLGTCTDARCCRVHTTRC-----CRDYPGEE---C 66
DB 62 CPP-----GTVYSAKCSKIRDTVCATCAENSYNEHWNVLTICQLCRPCDPVWGLBEIAPC 116
QY 67 CS--EWDCMCVQPEPHCGDP--CTTCR--HHCPGPGQVQSGKFSFG-FQCIDCASGTF 120
DB 117 TSKRKTQCR--QPGWFCAAWALECTHCELLSDCPGTEAELEKDEYKGNHNCVPCAGHF 175
QY 121 --SGHGHCXKPTWDTCTQGFGLTVFPNGKTHNAVCPGSPPAEPGLG-----WLTVVULL 171
DB 176 QNTSSPSARCQPHTRCENQGLVEAPGTAQSDTTT---KNPLEPLPPEMSGTMLLAVLL 232
QY 172 AVAACVLLLTSAQLGLHQLWLRSCMWPRETQL-----LLEVPPTS 213
DB 233 PLAFLLLATV-----FSCIWKSHPSLCKRGLSLKRRPQGE 269
RESULT 10
JC7705
death receptor-6 - chicken
C:Species: Gallus gallus (chicken)
C:Date: 09-Nov-2001 #sequence_revision 09-Nov-2001 #text_change 09-Jul-2004
C:Accession: JC7705
R:Bridgham, J.T.; Bobe, J.; Goetz, F.W.; Johnson, A.L.
Biochem. Biophys. Res. Commun. 284, 1109-1115, 2001
A:Title: Conservation of death receptor-6 in avian and piscine vertebrates.
A:Reference number: JC7705; MUID:21308433; PMID:11414698
A:Accession: JC7705
A:Molecule type: mRNA
A:Residues: 1-651 <BRI>
A:Cross-references: UNIPROT:Q98SM6; GB:AF349908
C:Comment: this receptor, a member of the tumor necrosis factor receptor family, belongs
trestia, activates a cell death and/or survival signaling cascade.
C:Genetics:
A:Gene: dr-6
C:Superfamily: tumor necrosis factor receptor type 1 (TNFR1); NGF receptor repeat homolo
C:Keywords: ovary
F:1-21/Domain: signal sequence #status predicted <SIG>
F:52-196/Domain: extracellular cysteine-rich, ligand-binding #status predicted <ECL>
F:332-350/Domain: transmembrane #status predicted <TM>
F:410-475/Domain: death domain #status predicted <DED>
F:551-651/Region: conserved cytoplasmic #status predicted

Query Match 9.4%; Score 130.5; DB 2; Length 651;
Best Local Similarity 29.8%; Pred. No. 0.0084;
Matches 39; Conservative 14; Mismatches 55; Indels 23; Gaps 6;
QY 48 RC-----VHTTRCCRDYPGEECCSEWDCMCVQPEPHCGDPCTTCRHHPCPGQ 98
DB 90 RCHPCRKPCCLPMIEKTHC-----TALTDRECTCLSGTFQINDTCVP---YTVCPGVW 139
QY 99 GVQSQGKFSFGQCICDCASGTFSGGHEG--HCKPMTDCTQGFGLTVFPNGKTHNAVCPVG 156
DB 140 GVRKKGTEDEVRCRCKPLRGTFSDVPSSVMKCTYTDGFGKMMVVVKPGTKESDNVC--X 197
QY 157 SPAPPLGWL 167
DB 198 SPASLPNTSLT 208

RESULT 11
A35356
tumor necrosis factor receptor 2 precursor [validated] - human
N:Alternate names: 75K tumor necrosis factor receptor; TNF receptor type 2
C:Species: Homo sapiens (man)
C:Date: 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 09-Jul-2004
C:Accession: A35356; A36475; A48416; A36007; A23666; B35010; I38094
R:Smith, C.A.; Davis, T.; Anderson, D.; Solam, L.; Beckmann, M.P.; Jerzy, R.; Dower, S.K.

Science 248, 1019-1023, 1990
A:Title: A receptor for tumor necrosis factor defines an unusual family of cellular and
A:Reference number: A33556; MUID:90260639; PMID:2160731
A:Accession: A33556
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-461 <SM1>
A:Cross-references: UNIPROT:P20333; GB:M32315; NID:g189185; PIDN:AAA59929.1; PID:g189186
R:Kohn, T.; Brewer, M.T.; Baker, S.L.; Schwartz, P.E.; King, M.W.; Hale, K.K.; Squires,
Proc. Natl. Acad. Sci. U.S.A. 87, 8331-8335, 1990
A:Title: A second tumor necrosis factor receptor gene product can shed a naturally occur
A:Reference number: A36475; MUID:91045991; PMID:2172983
A:Accession: A36475
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-195, 'R', 197-461 <KOH>
A:Cross-references: GB:M55994; GB:M38549; NID:g339757; PIDN:AAA36755.1; PID:g339758
R:Demic, Z.; Loetscher, H.; Gubler, U.; Pan, Y.C.; Lahm, H.W.; Gentz, R.; Brockhaus, M.
Cytokine 2, 231-237, 1990
A:Title: Two human TNF receptors have similar extracellular, but distinct intracellular,
A:Reference number: A48416; MUID:91370690; PMID:1966549
A:Accession: A48416
A>Status: preliminary
A:Molecule type: protein
A:Residues: 23-461 <DEM>
A:Cross-references: GB:S63368; NID:g235648; PIDN:AAB19824.1; PID:g235649
R:Heiler, R.A.; Song, K.; Onasch, M.A.; Fischer, W.H.; Chang, D.; Ringold, G.M.
Proc. Natl. Acad. Sci. U.S.A. 87, 6151-6155, 1990
A:Title: Complementary DNA cloning of a receptor for tumor necrosis factor and demonstra
A:Reference number: A36007; MUID:90349572; PMID:2166646
A:Accession: A36007
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 116-140, 'P', 142-195, 'R', 197-362, 'T', 364-461 <HEL>
A:Cross-references: GB:M35857; NID:g339751; PIDN:AAA63262.1; PID:g339752
R:Loetscher, H.; Schlaeger, E.J.; Lahm, H.W.; Pan, Y.C.E.; Lesslauer, W.; Brockhaus, M.
J. Biol. Chem. 265, 20131-20138, 1990
A:Title: Purification and partial amino acid sequence analysis of two distinct tumor nec
A:Reference number: A23666; MUID:91056048; PMID:2173696
A:Accession: A23666
A>Status: preliminary
A:Molecule type: protein
A:Residues: 23-40; 65-69; 136-141; 300-306 <LOB>
R:Engelmann, H.; Novick, D.; Wallach, D.
J. Biol. Chem. 265, 1531-1536, 1990
A:Title: Two tumor necrosis factor-binding proteins purified from human urine. Evidence
A:Reference number: A35010; MUID:90110215; PMID:2153136
A:Accession: B35010
A>Status: preliminary
A:Molecule type: protein
A:Residues: 27-31 <ENG>
R:Kuhnert, P.; Kemper, O.; Wallach, D.
Gene 150, 381-386, 1994
A:Title: Cloning, sequencing and partial functional characterization of the 5' region of
A:Reference number: I38094; MUID:95121934; PMID:7821811
A:Accession: I38094
A>Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-37 <RES>
A:Cross-references: EMBL:X80021; NID:g666044; PIDN:CAA56324.1; PID:g825701
C:Genetics:
A:Gene: GDB:TNFR2
A:Cross-references: GDB:125914; OMIM:191191
A:Map position: lp36.2-lp36.2
A:Introns: 26/3
A:Note: the list of introns is incomplete
C:Superfamily: tumor necrosis factor receptor type 2 (TNFR2); NGF receptor repeat homolo
C:Keywords: duplication; glycoprotein; receptor; transmembrane protein
F:1-22/Domain: signal sequence #status predicted <SIG>
F:23-416/Product: tumor necrosis factor receptor 2 #status experimental <MAT>
F:40-76/Domain: NGF receptor repeat homology <NGL>
F:78-119/Domain: NGF receptor repeat homology <NG2>

F:120-162/Domain: NGF receptor repeat homology <NG3>
F:164-201/Domain: NGF receptor repeat homology <NG4>
F:262-279/Domain: transmembrane #status predicted <TN>
F:280-461/Domain: intracellular #status predicted <INT>
F:171,193/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match	9.3%;	Score 129;	DB 1;	Length 461;
Best Local Similarity	22.4%;	Pred. No. 0.0085;		
Matches	63;	Conservative 27;	Mismatches 81;	Indels 110; Gaps 15;

QY	34	CGPG---RLLTGGTDARC-----	CRVHTTRCCRDYPCGECCECSD--	71.
DB	57	CSPGQAKVCTKTSDTVCDSCEDSTYTLWNVPECLSCGRCCSDQVETQACTREQNR		116
QY	72	-CMCQVQPEFHC-----GDPCTTCRHHPCPPGQSQGKFSFGQCIDCAGTFSG--		122
DB	117	ITCT-RPGHYCALSKOEGCCLCAPLR--KCRPGFVGARFGTETSDVCKPCAPGTFSNTT		173
QY	123	GHEGCKPWTDCTQFGFLTVFPGNKTHNAV-----VPG-----		156
DB	174	SSTDICRPHOICN-----VVAIPGNASMDAVCTSTSPTRMAPGAVHLPQPVSTRSQHTQP		229
QY	157	-----SPRAE-----PLGW-----LTVLLAAVAAVLLLTSAQ		184
DB	230	TPESTAPSTFLLPMGPSPPAEGSGDPALPGLIVGTALGLLIIGVNVCMINT----		285
QY	185	LGLHIWQLRSQCMWPPRETQLLLEVPSTED-ARSCQFPPEE		224
DB	286	-----QVKKK---PLCLQREAKVPHLPADKARGTQGPQQ		317

RESULT 12
T13954
MEGF6 protein - rat
C:Species: Rattus norvegicus (Norway rat)
C>Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 09-Jul-2004
C:Accession: T13954
R:Nakayama, M.; Nakajima, D.; Nagase, T.; Nomura, N.; Seki, N.; Ohara, O.
Genomics 51, 27-34, 1998
A:Title: Identification of high-molecular-weight proteins with multiple EGF-like motifs
A:Reference number: Z14126; MUID:98360089; PMID:9693030
A:Accession: T13954
A>Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-1574 <NAK>
A:Cross-references: UNIPROT:O88281; EMBL:AB011532; NID:g3449293; PIDN:BAA32462.1; PID:g3449293
A:Experimental source: strain Sprague-Dawley; brain
C:Genetics:
A:Gene: MEGF6

Query Match	9.2%;	Score 127.5;	DB 2;	Length 1574;
Best Local Similarity	27.7%;	Pred. No. 0.028;		
Matches	53;	Conservative 12;	Mismatches 65;	Indels 61; Gaps 11;

QY	45	TDARCCRVHTTRCCRDY---PGEE-CCSEWDCMCVQPEFHCPCCTT-----CRHHPCP		95
DB	99	TEART-----VFRCCPGWSQKPGQEGCLSDVD-ECASANGGCEGPCCNVTGVGYCR--CP		150
QY	96	PGQVQSQKFSFGFCIDCAGTFSGGHGHCKPWTCTQFGFLTVFPGNKTHNAVCP		155
DB	151	PGYQLQGDGK-----TCQDVDECAHNGGQ-----HRCVNTP		183
QY	156	GS-----PPAEPGLWTLTVLLAAVAAVLLLTSAQ---LGLHIWQLRSQCMWPPRETQLLLE		207
DB	184	GSYLCECKPFGRLHTDGRCTCLAISSCTLNGGCGQCHQCVQLTVTHRCQCRPQLQLQ-----		239
QY	208	VPESTEDARSC		218
DB	240	-----EDGRC		245

RESULT 13
A60771

B-cell activation protein CD40 precursor - human
N:Alternate names: B-cell surface antigen Bp50
C:Species: Homo sapiens (man)
C:Date: 03-Jun-1993 #sequence_revision 03-Feb-1994 #text_change 09-Jul-2004
C:Accession: S04460; A60771
R:Stamenkovic, I.; Clark, E.A.; Seed, B.
EMBO J. 8, 1403-1410, 1989
A:Title: A B-lymphocyte activation molecule related to the nerve growth factor receptor
A:Reference number: S04460; MUID:89356608; PMID:2475341
A:Accession: S04460
A:Molecule type: mRNA
A:Residues: 1-277 <STA>
A:Cross-references: UNIPROT:P25942; EMBL:X60592; NID:G29850; PIDN:CAA43045.1; PID:G29851
R:Braesch-Andersen, S.; Paulie, S.; Koho, H.; Nika, H.; Aspenstroem, P.; Perlmann, P.
J. Immunol. 142, 562-567, 1989
A:Title: Biochemical characteristics and partial amino acid sequence of the receptor-like
A:Reference number: A60771; MUID:89093941; PMID:2463309
A:Accession: A60771
A:Molecule type: protein
A:Title: A B-lymphoma cell line Raji
A:Experimental source: Burkitt lymphoma cell line Raji
C:Genetics:
A:Gene: GDB:CD40
A:Cross-references: GDB:215268; OMIM:109535
A:Map position: 20q12-20q13.2
C:Superfamily: CD27 antigen; NGF receptor repeat homology
C:Keywords: B-cell; glycoprotein; phosphoprotein; surface antigen; transmembrane protein
F:1-20/Domain: signal sequence #status predicted <SIG>
F:21-277/Product: B-cell activation protein CD40 #status experimental <MAT>
F:21-193/Domain: extracellular #status predicted <EXT>
F:194-215/Domain: transmembrane #status predicted <TM>
F:216-277/Domain: intracellular #status predicted <CYT>
F:153,180/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 8.9%; Score 124; DB 2; Length 277;
Best Local Similarity 23.7%; Pred. No. 0.014; Mismatches 117; Indels 26; Gaps 8;
Matches 51; Conservative 21; Mismatches 117; Indels 26; Gaps 8;
QY 34 CGPGRLLLTGTGDARCCRVHTTRCCRDYPG---EECCSEWDCMVQVPF-FHCGDPCCVT 88
DB 62 CGSEFELDTWNERHHC---HHQKCDPNLGLRVQKGTSETDTICTCEGWHCTSEACHS 118
QY 89 C-RHHPCPPGQVQSGKFSFGFCIDCASGTFSGHEG--HCKPMTDCTQGFGLTVFPFG 145
DB 119 CVLHRSCEPGFKVIQATGVSDTICBPCVGFVSNVSSAFKCHPWTSCETKDLVVQQAG 178
QY 146 NKTHNAVCPGSPAPPLGMLTV--VLLAAVACVLL-----TSAQLGLHIWQLRS 194
DB 179 TNKTDVVC---GPQRLRALVVIPIFGILFAILLVLVFIKKVAKPTNKAPHKQEPQ 234
QY 195 QCWMPRETQLLLEVPPTEDARSCQPFEEGERS 229
DB 235 EINFPPDLLSGSNTAAPVQETHLGCQPVTOBDGKES 269

RESULT 14
I48854
gene murine tumor necrosis factor receptor 2 protein - mouse (fragment)
C:Species: Mus musculus (house mouse)
C:Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 09-Jul-2004
C:Accession: I48854
R:Powell, E.B.; Wicker, L.S.; Peterson, L.B.; Todd, J.A.
Mamm. Genome 5, 726-727, 1994
A:Title: Allelic variation of the type 2 tumor necrosis factor receptor gene.
A:Reference number: I48854; MUID:95178848; PMID:7673884
A:Accession: I48854
A:Status: preliminary; translated from GB/EMBL/DDBJ
A:Molecule type: mRNA
A:Residues: 1-459 <RES>
A:Cross-references: UNIPROT:Q62327; EMBL:X76401; NID:G433830; PIDN:CAA53981.1; PID:G43384
C:Superfamily: tumor necrosis factor receptor type 2 (TNFR2); NGF receptor repeat homology
F:151-188/Domain: NGF receptor repeat homology <NGF>

Query Match 8.8%; Score 121.5; DB 2; Length 459;
Best Local Similarity 21.0%; Pred. No. 0.032; Mismatches 96; Indels 101; Gaps 12;
Matches 60; Conservative 29; Mismatches 96; Indels 101; Gaps 12;
QY 48 RCCRVHTTRCCRDYPGBECCSEWD---CMCVQVPBF-----HCGDPCCTTC-RHHPCPPGQ 98
DB 77 RTCLSCSSSCSDQVETRACTKQNRVACACAGRYCALKTHSGS--CRQCMRLSKCGPGF 134
QY 99 QVQSGKPSFGFCIDCASGTFSG--GHEGCKPMTDCTQGFGLTVFPGNKTHNAVCPVG 156
DB 135 GVASSRAPNGVNLKACAPGTFTSDTSDVCRPHRIGS-----ILAIPEGNASTDVAVCAPE 190
QY 157 SP-----PAE-----PAGM 165
DB 191 SPTLSAIPRTLYVSOPEPTRSQPLDQEPGSPQTSPIILTSLSGSTPIIEOSTKGGISLPIGL 250
QY 166 -----LTWLLAAVAAVCLLLTSAQLGL-----HIWQLRSQCMWMPRETQLLLEVP 210
DB 251 IVGVTSLGLMLGLVNCFLVQRKKPSCQLORDAKVPHVDEKSDQDAVGLCQHLTTAP 310
QY 211 STE-----DARS-----CQPFEEGERSAEKGRIGD 238
DB 311 SSSSSLESSASAGDRRAPPGHPOARVMABAQGSQEARASSRISD 356

RESULT 15
B38634
tumor necrosis factor receptor type 2 precursor - mouse
C:Species: Mus musculus (house mouse)
C:Date: 30-Jun-1992 #sequence_revision 30-Jun-1992 #text_change 09-Jul-2004
C:Accession: B38634; A40254; S54816
R:Lewis, M.; Tartaglin, L.A.; Lee, A.; Bennett, G.L.; Rice, G.C.; Wong, G.H.W.; Chen, B.;
Proc. Natl. Acad. Sci. U.S.A. 88, 2830-2834, 1991
A:Title: Cloning and expression of cDNAs for two distinct murine tumor necrosis factor re
A:Reference number: A38634; MUID:91187885; PMID:1849278
A:Accession: B38634
A:Molecule type: mRNA
A:Residues: 1-474 <LEW>
A:Cross-references: UNIPROT:P25119; GB:M60469; NID:G199827; PIDN:AAA39752.1; PID:G199828
R:Goodwin, R.G.; Anderson, D.; Jerzy, R.; Davis, T.; Brannan, C.I.; Copeland, N.G.; Jenk
Mol. Cell. Biol. 11, 3020-3026, 1991
A:Title: Molecular cloning and expression of the type 1 and type 2 murine receptors for t
A:Reference number: A40254; MUID:91246168; PMID:1645445
A:Accession: A40254
A:Molecule type: mRNA
A:Residues: 1-474 <GOO>
A:Cross-references: GB:M60469; NID:G199827; PIDN:AAA39752.1; PID:G199828
R:Kisnerghis, M.; Fallowes, R.; Feldmann, M.; Chernajovsky, Y.
submitted to the EMBL Data Library, May 1995
A:Description: Characterization of the promoter region of the murine p75-TNF receptor.
A:Reference number: S54816
A:Accession: S54816
A:Molecule type: DNA
A:Residues: 1-22 <KIS>
A:Cross-references: EMBL:X87128; NID:G809043; PIDN:CAA60618.1; PID:G809044
C:Superfamily: tumor necrosis factor receptor type 2 (TNFR2); NGF receptor repeat homolo
C:Keywords: cytokine receptor; transmembrane protein
F:1-22/Domain: signal sequence #status predicted <SIG>
F:23-474/Product: tumor necrosis factor receptor type 2 #status predicted <MAT>
F:40-77/Domain: NGF receptor repeat homology <NGI>
F:79-120/Domain: NGF receptor repeat homology <NG2>
F:166-203/Domain: NGF receptor repeat homology <NG4>

Query Match 8.7%; Score 121; DB 2; Length 474;
Best Local Similarity 21.1%; Pred. No. 0.036; Mismatches 92; Indels 102; Gaps 11;
Matches 59; Conservative 27; Mismatches 92; Indels 102; Gaps 11;
QY 46 DARCCRVHTTRCCRDYPGBECCSEWDCMVQVPFHCDDPCCTTC-RHHPCPPGQVQSG 104
DB 107 EIRACTKQNRVACACAGRYCAL-----KTHSGS--CRQCMRLSKCGPGFGVASSR 155
QY 105 KFSFGFCIDCASGTFSG--GHEGCKPMTDCTQGFGLTVFPGNKTHNAVCPVGPSP---- 158

```

Db      156 APNGVLCACAPGTSSTSDVCRPHRCS-----ILAFGNASTDAVCAPESPTLSA 211
QY      159 -----PAE-----PLGN-----165
Db      212 IPRTLVSQPEPTRSQPLDQEPGPSQTPSILTSLSGTPIEQSTKGGISLPIGLIYGVTS 271
QY      166 LTVVLLAVALVLLTSAQLGL-----HIWQLRSOCWMPRETQLLLEVPSTE--- 213
Db      272 LGLMLGLVNCIILVORKKPSCLORDAKVPHVDEKSDQAVGLEQOQHLLTTAPSSSSSS 331
QY      214 -----DARS-----COFPEEERGERSAEEKRLGD 238
Db      332 LESSASAGDERRAPPGGHPQARVMAEAGQFOEARASSRISD 371

```

Search completed: October 26, 2005, 15:52:34
 Job time : 26.693 secs

THIS PAGE BLANK (687-10)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 26, 2005, 15:29:08 ; Search time 118.701 Seconds
(without alignments)
1039.676 Million cell updates/sec

Title: US-09-545-998B-4
Perfect score: 1386
Sequence: 1 MAQHGAMGAFRALCGLALIC.....EEBGRSAAEXKRLGLDW 241

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues
Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Uniprot 03:.*
1: uniprot_sprot:.*
2: uniprot_trembl:.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1386	100.0	241	1 TR18 HUMAN	Q9Y5U5 homo sapien
2	735.5	53.1	228	1 TR18_MOUSE	Q35714 mus musculu
3	735.5	53.1	250	2 Q8C4K3	Q8C4K3 mus musculu
4	202	14.6	275	2 Q80WM9	Q80WM9 mus musculu
5	201.5	14.5	276	2 Q71F55	Q71F55 mus musculu
6	197	14.2	256	1 TNR9_MOUSE	P20334 mus musculu
7	195.5	14.1	255	1 TNR9_HUMAN	Q07011 homo sapien
8	191	13.8	270	2 Q75SV8	Q75SV8 felis silve
9	182.5	13.2	290	2 Q76L84	Q76L84 paralichthy
10	182	13.1	267	2 Q02764	Q02764 oryctolagus
11	177	12.8	276	2 Q9DDD2	Q9DDD2 gallus gall
12	175	12.6	272	1 TNR4_MOUSE	P47741 mus musculu
13	174.5	12.6	196	2 Q8VC17	Q8VC17 mus musculu
14	170.5	12.3	211	2 Q8R037	Q8R037 mus musculu
15	170	12.3	274	2 Q7YR15	Q7YR15 canis fami
16	168.5	12.2	271	1 TNR4_RAT	P15725 rattus norv
17	162	11.7	277	1 TNR4_HUMAN	P43489 homo sapien
18	158.5	11.4	467	2 Q800T0	Q800T0 gallus gall
19	153	11.0	300	1 TF6B_HUMAN	Q95407 homo sapien
20	150	10.8	616	1 TR11_HUMAN	Q9Y6Q6 homo sapien
21	148.5	10.7	278	2 Q8SQ34	Q8SQ34 sus scrofa
22	146	10.5	401	2 Q6P112	Q6P112 mus musculu
23	144.5	10.4	289	1 TNR5_BOVIN	Q28203 bos taurus
24	144.5	10.4	269	1 TNR5_MOUSE	P27512 mus musculu
25	143.5	10.4	277	2 Q8WMQ2	Q8WMQ2 ovis aries
26	143.5	10.4	289	2 Q8K2X6	Q8K2X6 mus musculu
27	142	10.2	401	1 T11B_RAT	Q8R727 rattus norv
28	142	10.2	483	2 Q800K7	Q800K7 paralichthy
29	141.5	10.2	169	2 Q3JK20	Q3JK20 rattus norv
30	141	10.2	401	1 T11B_MOUSE	Q08712 mus musculu
31	139.5	10.1	457	2 Q8IV56	Q8IV56 homo sapien

000300 homo sapien
Q98sm6 gallus gall
Q9avb0 phytolacca
Q7t2h3 oncorhynchu
Q6glh3 xenopus lae
Q35105 mus musculu
P15800 rattus norv
P36941 homo sapien
P50284 mus musculu
Q75509 homo sapien
P20333 h tumor nec
Q88281 rattus norv
Q61292 mus musculu
Q8r0y0 mus musculu

32 138 10.0 401 1 T11B_HUMAN
33 137.5 9.9 651 2 Q98SM6
34 137 9.9 361 2 Q9AVB0
35 135.5 9.8 318 2 Q7T2H3
36 135.5 9.8 287 2 Q6GLH3
37 134.5 9.7 625 1 TR11_MOUSE
38 134.5 9.7 1801 1 LMB2_MOUSE
39 133 9.6 435 1 TNR3_HUMAN
40 130.5 9.4 415 1 TNR3_MOUSE
41 129.5 9.3 655 1 TR21_HUMAN
42 129 9.3 461 1 TR1B_HUMAN
43 127.5 9.2 1574 1 EFL3_RAT
44 127.5 9.2 1799 1 LMB2_MOUSE
45 126.5 9.1 1799 2 Q8R0Y0

ALIGNMENTS

RESULT 1
ID TR18_HUMAN STANDARD; PRT; 241 AA.
AC Q9Y5U5; Q9S851; Q9NY39;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 25-JAN-2005 (Rel. 46, Last annotation update)
DE Tumor necrosis factor receptor superfamily member 18 precursor
DE (Glucocorticoid-induced TNFR-related protein) (Activation-inducible
DE TNFR family receptor) (UNQ319/PRO364).
GN Name=TNFRSF18; Synonyms=AITR, GTR;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORM 1), AND INTERACTIONS WITH TRAF1; TRAF2 AND TRAF3.
RC TISSUE=Bone marrow;
RX MEDLINE=99175482; PubMed=10074428; DOI=10.1016/S0960-9822(99)80093-1;
RA Gurney A.L., Marsters S.A., Huang R.M., Pitti R.M., Mark D.T.,
Baldwin D.T., Gray A.M., Dowd A.D., Brush A.D., Heldens A.D.,
RA Schow A.D., Goddard A.D., Wood W.I., Baker K.P., Godowski P.J.,
RA Ashkenazi A.;
RT "Identification of a new member of the tumor necrosis factor family
and its receptor, a human ortholog of mouse GITR.";
RL Curr. Biol. 9:215-218(1999).
RN [2]
RP SEQUENCE FROM N.A. (ISOFORM 1).
RC TISSUE=T-cell;
RX MEDLINE=99156876; PubMed=10037686; DOI=10.1074/jbc.274.10.6056;
RA Kwon B., Yu K.-Y., Ni J., Yu G.-L., Jang I.-K., Kim Y.-J., Xing L.,
Liu D., Wang S.-X., Kwon B.S.;
RT "Identification of a novel activation-inducible protein of the tumor
necrosis factor receptor superfamily and its ligand.";
RL J. Biol. Chem. 274:6056-6061(1999).
RN [3]
RP SEQUENCE FROM N.A. (ISOFORM 2).
RC TISSUE=Thymus;
RX MEDLINE=20292073; PubMed=10936847;
RA Nocentini G., Ronchetti S., Bartoli A., Spinicelli S., Delfino D.,
Brunetti L., Migliorati G., Ricciardi C.;
RT "Identification of three novel mRNA splice variants of GITR.";
RL Cell Death Differ. 7:408-410(2000).
RN [4]
RP SEQUENCE FROM N.A. (ISOFORM 1).
RC MEDLINE=22887296; PubMed=12975309; DOI=10.1101/gr.1293003;
RA Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D., Brush J.,
Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
Eaton D., Foster J., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
Lewis L., Liao D., Mark M., Robbie E., Sanchez C., Schoenfeld J.,
Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
Vandlen R., Watanabe C., Wiedand D., Woods K., Xie M.-H., Yansura D.,

RA Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A., Wood W.I.,
 RA Godowski P., Gray A.;
 RA "The secreted protein discovery initiative (SPDI), a large-scale
 RT effort to identify novel human secreted and transmembrane proteins: a
 RT bioinformatics assessment.";
 RL Genome Res. 13:2265-2270(2003).
 RN [5]
 RP SEQUENCE OF 26-40.
 RX PubMed=15340161; DOI=10.1110/ps.04682504;
 RA Zhang Z., Henzel W.J.;
 RT "Signal peptide prediction based on analysis of experimentally
 RT verified cleavage sites.";
 RL Protein Sci. 13:2819-2824(2004).
 CC -!- FUNCTION: Receptor for TNFRSF18. Seems to be involved in
 CC interactions between activated T lymphocytes and endothelial cells
 CC and in the regulation of T cell receptor-mediated cell death.
 CC Mediated NF-kappa-B activation via the TRAF2/NIK pathway.
 CC -!- SUBUNIT: Binds to TRAF1, TRAF2, and TRAF3, but not TRAF5 and
 CC TRAF6.
 CC -!- SUBCELLULAR LOCATION: Type I membrane protein (isoform 1).
 CC Secreted (isoform 2).
 CC -!- ALTERNATIVE PRODUCTS:
 CC Event=Alternative splicing; Named isoforms=2;
 CC Name=1;
 CC IsoId=Q9Y5U5-1; Sequence=Displayed;
 CC Name=2; Synonyms=GITR-D;
 CC IsoId=Q9Y5U5-2; Sequence=VSP_006508;
 CC -!- TISSUE SPECIFICITY: Expressed in lymph node, peripheral blood
 CC leukocytes and weakly in spleen.
 CC -!- INDUCTION: Up-regulated in peripheral mononuclear cells after
 CC antigen stimulation/lymphocyte activation.
 CC -!- SIMILARITY: Contains 3 TNFR-Cys repeats.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; AF125304; AAD22635.1; -;
 DR EMBL; AF117297; AAD19694.1; -;
 DR EMBL; AF241229; AAF63506.1; -;
 DR EMBL; AY358877; AAQ89236.1; -;
 DR Genbank; HGNC:11914; TNFRSF18.
 DR MIM; 603905; -;
 DR GO; GO:0005031; P:tumor necrosis factor receptor activity; TAS.
 DR GO; GO:0006916; P:anti-apoptosis; TAS.
 DR GO; GO:0007165; P:signal transduction; TAS.
 DR InterPro; IPR001368; TNFR C6.
 DR PROSITE; PS00652; TNFR_NGFR_1; FALSE_NEG.
 DR PROSITE; PS50050; TNFR_NGFR_2; FALSE_NEG.
 KW Alternative splicing; Direct protein sequencing; Glycoprotein;
 RX Receptor; Repeat; Signal; Transmembrane.
 FT SIGNAL 1 25
 FT CHAIN 26 241
 FT Tumor necrosis factor receptor
 FT superfamily member 18.
 FT DOMAIN 26 162
 FT Extracellular (Potential).
 FT TRANSMEM 163 183
 FT POTENTIAL 184 241
 FT CYTOPLASMIC (Potential).
 FT REPEAT 34 72
 FT TNFR-Cys 1.
 FT REPEAT 74 112
 FT TNFR-Cys 2.
 FT REPEAT 115 153
 FT TNFR-Cys 3.
 FT By similarity.
 FT DISULFID 34 49
 FT By similarity.
 FT DISULFID 74 86
 FT By similarity.
 FT DISULFID 81 94
 FT By similarity.
 FT DISULFID 115 134
 FT By similarity.
 FT DISULFID 128 153
 FT By similarity.
 FT CARBOHYD 146 146
 FT N-linked (GlcNAc...) (Potential).
 FT VARSPLIC 135 241
 FT TOPGEFTVPGNKTTHNAVCPGSPPAEPLGMLTVVLLAVAA
 FT CVDLLLSAQGLHIWQLRSQCMWPRETQLLLEVPSTEDAR
 FT SCQFPEERGERSAEKGRLGDLUV -> CWRCCRPRKPTPE

FT AASPRKSGSDRORRRGSGWETCGCEPRPGPPTAASPSP
 FT GAPQAGALRSALGRALLPWQKQWVGSGSDQRPGCCSAA
 FT AAGPCRRERETQSPPSSLAGPDGVGS (in isoform
 FT 2).
 FT /FTid=VSP_006508.
 FT SQQMWPPE -> K (in Ref. 2).
 FT CONFLICT 194 201
 FT SEQUENCE 241 AA; 26000 MW; 90DC3B4AA7E82CBE CRC64;
 SQ
 Query Match 100.0%; Score 1386; DB 1; Length 241;
 Best Local Similarity 100.0%; Pred. No. 9.9e-110;
 Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MAQHGAMGAFALCGALLCALSLGQRTGGPGCGPGRLLLTGTGDARCCRVHTRCCRD 60
 DB 1 MAQHGAMGAFALCGALLCALSLGQRTGGPGCGPGRLLLTGTGDARCCRVHTRCCRD 60
 QY 61 YPGECCSEWDCMCVQPEFHCGDPCCTTCRHHPCPPGQVSGQVSGQKFSFGFCIDCASGTF 120
 DB 61 YPGECCSEWDCMCVQPEFHCGDPCCTTCRHHPCPPGQVSGQVSGQKFSFGFCIDCASGTF 120
 QY 121 SGGHEGHCCKPMTDCTQFGFLTVFPGNKTHNAVCPGSPPAEPLGMLTVVLLAVAAVLL 180
 DB 121 SGGHEGHCCKPMTDCTQFGFLTVFPGNKTHNAVCPGSPPAEPLGMLTVVLLAVAAVLL 180
 QY 181 TSAQGLHIWQLRSQCMWPRETQLLLEVPSTEDARSCQFPEERGERSAEKGRLGDLW 240
 DB 181 TSAQGLHIWQLRSQCMWPRETQLLLEVPSTEDARSCQFPEERGERSAEKGRLGDLW 240
 QY 241 V 241
 DB 241 V 241
 RESULT 2
 TR18 MOUSE
 ID TR18 MOUSE STANDARD; PRT; 228 AA.
 AC Q35714; Q9JUKR1; Q9JUKR2; Q9JUKR3;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 25-OCT-2004 (Rel. 45, Last annotation update)
 DE Tumor necrosis factor receptor superfamily member 18 precursor
 DE (Glucocorticoid-induced TNFR-related protein).
 DE Name=tnfrsf18; Synonyms=Gitr;
 GN Mus musculus (Mouse).
 OS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A. (ISOFORM A).
 RC STRAIN=C3H;
 RX MEDLINE=97322352; PubMed=9177197; DOI=10.1073/pnas.94.12.6216;
 RA Nocentini G., Giunchi L., Ronchetti S., Krausz L.T., Bartoli A.,
 RA Moraca R., Migliorati G., Riccardi C.;
 RT "A new member of the tumor necrosis factor/nerve growth factor
 RT receptor family inhibits T cell receptor-induced apoptosis.";
 RL Proc. Natl. Acad. Sci. U.S.A. 94:6216-6221(1997).
 RN [2]
 RP SEQUENCE FROM N.A. (ISOFORM A).
 RC STRAIN=BALE/c;
 RX MEDLINE=20256302; PubMed=10798444; DOI=10.1089/104454900314474;
 RA Nocentini G., Bartoli A., Ronchetti S., Giunchi L., Cupelli A.,
 RA Delfino D., Migliorati G., Riccardi C.;
 RT "Gene structure and chromosomal assignment of mouse Gitr, a member of
 RT the tumor necrosis factor/nerve growth factor receptor family.";
 RL DNA Cell Biol. 19:205-217(2000).
 RN [3]
 RP SEQUENCE FROM N.A. (ISOFORMS B; C AND D).
 RC TISSUE=Thymus;
 RX MEDLINE=20292073; PubMed=10836847;
 RA Nocentini G., Ronchetti S., Bartoli A., Spinicelli S., Delfino D.,
 RA Brunetti L., Migliorati G., Riccardi C.;
 RT "Identification of three novel mRNA splice variants of Gitr.";
 RL Cell Death Differ. 7:408-410(2000).

[illegible]

DE superfamily, member 18, full insert sequence.
GN Name=Tnfrsf18;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]_Tnfrsf18; 303:19-44(1999).
RN SEQUENCE FROM N.A.
RP STRAIN=C57BL/6J; TISSUE=Head;
RX MEDLINE=99279253; PubMed=10349636; DOI=10.1016/S0076-6879(99)03004-9;
RA Carninci P., Hayashizaki Y.;
RT "High-efficiency full-length cDNA cloning.";
RL Meth. Enzymol. 303:19-44(1999).
RN [2]
RN SEQUENCE FROM N.A.
RP STRAIN=C57BL/6J; TISSUE=Head;
RX MEDLINE=21085660; PubMed=11217851; DOI=10.1038/35055500;
RA RIKEN FANTOM Consortium;
RT "Functional annotation of a full-length mouse cDNA collection.";
RL Nature 409:685-690(2001).
RN [3]
RN SEQUENCE FROM N.A.
RP STRAIN=C57BL/6J; TISSUE=Head;
RX MEDLINE=20499374; PubMed=11042159; DOI=10.1101/gr.145100;
RA Carninci P., Shibata Y., Hayatsu N., Sugahara Y., Shibata K., Itoh M.,
RA Konno H., Okazaki Y., Muramatsu M., Hayashizaki Y.;
RT "Normalization and subtraction of cap-trapper-selected cDNAs to
RT prepare full-length cDNA libraries for rapid discovery of new genes.";
RL Genome Res. 10:1617-1630(2000).
RN [5]
RN SEQUENCE FROM N.A.
RP STRAIN=C57BL/6J; TISSUE=Head;
RX MEDLINE=20530913; PubMed=11076861; DOI=10.1101/gr.152600;
RA Shibata K., Itoh M., Aizawa K., Nagaoka T., Sasaki N., Carninci P.,
RA Konno H., Akiyama J., Nishi K., Katsunai T., Tashiro H., Itoh M.,
RA Sumi N., Ishii Y., Nakamura S., Hazama M., Nishine T., Harada A.,
RA Yamamoto R., Matsumoto H., Sakaguchi S., Ikegami T., Kashiwagi K.,
RA Fujiwaki S., Inoue K., Togawa Y., Izawa M., Ohara E., Watahiki M.,
RA Yoneda Y., Ishikawa T., Ozawa K., Tanaka T., Matsuura S., Kawai J.,
RA Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.;
RT "RIKEN integrated sequence analysis (RISA) system-384 format
RT sequencing pipeline with 384 multicapillary sequencer.";
RL Genome Res. 10:1757-1771(2000).
RN [6]
RN SEQUENCE FROM N.A.
RP STRAIN=C57BL/6J; TISSUE=Head;
RX MEDLINE=20530913; PubMed=11076861; DOI=10.1101/gr.152600;
RA Shibata K., Itoh M., Aizawa K., Nagaoka T., Sasaki N., Carninci P.,
RA Konno H., Akiyama J., Nishi K., Katsunai T., Tashiro H., Itoh M.,
RA Sumi N., Ishii Y., Nakamura S., Hazama M., Nishine T., Harada A.,
RA Yamamoto R., Matsumoto H., Sakaguchi S., Ikegami T., Kashiwagi K.,
RA Fujiwaki S., Inoue K., Togawa Y., Izawa M., Ohara E., Watahiki M.,
RA Yoneda Y., Ishikawa T., Ozawa K., Tanaka T., Matsuura S., Kawai J.,
RA Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.;
RT "RIKEN integrated sequence analysis (RISA) system-384 format
RT sequencing pipeline with 384 multicapillary sequencer.";
RL Genome Res. 10:1757-1771(2000).
RN [6]
RN SEQUENCE FROM N.A.
RP STRAIN=C57BL/6J; TISSUE=Head;
RX MEDLINE=20530913; PubMed=11076861; DOI=10.1101/gr.152600;
RA Adachi J., Aizawa K., Akimura T., Arakawa T., Bono H., Carninci P.,
RA Fukuda S., Furuno M., Hanagaki T., Hara A., Hashizume W.,
RA Hayashida K., Hayatsu N., Hiramoto K., Hiraoka T., Hirozane T.,
RA Hori F., Imotani K., Ishii Y., Itoh M., Kagawa I., Kasukawa T.,
RA Katoh H., Kawai J., Kojima Y., Kondo S., Konno H., Kouda M., Koya S.,
RA Kurihara C., Matsuyama T., Miyazaki A., Murata M., Nakamura M.,
RA Nishi K., Nomura K., Numazaki R., Ohno M., Ohsato N., Okazaki Y.,
RA Saito R., Saitoh H., Sakai C., Sakai K., Sakazume N., Sano H.,
RA Sasaki D., Shibata K., Shingawa A., Shiraki T., Sogabe Y., Tagami M.,
RA Tagawa A., Takahashi F., Takaku-Akahira S., Takeda Y., Tanaka T.,
RA Tomaru A., Tova T., Yasunishi A., Muramatsu M., Hayashizaki Y.;
RT Submitted (APR-2002) to the EMBL/GenBank/DBJ databases.
RL EMBL; AK081878; BAC39357.1; -;
DR MGD; MGI:894675; Tnfrsf18.
DR GO; GO:0005615; C:extracellular space; TAS.
DR GO; GO:0016021; C:integral to membrane; TAS.
DR InterPro; IPR006210; IEFG.
DR InterPro; IPR001368; TNFR_c6.
DR SMART; SM00181; EGF; 1.

DR SMART; SM00208; TNFR; 2.
KW Receptor.
SQ SEQUENCE 250 AA; 27814 MW; 6963E94F414C16B4 CRC64;
Query Match 53.1%; Score 735.5; DB 2; Length 250;
Best Local Similarity 57.0%; Pred. No. 1.7e-54;
Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;
QY 7 MGAFRALCGLALLCALSLGQ-RPTGGPGCGRGLLLGTGTARDCCRVHTTRCCRDYDPEE 65
Db 1 MGAWAMLYGVSMCLVLDLQSPVVEEPCGKPGKVGQSGNNTTRCCSLYA-----PGKE 53
QY 66 CCSEWDQMCVQPEFHCGDPCCTTCRHHPCPGQGVQSQGKFSFGQCIDCASGTFSGGHE 125
Db 54 DCPXERCICVTPEYHCGDPQCKICKHFCQGVQGVQSGDVFGRFCVACAMGTFSAGRD 113
QY 126 GHCKPWTDTCTQFGLTVPFGNKNHNAVCPGSPAPAEPLGWLTVLLVAACVLLLTSAQL 185
Db 114 GHCLRWNTCSQFGLTWPFGNKNHNAVCIPEPLPTEQYGHLLTVFLVMAACIFFLTTLVQL 173
QY 186 GLHIWQLRSQCMWPRETOLLLEVPSTEDARSCQPPPEERGERSAEKGRIGDLW 240
Db 174 GLHIWQLRRQHMCPRETQPFPAEVQLSAEDACSFQPPPEERGEQT-EERCHLGRW 227
RESULT 4
Q80WM9 PRELIMINARY; PRT; 275 AA.
AC Q80WM9;
DT 01-JUN-2003 (TRENBLrel. 24, Created)
DT 01-JUN-2003 (TRENBLrel. 24, Last sequence update)
DE 01-MAR-2004 (TRENBLrel. 26, Last annotation update)
DT Tumor necrosis factor receptor superfamily member 14 precursor.
GN Name=Tnfrsf14;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RN SEQUENCE FROM N.A.
RP STRAIN=C57BL/6J; TISSUE=Thymus;
RA Benancia F., Consejo-Garcia J.R., Courreges M.C., Coukos G.;
RL Submitted (MAR-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY264405; AAC9081.1; -;
DR HSSP; Q92956; IJMA.
DR MGD; MGI:2675303; Tnfrsf14.
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0004888; F:transmembrane receptor activity; IEA.
DR GO; GO:0006915; P:apoptosis; IEA.
DR GO; GO:0006955; P:immune response; IEA.
DR GO; GO:0007165; P:signal transduction; IEA.
DR InterPro; IPR008063; Fas receptor.
DR InterPro; IPR001368; TNFR_c6.
DR Pfam; PF00020; TNFR_c6; 3-
DR PRINTS; PR01680; FASRECEPTOR.
DR SMART; SM00208; TNFR; 4.
DR PROSITE; PS00652; TNFR_NGFR_1; UNKNOWN_1.
DR PROSITE; PS00500; TNFR_NGFR_2; 3.
KW Receptor; Signal.
FT SIGNAL 1 38 Potential.
SQ SEQUENCE 275 AA; 30171 MW; C4A7EAD8EFC0521D CRC64;
Query Match 14.6%; Score 202; DB 2; Length 275;
Best Local Similarity 24.6%; Pred. No. 3.6e-09;
Matches 65; Conservative 32; Mismatches 93; Indels 74; Gaps 12;
QY 22 LSLGQPTGGPCGGRLLLTGTGTARDCCRV-----HTTRCCRDYDPEEC----- 66
Db 30 LNLQRLISAQPSCRQOEFLVGD-----ECCPMCPGVHVKVCEHTGTVCACPPQTYTA 85
QY 67 -----CSEWD-----CMCVQPEFHC-----GDPCCCTTCTRHHP 94
Db 86 HANGLSKCLPCGVCDPMGLLTWQECSSWKDTCVRCI-PGYFCENQDGSCHCSTCLQHTTC 144

```
QY 95 PPGQVQSOGKFSFGQICDCASGTFPS-CGHEGCHKPWTDCQTQPGFLTVFPGNKTINAVC 153
Db 145 PPGQVKEKRGTHDQDVTVCADCTGTGSLGGTQBECLPWTNCSAFQ-QEVRRGNTSTDTTC 203
QY 154 VPGSPPAEPLGMLTVLLAV----AACVLLLTSAQLGLHIWQLRSQCMWPRETQLLLVLP 209
Db 204 -----SSQVYVYVSVLLPLVIVGAGIAGFLICTRRHLTSSVAKE-----LE-P 247
QY 210 PSTEDARSCQPFEEGERSAEK 233
Db 248 FQEQENTIRFPVTEVGFATEE 271

RESULT 5
QY1F55 PRELIMINARY; PRT; 276 AA.
AC Q71F55;
DT 05-JUL-2004 (T-EMBLrel. 27, Created)
DT 05-JUL-2004 (T-EMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (T-EMBLrel. 27, Last annotation update)
DE Herpes virus entry mediator.
GN Name=Hvem;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=129/SVJ;
RA Rickert S., Granger S.W., Ko M., Shukla D., Spear P.G., Kronenberg M.,
RL Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF515707; AAQ08183.1; -.
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0004888; F:transmembrane receptor activity; IEA.
DR GO; GO:0006915; P:apoptosis; IEA.
DR GO; GO:0006955; P:immune response; IEA.
DR GO; GO:0007165; P:signal transduction; IEA.
DR InterPro; IPR008063; Fas receptor.
DR InterPro; IPR001368; TNFR c6.
DR Pfam; PF00020; TNFR c6; 3.
DR PRINTS; PR01680; FASRECEPTOR.
DR SMART; SM00208; TNFR; 4.
DR PROSITE; PS00652; TNFR NGFR 1; UNKNOWN_1.
DR PROSITE; PS50050; TNFR NGFR 2; 3.
SQ SEQUENCE 276 AA; 30327 MW; 4A615FB2629E9125 CRC64;

Query Match 14.58; Score 201.5; DB 2; Length 276;
Best Local Similarity 23.94; Pred. No. 4e-09;
Matches 64; Conservative 35; Mismatches 88; Indels 81; Gaps 12;

QY 22 LSLGQRTGPGGCGPGRLLLTGTGDARCCRV-----HTTRCCRDYPGEEC----- 66
Db 30 LNLQLRISAQPSCRQEBFLVGD-----ECCPMCPGHVHKVCSEHTGVCAPCPQYYTA 85
QY 67 -----CSEWD-----CMCVQPEFHC-----GDPCTTCRHHC 94
Db 86 HANGLSKCLPCGVCDDPDMGLLTWQECSSWKDVTVCRCI-PGVFCBNQDQSHCSTCLQHTTC 144
QY 95 PPGQVQSOGKFSFGQICDCASGTFPS-CGHEGCHKPWTDCQTQPGFLTVFPGNKTINAVC 153
Db 145 PPGQVKEKRGTHDQDVTVCADCTGTGSLGGTQBECLPWTNCSAFQ-QEVRRGNTSTDTTC 203
QY 154 VPGSPPAEPLGMLTVLLAV----AACVLLLTSAQLGLHIWQLRSQCMWPRETQLLLLE 207
Db 204 -----SSQVYVYVSVLLPLVIVGAGIAGFLICTRRHL-----HTSSVAKE 244
QY 208 VPPSTEDAR--SCOFFPEERGERSAEK 233
Db 245 LEPPQEQEQENTIRFPVTEVGFATEE 272
```

RESULT 6

```
TNR9 MOUSE
ID TNR9 MOUSE STANDARD; PRT; 256 AA.
AC P20334;
DT 01-FEB-1991 (Rel. 17, Created)
DT 01-FEB-1991 (Rel. 17, Last sequence update)
DT 25-OCT-2004 (Rel. 45, Last annotation update)
DE Tumor necrosis factor receptor superfamily member 9 precursor (4-1BB
DE ligand receptor) (T-cell antigen 4-1BB) (CD137 antigen).
GN Name=Tnfrsf9; Synonyms=Cd137, Cd157, ILA, Ly63;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=BALB/c;
RX MEDLINE=89184547; PubMed=2784565;
RA Kwon B.S., Weissman S.M.;
RT "cDNA sequences of two inducible T-cell genes.";
RL Proc. Natl. Acad. Sci. U.S.A. 86:1963-1967(1989).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=BALB/c;
RX MEDLINE=94179805; PubMed=8133039;
RA Kwon B.S., Kozak C.A., Kim K.K., Pickard R.T.;
RT "Genomic organization and chromosomal localization of the T-cell
RT antigen 4-1BB.";
RL J. Immunol. 152:2256-2262(1994).
RN [3]
RP CHARACTERIZATION, AND SEQUENCE OF 24-29.
RX MEDLINE=93139510; PubMed=7678621;
RA Pollock K.E., Kim Y.-J., Zhou Z., Hurtado J., Kin K.K., Pickard R.T.,
RA Kwon B.S.;
RT "Inducible T cell antigen 4-1BB. Analysis of expression and
RT function.";
RL J. Immunol. 150:771-781(1993).
CC -I- FUNCTION: Receptor for TNFSF14/4-1BBL. Possibly active during T
CC cell activation.
CC -I- SUBUNIT: Principally an homodimer, but also found as a monomer.
CC Associates with p56-LCK. Interacts with TRAF1, TRAF2 and TRAF3 (By
CC similarity).
CC -I- SUBCELLULAR LOCATION: Type I membrane protein.
CC -I- TISSUE SPECIFICITY: Expressed on the surface of activated T cells.
CC -I- INDUCTION: Optimal by PMA and ionomycin.
CC -I- SIMILARITY: Contains 4 TNFR-Cys repeats.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; J04492; AAA0167.1; -.
CC EMBL; U02567; AAA93113.1; -.
CC PIR; B32393; B32393.
CC PDB; 1D0J; X-ray; G/H/I/J/K=230-236.
CC MGD; MGI:1101059; Tnfrsf9.
CC InterPro; IPR009030; Grow_fac_recept.
CC InterPro; IPR001368; TNFR c6.
CC Pfam; PF00020; TNFR c6; 1.
CC SMART; SM00208; TNFR; 2.
CC PROSITE; PS00652; TNFR NGFR 1; 1.
CC PROSITE; PS50050; TNFR NGFR 2; FALSE NEG.
CC 3D-structure; Direct protein sequencing; Glycoprotein; Receptor;
CC Repeat; Signal; Transmembrane.
FT SIGNAL 1 23
FT CHAIN 24 256 Tumor necrosis factor receptor
FT superfamily member 9.
FT DOMAIN 24 187 Extracellular (Potential).
FT TRANSMEM 188 208 Potential.
FT DOMAIN 209 256 Cytoplasmic (Potential).
```

```
FT REPEAT      24 45      TNFR-Cys 1.
FT REPEAT      46 85      TNFR-Cys 2.
FT REPEAT      86 117     TNFR-Cys 3.
FT REPEAT     118 159     TNFR-Cys 4.
FT DISULFID    28 37      By similarity.
FT DISULFID    31 44      By similarity.
FT DISULFID    47 61      By similarity.
FT DISULFID    64 77      By similarity.
FT DISULFID    67 85      By similarity.
FT DISULFID    87 93      By similarity.
FT DISULFID    98 105     By similarity.
FT DISULFID   101 116     By similarity.
FT DISULFID   119 133     By similarity.
FT DISULFID   139 158     By similarity.
FT CARBOHYD    128 128     N-linked (GlcNAc...) (Potential).
FT CARBOHYD    138 138     N-linked (GlcNAc...) (Potential).
SQ SEQUENCE    256 AA; 27598 MW; 93A10D03C60813CA CRC64;

Query Match      14.2%; Score 197; DB 1; Length 256;
Best Local Similarity 28.8%; Pred. No. 9e-09;
Matches 64; Conservative 25; Mismatches 85; Indels 48; Gaps 10;

QY 34 CGPGRLL-LIGTGTDRACRCRVHTRCCRDYVPGECGSEW---DCMCVQPFHCGDPCCTTC 89
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 90 RHHPCPPGQGVOSQGRKFSFGQICDASGTFSGGH-EGHCKPWTDTQFGPLTVFPFGNKT 148
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 102 -EKDCRPGQELTKQG-----CKTSLGTFNDQNGTGVCRPWTNCSLDGRSVLKTGTTE 153
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 149 HNAVCPV-----GSPAPPLGWLTVLLAVACULLLTSQAIGHIWLQ 192
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 154 KDVVCPVPVSPSPSTTSVTPGSGHSLQVLTLFLALTSALLIAL-----IFITLL 207
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 193 RSQCWPPTQLLEVP-----STEDARSCQPEERG 226
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 208 FSVLKWIRKFFPHFKQPPKKTGAQAQEDACSCRCQPEERG 249
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

RESULT 7
TNR9_HUMAN
ID TNR9_HUMAN STANDARD; PRT; 255 AA.
AC Q07011;
DT 01-FEB-1995 (Rel. 31, Created)
DT 01-FEB-1995 (Rel. 31, Last sequence update)
DT 25-JAN-2005 (Rel. 46, Last annotation update)
DE Tumor necrosis factor receptor superfamily member 9 precursor (4-1BB
DE ligand receptor) (T-cell antigen 4-1BB homolog) (T-cell antigen ILA)
DE (CD137 antigen).
GN Name=TNFRSF9; Synonyms=CD137, ILA;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Blood;
RX MEDLINE=94374434; PubMed=8088337;
RA Alderson M.R., Smith C.A., Tough T.W., Davis-Smith T., Armitage R.J.,
RA Falk B., Roux E., Baker E., Sutherland G.R., Din W.S., Goodwin R.G.;
RT "Molecular and biological characterization of human 4-1BB and its
RT ligand.";
RL Eur. J. Immunol. 24:2219-2227(1994).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Blood;
RX MEDLINE=94085794; PubMed=8262389; DOI=10.1016/0378-1119(93)90110-O;
RA Schwarz H., Tuckwell J., Lotz M.;
RT "A receptor induced by lymphocyte activation (ILA): a new member of
RT the human nerve-growth-factor/tumor-necrosis-factor receptor family.";
RL Gene 134:295-298(1993).
RN [3]
RP REVISION TO 107.
```

```
RA Schwarz H.;
RL Submitted (MAR-1999) to the EMBL/GenBank/DBJ databases.
RN [4]
RP SEQUENCE FROM N.A.
RC TISSUE=Blood;
RX MEDLINE=95347766; PubMed=7622190; DOI=10.1016/0165-2478(94)00227-I;
RA Zhou Z., Kim S., Hurtado J., Lee Z.H., Kim K.K., Pollok K.E.,
RA Kwon B.S.;
RT "Characterization of human homologue of 4-1BB and its ligand.";
RL Immunol. Lett. 45:67-73(1995).
RN [5]
RP SEQUENCE FROM N.A.; AND VARIANTS THR-56; ASN-115 AND ASP-176.
RA Rieder M.J., Livingston R.J., Daniels M.R., Chung M.-W.,
RA Miyamoto K.E., Nguyen C.P., Nguyen D.A., Poel C.L., Robertson P.D.,
RA Schackwitz W.S., Sherwood J.K., Witrak L.A., Nickerson D.A.;
RT "NIH-SNPs, environmental genome project, NIHES ES15478, Department
RT of Genome Sciences, Seattle, WA (URL: http://egp.gs.washington.edu).";
RL Submitted (OCT-2003) to the EMBL/GenBank/DBJ databases.
RN [6]
RP SEQUENCE FROM N.A.
RA Pearce A.;
RL Submitted (OCT-1999) to the EMBL/GenBank/DBJ databases.
RN [7]
RP SEQUENCE FROM N.A.
RC TISSUE=Kidney;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T.T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldi M.F., Casavant T.L., Schetz T.E.,
RA Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan M., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalilus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [8]
RP SEQUENCE OF 24-38
RX PubMed=15340161; DOI=10.1110/ps.04682504;
RA Zhang Z., Hensel W.J.;
RT "Signal peptide prediction based on analysis of experimentally
RT verified cleavage sites.";
RL Protein Sci. 13:2819-2824(2004).
RN [9]
RP INTERACTIONS WITH TRAF1; TRAF2 AND TRAF3.
RX MEDLINE=98078711; PubMed=9418902;
RA Arch R.H., Thompson C.B.;
RT "4-1BB and Oxa40 are members of a tumor necrosis factor (TNF)-nerve
RT growth factor receptor subfamily that bind TNF receptor-associated
RT factors and activate nuclear factor kappaB.";
RL Mol. Cell. Biol. 18:558-565(1998).
RN [10]
RP INTERACTIONS WITH TRAF1 AND TRAF2.
RX MEDLINE=98270914; PubMed=9607925;
RA Saoulli K., Lee S.Y., Cannons J.L., Yeh W.C., Santana A.,
RA Goldstein M.D., Bangia N., DeBenedette M.A., Mak T.W., Choi Y.,
RA Watts T.H.;
RT "CD28-independent, TRAF2-dependent costimulation of resting T cells by
RT 4-1BB ligand.";
RL J. Exp. Med. 187:1849-1862(1998).
RN [11]
RP INTERACTION WITH LRR-REPEAT PROTEIN 1/LRR-1.
RX MEDLINE=21662677; PubMed=11804328;
```

RA Jang I.-K., Lee Z.-H., Kim H.-H., Hill J.M., Kim J.-D., Kwon B.S.;
RT "A novel leucine-rich repeat protein (LRR-1): potential involvement in
RL 4-lbB-mediated signal transduction.";
RL Mol. Cells 12:304-312(2001).
CC -!- FUNCTION: Receptor for TNFSF14/4-1bBL. Possibly active during T
CC cell activation.
CC -!- SUBUNIT: Interacts with TRAF1, TRAF2 and TRAF3. Interacts with
CC LRR-repeat protein 1/LRR-1.
CC -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC -!- TISSUE SPECIFICITY: Expressed on the surface of activated T cells.
CC -!- SIMILARITY: Contains 4 TNFR-Cys repeats.
CC -!- DATABASE: NAME=PROW; NOTE=CD guide CDw137 entry;
CC WWW="http://www.ncbi.nlm.nih.gov/prov/cd/cdwl37.htm".
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC
CC -----
CC EMBL: U03397; AAA53133.1; -;
CC EMBL: L12964; AAA62478.2; -;
CC EMBL: AY438976; AAR05440.1; -;
CC EMBL: AL009183; CAB57398.1; -;
CC EMBL: BC006196; AAH06196.1; -;
CC PIR: I38426; I38426.
CC HSSP: Q92956; IJMA.
CC Genew; HGNC:11924; TNFRSF9.
CC H-InvDB: HIX0000096; -;
CC MIM: 602250; -;
CC GO: GO:005887; C: integral to plasma membrane; TAS.
CC GO: GO:0004872; F: receptor activity; TAS.
CC GO: GO:0006917; P: induction of apoptosis; TAS.
CC GO: GO:0008285; P: negative regulation of cell proliferation; TAS.
CC InterPro: IPR001368; TNFR c6.
CC Pfam: PF00020; TNFR c6; 2.
CC SMART: SM00208; TNFR; 2.
CC PROSITE: PS00652; TNFR NGFR 1; 1.
CC PROSITE: PS50050; TNFR NGFR 2; 1.
CC Direct protein sequencing; Glycoprotein; Polymorphism; Receptor;
KW Repeat; Signal; Transmembrane.
FT SIGNAL 1 23
FT CHAIN 24 255

FT FT DOMAIN 24 186 Tumor necrosis factor receptor
FT FT TRANSMEM 187 213 superfamily member 9.
FT FT DOMAIN 214 255 Extracellular (Potential).
FT FT REPEAT 24 45 Cytoplasmic (Potential).
FT FT REPEAT 47 86 TNFR-Cys 1.
FT FT REPEAT 87 118 TNFR-Cys 2.
FT FT REPEAT 119 159 TNFR-Cys 3.
FT FT DOMAIN 214 255 TNFR-Cys 4.
FT FT DISULFID 28 37 Interaction with LRR-1.
FT FT DISULFID 31 45 By similarity.
FT FT DISULFID 48 62 By similarity.
FT FT DISULFID 65 78 By similarity.
FT FT DISULFID 68 86 By similarity.
FT FT DISULFID 88 94 By similarity.
FT FT DISULFID 99 106 By similarity.
FT FT DISULFID 102 117 By similarity.
FT FT DISULFID 121 133 By similarity.
FT FT DISULFID 139 158 By similarity.
FT FT CARBOHYD 138 138 N-linked (GlcNAc...) (potential).
FT FT CARBOHYD 149 149 N-linked (GlcNAc...) (potential).
FT FT VARIANT 56 56 A -> T.
FT FT VARIANT 115 115 /FTId=VAR_018920.
FT FT VARIANT 176 176 K -> N.
FT FT VARIANT 176 176 A -> D.
FT FT SEQUENCE 255 AA; 27899 MW; F3A563F5E5F00460 CRC64;
SQ

Query Match 14.1%; Score 195.5; DB 1; Length 255;
Best Local Similarity 28.8%; Pred. No. 1.2e-08;
Matches 66; Conservative 21; Mismatches 81; Indels 61; Gaps 12;
QY 34 CQPGELLGTGDARCCRVHTTRCCRDYPG-----EECCS-----EWDGMCVQPEHCGDP 84
DB 48 CPNFSFSSAGG--QRTCDI-----CRQCKGVPRTRKESSTNAECDC---TPGFHCLGA 97
QY 85 CTTTCRHHPCCPPGQGVQSQGKFSFGQCIDCASGTFSGGHEGHCKEPTDCTQFGFLTVPF 144
DB 98 GCSMC-EQDCKGQGLTKG-----CKDCCFGFNDQKRGICRWTNCSLDGKSVLVN 149
QY 145 GNKTHNAVCPG-----SPPA-----BPLGLMTVV--LLAVAACVLLTSAQLGLH 188
DB 150 GTKERDVCVGPADLSPGASSVTPAPAREPGHSPQIIISFFLATSTALLFFLFTLTLR 209
QY 189 -----TWOLRSQCMWRETQLLLEVPSTEDARSCOPPEERG 226
DB 210 FSVVKRGKRLLYIFKQPFMRPVQT-----TQEDGCSRPFPEEEG 251

RESULT 8

Q75SV8 PRELIMINARY; PRT; 270 AA.
AC Q75SV8;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE CD134 homologue.
OS Felis silvestris catus (Cat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Carnivora; Fissipedia; Felidae; Felis.
OX NCBI_TaxID=9685;
RN [1]
RP SEQUENCE FROM N.A.
RA Shimojima M., Miyazawa T., Ikeda Y., McMonagle E.L., Haining H.,
RA Akashi H., Takeuchi Y., Hosie M.J., Willett B.J.;
RT "Use of CD134 as a primary receptor by the feline immunodeficiency
RT virus".
RL Science 0:0-0(2004).
DR EMBL: AB128982; BAD11363.1; -;
DR GO: GO:0004872; F: receptor activity; IEA.
DR InterPro: IPR001368; TNFR c6.
DR Pfam: PF00020; TNFR c6; 2.
DR SMART: SM00208; TNFR; 3.
DR PROSITE: PS00652; TNFR NGFR 1; 2.
DR PROSITE: PS50050; TNFR NGFR 2; 2.
DR SEQUENCE 270 AA; 28731 MW; 36A40BAD261140D1 CRC64;
SQ

Query Match 13.8%; Score 191; DB 2; Length 270;
Best Local Similarity 27.3%; Pred. No. 3e-08;
Matches 65; Conservative 20; Mismatches 73; Indels 80; Gaps 12;
QY 39 LLLGTGTDAACCRVHTT-----RCCRDYP---GEE---CCSEWDCMCVQPEFHCG----- 82
DB 22 LVLTGTAALHC--VGNTYPKDGKCCSECPGPGYMGESRCSGDQDTKCIQ----CASGFYNE 75
QY 83 -----DPC--CTTCRHHHP-----CPPGQ-----GVQSOGKFSFGFQCIDCASGTF 121
DB 76 AVNVECKPCTQCNQRSGSEPKQRCPTPTQTVCRCRGTEPDGVDGVDCAFCPPGHFS 135
QY 122 GHEGHCCKPMTDCTQFGFLTVPFGNKTNNVAVCPGSPAPPLGWLTVVLLAACAVALLT 181
DB 136 PGDDQACKPMTNCTLAGKRTLRLPASQGSDAVCEDRSPATT----- 176
QY 182 SAQLGLHIWOLRSQCMWRETQLLLEVPSTEDARSCQFP-----EEERGSAAEKG 234
DB 177 -----PWETQGPVVRPTTQ-----PITAMPRTSQEPPTPAEPPRGQLAAVLG 221

RESULT 9
Q76LBA

```
ID Q76LB4 PRELIMINARY; PRT; 290 AA.
AC Q76LB4;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE CD40.
GN Name=CD40;
OS Parvulthys olivaceus (Japanese flounder).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
OC Acanthomorpha; Acanthopterygii; Percomorpha; Pleuronectiformes;
OC Pleuronectoidae; Parvulthysidae; Parvulthys.
OX NCBI_TaxID=8255;
RN [1]
RP SEQUENCE FROM N.A.
RA Park C., Hirono I., Aoki T.;
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RA Park C., Hirono I., Aoki T.;
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB081752; BAC87848.1; -.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR006209; EGF-like.
DR SMART; SM00208; TNFR_2.
DR PROSITE; PS01186; EGF 2; UNKNOWN 1.
DR PROSITE; PS00050; TNFR_NGFR_2; 1.
DR PROSITE; PS00050; TNFR_NGFR_2; 1.
SQ SEQUENCE 290 AA; 32396 MW; B6FCF9E35305DFAA CRC64;

Query Match 13.2%; Score 182.5; DB 2; Length 290;
Best Local Similarity 25.8%; Pred. No. 1.7e-07;
Matches 63; Conservative 24; Mismatches 108; Indels 49; Gaps 11;

QY 34 CGPG--RLLLGTCDARCRVHTTRCCRDYPGECC-----SEW 70
DB 40 CGPGTRMSQSTCTDPOCAECGNREYQDRYTREAQCRQPCYCDPNKLNLTVPESKTKOS 99

QY 71 DMCVQPEPHGDPCCCTTC-RHHPCCPGQVSGQKFSFGQCIDCASGTFSGGH--EGH 127
DB 100 PCICLL-GFHCSSGTCVTCVPHATCKPGQWAKIKGNLTHDTCVCESPGSGFSTSHSSV 158

QY 128 CRPWTCTQFGFLTVFPGNKTHNAVCPGSPPAELGMLTVVL-----LAAVACVLLTSA 183
DB 159 CTKWTEC-ESGYHIQSGTNSDNICV--EPPRHGGGLIACVAVGSLAVVGLMVCCKG 215

QY 184 QLGLHIWQLRSQCMWPRETQLLEVPSS-----TEDARSCQPEER---GERSAE 231
DB 216 ETQKRAKDYLESCHGDKEN---LQREPSLVLTLDLTENHELLLPTEBEMKIPKTR 272

QY 232 EKGR 235
DB 273 TKGR 276

RESULT 10
O02764 PRELIMINARY; PRT; 267 AA.
AC O02764;
DT 01-JUL-1997 (TrEMBLrel. 04, Created)
DT 01-JUL-1997 (TrEMBLrel. 04, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE OX40 precursor (Fragment).
OS Oryctolagus cuniculus (Rabbit).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
OX NCBI_TaxID=9986;
RN [1]
RP SEQUENCE FROM N.A.
RA STRAIN=Chbb.HM;
RC Isono T., Seto A.;
RL Submitted (MAY-1997) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB003911; BAA20059.1; -.

DR HSP; Q92956; 1JWA.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR001368; TNFR_c6.
DR Pfam; PF00020; TNFR_c6; 2.
DR SMART; SM00208; TNFR_3.
DR PROSITE; PS00652; TNFR_NGFR_1; 2.
DR PROSITE; PS00050; TNFR_NGFR_2; 2.
DR PROSITE; PS00050; TNFR_NGFR_2; 2.
KW Signal.
FT SIGNAL 1 18 Potential.
FT CHAIN 19 267 OX40.
SQ SEQUENCE 267 AA; 28489 MW; ABB4CD3D173C9500B CRC64;

Query Match 13.1%; Score 182; DB 2; Length 267;
Best Local Similarity 27.8%; Pred. No. 1.7e-07;
Matches 68; Conservative 15; Mismatches 88; Indels 74; Gaps 12;

QY 12 ALCGLA-LLCALSLGQRTGGPGC-----GPGRLLL-----GTGTDARCCRVHTTRCCRD 60
DB 4 AALGLALLLLGLLLGAEPR--PDCVGDYVPGDRCCLCQPGYGMVSRNRSQDTICHPC 61

QY 61 YPG--EECCSEWDCM-CVQ-----PEFHCGDPCCTTCRHHPCCPGQVSGQKFSFG 109
DB 62 BPGFYNEAVNYQACKPCTQCNRSSGSEPGQECTHTRDIVCR---CRP--GTQPLNGYKHG 116

QY 110 FOCIDCASGTFSGGHEGCKPMTDCTQFGFLTVFPGNKTHNAV-----VPGS 157
DB 117 VDCAPCQGHFSEGNRRACRPWTNCTLAGKRTLQPASSISDAVCDRSSLATQPMETPSA 176

QY 158 PRAEPLGMLTVLLAAVACVLLTSAQLGLHIWQLRSQCMWPRETQLLEVPSPSTEDARS 217
DB 177 PYRPPTA-----RTSTAWPTAQ-----GFSPTLEA 203

QY 218 CQPE 222
DB 204 SKGPQ 208

RESULT 11
Q9DD2 PRELIMINARY; PRT; 276 AA.
AC Q9DD2;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE CD40-homologue.
GN Name=TNFRSF5;
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
OX NCBI_TaxID=9031;
RN [1]
RP SEQUENCE FROM N.A.
RA Tregaskes C.A.;
RL Thesis (2001), University of Reading, Reading, UNITED KINGDOM.
DR EMBL; AJ293700; CAC20218.1; -.
DR HSP; Q92956; 1JWA.
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0004888; F:transmembrane receptor activity; IEA.
DR GO; GO:0006915; P:apoptosis; IEA.
DR GO; GO:0006955; P:immune response; IEA.
DR GO; GO:0007165; P:signal transduction; IEA.
DR InterPro; IPR008063; Fas receptor.
DR InterPro; IPR001005; Myb_DNA binding.
DR InterPro; IPR001368; TNFR_c6.
DR Pfam; PF00020; TNFR_c6; 2.
DR PRINTS; PR01680; FASRECEPTOR.
DR SMART; SM00208; TNFR_3.
DR PROSITE; PS00037; MYB 1; UNKNOWN 1.
DR PROSITE; PS00652; TNFR_NGFR_1; UNKNOWN 1.
DR PROSITE; PS00050; TNFR_NGFR_2; 3.
DR PROSITE; PS00050; TNFR_NGFR_2; 3.
SQ SEQUENCE 276 AA; 30009 MW; 4040B7E0DB82454E CRC64;
```

DR	HSP; Q92956; LjWA.
DR	MGD; MG1:104512; Tnfrsf4.
DR	GO; GO:005886; C:plasma membrane; IDA.
DR	GO; GO:006968; P:cellular defense response; IMP.
DR	InterPro; IPR001368; TNFR_c6.
DR	Pfam; PF00020; TNFR_c6; 3-
DR	SMART; SM00208; TNFR_3.
DR	PROSITE; PS00552; TNFR_NGFR_1; 2.
DR	PROSITE; PS00550; TNFR_NGFR_2; 2.
KW	Antigen; Glycoprotein; Receptor; Repeat; Signal; Transmembrane.
FT	SIGNAL 1 19 Potential.
FT	CHAIN 20 272 Tumor necrosis factor receptor superfamily member 4.
FT	DOMAIN 20 211 Extracellular (Potential).
FT	TRANSMEM 212 236 Potential.
FT	DOMAIN 237 272 Cytoplasmic (Potential).
FT	REPEAT 26 61 TNFR-Cys 1.
FT	REPEAT 62 103 TNFR-Cys 2.
FT	REPEAT 104 124 TNFR-Cys 3 (incomplete).
FT	REPEAT 125 165 TNFR-Cys 4.
FT	DISULFID 27 38 By similarity.
FT	DISULFID 39 52 By similarity.
FT	DISULFID 42 60 By similarity.
FT	DISULFID 63 77 By similarity.
FT	DISULFID 80 95 By similarity.
FT	DISULFID 83 103 By similarity.
FT	DISULFID 105 123 By similarity.
FT	DISULFID 126 139 By similarity.
FT	DISULFID 145 164 By similarity.
FT	CARBOHYD 144 144 N-linked (GLNac..) (Potential).
FT	CONFLICT 15 15 A -> G (in Ref. 2).
FT	SEQUENCE 272 AA; 30153 MW; 06E7BB4156FD08E CRC64;
QY	Query Match 12.6%; Score 175; DB 1; Length 272;
DB	Best Local Similarity 26.7%; Pred. No. 7e-07;
DB	Matches 58; Conservative 19; Mismatches 70; Indels 70; Gaps 10;
QY	39 LLIGTGTGAR--CCRVT-----TRCRD-YPG---EECCSEWDCMVQPEFHCGDPC-- 85
DB	14 LALTGLGVARRLNCVKHTVPSSGHKKCRECPQHGMVSRCDHTRDTLC-----HFCET 65
QY	86 -----CTTCRHHP-----CPPGGVGVSQGKFSFGQCID 114
DB	66 GFNEAVNYDYTKCQTCHNRSGSELKNCTPTQDTVCRCRPGTPQRQDSGYKLGVDCVP 125
QY	115 CASGTSGSGHGHCCKPWTDTCTQGFITVPGNKTHNAVCVGPSPPAEPLGLTWTVLLAVA 174
DB	126 CPDHFPSPGNQAQKPWTNTLSGKTTRHPASDLDAVCEDRS-----LLA-- 171
QY	175 ACVLILTSAGLGIHWQLRSQCMWPRETQLLEVPSS 211
DB	172 --TLLETORTPTRPRTTVQSTTVMPRTSE--LPSPPT 204
RESULT	13
Q8VC17	ID Q8VC17 PRELIMINARY; PRY; 196 AA.
AC	Q8VC17;
DT	01-MAR-2002 (T-EMBLrel. 20, Created)
DT	01-MAR-2002 (T-EMBLrel. 20, Last sequence update)
DT	01-MAR-2004 (T-EMBLrel. 26, Last annotation update)
DE	Tnfrsf14 protein (Fragment).
DE	Name=Tnfrsf14;
GN	Mus musculus (Mouse).
OS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX	NCBI_TaxID=10090;
RN	[1]
RP	SEQUENCE FROM N.A.
RC	STRAIN=FVB/N; TISSUE=liver;
RX	MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA	Straubeberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,


```

RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RA "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=FVB/N; TISSUE=Liver;
RA Strausberg R.;
RL Submitted (JAN-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC022125; AAH22125.1; -.
DR HSSP; Q92956; 1JWA.
DR MGD; MGI:1101059; Tnf1sf14.
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0004888; F:transmembrane receptor activity; IEA.
DR GO; GO:0006915; P:apoptosis; IEA.
DR GO; GO:0006955; P:immune response; IEA.
DR GO; GO:0007165; P:signal transduction; IEA.
DR Pfam; PF00020; TNFR_c6; 2.
DR PRINTS; PR01680; FASRECEPTOR.
DR SMART; SM00208; TNFR; 3.
DR PROSITE; PS50050; TNFR_NGFR_2; 1.
FT NON TER 1
SQ SEQUENCE 196 AA; 21555 MW; 2AB3FF8905E260E8 CRC64;

Query Match 12.6%; Score 174.5; DB 2; Length 196;
Best Local Similarity 27.3%; Pred. No. 5.7e-07;
Matches 50; Conservative 28; Mismatches 68; Indels 37; Gaps 9;

QY 67 CSEWD---CMCQVQPEHC---GDPCTTCRHHPGPPGGVQSQKFSFGQICDASGT 119
DB 31 CSSWKDVTVCRCI-PGYFCENQDGHSCSTCLQHTTCCPPGQVRKRGTHDQDTVCADCLGT 89

QY 120 FS-GGHEGHCPTWDTQTFGLTVFPQNKTHNAVCPGSPPAEPLGWLTVLLAVA---- 174
DB 90 FSLGGTQECLPWTNGSAFQ-QEVRGKTNSTDTTC-----SSQVYVYVSIPLPLVIGV 143

QY 175 --ACVLLTSAQLGLHIWQLRSCQWMPRETQLLLEVPPTEDAR--SCOFFPEERGERSA 230
DB 144 GIAGFLICTRRHL-----HTSSVAKELEPPQEQEQENTIRFPVTEVGFAET 189

QY 231 EEK 233
DB 190 EEE 192

RESULT 14
Q8R037 PRELIMINARY; PRT; 211 AA.
AC Q8R037;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Tnf1sf9 protein.
GN Name=Tnf1sf9;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
OX NCBI_TaxID=10090;
RN [1] Canis familiaris (Dog).

```

```

RP SEQUENCE FROM N.A.
RC TISSUE=Uterus;
RA MEDLINE=23388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RA "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Uterus;
RA Strausberg R.;
RL Submitted (APR-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC028507; AAH28507.1; -.
DR HSSP; Q92956; 1JWA.
DR MGD; MGI:1101059; Tnf1sf9.
DR GO; GO:0005615; C:extracellular space; TAS.
DR GO; GO:0016021; C:integral to membrane; TAS.
DR InterPro; IPR011061; Antihaemostatic.
DR InterPro; IPR006209; EGF like.
DR InterPro; IPR001368; TNFR_c6.
DR Pfam; PF00020; TNFR_c6; 1.
DR SMART; SM00208; TNFR; 2.
DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
DR PROSITE; PS00652; TNFR_NGFR 1; 1.
SQ SEQUENCE 211 AA; 22452 MW; 1EECA84EA32A8D50 CRC64;

Query Match 12.3%; Score 170.5; DB 2; Length 211;
Best Local Similarity 27.3%; Pred. No. 1.3e-06;
Matches 54; Conservative 22; Mismatches 77; Indels 45; Gaps 8;

QY 34 CGPGR-L-LIGTGDARCRVHTTRCCRDYPGEECCSEW---DCMCVQPEFHGDPCTTC 89
DB 47 CFPSTFSIGGPNCNICRV-----CAGYFRFKKFCSTHNAECIE-GFHLGLGPQCTRC 101

QY 90 RHHPGPPGGVQSQKFSFGQICDASGTFSGGH-EGHCKEWTDTCTQGFITVFPENKT 148
DB 102 -EKDCRPQGLTKQG-----CKTCSLGTENDQGTGVCRTWNGSLDGRSVLKTGTT 153

QY 149 HNAVCPGSPPAEPLGWLTVLLAVAACVLLTSAQLGLHIWQLRSCQWMPRETQLL 208
DB 154 KDVVCGPPVVSFSPSTTISVTPEGGPAFKKTTGAQ----- 189

QY 209 PPSSTEDARSCOFFPEER 226
DB 190 ---EEDACSCRCPOEEG 204

RESULT 15
Q7YRL5 PRELIMINARY; PRT; 274 AA.
AC Q7YRL5;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE CD40.
GN Name=CD40;
OS Canis familiaris (Dog).

```


THIS PAGE BLANK (USPTO)